Disruption	O

of	O
the	O
human	B-DNA
SCL	I-DNA
locus	E-DNA
by	O
``	O
illegitimate	O
''	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
.	O
A	O

fusion	B-DNA
complementary	I-DNA
DNA	E-DNA
in	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
HSB-2	E-cell_line
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	B-GP
transcription	I-GP
factor	E-GP
SCL	S-GP
.	O
The	O

fusion	B-DNA
cDNA	E-DNA
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	B-DNA
locus	E-DNA
,	O
SIL	S-DNA
(	O
SCL	B-DNA
interrupting	I-DNA
locus	E-DNA
)	O
,	O
and	O
the	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	E-DNA
of	O
SCL	S-GP
.	O
Similar	O

to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B-DNA
5	I-DNA
'	I-DNA
regulatory	I-DNA
region	E-DNA
.	O
This	O

event	O
is	O
probably	O
mediated	O
by	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	S-GP
or	O
a	O
T	B-GP
cell	I-GP
receptor	E-GP
.	O
Two	O

other	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
CEM	S-cell_line
and	O
RPMI	B-cell_line
8402	E-cell_line
,	O
have	O
essentially	O
identical	O
deletions	O
.	O
Thus	O

,	O
in	O
lymphocytes	S-cell_type
,	O
growth-affecting	B-DNA
genes	E-DNA
other	O
than	O
immune	B-GP
receptors	E-GP
risk	O
rearrangements	O
.	O
Thyroid	B-GP

hormone	I-GP

receptors	E-GP
form	O
distinct	O
nuclear	B-GP
protein-dependent	I-GP
and	I-GP
independent	I-GP
complexes	E-GP
with	O
a	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	E-DNA
.	O
We	O
have	O

examined	O
the	O
binding	O
of	O
nuclear	B-GP
proteins	E-GP
and	O
recombinant	B-GP
thyroid	I-GP
hormone	I-GP
receptors	E-GP
(	O
TRs	S-GP
)	O
to	O
the	O
palindromic	B-DNA
thyroid	I-DNA
hormone	I-DNA
responsive	I-DNA
element	E-DNA
AGGTCATGACCT	O
(	O
TREp	S-DNA
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
Four	O
specific	O

protein-DNA	B-GP
complexes	E-GP
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	B-cell_line
pituitary	I-cell_line
(	I-cell_line
GH3	I-cell_line
)	I-cell_line
cells	E-cell_line
with	O
a	O
TREp-containing	B-DNA
DNA	I-DNA
fragment	E-DNA
.	O
This	O
was	O

compared	O
with	O
the	O
TREp	S-DNA
binding	O
of	O
reticulocyte	B-GP
lysate-synthesized	I-GP
TRs	E-GP
.	O
TR	B-GP
alpha	I-GP

1	E-GP
and	O
TR	B-GP
beta	I-GP
2	E-GP
each	O
formed	O
a	O
single	O
major	O
TR	B-GP
:	I-GP
TREp	I-GP
complex	E-GP
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-GP
beta	I-GP
1	E-GP
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	S-DNA
as	O
an	O
oligomer	S-GP
.	O
Interestingly	O
,	O

coincubation	O
of	O
35S-TR	B-GP
alpha	I-GP
1	E-GP
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	S-DNA
resulted	O
in	O
not	O
only	O
the	O
35S-TR	B-GP
:	I-GP
TREp	I-GP
complex	E-GP
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S-TR	B-GP
alpha	I-GP
1	E-GP
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O
Incubation	O
of	O

each	O
of	O
the	O
TRs	S-GP
with	O
NE	O
from	O
COS-7	B-cell_line
cells	E-cell_line
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	S-GP
to	O
mediate	O
T3-responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	B-GP
shifted	I-GP
complex	E-GP
.	O
A	O
similar	O

,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	B-GP
:	I-GP
TRE	I-GP
complex	E-GP
was	O
also	O
present	O
in	O
NE	O
from	O
T3-unresponsive	B-cell_line
JEG-3	I-cell_line
cells	E-cell_line
.	O
At	O
high	O

concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	S-GP
bound	O
to	O
TREp	S-DNA
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O
Truncation	O
of	O

TR	B-GP
alpha	I-GP
1	E-GP
at	O
amino	B-GP
acid	I-GP
210	E-GP
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl-terminus	S-GP
of	O
the	O
TRs	S-GP
is	O
essential	O
for	O
interaction	O
with	O
nuclear	B-GP
proteins	E-GP
.	O
(	O
ABSTRACT	O

TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Cell-specific	O
differences	O

in	O

activation	O
of	O
NF-kappa	B-DNA
B	I-DNA
regulatory	I-DNA
elements	E-DNA
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
and	I-DNA
beta	I-DNA
interferon	I-DNA
promoters	E-DNA
by	O
tumor	B-GP
necrosis	I-GP
factor	E-GP
.	O
Three	O
aspects	O
of	O

the	O
involvement	O
of	O
tumor	B-GP
necrosis	I-GP
factor	E-GP
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O
Tumor	B-RNA
necrosis	I-RNA
factor	I-RNA

alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
mRNA	E-RNA
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	B-cell_line
U937	I-cell_line
cells	E-cell_line
and	O
in	O
a	O
chronically	B-cell_line
HIV	I-cell_line
infected	I-cell_line
U937	I-cell_line
cell	I-cell_line
line	E-cell_line
(	O
U9-IIIB	S-cell_line
)	O
.	O
TNF-alpha	B-RNA
RNA	E-RNA
was	O

undetectable	O
in	O
U937	B-cell_line
cells	E-cell_line
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	B-cell_line
cells	E-cell_line
.	O
Paramyxovirus	O
infection	O
induced	O

a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B-RNA
RNA	E-RNA
in	O
U9-IIIB	B-cell_line
cells	E-cell_line
compared	O
with	O
U937	B-cell_line
cells	E-cell_line
,	O
suggesting	O
that	O
HIV-infected	B-cell_line
monocytic	I-cell_line
cells	E-cell_line
produced	O
higher	O
levels	O
of	O
TNF-alpha	S-GP
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O
The	O
effects	O
of	O

TNF-alpha	S-GP
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
plasmids	E-DNA
linked	O
to	O
regulatory	B-DNA
elements	E-DNA
from	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
and	O
the	O
beta	B-DNA
interferon	I-DNA
promoter	E-DNA
.	O
In	O
U937	B-cell_line
and	I-cell_line

Jurkat	I-cell_line
T	I-cell_line
lymphoid	I-cell_line
cells	E-cell_line
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	B-DNA
promoters	E-DNA
by	O
TNF-alpha	S-GP
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context-specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF-kappa	B-DNA
B-containing	I-DNA
plasmids	E-DNA
correlated	O
directly	O
with	O
induction	O
of	O
NF-kappa	B-GP
B	E-GP
DNA-binding	O
activity	O
.	O
Although	O
the	O
intact	O

beta	B-DNA
interferon	I-DNA
promoter	E-DNA
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF-alpha	S-GP
,	O
multimers	O
of	O
the	O
PRDII	B-DNA
NF-kappa	I-DNA
B-binding	I-DNA
domain	E-DNA
were	O
inducible	O
by	O
both	O
agents	O
.	O
TNF-alpha	S-GP
was	O
able	O

to	O
increase	O
expression	O
of	O
the	O
HIV	B-DNA
LTR	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
,	O
but	O
in	O
monocytic	B-cell_type
cells	E-cell_type
,	O
TNF-alpha	S-GP
did	O
not	O
induce	O
the	O
HIV	B-DNA
LTR	E-DNA
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O
This	O
level	O
of	O

NF-kappa	B-GP
B	E-GP
-independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF-alpha	S-GP
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
viral	B-RNA
RNA	E-RNA
production	O
in	O
U937	B-cell_line
cells	E-cell_line
.	O
However	O
,	O
in	O

Jurkat	B-cell_line
cells	E-cell_line
,	O
TNF-alpha	S-GP
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV-1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	B-RNA
RNA	E-RNA
synthesis	O
,	O
indicating	O
that	O
in	O
T	B-cell_type
cells	E-cell_type
HIV-1	O
multiplication	O
was	O
stimulated	O
by	O
TNF-alpha	S-GP
treatment	O
.	O
Functional	O
analysis	O
of	O

cis-linked	B-DNA

regulatory	I-DNA
sequences	E-DNA
in	O
the	O
HLA	B-DNA
DRA	I-DNA
promoter	E-DNA
by	O
transcription	O
in	O
vitro	O
.	O
Two	O
consensus	O
sequences	O
,	O

called	O
X	B-DNA
and	I-DNA
Y	I-DNA
boxes	E-DNA
,	O
capable	O
of	O
binding	O
nuclear	B-GP
proteins	E-GP
and	O
regulating	O
expression	O
in	O
B	B-cell_type
cells	E-cell_type
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
promoters	E-DNA
.	O
Unlike	O
other	O
class	B-DNA
II	I-DNA

promoters	E-DNA
,	O
the	O
HLA-DR	B-DNA
alpha	I-DNA
(	I-DNA
DRA	I-DNA
)	I-DNA
promoter	E-DNA
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	E-DNA
of	O
immunoglobulin	B-DNA
variable	I-DNA
region	I-DNA
promoters	E-DNA
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O
This	O
``	O
octamer	S-DNA
``	O

in	O
the	O
context	O
of	O
DRA	S-GP
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	S-GP
(	O
OTF-1	S-GP
)	O
and	O
lymphoid-specific	B-GP
(	I-GP
OTF-2	I-GP
)	I-GP
``	I-GP
octamer	I-GP
''	I-GP
binding	I-GP
proteins	E-GP
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
``	B-GP
octamer	I-GP
''	I-GP
complex	E-GP
was	O
found	O
.	O
In	O
order	O
to	O
characterize	O

the	O
function	O
of	O
cis-acting	B-DNA
elements	E-DNA
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	B-DNA
promoter	I-DNA
construct	E-DNA
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	B-cell_type
cells	E-cell_type
than	O
in	O
extracts	O
from	O
class	B-cell_line
II-negative	I-cell_line
HeLa	I-cell_line
cells	E-cell_line
.	O
5	O
'	O
deletion	O
constructs	O

which	O
lacked	O
the	O
Y	B-DNA
box	E-DNA
,	O
but	O
retained	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	E-DNA
and	O
TATA	B-DNA
box	E-DNA
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	B-DNA
box	E-DNA
reduced	O
transcription	O
by	O
95	O
%	O
.	O
Using	O
supercoiled	O
,	O
but	O

not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	B-DNA
consensus	I-DNA
element	E-DNA
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	B-DNA
box	I-DNA
sequences	E-DNA
in	O
transient	O
expression	O
assays	O
.	O
Demonstration	O
of	O
the	O
complete	O

dependence	O
on	O
the	O
Y	B-DNA
box	E-DNA
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	B-DNA
promoter	E-DNA
,	O
the	O
DRA	B-DNA
``	I-DNA
octamer	I-DNA
''	E-DNA
does	O
not	O
utilize	O
OTF-2	S-GP
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	B-DNA
promoters	E-DNA
in	O
B	B-cell_type
cells	E-cell_type
.	O
Lipopolysaccharide	O
is	O
a	O
potent	O

monocyte/macrophage-specific	O

stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O

stimulates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1-long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
HIV-1-LTR	I-DNA
)	I-DNA
CAT	I-DNA
constructs	E-DNA
transfected	O
into	O
monocyte/macrophage-like	B-cell_line
cell	I-cell_line
lines	E-cell_line
but	O
not	O
a	O
T	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O
This	O
effect	O
appears	O
to	O
be	O

mediated	O
through	O
the	O
induction	O
of	O
nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
(	O
NF-kappa	B-GP
B	E-GP
)	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O

that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B-GP
B	E-GP
in	O
U937	S-cell_line
and	O
THP-1	B-cell_line
cells	E-cell_line
.	O
LPS	O
is	O
also	O
shown	O
to	O

dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	B-cell_line
infected	I-cell_line
monocyte/macrophage-like	I-cell_line
cloned	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
U1	S-cell_line
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O
The	O
stimulation	O
of	O
viral	O
production	O

from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	B-GP
colony-stimulating	I-GP
factor	E-GP
(	O
GM-CSF	S-GP
)	O
before	O
treatment	O
with	O
LPS	O
.	O
This	O
stimulation	O
of	O
HIV-1	O
production	O

is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	B-RNA
RNA	E-RNA
and	O
and	O
activation	O
of	O
NF-kappa	B-GP
B	E-GP
.	O
LPS	O
is	O
not	O
able	O
to	O

induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O
The	O
effect	O
of	O
LPS	O
on	O

HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O
Steroid	O
dose	O
sparing	O
:	O
pharmacodynamic	O

responses	O

to	O
single	O
versus	O
divided	O
doses	O
of	O
methylprednisolone	O
in	O
man	O
.	O
Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O

of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O
This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O

administering	O
MP	O
in	O
divided	O
doses	O
.	O
Two	O
types	O
of	O
responses	O
were	O
compared	O

after	O
a	O
single	O
MP	O
dose	O
(	O
40	O
mg	O
bolus	O
)	O
and	O
a	O
divided	O
regimen	O
(	O
20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later	O
)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O
The	O
suppression	O
of	O
basophils	S-cell_type
measured	O
as	O

whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours	O
.	O
The	O
37.5	O
%	O
reduction	O
in	O
dose	O

produced	O
a	O
23	O
%	O
overall	O
decreased	O
blood	O
histamine	O
response	O
.	O
A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O

distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O
A	O
slower	O
initial	O
decline	O
in	O
blood	O

histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	B-cell_type
cell	E-cell_type
return	O
to	O
blood	O
.	O
The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O

MP	O
of	O
about	O
5	O
ng/ml	O
were	O
similar	O
for	O
both	O
regimens	O
.	O
The	O
decline	O
and	O
return	O
of	O
cortisol	O

concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O
The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O

MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng/ml	O
.	O
Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O

corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
``	O
dose-sparing	O
''	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O
This	O
study	O
supports	O
previous	O
clinical	O
observations	O

that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O

2D2	O

production	O
by	O
T	B-cell_type
lymphocytes	E-cell_type
and	O
alveolar	B-cell_type
macrophages	E-cell_type
recovered	O
by	O
lavage	O
from	O
normocalcemic	O
patients	O
with	O
tuberculosis	O
.	O
To	O
compare	O
extra-renal	O
1	O
,	O
25	O
(	O

OH	O
)	O
2D3	O
production	O
in	O
different	O
types	O
of	O
granulomatous	O
disease	O
,	O
and	O
to	O
identify	O
the	O
cell	O
types	O
responsible	O
,	O
we	O
have	O
evaluated	O
the	O
conversion	O
of	O
25	O
(	O
OH	O
)	O
D3	O
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
uncultured	B-cell_type
cells	E-cell_type
recovered	O
by	O
bronchoalveolar	O
lavage	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	E-cell_type
from	O
normocalcemic	O
patients	O
with	O
sarcoidosis	O
and	O
tuberculosis	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O

was	O
produced	O
both	O
by	O
lavage	B-cell_type
cells	E-cell_type
(	O
12/12	O
tuberculosis	O
patients	O
,	O
2/6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
3/5	O
tuberculosis	O
patients	O
,	O
0/3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls	O
,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O

production	O
by	O
lavage	B-cell_type
cells	E-cell_type
from	O
tuberculosis	O
patients	O
correlated	O
with	O
the	O
number	O
of	O
CD8+	O
T	B-cell_type
lymphocytes	E-cell_type
present	O
but	O
not	O
other	O
cell	O
types	O
.	O
T	B-cell_type
lymphocytes	E-cell_type
appeared	O
to	O
be	O
an	O
important	O

source	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
,	O
since	O
purified	O
T	B-cell_type
lymphocytes	E-cell_type
from	O
all	O
patients	O
with	O
tuberculosis	O
produced	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
these	O
cells	O
correlated	O
closely	O
with	O
that	O
produced	O
by	O
unseparated	O
lavage	B-cell_type
cells	E-cell_type
.	O
Because	O
1	O
,	O
25	O
(	O
OH	O
)	O

2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	S-cell_type
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage-lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O
Megakaryocytic	B-cell_line
and	I-cell_line
erythrocytic	I-cell_line
lineages	E-cell_line
share	O
specific	O
transcription	B-GP

factors	E-GP

.	O
Erythroid-specific	B-DNA
genes	E-DNA
contain	O
binding	O
sites	O
for	O
NF-E1	S-GP
(	O

also	O
called	O
GF-1	S-GP
and	O
Eryf-1	S-GP
;	O
refs	O
1-3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA-binding	B-GP
protein	E-GP
of	O
the	O
erythrocytic	B-cell_type
lineage	E-cell_type
.	O
NF-E1	S-GP
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O

erythrocytic	B-cell_type
lineage	E-cell_type
.	O
A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O

protein	O
is	O
found	O
in	O
both	O
a	O
human	B-cell_line
megakaryocytic	I-cell_line
cell	I-cell_line
line	E-cell_line
and	O
purified	B-cell_line
human	I-cell_line
megakaryocytes	E-cell_line
;	O
it	O
binds	O
to	O
promoter	B-DNA
regions	E-DNA
of	O
two	O
megakaryocytic-specific	B-DNA
genes	E-DNA
.	O
The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O

this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	B-GP
protein	E-GP
;	O
also	O
,	O
NF-E1	B-RNA
messenger	I-RNA
RNA	E-RNA
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	B-cell_line
and	I-cell_line
erythroid	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O

NF-E1	S-GP
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic-specific	B-DNA
promoter	E-DNA
.	O
We	O
also	O
find	O
that	O
NF-E2	S-GP
,	O
another	O
trans-acting	B-GP

factor	E-GP
of	O
the	O
erythrocytic	B-cell_type
lineage	E-cell_type
,	O
is	O
present	O
in	O
megakaryocytes	S-cell_line
.	O
Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O

mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans-acting	B-GP
factors	E-GP
.	O
Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O

association	O
between	O
the	O
erythrocytic	B-cell_line
and	I-cell_line
the	I-cell_line
megakaryocytic	I-cell_line
lineages	E-cell_line
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	E-cell_type
in	O
most	O
erythroblastic	B-cell_line
and	I-cell_line
megakaryoblastic	I-cell_line
permanent	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
Transcriptional	O
down-regulation	O
of	O
c-myc	S-DNA
expression	O
by	O
protein	O
synthesis-dependent	O

and	O

-independent	O
pathways	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O
We	O
show	O
that	O
in	O
the	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line

cell	I-cell_line
line	E-cell_line
Molt4	B-RNA
c-myc	I-RNA
mRNA	E-RNA
and	O
protein	O
expression	O
is	O
down-regulated	O
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O
A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O

decreased	O
c-myc	S-DNA
transcription	O
.	O
Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O

when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O
The	O
calcium	O
ionophore-induced	O
c-myc	S-DNA
suppression	O
,	O
however	O
,	O
strictly	O

requires	O
de	O
novo	O
protein	O
synthesis	O
.	O
Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O

in	O
c-myc	S-DNA
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O
The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O

rapidly	O
calcium-dependent	B-GP
induced	I-GP
gene	I-GP
product	E-GP
.	O
Oestrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
analysis	O
in	O
B-cell	O
chronic	O

lymphocytic	O

leukemia	O
:	O
correlation	O
of	O
biochemical	O
and	O
immunocytochemical	O
methods	O
.	O
Oestrogen	B-GP
receptors	E-GP
(	O
ER	S-GP
)	O
are	O
present	O
in	O
neoplastic	B-cell_type
lymphoid	I-cell_type

cells	E-cell_type
and	O
have	O
been	O
considered	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
differentiation	O
.	O
Tamoxifen	O
,	O
an	O
oestrogen	O
antagonist	O
,	O
has	O
been	O
given	O
in	O

some	O
patients	O
with	O
CLL	O
and	O
Hodgkin	O
's	O
disease	O
,	O
with	O
dramatic	O
response	O
in	O
single	O
cases	O
.	O
Until	O
now	O
,	O
ER	S-GP
status	O
has	O
been	O
assessed	O
using	O
a	O

steroid	O
binding	O
assay	O
(	O
SBA	O
)	O
which	O
has	O
many	O
inherent	O
problems	O
.	O
Recently	O
,	O
the	O
development	O
of	O
monoclonal	O
antibodies	O
directed	O
against	O
ER	S-GP

has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	O
carcinomas	O
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O
We	O
studied	O
49	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O

CLL	O
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O
In	O
30	O
of	O
these	O
cases	O
ER	S-GP
enzyme	O
immunoassay	O
(	O
ER	S-GP

-EIA	O
)	O
was	O
also	O
performed	O
.	O
Cultured	B-cell_line
MCF-7	I-cell_line
cells	E-cell_line
,	O
derived	O
from	O
a	O
pleural	O
effusion	O
of	O

a	O
breast	O
cancer	O
patient	O
,	O
known	O
to	O
contain	O
high	O
levels	O
of	O
ER	S-GP
were	O
used	O
as	O
a	O
positive	O
control	O
(	O
40-48	O
%	O
ER	B-cell_type
positive	I-cell_type
cells	E-cell_type
by	O
immunocytochemistry	O
;	O
200	O
fmol/mg	O
protein	O
by	O
EIA	O
)	O
.	O
All	O
of	O
the	O
CLL	O
cases	O
except	O
two	O
(	O
96	O
%	O

)	O
were	O
negative	O
for	O
ER	S-GP
(	O
less	O
than	O
1	O
%	O
staining	O
;	O
less	O
than	O
4	O
fmol/mg	O
protein	O
)	O
.	O
The	O
two	O
positive	O
cases	O
expressed	O
granular	O
ER	S-GP
staining	O
over	O
the	O

nucleus	O
(	O
9.2	O
and	O
12.1	O
%	O
positive	O
cells	O
)	O
and	O
were	O
positive	O
by	O
EIA	O
and	O
SBA	O
.	O
It	O
is	O
concluded	O
that	O
(	O
i	O
)	O
patients	O
with	O
CLL	O

rarely	O
express	O
ER	S-GP
and	O
(	O
ii	O
)	O
immunocytochemical	O
staining	O
of	O
cytospin	O
preparations	O
is	O
a	O
valid	O
technique	O
for	O
the	O
measurement	O
of	O
ER	S-GP
.	O
It	O
is	O
of	O
interest	O
that	O
one	O
of	O
the	O
positive	O
cases	O

was	O
diagnosed	O
as	O
CLL	O
with	O
Richter	O
's	O
transformation	O
confirming	O
earlier	O
findings	O
.	O
Type-II	B-GP
estrogen	I-GP
binding	I-GP
sites	E-GP
in	O
a	O
lymphoblastoid	B-cell_line
cell	I-cell_line
line	E-cell_line
and	O

growth-inhibitory	O

effect	O
of	O
estrogen	O
,	O
anti-estrogen	O
and	O
bioflavonoids	O
.	O
Type-II	B-GP
estrogen-binding	I-GP
sites	E-GP
(	O
type-II	B-GP
EBS	E-GP
)	O
have	O
been	O
demonstrated	O
in	O

the	O
human	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	E-cell_line
IM-9	S-cell_line
using	O
a	O
whole-cell	O
assay	O
with	O
(	O
6	O
,	O
7-3H	O
)	O
estradiol	O
(	O
3H-E2	O
)	O
as	O
tracer	O
.	O
Competition	O
analysis	O
showed	O
that	O
the	O
anti-estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O

and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type-II	B-GP
EBS	E-GP
.	O
Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O

)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose-dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O
The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O

TAM	O
for	O
type-II	B-GP
EBS	E-GP
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O
Moreover	O
,	O
hesperidin	O
,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O

type-II	B-GP
EBS	E-GP
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O
Cell-cycle	O
analysis	O
showed	O
that	O
the	O
growth-inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O

or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O
Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti-estrogen	O
concentrations	O
and	O
flavonoids	O

may	O
regulate	O
IM-9	S-cell_line
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type-II	B-GP
EBS	E-GP
.	O
[	O
Glucocorticoid	B-GP
receptors	E-GP
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
of	O
patients	O
with	O
bronchial	O

asthma	O

]	O
Quantitation	O
of	O
glucocorticoid	B-GP
receptors	E-GP
(	O
GCR	S-GP
)	O
and	O
the	O
study	O
of	O
their	O

affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	S-GP
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O
It	O
is	O
stated	O
that	O
GCR	S-GP
of	O
healthy	O
controls	O
and	O
GCS-untreated	O
patients	O
outnumbered	O

those	O
of	O
cortisol-dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O
Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	S-GP
count	O
in	O
cortisol-dependent	O
BA	O
tends	O
to	O

rise	O
.	O
Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	S-GP
level	O
estimated	O
by	O
3H-triamcinolone	O
acetonide	O

.	O
Two	O
glucocorticoid	B-GP
binding	I-GP
sites	E-GP
on	O
the	O
human	B-GP
glucocorticoid	I-GP
receptor	E-GP
.	O
Glucocorticoids	O
are	O

known	O

to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	B-cell_type
cells	E-cell_type
via	O
interactions	O

with	O
the	O
glucocorticoid	B-GP
receptor	E-GP
(	O
GR	S-GP
)	O
.	O
Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	S-GP
with	O
one-site	O
kinetics	O
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O

which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A-ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	B-cell_line
C7	I-cell_line
cells	E-cell_line
(	O
a	O
human	B-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
T-cell	I-cell_line
line	E-cell_line
)	O
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O

similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O
The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O

consistent	O
with	O
CVZ	O
's	O
enhanced	O
biological	O
effects	O
.	O
In	O
mutant	O
leukemic	B-cell_type
cells	E-cell_type
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O

both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	B-cell_line
C7	I-cell_line
cells	E-cell_line
.	O
We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B-GP
affinity	I-GP

CVZ	I-GP
binding	I-GP
site	E-GP
.	O
We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O

site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B-cell	B-cell_line
line	E-cell_line
,	O
IM-9	S-cell_line
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
's	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	B-GP
's	I-GP
binding	I-GP
sites	E-GP
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	S-GP
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ-resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O
These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	B-GP
binding	I-GP
sites	E-GP
on	O
the	O

human	O
GR	S-GP
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O
Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	B-DNA
genes	E-DNA
in	O
primary	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
:	O

assaying	O

for	O
a	O
viral	O
transactivator	S-GP
activity	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
cells	E-cell_type
.	O
In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O

of	O
an	O
exogenous	B-DNA
promoter	E-DNA
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O
The	O
infection	O
of	O
a	O
variety	O
of	O
cultured	O
and	O
primary	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
with	O
a	O
recombinant	O

retrovirus	O
containing	O
a	O
histone	B-DNA
promoter-driven	I-DNA
beta-galactosidase	I-DNA
gene	E-DNA
is	O
shown	O
to	O
result	O
in	O
the	O
expression	O
of	O
beta-galactosidase	S-GP
in	O
50	O
%	O
to	O
100	O
%	O
of	O
the	O
cells	O
.	O
A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta-galactosidase	B-DNA
gene	E-DNA
with	O
an	O
adenovirus	B-DNA

E2	I-DNA
promoter	E-DNA
,	O
results	O
in	O
beta-galactosidase	S-GP
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	S-cell_line
and	O
primary	B-cell_type
cells	E-cell_type
.	O
Since	O
the	O
adenovirus	B-DNA
E2	I-DNA
promoter	E-DNA
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O

regulated	O
by	O
transactivators	S-GP
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B-GP
gene	I-GP
products	E-GP
.	O
[	O
The	O
effect	O
of	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O

and	O

immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O
Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	O

)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O
The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O

and	O
ionized	O
Ca2+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	O
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	B-cell_type
and	I-cell_type
0-lymphocytes	E-cell_type
.	O
Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O

found	O
to	O
be	O
minimal	O
in	O
lymphocytes	S-cell_type
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	O
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O
Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	O
with	O
simultaneous	O
correction	O
of	O
vitamin	O
D	O
deficiency	O
were	O
apparently	O
responsible	O

for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	O
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	O
kidney	O
insufficiency	O
.	O
[	O
The	O
role	O
of	O
glucocorticoid	B-GP
receptors	E-GP
and	O
HLA	B-GP
antigens	E-GP
in	O
the	O
pathogenesis	O
of	O
Cushing	O
's	O

syndrome	O

]	O
Lymphocytic	O
levels	O
of	O
glucocorticoid	B-GP
receptors	E-GP
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko-Cushing	O
's	O
syndrome	O
.	O

Incidence	O
of	O
HLA	B-GP
antigens	E-GP
was	O
determined	O
in	O
94	O
of	O
them	O
.	O
A	O
significant	O
rise	O
of	O
A10	S-GP

and	O
B27	B-GP
antigen	E-GP
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O

these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko-Cushing	O
's	O
syndrome	O
.	O
The	O
levels	O
of	O
glucocorticoid	B-GP
receptors	E-GP
in	O
lymphocytes	S-cell_type
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O

both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O
The	O
patients	O
carrying	O
B27	B-GP
antigen	E-GP
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O

free	O
of	O
the	O
antigen	O
carriage	O
.	O
Antigen	B-GP
B27	E-GP
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B-GP
receptors	E-GP
in	O
blood	B-cell_type
lymphocytes	E-cell_type

.	O
Effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	B-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	E-cell_line
RWLeu-4	S-cell_line

.	O

The	O
effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O

macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	B-cell_line
chromosome-positive	I-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
RWLeu-4	S-cell_line
,	O
were	O
investigated	O
.	O
Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000-3000	O
sites/cell	O
,	O
and	O
half-maximal	O
binding	O

occurring	O
at	O
0.21-0.33	O
nM	O
.	O
Treatment	O
of	O
RWLeu-4	B-cell_line
cells	E-cell_line
with	O
VD3	O
induced	O
24R-hydroxylase	S-GP
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O

many	O
tissues	O
.	O
Exposure	O
of	O
RWLeu-4	B-cell_line
cells	E-cell_line
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O

dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O
Exposure	O
of	O
RWLeu-4	B-cell_line
cells	E-cell_line
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O

to	O
differentiate	O
into	O
macrophage/monocyte	B-cell_type
type	I-cell_type
cells	E-cell_type
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic	O
.	O
Progressive	O
expression	O
of	O
cell	B-GP
surface	I-GP
maturation-specific	I-GP
antigens	E-GP
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	E-cell_type
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	B-cell_line

cells	E-cell_line
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O
c-myc	B-RNA
RNA	E-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	B-cell_line
cells	E-cell_line
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O

with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O
Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr-abl	B-GP
oncogene	I-GP
product	E-GP
was	O
decreased	O
approximately	O

50	O
%	O
by	O
VD3	O
treatment	O
.	O
Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O

hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O
A	O
new	O
member	O
of	O
the	O
leucine	B-GP
zipper	I-GP
class	E-GP
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B-DNA
DR	I-DNA
alpha	I-DNA

promoter	E-DNA

.	O
Several	O
mutants	O
derived	O
from	O
transformed	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	E-cell_line
are	O
defective	O
in	O
expressing	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA

)	I-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
.	O
The	O
failure	O
to	O
express	O
a	O
class	B-DNA
II	I-DNA
gene	E-DNA
in	O
at	O
least	O
one	O
such	O
mutant	B-cell_line
line	E-cell_line
has	O
been	O
mapped	O

to	O
the	O
MHC	B-DNA
class	I-DNA
II	I-DNA
X	I-DNA
box	E-DNA
,	O
a	O
conserved	B-DNA
transcriptional	I-DNA
element	E-DNA
in	O
the	O
promoter	B-DNA
region	E-DNA
.	O
A	O
complementary	B-DNA
DNA	E-DNA
encoding	O
a	O
DNA-binding	B-GP
protein	E-GP
(	O
human	B-GP
X	I-GP
box	I-GP
binding	I-GP
protein	E-GP
,	O
hXBP-1	S-GP
)	O
whose	O
target	O

is	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
X	I-DNA
box	E-DNA
and	O
the	O
3	B-DNA
'	I-DNA
flanking	I-DNA
region	E-DNA
has	O
now	O
been	O
cloned	O
.	O
This	O
complementary	B-DNA
DNA	E-DNA
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c-jun	B-GP
proto-oncogene	I-GP
product	E-GP
,	O
and	O
its	O
target	O

sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	B-DNA
target	I-DNA
sequence	E-DNA
of	O
c-jun	S-DNA
.	O
Mutation	O
of	O
the	O
hXBP-1	B-DNA
DNA	I-DNA
target	I-DNA
sequence	E-DNA
decreased	O
DR	B-DNA
alpha	I-DNA
promoter	E-DNA
activity	O
in	O
vivo	O
.	O
These	O
studies	O
suggest	O

that	O
the	O
hXBP-1	B-GP
protein	E-GP
acts	O
as	O
a	O
transcription	B-GP
factor	E-GP
in	O
B	B-cell_type
cells	E-cell_type
.	O
Pseudohypoaldosteronism	O
in	O

eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O
Pseudohypoaldosteronism	O
is	O

a	O

rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	O
and	O
hyperkalemia	O

despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	O
.	O
The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O
Absent	O

or	O
greatly	O
diminished	O
type	O
I	B-GP
aldosterone	I-GP
receptors	E-GP
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	E-cell_type
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O

lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O
We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O
There	O
was	O

evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O

appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O
In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	B-GP
receptor	E-GP
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O

parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O
In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O

binding	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	E-cell_type
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O
These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O
In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O

newborn	O
daughter	O
,	O
who	O
were	O
both	O

also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O
It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O

the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O
Perceived	O
social	O
support	O
and	O
tumor	O
estrogen/progesterone	B-GP
receptor	E-GP
status	O
as	O
predictors	O
of	O
natural	B-cell_type
killer	I-cell_type
cell	E-cell_type
activity	O
in	O
breast	O
cancer	O
patients	O

.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	O
killer	B-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	E-cell_type
activity	O
in	O
61	O
Stage	O
I	O
and	O

II	O
breast	O
cancer	O
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70	O
,	O
who	O
were	O
accrued	O
to	O
this	O
project	O
.	O
All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital	O
,	O
or	O
at	O

their	O
first	O
outpatient	O
visit	O
,	O
within	O
two	O
weeks	O
of	O
discharge	O
.	O
A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support	O
,	O
as	O
a	O
potential	O
``	O
stress	O

''	O
buffer	O
,	O
related	O
to	O
NK	O
activity	O
.	O
In	O
the	O
main	O
model	O
reported	O
here	O
,	O
we	O
found	O
that	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
could	O
be	O
explained	O

by	O
five	O
variables	O
.	O
Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O

,	O
perceived	O
social	O
support	O
from	O
the	O
patient	O
's	O
physician	O
,	O
estrogen	B-GP
receptor	E-GP
-negative	O
tumor	O
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(	O
R2	O
=	O
0.33	O
,	O
F	O
(	O
5	O
,	O
55	O
)	O
=	O
5.5	O
,	O
p	O
less	O
than	O
0.0004	O
)	O
.	O
Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	O
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O

play	O
in	O
modulating	O
such	O
activity	O
.	O
[	O
Estrogen	B-GP
receptor	E-GP
content	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O
ER	O
content	O
in	O
lymphocytes	S-cell_type
of	O

peripheral	O

blood	O
from	O
27	O
SLE	O
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran-coated	O
charcoal	O
assay	O

.	O
ER	S-GP
content	O
in	O
lymphocytes	S-cell_type
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol/mg	O
of	O
lymphocyte	B-GP
cytosolic	I-GP
protein	E-GP
and	O
fmol/micrograms	O
of	O
lymphocyte	B-DNA
DNA	E-DNA

.	O
The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	S-GP
content	O
of	O
lymphocytes	S-cell_type
from	O
the	O
controls	O
and	O
that	O
from	O

patients	O
with	O
SLE	O
.	O
But	O
the	O
logarithmic	O
mean	O
of	O
ER	S-GP
content	O
in	O
lymphocytes	S-cell_type
,	O
expressed	O
by	O
fmol/mg	O
of	O
cytosolic	B-GP
protein	E-GP
,	O
in	O
14	O
patients	O
with	O

active	O
SLE	O
(	O
0.9356	O
+/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O
The	O
normal	O
upper	O
limit	O
of	O
ER	S-GP
content	O
in	O
lymphocytes	S-cell_type
,	O
expressed	O
by	O
fmol/micrograms	O
of	O
DNA	O
,	O
was	O
0.136	O
.	O
The	O
elevated	O

rate	O
of	O
ER	S-GP
content	O
in	O
lymphocytes	S-cell_type
in	O
14	O
active	O
SLE	O
(	O
92.9	O
%	O
)	O
was	O
also	O
higher	O
than	O
that	O

in	O
quieiescent	O
patients	O
(	O
23.1	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
10	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O
Moreover	O
,	O
the	O
elevated	O
level	O
of	O
ER	S-GP
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	B-GP
antibody	E-GP
and	O
hypocomplementemia	O
.	O

An	O
in	O
vitro	O
globin	B-DNA
gene	E-DNA
switching	O
model	O
based	O
on	O
differentiated	B-cell_type
embryonic	I-cell_type
stem	I-cell_type
cells	E-cell_type
.	O
We	O
used	O
mouse	B-cell_type
embryonic	I-cell_type
stem	I-cell_type
(	I-cell_type
ES	I-cell_type

)	I-cell_type

cells	E-cell_type
to	O
study	O
globin	B-DNA
gene	E-DNA
expression	O
and	O
switching	O
in	O
vitro	O
.	O
We	O
show	O
that	O

ES-derived	B-cell_type
embryoid	I-cell_type
bodies	E-cell_type
express	O
the	O
full	O
complement	O
of	O
mouse	B-DNA
embryonic	I-DNA
globin	I-DNA
genes	E-DNA
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O

on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	B-DNA
genes	E-DNA
.	O
In	O
addition	O
,	O
the	O
erythroid-specific	B-GP
transcription	I-GP
factor	E-GP
NF-E1	S-GP
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	S-GP
in	O
embryoid	B-cell_type
bodies	E-cell_type
.	O

We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O
When	O
the	O
human	B-DNA

epsilon-	I-DNA
or	I-DNA
beta-globin	I-DNA
genes	E-DNA
driven	O
by	O
the	O
dominant	B-DNA
control	I-DNA
region	E-DNA
(	O
DCR	S-DNA
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O

the	O
human	B-DNA
epsilon-globin	I-DNA
gene	E-DNA
,	O
in	O
contrast	O
to	O
the	O
beta-globin	B-DNA
gene	E-DNA
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	S-DNA
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	B-DNA
gene	E-DNA
.	O
We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon-globin	B-DNA
gene	E-DNA
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	E-DNA
.	O

Cloning	O
of	O
a	O
mitogen-inducible	B-DNA
gene	E-DNA
encoding	O
a	O
kappa	B-GP
B	I-GP
DNA-binding	I-GP
protein	E-GP
with	O
homology	O
to	O
the	O
rel	B-DNA
oncogene	E-DNA
and	O
to	O
cell-cycle	B-DNA
motifs	E-DNA
.	O

We	O

have	O
cloned	O
and	O
characterized	O
a	O
mitogen-inducible	B-DNA
gene	E-DNA
isolated	O
from	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
that	O
predicts	O
a	O
protein	O
of	O
968	B-GP
amino	I-GP
acids	E-GP
.	O
The	O

amino-terminal	B-GP
domain	E-GP
has	O
regions	O
homologous	O
to	O
the	O
oncogene	B-DNA
rel	E-DNA
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	S-DNA
of	O
Drosophila	O
.	O
The	O
carboxy-terminal	B-GP
domain	E-GP

contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell-cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O

differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	B-DNA
human	I-DNA
oncogene	I-DNA
bcl-3	E-DNA
and	O
in	O
the	O
ankyrin	B-GP
protein	E-GP
.	O
A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA-binding	B-GP
protein	E-GP
which	O
interacts	O
specifically	O
with	O
the	O
kappa	B-DNA
B	I-DNA

binding	I-DNA
site	E-DNA
found	O
in	O
many	O
inducible	B-DNA
genes	E-DNA
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O
This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O
Extrarenal	O

receptor-effector-mechanisms	O
for	O
aldosterone	O
:	O
the	O
sequence	O
of	O
effects	O
on	O
the	O
cellular	O
electrolyte	O
transport	O
in	O
human	B-cell_type
lymphocytes	E-cell_type
and	O
their	O
implications	O
for	O
disorders	O
of	O

the	O

water	O
and	O
electrolyte	O
balances	O
.	O
High	O
affinity	O
aldosterone	O
binding	O
sites	O
have	O
not	O
only	O
been	O
described	O
in	O
the	O
classic	O
target	O
tissues	O
such	O
as	O
the	O
renal	O
tubules	O
,	O
but	O
also	O
in	O

non-classic	O
target	O
tissues	O
such	O
as	O
the	O
hippocampus	O
,	O
mammary	O
gland	O
,	O
endothelial	B-cell_type
cells	E-cell_type
and	O
,	O
recently	O
,	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
.	O
An	O
in	O
vitro	O
effect	O
of	O
aldosterone	O
on	O
intracellular	O
sodium	O
,	O
potassium	O
and	O
calcium	O
concentrations	O
and	O
cell	O
volume	O
was	O
shown	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
.	O

In	O
the	O
absence	O
of	O
aldosterone	O
,	O
the	O
intracellular	O
Na+	O
,	O
K+	O
and	O
Ca2+	O
concentrations	O
and	O
the	O
cell	O
volume	O
decreased	O
significantly	O
,	O
but	O
remained	O
constant	O

when	O
aldosterone	O
(	O
1.4	O
nmol/l	O
)	O
was	O
added	O
to	O
the	O
incubation	O
medium	O
.	O
These	O
effects	O
of	O
aldosterone	O
were	O
blocked	O
by	O
the	O
aldosterone	O
antagonist	O
canrenone	O
(	O
140	O
nmol/l	O
)	O
.	O
The	O
sodium/proton	B-GP
exchanger	E-GP
of	O
the	O
cell	O
membrane	O
could	O

be	O
identified	O
as	O
the	O
primary	O
target	O
of	O
the	O
aldosterone	O
action	O
,	O
possibly	O
non-genomically	O
mediated	O
through	O
membrane	B-GP

receptors	E-GP
.	O
The	O
clinical	O
significance	O
of	O
this	O
model	O
was	O
underlined	O
by	O
the	O
demonstration	O
of	O
absent	O
or	O
a	O
decreased	O
number	O
of	O
mineralocorticoid	B-GP
receptors	E-GP
and	O
the	O
lack	O
of	O

electrolyte	O
response	O
to	O
aldosterone	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
of	O
patients	O
with	O
pseudohypoaldosteronism	O
and	O
aldosteronism	O
.	O
Additionally	O
,	O
an	O
abnormal	O
effector	O
mechanism	O
could	O
be	O
demonstrated	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
from	O
essential	O
hypertensives	O
.	O
These	O
studies	O
are	O
the	O
first	O
to	O
demonstrate	O

the	O
significance	O
of	O
extrarenal	B-GP
,	I-GP
nonepithelial	I-GP
mineralocorticoid	I-GP
receptors	E-GP
and	O
the	O
related	O
effector	O
mechanism	O
in	O
different	O
disorders	O
of	O

the	O
water	O
and	O
electrolyte	O
balance	O
in	O
man	O
.	O
Immunohistochemical	O
study	O
of	O
steroid	O
hormones	O
and	O
an	O
estrogen	O
binding	O
assay	O
in	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	E-cell_type
.	O
Immunohistochemically	O
,	O
the	O
immunoreaction	O
against	O
5	O
steroid	O
hormone	O

anti-sera	O

(	O
estradiol	O
,	O
estriol	O
,	O
cortisol	O
,	O
progesterone	O
and	O
testosterone	O
)	O
was	O
examined	O
in	O
39	O
cases	O

with	O
the	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	E-cell_type
(	O
fibrosarcoma	O
:	O
8	O
,	O
malignant	O
fibrous	O
histiocytoma	O
:	O
6	O
,	O
rhabdomyosarcoma	O
:	O
10	O
,	O
leiomyosarcoma	O
:	O
10	O
,	O
liposarcoma	O
:	O
5	O
)	O
.	O
Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O
Immunostained	B-cell_type
tumor	I-cell_type
cells	E-cell_type
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O

where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O
The	O
majority	O
of	O
the	O
positive	O
cases	O
occurred	O

in	O
female	O
cases	O
.	O
Furthermore	O
,	O
the	O
existence	O
of	O
estrogen	B-GP
receptor	E-GP
(	O
estrogen	O
binding	O
activity	O
)	O
was	O
examined	O

histochemically	O
in	O
39	O
cases	O
and	O
it	O
was	O
detected	O
in	O
8	O
.	O

We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	E-cell_type
.	O
Involvement	O
of	O
cyclic	B-GP
AMP-dependent	I-GP
protein	I-GP

kinases	E-GP
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	S-GP
.	O
Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B-GP
AMP-dependent	I-GP
protein	I-GP

kinases	E-GP

in	O
interleukin-1	B-cell_line
(	I-cell_line
IL-1	I-cell_line
)	I-cell_line
-responsive	I-cell_line
cells	E-cell_line
blocked	O
IL-1-induced	B-DNA
gene	E-DNA
transcription	O
that	O
was	O
driven	O

by	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
enhancer	E-DNA
or	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
.	O
This	O
inhibitor	O
did	O
not	O
affect	O
protein	B-GP
kinase	I-GP
C	E-GP
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	B-GP
AMP-dependent	I-GP
protein	I-GP
kinases	E-GP
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O

IL-1	S-GP
in	O
a	O
number	O
of	O
responsive	B-cell_type
cell	I-cell_type
types	E-cell_type
.	O
The	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
ORI1yt	I-DNA
enhancer	E-DNA
is	O
not	O
B-cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	B-GP
transcription	I-GP
factors	I-GP
R	I-GP
and	I-GP
Z	E-GP
.	O

The	O

Epstein-Barr	B-DNA
virus	I-DNA
DR	I-DNA
promoter	E-DNA
is	O
located	O
upstream	O
of	O
the	O
PstI	B-DNA
repeats	E-DNA
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	B-DNA
box	E-DNA
,	O
it	O
contains	O
an	O
upstream	B-DNA
region	E-DNA
(	O

positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	B-GP
(	I-GP
Z	I-GP
)	E-GP
(	O
the	O
BZLF1-encoded	B-GP
transcription	I-GP
factor	E-GP
)	O
and	O
an	O
enhancer	S-DNA
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	S-DNA
.	O
Domain	B-DNA
B	E-DNA
has	O
been	O
described	O
as	O
a	O
B-cell-specific	B-DNA
EB1-responsive	I-DNA
element	E-DNA
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040-3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O

EB1	S-GP
and	O
R	S-GP
,	O
an	O
EBV	B-GP
early	I-GP
product	E-GP
encoded	O
by	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
BRLF1	E-DNA
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313-321	O
,	O
1990	O
)	O
.	O
We	O
show	O
here	O
that	O
domain	B-DNA
B	E-DNA
is	O
an	O
R-responsive	B-DNA
element	E-DNA
in	O
HeLa	B-cell_line
cells	E-cell_line
and	O
is	O
therefore	O
not	O
an	O
EB1-responsive	B-DNA
B-cell-specific	I-DNA
element	E-DNA
.	O
However	O
,	O
there	O
is	O
an	O

EB1-binding	B-DNA
site	E-DNA
(	O
ZRE-B	S-DNA
)	O
located	O
within	O
the	O
R-responsive	B-DNA
enhancer	I-DNA
region	E-DNA
.	O
ZRE-B	S-DNA
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R-dependent	O
enhancer	O
activity	O

.	O
Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	S-GP
and	O
EB1	S-GP
when	O
activating	O
the	O
B	B-DNA

domain	E-DNA
(	O
ZRE-B	S-DNA
plus	O
the	O
R-responsive	B-DNA
element	E-DNA
)	O
positioned	O
as	O
an	O

enhancer	S-DNA
.	O
ZRE-B	S-DNA
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	B-DNA
inducible	I-DNA
enhancer	E-DNA
.	O
We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	B-DNA
enhancer	E-DNA
B	B-DNA
domain	E-DNA
,	O
either	O
alone	O
or	O
in	O

combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R-activating	O
signal	O
to	O

the	O
rabbit	B-DNA
beta-globin	I-DNA
promoter	E-DNA
.	O
We	O
found	O
that	O
the	O
R-responsive	B-DNA
element	E-DNA
is	O
composed	O
of	O
four	O
protoenhancers	S-DNA
that	O
span	O
the	O
whole	O
B	B-DNA
domain	E-DNA
.	O
These	O
protoenhancers	S-DNA
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O

R	S-GP
.	O
One	O
of	O
the	O
protoenhancers	S-DNA
contains	O
the	O
overlapping	B-DNA
palindromes	E-DNA
5'-TTGTCCcgtGGACAAaTGTCC-3'	O
.	O
However	O
,	O
one	O
palindrome	S-DNA
,	O
either	O

alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	B-DNA
palindromes	E-DNA
did	O
not	O
respond	O

to	O
R	O
.	O
Nuclear	O
3	B-GP
,	I-GP
5	I-GP
,	I-GP
3'-triiodothyronine	I-GP
receptors	E-GP

(	O
T3R	S-GP
)	O
of	O
circulating	B-cell_type
human	I-cell_type
lymphocytes	E-cell_type
in	O
hyper-	O
and	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
.	O
The	O
clinical	O
implications	O
of	O
nuclear	O

T3R	S-GP

alterations	O
of	O
circulating	B-cell_type
lymphocytes	E-cell_type
in	O
hyperthyroidism	O
,	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
were	O
investigated	O
.	O
Nuclear	O
T3R	S-GP
in	O
lymphocytes	S-cell_type
was	O
determined	O
by	O
radio-ligand	O

binding	O
analysis	O
.	O
The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O

was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O
In	O
hyperthyroidism	O
nuclear	O

T3	O
maximal	O
binding	O
capacity	O
(	O
MBC	O
)	O
was	O
unaltered	O
,	O
whereas	O
in	O
hypothyroidism	O
the	O
MBC	O
was	O
significantly	O
increased	O
.	O
In	O
the	O
patients	O
with	O
diabetes	O
mellitus	O

,	O
chronic	O
renal	O
failure	O
and	O
hepatic	O
cirrhosis	O
,	O
the	O
nuclear	B-GP
T3R	E-GP
MBC	O
of	O
lymphocytes	S-cell_type
was	O
about	O
1.5-1.6	O
times	O
of	O
the	O
normal	O
controls	O

.	O
It	O
was	O
concluded	O
that	O
there	O
existed	O
hormonal	O
regulation	O
of	O
nuclear	B-GP
T3R	E-GP
,	O
and	O
up-regulation	O
was	O
seen	O
in	O
hypothyroidism	O
and	O
low	O
T3	O
syndrome	O
.	O
Lymphocyte	B-cell_line
cell	I-cell_line
lines	E-cell_line
from	O
vitamin	O

D-dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B-GP
alpha	I-GP
,	I-GP
25-dihydroxyvitamin	I-GP
D3	I-GP
receptor	E-GP
.	O
Lymphocyte	B-cell_line
cell	I-cell_line
lines	E-cell_line
were	O
established	O
from	O
five	O

patients	O

with	O
vitamin	O
D-dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR-II	O
)	O
.	O
These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T-lymphotrophic	O
virus	O

type	O
I	O
(	O
HTLV-I	O
)	O
.	O
Binding	O
of	O
[	O
3H	O
]	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O

25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O

binding	O
studies	O
using	O
a	O
T-lymphocyte	B-cell_line
cell	I-cell_line
line	E-cell_line
(	O
S-LB1	S-cell_line
)	O
from	O
a	O
normal	O
individual	O
.	O
The	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
of	O
S-LB1	S-cell_line
was	O
comparable	O
to	O
the	O
well-characterized	O
chick	B-GP
intestinal	I-GP
1	I-GP
,	I-GP
25	I-GP
(	I-GP
OH	I-GP
)	I-GP
2D3	I-GP
receptor	E-GP
in	O
terms	O
of	O

its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5-20	O
%	O
sucrose	O
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA-cellulose	O
.	O
Three	O
cell	B-cell_line
lines	E-cell_line
established	O
from	O
patients	O
with	O
VDDR-II	O
(	O
Rh-	O
VDR	S-GP
,	O
Sh-	O
VDR	S-GP
,	O
and	O
Ab-	O
VDR	S-GP
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O

)	O
2D3	O
to	O
a	O
receptor	S-GP
and	O
treatment	O
of	O
the	O
cultured	B-cell_line
cells	E-cell_line
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	O
,	O
25-dihydroxy-vitamin	O
D3	O
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	B-GP
1	I-GP
,	I-GP
25	I-GP
(	I-GP
OH	I-GP
)	I-GP
2D3	I-GP
receptor	E-GP
.	O
In	O
a	O
fourth	O
cell	B-cell_line
line	E-cell_line
,	O
A1-VDR	S-cell_line
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-GP
(	I-GP
OH	I-GP
)	I-GP
D3-24-hydroxylase	E-GP

activity	O
was	O
not	O
detectable	O
.	O
Induction	O
of	O
24	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	B-cell_line
line	E-cell_line
,	O
designated	O
Ro-VDR	S-cell_line
,	O

although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	B-cell_line
cell	I-cell_line
line	E-cell_line
from	O
a	O
normal	O
donor	O
.	O
The	O
capacity	O
of	O
the	O
receptor	S-GP
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro-VDR	S-cell_line
.	O
In	O
all	O
cell	B-cell_line
lines	E-cell_line
where	O
1	O
,	O
25	O
(	O
OH	O
)	O

2D3	O
binding	O
to	O
a	O
receptor	S-GP
was	O
detectable	O
,	O
the	O
receptor	S-GP
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3.7	O
S	O

on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O
Binding	O
and	O
elution	O
properties	O
to	O
DNA-cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro-VDR	S-cell_line
and	O
A1-VDR	B-cell_line
cells	E-cell_line
where	O
elution	O
from	O
DNA-cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O

is	O
typical	O
of	O
the	O
1	B-GP
,	I-GP
25	I-GP
(	I-GP
OH	I-GP
)	I-GP
2D3	I-GP
receptor	E-GP
.	O
While	O
Ro-VDR	B-cell_line
cells	E-cell_line
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	B-GP
1	I-GP
,	I-GP
25	I-GP
(	I-GP
OH	I-GP
)	I-GP
2D3	I-GP
receptor	E-GP
,	O
neither	O
the	O
unoccupied	O
nor	O
the	O
occupied	O
receptor	S-GP
from	O
A1-VDR	B-cell_line
cells	E-cell_line

was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O
In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	S-RNA
coding	O
for	O
both	O
the	O
c-myc	B-DNA
oncogene	E-DNA
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte-monocyte	O

colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B-GP
,	I-GP
25	I-GP
(	I-GP
OH	I-GP
)	I-GP
2D3	I-GP
receptor	E-GP
status	O
of	O
these	O
cells	O
.	O
Use	O
of	O
these	O
cell	B-cell_line
lines	E-cell_line
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect	O
(	O
s	O
)	O
in	O
the	O
receptor	S-GP
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
vitamin	O

D-dependent	O
rickets	O
type	O
II	O
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O
Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	S-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cells	E-cell_line
.	O
AP-1	S-GP
,	O
the	O
polypeptide	O
product	O
of	O
c-jun	S-DNA
,	O
recognizes	O
and	O
binds	O
to	O
specific	O

DNA	O

sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	S-DNA
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O

12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	S-DNA
gene	O
expression	O
in	O
HL-60	B-cell_line
cells	E-cell_line
during	O
monocytic	O
differentiation	O
.	O
Low	O
levels	O
of	O
c-jun	B-RNA
transcripts	E-RNA
were	O
detectable	O
in	O
untreated	B-cell_line
HL-60	I-cell_line

leukemic	I-cell_line
cells	E-cell_line
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O

32	O
nM	O
TPA	O
.	O
Similar	O
kinetics	O
of	O
c-jun	S-DNA
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	B-cell_line
U-937	E-cell_line
and	O
THP-1	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
.	O
Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O

another	O
activator	O
of	O
protein	B-GP
kinase	I-GP
C	E-GP
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O
Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O

(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	S-DNA
expression	O
.	O
TPA	O
treatment	O
of	O
HL-60	B-cell_line

cells	E-cell_line
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c-jun	S-DNA
transcripts	O
.	O
Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	S-DNA
gene	O
transcription	O
in	O
untreated	B-cell_line
HL-60	I-cell_line

cells	E-cell_line
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3.3-fold	O
.	O
Treatment	O
of	O
HL-60	B-cell_line
cells	E-cell_line
with	O
both	O

TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c-jun	S-DNA
transcription	O
.	O
The	O
half-life	O
of	O
c-jun	B-RNA
RNA	E-RNA
as	O
determined	O
by	O
treating	O
HL-60	B-cell_line
cells	E-cell_line

with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O
In	O
contrast	O
,	O
the	O
half-life	O
of	O
c-jun	B-RNA
RNA	E-RNA
in	O
TPA-treated	B-cell_line

HL-60	I-cell_line
cells	E-cell_line
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O
These	O
findings	O
suggested	O
that	O
the	O
increase	O

in	O
c-jun	B-RNA
RNA	E-RNA
observed	O
during	O
TPA-induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O
[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B-GP
receptors	E-GP
in	O

patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O
As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	O
were	O
examined	O
.	O

Four	O

variants	O
of	O
changes	O
in	O
the	O
thyroid	O
status	O
,	O
characteristic	O
of	O
children	O
with	O
different	O

variants	O
of	O
nephrotic	O
syndrome	O
were	O
distinguished	O
:	O
1	O
)	O
biochemical	O
signs	O
of	O
primary	O
hypothyroidism	O
,	O
2	O
)	O

biochemical	O
signs	O
of	O
secondary	O
hypothyroidism	O
,	O
3	O
)	O
low	O
content	O
of	O
T3	O
,	O
4	O
)	O
dysfunction	O
of	O
the	O
hypophyseal	O
and	O
thyroid	O
system	O
.	O
It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	B-GP
receptors	E-GP
,	O
thyroid	O
hormones	O
that	O
the	O
low	O
level	O
of	O
steroid	B-GP
receptors	E-GP
,	O
thyroid	O
hormones	O
(	O
T3	O
and	O
T4	O
)	O
and	O
cortisol	O
is	O

typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	O
dysplasia	O
.	O
It	O
is	O
assumed	O
that	O
superaddition	O
under	O
such	O
conditions	O
of	O
immune	O
glomerulopathy	O
(	O
glomerulonephritis	O
and	O
nephrotic	O
syndrome	O
)	O
gives	O
rise	O
to	O
the	O
resistance	O
to	O
the	O
treatment	O
with	O
glucocorticoids	O
.	O
Lymphoid	O
specific	O
gene	O

expression	O
of	O
the	O
adenovirus	B-DNA
early	I-DNA
region	I-DNA
3	I-DNA
promoter	E-DNA
is	O
mediated	O
by	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
motifs	E-DNA
.	O
A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	B-cell_type
cells	E-cell_type
.	O

However	O

,	O
analysis	O
of	O
the	O
viral	B-DNA
control	I-DNA
elements	E-DNA
and	O
the	O
cellular	B-GP
factors	E-GP
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	S-cell_type
has	O

not	O
been	O
reported	O
.	O
The	O
adenovirus	B-GP
early	I-GP
region	I-GP
3	I-GP
(	I-GP
ES	I-GP
)	I-GP

gene	I-GP
products	E-GP
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	B-GP
I	I-GP
MHC	I-GP
antigens	E-GP
,	O
thus	O
preventing	O
their	O
cell	O
surface	O

expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O
To	O
determine	O
whether	O
different	O
cellular	B-GP
factors	E-GP
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	S-cell_type
as	O
compared	O
with	O
HeLa	B-cell_line
cells	E-cell_line
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-DNA
promoter	E-DNA
in	O
both	O
cell	O

types	O
were	O
performed	O
.	O
These	O
studies	O
detected	O
two	O
novel	B-DNA
domains	E-DNA
referred	O
to	O
as	O
L1	S-DNA
and	O
L2	S-DNA
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O
Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O

found	O
to	O
bind	O
the	O
cellular	B-GP
factor	I-GP
NF-kappa	I-GP
B	E-GP
.	O
Transfections	O
of	O
E3	B-DNA
constructs	E-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	E-DNA
revealed	O
that	O
mutagenesis	O

of	O
the	O
distal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	E-DNA
(	O
L2	S-DNA
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	B-cell_line
cells	E-cell_line
,	O

but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	B-cell_type
cells	E-cell_type
.	O
In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	E-DNA
(	O
L1	S-DNA
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	B-cell_line
cells	E-cell_line
and	O
lymphoid	B-cell_type
cells	E-cell_type
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O

reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
when	O
coupled	O
to	O
the	O
L2	S-DNA
mutation	O
.	O
Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	S-DNA
and	O
L2	B-DNA
domains	E-DNA
indicated	O
that	O
the	O
primary	B-DNA
sequence	E-DNA
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	B-DNA
promoter	E-DNA
was	O
critical	O
for	O
regulating	O

gene	O
expression	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Characterization	O
of	O
defensin	S-GP
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B-DNA
virulence	I-DNA
regulon	E-DNA
of	O
Salmonella	O
typhimurium	O
.	O
The	O
defensin	S-GP
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O

mutations	O
in	O
the	O
phoP/phoQ	B-DNA
two-component	I-DNA
virulence	I-DNA
regulon	E-DNA

were	O

tested	O
by	O
using	O
purified	B-GP
defensins	E-GP
NP-1	S-GP
and	O
NP-2	S-GP
.	O
Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O

regulatory	B-DNA
pair	E-DNA
(	O
phoP	S-DNA
[	O
transcriptional	B-DNA
activator	E-DNA
]	O
or	O
phoQ	S-DNA
[	O
membrane	B-GP
sensor	I-GP
kinase	E-GP
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	S-GP
.	O
The	O
predicted	O
periplasmic	B-GP

domain	E-GP
of	O
the	O
PhoQ	B-GP
protein	E-GP
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	B-GP
proteins	E-GP
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	S-GP
.	O
Because	O
insertion	O
mutations	O
in	O

phoP	S-DNA
are	O
polar	O
on	O
phoQ	S-DNA
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B-GP
protein	E-GP
in	O
the	O
absence	O
of	O
PhoP	S-GP
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	B-GP

gene	I-GP
product	E-GP
.	O
We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	S-GP
without	O
PhoP	S-GP
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	S-GP
.	O
This	O
implied	O
that	O

a	O
pag	B-GP
(	I-GP
phoP-activated	I-GP
gene	I-GP
)	I-GP
product	E-GP
is	O
responsible	O
for	O
defensin	S-GP
resistance	O
.	O
We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	S-GP
NP-1	S-GP
,	O
NP-5	S-GP
,	O
and	O
HNP-1	S-GP
to	O
activate	O
pag	S-DNA

expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O
Defensin	O
resistance	O
is	O
not	O
the	O
only	O

virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP-PhoQ	B-GP
regulon	E-GP
because	O
mutations	O
in	O
pagC	S-DNA
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	B-DNA
locus	E-DNA
that	O
resulted	O
in	O
constitutive	O
pag	S-DNA
activation	O
(	O

phenotype	O
PhoPc	S-GP
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	S-GP
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	S-cell_type
.	O
The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	S-DNA
-phoQ	S-DNA
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B-GP
proteins	E-GP
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O

S.	O
typhimurium	O
survival	O
within	O
macrophages	S-cell_type
.	O
Stimulation	O
of	O
a	O
human	B-cell_line
T-cell	I-cell_line
clone	E-cell_line
with	O
anti-CD3	S-GP
or	O
tumor	B-GP
necrosis	I-GP
factor	E-GP
induces	O
NF-kappa	B-GP
B	E-GP
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer-dependent	O
transcription	O
.	O
The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O

the	O

control	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	B-DNA
sequence	E-DNA
and	O
the	O
translocation	O
of	O

the	O
HIV	B-GP
enhancer-binding	I-GP
protein	E-GP
NF-kappa	B-GP
B	E-GP
were	O
analyzed	O
in	O
two	O
human	O
T-cell	B-cell_line
clones	E-cell_line
stimulated	O
through	O
their	O
T-cell	B-GP
receptor	I-GP
complex	E-GP
or	O
by	O
tumor	B-GP
necrosis	I-GP
factor	E-GP
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B-GP
B	E-GP
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	B-DNA
LTR	E-DNA
or	O
the	O
HIV	B-DNA
enhancer	E-DNA
.	O
Interleukin	B-GP
2	E-GP
induced	O
proliferation	O
but	O
not	O
NF-kappa	B-GP
B	E-GP
translocation	O
or	O
LTR	S-DNA
transactivation	O
.	O
Phorbol	O

ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	B-DNA
LTR	E-DNA
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B-GP
necrosis	I-GP
factor	E-GP
or	O
antibody	O
to	O
CD3	S-GP

did	O
not	O
.	O
The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-GP

B	E-GP
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O
Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	B-GP
B	E-GP

by	O
tumor	B-GP
necrosis	I-GP
factor	E-GP
or	O
antibody	B-GP
to	I-GP
CD3	E-GP
is	O
not	O
sufficient	O
to	O
induce	O
HIV	B-DNA
enhancer	E-DNA
-dependent	O
transcription	O
in	O
cloned	B-cell_line
T	I-cell_line
cells	E-cell_line
contrasts	O
with	O
results	O
obtained	O
in	O
most	O

lymphoblastoid	B-cell_line
T-cell	I-cell_line
lines	E-cell_line
and	O
indicates	O
that	O
normal	O
T	B-cell_type
lymphocytes	E-cell_type
differ	O
from	O
tumoral	B-cell_type
T	I-cell_type
cells	E-cell_type
in	O
terms	O
of	O
requirements	O
for	O
HIV	B-DNA
LTR	E-DNA
activation	O
.	O
Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-GP
B	E-GP
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-GP
B	I-GP
complex	E-GP
with	O
the	O
HIV	B-DNA
enhancer	E-DNA
.	O

Decreased	O
concentration	O
of	O
1	B-GP
,	I-GP
25-dihydroxyvitamin	I-GP
D3	I-GP
receptors	E-GP
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	E-cell_type
of	O
patients	O
with	O
X-linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O
Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O

primary	O

defect	O
in	O
X-linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O
However	O
,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
can	O
not	O
be	O
explained	O
by	O

hypophosphatemia	O
alone	O
.	O
Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	S-GP
)	O
,	O

abnormalities	O
of	O
VDR	S-GP
have	O
been	O
postulated	O
in	O
XLH	O
.	O
In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O

the	O
concentration	O
of	O
VDR	S-GP
in	O
PHA-activated	B-cell_line
peripheral	I-cell_line
mononuclear	I-cell_line
cells	E-cell_line
from	O
10	O
XLH	O
patients	O
.	O
Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21.7	O
+/-	O
5.1	O

fmol/mg	O
protein	O
,	O
mean	O
+/-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60.7	O
+/-	O
4.0	O
)	O
.	O
On	O
the	O
contrary	O
,	O
there	O

was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate-supplemented	O
patients	O
(	O
58.3	O
+/-	O
2.7	O
)	O
and	O
controls	O
.	O
There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	S-GP
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O

less	O
than	O
0.05	O
)	O
.	O
In	O
two	O
patients	O
,	O
VDR	S-GP
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O
These	O
results	O

indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	S-GP
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O

resistance	O
in	O
XLH	O
.	O
Two	O
distinct	O
forms	O
of	O
active	B-GP
transcription	I-GP
factor	I-GP
CREB	E-GP
(	O
cAMP	B-GP

response	I-GP
element	I-GP
binding	I-GP
protein	E-GP
)	O
.	O
Mammalian	B-cell_type
cells	E-cell_type
express	O
two	O
distinct	O
forms	O
of	O
transcription	B-GP
factor	I-GP
CREB	E-GP
(	O
cAMP	B-GP
response	I-GP
element	I-GP
binding	I-GP
protein	E-GP
)	O
that	O
are	O

apparently	O

the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B-RNA
gene	I-RNA
transcript	E-RNA
.	O
The	O
two	O
proteins	O
differ	O
by	O

a	O
14-amino	B-GP
acid	I-GP
serine-rich	I-GP
insertion	E-GP
present	O
in	O
one	O
of	O
the	O
CREB	B-GP
isoforms	E-GP
.	O
We	O
show	O
that	O
both	O
CREB	B-GP
isoforms	E-GP
are	O
expressed	O
in	O
many	B-cell_type
cell	I-cell_type
types	E-cell_type
and	O
mammalian	O
species	O
.	O
Both	O
encode	O

proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
in	I-DNA
vitro	E-DNA
.	O
As	O
expected	O
for	O
proteins	O
of	O
this	O

class	O
,	O
the	O
CREB	B-GP
proteins	E-GP
bind	O
DNA	O
as	O
dimers	O
.	O
Both	O
proteins	O
impart	O
cAMP-regulated	O
transcriptional	O
activity	O

to	O
a	O
heterologous	B-DNA
DNA-binding	I-DNA
domain	E-DNA
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O

activity	O
of	O
CREB	S-GP
.	O
The	O
presence	O
of	O
multiple	O
CREB	B-GP
isoforms	E-GP
with	O
identical	O
DNA-binding	O
specificities	O
but	O
differences	O

in	O
the	O
presumed	O
regulatory	B-GP
domain	E-GP
raises	O
the	O
possibility	O
that	O
CREB	B-GP
proteins	E-GP
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O

transcription	O
.	O
Human	O
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion-associated	B-GP
regulatory	I-GP
protein	E-GP
.	O
The	O
vpr	B-GP
product	E-GP
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	B-cell_type

cells	E-cell_type

.	O
Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O

multiple	O
copies	O
of	O
the	O
vpr	B-GP
protein	E-GP
.	O
The	O
vpr	B-GP
product	E-GP
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O
This	O
observation	O

raises	O
the	O
possibility	O
that	O
vpr	S-DNA
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O

protein	O
synthesis	O
occurs	O
.	O
A	O
novel	O
B-cell	B-GP
lineage-specific	I-GP
transcription	I-GP
factor	E-GP
present	O
at	O
early	O
but	O
not	O
late	O
stages	O
of	O

differentiation	O
.	O
A	O
novel	O
B-cell-specific	B-GP
transcription	I-GP
factor	E-GP
,	O
BSAP	S-GP
,	O
was	O
identified	O
as	O
a	O
mammalian	B-GP
homolog	E-GP
of	O
the	O
sea	B-GP
urchin	I-GP
protein	E-GP
TSAP	S-GP
,	O

which	O

interacts	O
with	O
the	O
promoters	S-DNA
of	O
four	O
tissue-specific	B-DNA
late	I-DNA
histone	I-DNA
H2A-2	I-DNA
and	I-DNA
H2B-2	I-DNA
genes	E-DNA
.	O
As	O
shown	O

by	O
mobility-shift	O
,	O
methylation	O
interference	O
,	O
and	O
mutational	O
analyses	O
,	O
the	O
mammalian	B-GP
protein	E-GP
BSAP	S-GP
recognizes	O
all	O
four	O
sea	B-DNA
urchin	I-DNA
binding	I-DNA
sites	E-DNA
in	O
a	O
manner	O
indistinguishable	O
from	O
TSAP	S-GP
;	O
however	O
,	O
the	O
two	O
proteins	O
differ	O
in	O
molecular	O

weight	O
.	O
BSAP	S-GP
is	O
exclusively	O
restricted	O
to	O
the	O
B-cell	O
lineage	O
of	O
lymphoid	O
differentiation	O
.	O
Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B-cell_type
differentiated	I-cell_type

plasma	I-cell_type
cells	E-cell_type
.	O
Moreover	O
,	O
BSAP	S-GP
is	O
clearly	O
a	O
B-cell-specific	B-GP
transcription	I-GP
factor	E-GP

,	O
as	O
a	O
wild-type	S-DNA
but	O
not	O
a	O
mutant	B-DNA
TSAP-binding	I-DNA
site	E-DNA
of	O
the	O
sea	O
urchin	O
functions	O
only	O
in	O
transfected	B-cell_line
B	I-cell_line
cells	E-cell_line
as	O
an	O
upstream	B-DNA
promoter	I-DNA
element	E-DNA
.	O
Competition	O
experiments	O
did	O

not	O
reveal	O
any	O
high-affinity	B-DNA
binding	I-DNA
site	E-DNA
for	O
BSAP	S-GP
in	O
known	O
regulatory	B-DNA
regions	E-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
class	I-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
genes	E-DNA
,	O
suggesting	O
that	O
BSAP	S-GP
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O

B-lymphoid-specific	B-DNA
genes	E-DNA
.	O
Octamer	B-GP
transcription	I-GP
factors	E-GP
and	O
the	O
cell	B-DNA
type-specificity	I-DNA
of	I-DNA
immunoglobulin	I-DNA
gene	E-DNA
expression	O
.	O
Antibodies	S-GP
are	O
produced	O
exclusively	O
in	O
B	B-cell_type
lymphocytes	E-cell_type
.	O
The	O
expression	O
of	O
the	O
antibody-encoding	B-DNA
genes	E-DNA
,	O
the	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	E-DNA
,	O
is	O
also	O
restricted	O
to	O

B	B-cell_type

cells	E-cell_type
.	O
The	O
octamer	B-DNA
sequence	E-DNA
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	S-DNA
and	O

the	O
enhancer	S-DNA
of	O
Ig	B-DNA
genes	E-DNA
,	O
and	O
plays	O

an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O
This	O
sequence	B-DNA
motif	E-DNA
is	O
a	O
binding	O
site	O
for	O
nuclear	B-GP
proteins	E-GP
,	O
the	O
so-called	O

octamer	B-GP
transcription	I-GP
factors	E-GP
(	O
Oct	S-GP
or	O
OTF	B-GP
factors	E-GP
)	O
.	O
The	O
Oct-1	B-GP
protein	E-GP
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct-2A	S-GP
and	O

Oct-2B	S-GP
are	O
found	O
mainly	O
in	O
B	B-cell_type
lymphocytes	E-cell_type
.	O
All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O
It	O
appears	O
that	O

the	O
B	O
cell-specific	O
expression	O
of	O
Ig	B-DNA
genes	E-DNA
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type-specific	B-GP
Oct	I-GP
factors	E-GP
,	O
and	O
that	O
there	O
are	O
both	O

quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	S-GP
and	O
Oct-2	B-GP
factors	E-GP
.	O
Recently	O
,	O

a	O
number	O
of	O
other	O
octamer	B-GP
factor	I-GP
variants	E-GP
were	O
identified	O
.	O
Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	B-RNA
transcript	E-RNA
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O

tuning	O
of	O
gene	O
expression	O
.	O
A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	B-DNA

Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	E-DNA
only	O
in	O
lymphocytes	S-cell_type
is	O
a	O
ubiquitously	B-GP
active	I-GP
transcription	I-GP
factor	E-GP
.	O
The	O
transcriptional	B-DNA
enhancer	E-DNA
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
constant	I-DNA
region	E-DNA
is	O
a	O
major	O

determinant	O

of	O
B-cell-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
.	O
Like	O
other	O
enhancers	S-DNA
,	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	E-DNA
contains	O
several	O
short	O
sequence	B-DNA
motifs	E-DNA

that	O
bind	O
specific	B-GP
transcription	I-GP
factors	E-GP
.	O
Each	O
binding	B-DNA
site	E-DNA
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	S-DNA
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O

activity	O
.	O
For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
components	E-DNA
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O

sequence	B-DNA
elements	E-DNA
.	O
We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	B-DNA
enhancer	I-DNA
motif	E-DNA
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	B-GP
transcription	I-GP

factor	E-GP
.	O
It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	B-cell_type
cells	E-cell_type
and	O
non-B	B-cell_type
cells	E-cell_type
,	O
where	O
it	O
can	O
mediate	O

transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	B-DNA
reporter	I-DNA
gene	E-DNA

,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	E-DNA
in	O
non-lymphoid	B-cell_type
cells	E-cell_type
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O

in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF-muE3	S-GP
,	O
was	O
detected	O
in	O
B	B-cell_type
cells	E-cell_type
but	O
not	O
in	O
non-B	B-cell_type
cells	E-cell_type
.	O
From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell-type-specific	O
transcription	O
in	O
B	B-cell_type
lymphocytes	E-cell_type
:	O
(	O
a	O
)	O
cell-specific	B-GP
factors	E-GP
such	O
as	O
Oct-2A	S-GP
and	O
Oct-2B	S-GP
that	O
are	O
not	O
expressed	O
in	O

most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	B-GP
factors	E-GP
such	O
as	O
NF-kappa	B-GP
B	E-GP
that	O
are	O
constitutively	O
active	O
in	O
B	B-cell_type
cells	E-cell_type
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	B-GP
active	I-GP
factors	E-GP
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	B-DNA
sequence	I-DNA
motif	E-DNA
.	O
This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	E-DNA
in	O
non-B	B-cell_type
cells	E-cell_type
,	O
perhaps	O
due	O
to	O
a	O
non-permissive	O
chromatin	S-DNA
structure	O
of	O
the	O

Ig	B-DNA
heavy	I-DNA
chain	I-DNA
locus	E-DNA
.	O
[	O
Endocrine	O
status	O
changes	O
in	O
children	O
with	O
bronchial	O
asthma	O
]	O
A	O
study	O
was	O
made	O
of	O
adrenocortical	O
function	O
by	O
measuring	O
blood	O
plasma	O
cortisol	O
concentration	O
and	O
amount	O
of	O
glucocorticoid	B-GP
receptors	E-GP
in	O
lymphocytes	S-cell_type
as	O
well	O
as	O
thyroid	O
function	O
by	O
measuring	O
blood	O
plasma	O
triidothyronine	O

and	O

thyroxine	O
concentration	O
in	O
58	O
bronchial	O
asthma	O
children	O
aged	O
1	O
to	O

14	O
years	O
.	O
The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out	O
.	O
TAR	S-DNA
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O

ester	O
stimulated	O
T	B-cell_type
lymphocytes	E-cell_type
.	O
Multiple	B-DNA
regulatory	I-DNA
elements	E-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
HIV	B-DNA
LTR	E-DNA
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O
Previous	O
transfection	O

studies	O

of	O
HIV	B-DNA
LTR	I-DNA
constructs	E-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	E-DNA
indicated	O
that	O
multiple	O
regulatory	B-DNA
regions	E-DNA

including	O
the	O
enhancer	S-DNA
,	O
SP1	S-DNA
,	O
TATA	S-DNA
and	O
TAR	B-DNA
regions	E-DNA
were	O
important	O
for	O
HIV	O
gene	O
expression	O
.	O
To	O
characterize	O
these	O
regulatory	B-DNA
elements	E-DNA
further	O
,	O

mutations	O
in	O
these	O
regions	O
were	O
inserted	O
into	O
both	O
the	O
5	O
'	O
and	O
3	O
'	O
HIV	B-DNA
LTRs	E-DNA
and	O
infectious	O
proviral	O
constructs	O
were	O
assembled	O
.	O
These	O
constructs	O
were	O
transfected	O
into	O
either	O
HeLa	B-cell_line
cells	E-cell_line
,	O
Jurkat	B-cell_line
cells	E-cell_line
or	O

U937	B-cell_line
cells	E-cell_line
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
phorbol	O
esters	O
which	O
have	O
previously	O
been	O
demonstrated	O
to	O
activate	O
HIV	O
gene	O
expression	O
.	O
Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O

of	O
p24	B-GP
gag	I-GP
protein	E-GP
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	O
constructs	O
.	O
Results	O
in	O
all	O
cell	O
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	S-DNA
,	O
TATA	S-DNA
and	O
the	O
TAR	O
loop	O
and	O
stem	O
secondary	O
structure	O

resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	B-DNA
motif	E-DNA
or	O
TAR	B-DNA
primary	I-DNA
sequence	E-DNA
resulted	O
in	O
only	O
slight	O

decreases	O
.	O
However	O
,	O
viruses	O
containing	O
mutations	O
in	O
either	O
the	O
TAR	B-DNA
loop	I-DNA
sequences	E-DNA
or	O
stem	O
secondary	O
structure	O
which	O
were	O
very	O
defective	O
for	O
gene	O
expression	O
in	O
untreated	O
Jurkat	B-cell_line
cells	E-cell_line
,	O
gave	O
nearly	O
wild-type	O
levels	O
of	O
gene	O
expression	O
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	E-cell_line
but	O
not	O
in	O

phorbol	B-cell_line
ester-treated	I-cell_line
HeLa	E-cell_line
or	O
U937	B-cell_line
cells	E-cell_line
.	O
High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	B-DNA
mutant	I-DNA
constructs	E-DNA
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	E-cell_line
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	B-DNA
region	E-DNA
or	O
by	O
disruption	O
of	O
the	O
tat	B-DNA
gene	E-DNA
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
case	O
of	O

hypersensitivity	O
to	O
thyroid	O
hormones	O
with	O
normally	O
functioning	O
thyroid	O
gland	O
and	O
increased	O
nuclear	O
triiodothyronine	B-GP
receptors	E-GP
.	O
A	O
52-year-old	O
male	O
presented	O
himself	O
with	O
tachycardia	O
crises	O
which	O
appeared	O
first	O
during	O
childhood	O
,	O
increased	O
in	O
frequency	O

without	O
goiter	O
or	O
exophthalmos	O
.	O
Cardiac	O
and	O

adrenergic	O

diseases	O
were	O
excluded	O
.	O
The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	O
,	O
free	O
T4	O
and	O
T3	O
,	O
TBG	O

,	O
radioiodine	O
uptake	O
,	O
TSH	O
and	O
T3	O
suppressibility	O
;	O
however	O
the	O
TSH	O
response	O
to	O
TRH	O
was	O
decreased	O
.	O
The	O
lymphocyte	B-GP
nuclear	I-GP
T3	I-GP

receptor	E-GP
was	O
found	O
with	O
an	O
affinity	O
close	O

to	O
that	O
of	O
normal	O
volunteers	O
(	O
Ka	O
:	O
1.42	O
x	O
10	O
(	O
10	O
)	O
M-1	O
vs	O
1.95	O
+/-	O
0.35	O
x	O
10	O
(	O
10	O
)	O
M-1	O
)	O
and	O
a	O
binding	O
capacity	O
markedly	O
increased	O

(	O
9.9	O
vs	O
3.7	O
+/-	O
0.4	O
fmol	O
T3/100	O
micrograms	O
DNA	O
)	O
.	O
Pindolol	O
was	O
inefficient	O
on	O
the	O
dysrhythmia	O
which	O
disappeared	O
with	O
carbimazole	O
and	O
relapsed	O
after	O
withdrawal	O
of	O
the	O
antithyroid	O
drug	O
.	O
Under	O
carbimazole	O
,	O
the	O
plasma	O
T4	O
markedly	O
decreased	O
(	O
27.7	O
+/-	O
3.6	O
nmol/l	O
)	O
but	O
the	O
patient	O
remained	O
euthyroid	O
.	O
The	O
clinical	O
course	O
and	O

the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O

hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B-GP
nuclear	I-GP
receptor	E-GP
sites	O
in	O
lymphocytes	S-cell_type
.	O
Induction	O
of	O
immediate	B-DNA
early	I-DNA
response	I-DNA

genes	E-DNA
by	O
macrophage	B-GP
colony-stimulating	I-GP
factor	E-GP
in	O
normal	B-cell_type
human	I-cell_type
monocytes	E-cell_type
.	O
A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	S-DNA
,	O
cytoskeletal	B-DNA
,	I-DNA
and	I-DNA
extracellular	I-DNA
matrix	I-DNA
genes	E-DNA
have	O
been	O
termed	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	E-DNA
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O

growth	B-GP

factor	E-GP
-stimulated	O
cell	O
proliferation	O
.	O
We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage-CSF	S-GP

(	O
M-CSF	S-GP
)	O
in	O
human	B-cell_type
monocytes	E-cell_type
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M-CSF	S-GP
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O
Normal	O
human	B-cell_type
monocytes	E-cell_type
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O

for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum-containing	O
medium	O
.	O
At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	B-cell_type
cells	E-cell_type
were	O
stimulated	O
with	O
M-CSF	S-GP
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O

blotting	O
.	O
RNA	O
from	O
control	O
resting	B-cell_type
cells	E-cell_type
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c-jun	S-RNA
,	O
fibronectin	B-RNA
receptor	E-RNA
,	O
and	O
actin	B-RNA
mRNA	E-RNA
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	S-GP
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O
The	O
c-jun	B-DNA

gene	E-DNA
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M-CSF	S-GP
addition	O
.	O
In	O
contrast	O
,	O
the	O

expression	O
of	O
actin	B-RNA
and	I-RNA
fibronectin	I-RNA
receptor	I-RNA
mRNA	E-RNA
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O

48	O
h	O
after	O
M-CSF	S-GP
addition	O
.	O
We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	B-DNA
specific	I-DNA
tyrosine	I-DNA
kinase	I-DNA
hck	I-DNA

gene	E-DNA
simultaneously	O
with	O
the	O
other	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	E-DNA
.	O
The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super-induced	O
the	O

expression	O
of	O
c-jun	S-DNA
and	O
hck	S-DNA
.	O
Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c-jun	S-DNA
,	O
hck	S-DNA
,	O
and	O
actin	B-DNA
genes	E-DNA
.	O
Therefore	O
,	O

in	O
normal	B-cell_type
human	I-cell_type
monocytes	E-cell_type
M-CSF	S-GP
induces	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	E-DNA
without	O
inducing	O
cell	O
proliferation	O
.	O
These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O

the	O
cells	O
in	O
response	O
to	O
CSF	S-GP
.	O
Inducible	O
nuclear	B-GP
factor	E-GP
binding	O
to	O
the	O
kappa	B-DNA

B	I-DNA
elements	E-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O

in	O
a	O
signal-dependent	O
manner	O
.	O
Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O

expression	O

of	O
a	O
distinct	O
set	O
of	O
lymphokine	B-DNA
genes	E-DNA
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	S-GP
.	O
In	O
addition	O
,	O
the	O
activation	O
of	O
the	O

human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O
To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B-GP
factors	E-GP
in	O
T	B-cell_type
cells	E-cell_type
.	O
Here	O
we	O

report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	B-GP
DNA-binding	I-GP
complexes	E-GP
,	O
the	O
kappa	B-GP
B	I-GP
complex	E-GP
within	O
the	O

HIV	B-DNA
enhancer	E-DNA
and	O
the	O
NFAT-1	B-GP
complex	E-GP
within	O
the	O
interleukin-2	B-DNA
enhancer	E-DNA
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O
The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	B-DNA

enhancer	E-DNA
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	S-GP
phytohemagglutinin	S-GP
whereas	O
phorbol	O
myristate	O
acetate-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O
This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B-GP
B	I-GP
complexes	E-GP
can	O
be	O
activated	O

via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O
Purification	O
of	O
TCF-1	B-GP
alpha	E-GP
,	O
a	O
T-cell-specific	B-GP
transcription	I-GP
factor	E-GP
that	O
activates	O
the	O
T-cell	B-DNA
receptor	I-DNA
C	I-DNA
alpha	I-DNA
gene	I-DNA
enhancer	E-DNA
in	O
a	O

context-dependent	O
manner	O
.	O
The	O
differentiation	O
of	O
T	B-cell_type
cells	E-cell_type
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O

little	O

is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O
We	O
have	O
purified	O
a	O
new	O
T-cell-specific	B-GP
factor	E-GP
,	O
TCF-1	B-GP
alpha	E-GP

,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	B-GP
T-cell	I-GP
receptor	E-GP
(	O
TCR	S-GP
)	O
.	O
TCF-1	B-GP
alpha	E-GP
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV-1	B-DNA

promoter	E-DNA
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	E-DNA
and	O
to	O
promoters	S-DNA
for	O
several	O
genes	S-DNA
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T-cell	O
development	O
than	O
the	O
TCR	B-DNA
alpha	I-DNA
gene	E-DNA
(	O
e.g.	O

,	O
p56lck	S-DNA
and	O
CD3	B-DNA
delta	E-DNA
)	O
.	O
Sequences	O
related	O
to	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
motif	E-DNA
(	O
5'-GGCACCCTTTGA-3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	B-DNA
TCR	I-DNA
delta	E-DNA
(	O
and	O
possibly	O
TCR	B-DNA
beta	E-DNA
)	O
enhancers	S-DNA
.	O
Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF-1	B-GP
alpha	E-GP
activity	O
is	O

derived	O
from	O
a	O
family	O
of	O
57-	B-GP
to	I-GP
53-kD	I-GP
proteins	E-GP
that	O
are	O
abundantly	O
expressed	O
in	O
mature	B-cell_line
and	I-cell_line
immature	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
(	O
Jurkat	S-cell_line
,	O
CCRF-CEM	S-cell_line
)	O
and	O
not	O
in	O
mature	B-cell_line

B	I-cell_line
cells	E-cell_line
(	O
JY	S-cell_line
,	O
Namalwa	S-cell_line
)	O
or	O
nonlymphoid	B-cell_line
(	I-cell_line
HeLa	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
A	O
small	O
95-bp	O
fragment	O
of	O
the	O
TCR	B-DNA
alpha	I-DNA
control	I-DNA
region	E-DNA
that	O
contains	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	E-DNA
juxtaposed	O
between	O
a	O
cAMP-response	B-DNA
element	E-DNA
(	O
the	O
CRE	S-DNA
or	O
T	B-DNA
alpha	I-DNA
1	I-DNA
motif	E-DNA
)	O
and	O
the	O
binding	B-DNA
site	E-DNA
for	O
a	O
distinct	O
lymphoid-specific	B-GP
protein	E-GP
(	O
TCF-2	B-GP
alpha	E-GP
)	O
behaved	O
as	O

a	O
potent	O
T-cell-specific	B-DNA
enhancer	E-DNA
in	O
vivo	O
.	O
Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	B-cell_line
(	I-cell_line
Jurkat	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	B-cell_line
(	I-cell_line
CCRF-CEM	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
.	O
Mutation	O
of	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	E-DNA
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	B-DNA

enhancer	I-DNA
repeats	E-DNA
.	O
The	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	E-DNA
was	O
also	O
required	O
for	O
TCR	S-GP
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	S-cell_line
but	O
not	O
HeLa	B-cell_line
cells	E-cell_line
,	O

confirming	O
that	O
TCF-1	B-GP
alpha	E-GP
is	O
a	O
T-cell-specific	B-GP
transcription	I-GP
factor	E-GP
.	O
Curiously	O
,	O
the	O
TCF-1	B-GP
alpha	E-GP
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O

removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	E-DNA
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	E-DNA
.	O
Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF-1	B-GP
alpha	E-GP
appears	O
to	O
depend	O

on	O
the	O
TCF-2	B-GP
alpha	E-GP
and	O
T	B-GP
alpha	I-GP
1	E-GP
(	O
CREB	S-GP
)	O
transcription	B-GP
factors	E-GP
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	E-DNA
.	O
Tandem	B-DNA
AP-1-binding	I-DNA
sites	E-DNA
within	O
the	O
human	B-DNA
beta-globin	I-DNA
dominant	I-DNA
control	I-DNA

region	E-DNA
function	O
as	O
an	O
inducible	B-DNA
enhancer	E-DNA
in	O
erythroid	B-cell_type
cells	E-cell_type
.	O
A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18-bp	B-DNA
DNA	I-DNA
segment	E-DNA
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	B-DNA
epsilon-globin	I-DNA
gene	E-DNA
within	O
the	O
dominant	B-DNA
control	E-DNA
or	O
locus-activating	B-DNA

region	E-DNA

.	O
This	O
enhancer	S-DNA
is	O
inducible	O
in	O
K562	B-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	E-cell_line
,	O
increasing	O
linked	O
gamma-globin	B-DNA
promoter	E-DNA
/luciferase	S-GP
gene	O
expression	O
to	O

170-fold	O
over	O
an	O
enhancerless	B-DNA
construct	E-DNA
.	O
The	O
enhancer	S-DNA
consists	O
of	O
tandem	B-DNA
AP-1-binding	I-DNA
sites	E-DNA
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O
DNA-protein	O
binding	O

assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B-GP
molecular	I-GP
weight	I-GP
complex	E-GP
on	O
the	O
enhancer	S-DNA
.	O
The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O

both	O
AP-1	B-DNA
sites	E-DNA
and	O
correlates	O
with	O
maximal	O
enhancer	S-DNA
activity	O
.	O
Induction	O
of	O
the	O
enhancer	S-DNA
may	O
have	O
a	O
role	O
in	O
the	O
increase	O

in	O
globin	B-DNA
gene	E-DNA
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O
Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O

a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
families	E-DNA
to	O
tandem	B-DNA
AP-1	I-DNA
consensus	I-DNA
sequences	E-DNA
.	O
Identification	O

of	O
a	O
novel	B-GP
factor	E-GP
that	O
interacts	O
with	O
an	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	E-DNA
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B-GP
cell-specific	I-GP

factor	E-GP
OTF2	S-GP
.	O
The	O
tissue-specific	O
expression	O
of	O
the	O
MOPC	B-DNA
141	I-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
gene	E-DNA
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O
B-cell-specific	O
transcription	O
of	O
this	O
gene	O

was	O

dependent	O
on	O
the	O
octamer	B-DNA
element	E-DNA
5'-ATGCAAAG-3	O
'	O
,	O
located	O
in	O
the	O
upstream	B-DNA
region	E-DNA
of	O
this	O
promoter	S-DNA
and	O
in	O
the	O
promoters	S-DNA
of	O
all	O
other	O
immunoglobulin	B-DNA

heavy-	I-DNA
and	I-DNA
light-chain	I-DNA
genes	E-DNA
.	O
The	O
interaction	O
of	O
purified	O
octamer	B-GP
transcription	I-GP
factors	E-GP
1	O
and	O
2	O
(	O
OTF1	S-GP
and	O

OTF2	S-GP
)	O
with	O
the	O
MOPC	B-DNA
141	I-DNA
promoter	E-DNA
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	B-GP
I	E-GP
footprinting	O
.	O
Purified	O
OTF1	S-GP
from	O
HeLa	B-cell_line
cells	E-cell_line
and	O
OTF1	S-GP
and	O
OTF2	S-GP
from	O
B	B-cell_type
cells	E-cell_type
bound	O
to	O
identical	O

sequences	O
within	O
the	O
heavy-chain	B-DNA
promoter	E-DNA
.	O
The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B-DNA
element	E-DNA
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B-GP
factors	E-GP
involves	O
cooperation	O
between	O

octamer	B-DNA
and	I-DNA
heptamer	I-DNA
sites	E-DNA
in	O
this	O
promoter	S-DNA
.	O
In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	B-DNA
element	E-DNA
,	O

the	O
N	B-DNA
element	E-DNA
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3'	O
.	O
The	O
N	B-DNA
element	E-DNA
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B-cell	O
and	O
HeLa-cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	B-DNA
element	E-DNA
,	O
it	O

can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B-cell	O
extracts	O
.	O
The	O
N	B-DNA
element	E-DNA
bound	O
a	O
transcription	B-GP
factor	E-GP
,	O
NTF	S-GP
,	O
that	O

is	O
ubiquitous	O
in	O
cell-type	O
distribution	O
,	O
and	O
NTF	S-GP
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	B-GP
described	I-GP
proteins	E-GP
that	O
bind	O
to	O
similar	O
sequences	O
.	O
Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	S-GP
and	O
OTF2	S-GP
interactions	O
(	O
both	O

with	O
their	O
cognate	B-DNA
DNA	I-DNA
elements	E-DNA
and	O
possibly	O
at	O
the	O
protein-protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell-specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O
NF-kappa	B-GP
B	E-GP
as	O
inducible	O

transcriptional	B-GP
activator	E-GP
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	E-DNA
.	O
The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte-macrophage	B-GP
colony-stimulating	I-GP
factor	E-GP
(	O
GM-CSF	S-GP
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	B-cell_type
cells	E-cell_type
with	O
phytohemagglutinin	S-GP
and	O
active	O
phorbolester	O
and	O
upon	O
expression	O
of	O
tax1	S-GP
,	O
a	O
transactivating	B-GP
protein	E-GP
of	O

the	O

human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O
The	O
same	O
agents	O
induce	O
transcription	O
from	O

the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
and	I-DNA
interleukin-2	I-DNA
genes	E-DNA
,	O
depending	O
on	O
promoter	B-DNA
elements	E-DNA
that	O
bind	O
the	O
inducible	B-GP
transcription	I-GP
factor	E-GP
NF-kappa	B-GP
B	E-GP
(	O
or	O
an	O
NF-kappa	B-GP
B-like	I-GP
factor	E-GP
)	O
.	O
We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM-CSF	B-DNA
gene	E-DNA
is	O
also	O
regulated	O
by	O
a	O
cognate	O

motif	O
for	O
the	O
NF-kappa	B-GP
B	I-GP
transcription	I-GP
factor	E-GP
.	O
A	O
recent	O
functional	O
analysis	O
by	O
Miyatake	O
et	O
al.	O
(	O
S.	O
Miyatake	O
,	O
M.	O
Seiki	O
,	O
M.	O
Yoshida	O
,	O
and	O
K.	O
Arai	O
,	O
Mol.	O
Cell.	O
Biol.	O
8	O

:	O
5581-5587	O
,	O
1988	O
)	O
described	O
a	O
short	B-DNA
promoter	I-DNA
region	E-DNA
in	O
the	O
GM-CSF	B-DNA
gene	E-DNA
that	O
conferred	O
strong	O
inducibility	O
by	O
T-cell-activating	O
signals	O
and	O
tax1	S-GP

,	O
but	O
no	O
NF-kappa	B-DNA
B-binding	I-DNA
motifs	E-DNA
were	O
identified	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	O
human	B-GP
NF-kappa	I-GP
B	E-GP
and	O
of	O
the	O
NF-kappa	B-GP
B	E-GP
activated	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
element	E-DNA
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T-cell-activating	O
signals	O
and	O
tax1	S-GP
.	O
As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O

and	O
oligonucleotide	O
competition	O
experiments	O
,	O
purified	O
NF-kappa	B-GP
B	E-GP
binds	O
at	O
positions	B-DNA
-82	I-DNA
to	I-DNA
-91	E-DNA
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM-CSF	B-DNA
promoter	E-DNA
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	B-DNA
functional	I-DNA
kappa	I-DNA
B	I-DNA
motif	E-DNA
in	O
the	O
beta	B-DNA

interferon	I-DNA
promoter	E-DNA
(	O
GGGAAATTCC	O
)	O
.	O
Two	O
kappa	B-DNA
B-like	I-DNA
motifs	E-DNA
at	O
positions	B-DNA
-98	I-DNA
to	I-DNA
-108	E-DNA
of	O
the	O
GM-CSF	B-DNA
promoter	E-DNA
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O
Our	O
data	O
provide	O
strong	O
evidence	O
that	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
gene	E-DNA
following	O
T-cell	O
activation	O
is	O
controlled	O
by	O
binding	O
of	O
the	O
NF-kappa	B-GP
B	I-GP
transcription	I-GP
factor	E-GP
to	O
a	O

high-affinity	B-DNA
binding	I-DNA
site	E-DNA
in	O
the	O
GM-CSF	B-DNA
promoter	E-DNA
.	O
Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	O
action	O
in	O
human	B-cell_type
tonsillar	I-cell_type
T-lymphocytes	E-cell_type
.	O
The	O
treatment	O

of	O
human	B-cell_type
tonsillar	I-cell_type
T-lymphocytes	E-cell_type
with	O
4-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	B-GP
receptor	E-GP
(	O
GR	S-GP
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O

This	O

increase	O
disappeared	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O
Alone	O
,	O
PMA	O
and	O

calcium	O
ionophore	O
A23187	O
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	S-GP
(	O
PHA	S-GP
)	O
,	O
leucine	O
and	O
,	O
in	O
particular	O
,	O
thymidine	O
incorporation	O
.	O
PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	S-GP
.	O
Alone	O
,	O

these	O
agents	O
failed	O
to	O
alter	O
the	O
suppressive	O
effect	O
of	O

dexamethasone	O
on	O
thymidine	O
and	O
leucine	O
incorporation	O
;	O
however	O
,	O
PMA-A23187	O
and	O
PMA	O
-PHA	S-GP
combinations	O
appeared	O
to	O
antagonize	O
the	O
suppression	O
by	O
dexamethasone	O
.	O
To	O
be	O
or	O
not	O
to	O
be	O
a	O
responder	O

in	O
T-cell	O
responses	O
:	O
ubiquitous	O
oligopeptides	O
in	O
all	O
proteins	O

.	O
Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language	O
.	O
Accordingly	O
,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O

The	O

reason	O
that	O
only	O
certain	O
individuals	O
of	O
particular	O
major	B-GP
histocompatibility	I-GP
complex	I-GP
(	I-GP
MHC	I-GP
)	I-GP
haplotypes	E-GP
can	O
mount	O
T-cell	O
responses	O

against	O
a	O
given	O
antigen	O
of	O
pathogens	O
is	O
found	O
in	O
the	O
fact	O
that	O
T-cell	B-GP
receptors	E-GP

are	O
designed	O
to	O
recognize	O
18-20	O
residue-long	O
peptide	O
fragments	O
sandwiched	O
between	O
two	O
alpha-helices	S-GP
of	O
class	B-GP
I	E-GP
or	O
class	O
II	O

MHC	O
molecules	O
.	O
At	O
this	O
range	O
of	O
peptide	O
lengths	O
,	O
most	O
would	O
appear	O
as	O
self	O
,	O
while	O
nonselfness	O
of	O
the	O
remainders	O
are	O
destined	O
to	O
be	O
quite	O
ambiguous	O
,	O
hence	O
creating	O
responders	O
and	O
nonresponders	O
.	O
Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	S-GP
and	O
either	O
FK506	O
or	O

rapamycin	O
.	O
Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B-GP
receptor	E-GP
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O

rapamycin	O

.	O
On	O
the	O
other	O
hand	O
,	O
interleukin	B-GP
2	E-GP
(	O
IL-2	S-GP
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O

Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	S-GP
(	O
immunosuppressant	B-GP
binding	I-GP
protein	E-GP
)	O
.	O
We	O
find	O

that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	B-GP
binding	I-GP
protein	E-GP
FKBP	S-GP
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O

the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	S-GP
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O
However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O

to	O
revert	O
FK506-mediated	O
inhibition	O
of	O
IL-2	S-GP
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF-AT	S-GP
,	O
a	O
T-cell-specific	B-GP
transcription	I-GP
factor	E-GP
necessary	O
for	O
IL-2	B-DNA
gene	E-DNA
activation	O
.	O
Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin-mediated	O
inhibition	O
of	O
IL-2	S-GP
-induced	O
proliferation	O
.	O
The	O

drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	S-GP
FKBP	S-GP
.	O
FKBP	S-GP
has	O
been	O
shown	O
to	O
catalyze	O
the	O

interconversion	O
of	O
the	O
cis-	O
and	O
trans-rotamers	O
of	O
the	O
peptidyl-prolyl	B-GP
amide	I-GP
bond	E-GP
of	O
peptide	O
substrates	O
;	O
here	O
we	O

show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	S-GP
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O
Neither	O
FKBP	S-GP
binding	O
nor	O

inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	S-GP
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O
Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	S-GP
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	B-GP
receptor	E-GP
-induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	S-GP
interferes	O
with	O
IL-2	S-GP
-induced	O
signals	O
.	O
Adherence-dependent	O

increase	O
in	O
human	B-RNA
monocyte	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	E-RNA
is	O
associated	O
with	O
increases	O
in	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
and	I-RNA
EGR2	I-RNA
mRNA	E-RNA
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	B-cell_type
monocyte	E-cell_type
to	O
a	O
tissue	B-cell_type
macrophage	E-cell_type
.	O
This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	B-GP

factors	E-GP

.	O
We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	S-RNA

encoding	O
profibrotic	O
growth	B-GP
factors	E-GP
such	O
as	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
B	I-GP
subunit	E-GP
(	O
PDGF	B-GP
[	I-GP
B	I-GP
]	E-GP
)	O
and	O

transforming	B-GP
growth	I-GP
factor-beta	E-GP
(	O
TGF-beta	S-GP
)	O
.	O
After	O
in	O
vitro	O
adherence	O
,	O
human	O

monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	E-RNA
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O
No	O
increase	O
in	O
TGF-beta	B-RNA
mRNA	E-RNA
was	O
observed	O
.	O
The	O
6-h	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	E-RNA
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O

when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O
The	O
6-h	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	E-RNA
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O

of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O
Adherence	O
to	O

either	O
fibronectin	O
or	O
collagen-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	E-RNA
accumulation	O
.	O
The	O
increased	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	E-RNA
observed	O
in	O
adherent	B-cell_type
monocytes	E-cell_type
was	O

accompanied	O
by	O
increases	O
in	O
mRNAs	S-RNA
of	O
the	O
early	B-DNA
growth	I-DNA
response	I-DNA
genes	E-DNA
c-fos	S-DNA
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	O
,	O
and	O

EGR2	O
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O
The	O
increase	O
in	O
c-jun	O
and	O
EGR2	O
,	O
but	O
not	O
c-fos	S-DNA
,	O

mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O
These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
EGR2	I-RNA
,	I-RNA
and	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	E-RNA
.	O
In	O
addition	O
,	O
the	O
increases	O
in	O
c-jun	S-DNA
,	O
EGR2	S-DNA
,	O
and	O
PDGF	B-GP

(	I-GP
B	I-GP
)	E-GP
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O
Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O

a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O
Single	O
cell	O
assay	O
of	O
a	O
transcription	B-GP
factor	E-GP
reveals	O
a	O

threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T-cell	B-GP
antigen	I-GP
receptor	E-GP
.	O
Stimulation	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
through	O
their	O
antigen	B-GP
receptor	E-GP

leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	B-GP
factors	E-GP
,	O
including	O
NF-AT	S-GP
and	O
NF-kappa	B-GP
B	E-GP
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O

immunologic	O

activation	O
.	O
To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	B-GP
factor	E-GP
in	O
individual	B-cell_type
viable	I-cell_type
cells	E-cell_type
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O

uses	O
the	O
fluorescence-activated	O
cell	O
sorter	O
to	O
quantitate	O
beta-galactosidase	S-GP
(	O
beta-gal	S-GP
)	O
.	O
We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF-AT	S-GP
transcriptional	O
activity	O
among	O
T	B-cell_type
cells	E-cell_type
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O

copies	O
of	O
the	O
NF-AT-binding	B-DNA
site	E-DNA
directs	O
transcription	O
of	O
the	O
lacZ	B-DNA
gene	E-DNA
.	O
Unexpectedly	O
,	O
stimulation	O
of	O
cloned	B-cell_line
stably	I-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	E-cell_line
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	O
expression	O
in	O
which	O

some	O
cells	O
express	O
no	O
beta-gal	S-GP
and	O
others	O
express	O
high	O
levels	O
.	O
This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	O
for	O
by	O
cell-cycle	O
position	O
or	O
heritable	O
variation	O
.	O
Further	O
results	O
,	O
in	O
which	O
beta-gal	S-GP
activity	O
is	O

correlated	O
with	O
NF-AT	S-GP
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	S-GP
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O
This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	S-GP
concentration-dependent	O
assembly	O
of	O
transcription	B-GP

complexes	E-GP
at	O
the	O
promoter	S-DNA
.	O
Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-GP
B	E-GP
or	O
the	O
entire	O
interleukin-2	B-DNA

enhancer	E-DNA
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B-GP
factors	E-GP
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B-DNA
genes	E-DNA
.	O
The	O
Epstein-Barr	B-DNA

virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
BMRF1	I-DNA
promoter	E-DNA
for	O
early	B-GP
antigen	E-GP
(	O
EA-D	S-GP
)	O
is	O
regulated	O
by	O

the	O
EBV	B-GP
transactivators	E-GP
,	O
BRLF1	S-GP
and	O
BZLF1	S-GP
,	O
in	O
a	O
cell-specific	O
manner	O
.	O
The	O
Epstein-Barr	B-GP
virus	I-GP
early	I-GP
antigen	I-GP
diffuse	I-GP
component	E-GP
(	O
EA-D	S-GP
)	O
is	O
essential	O
for	O
Epstein-Barr	O
virus	B-DNA
DNA	E-DNA
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O

during	O

latent	O
infection	O
.	O
We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	S-DNA
(	O
BMRF1	S-DNA
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	B-GP
viral	I-GP
transactivators	E-GP
,	O
BZLF1	S-GP

(	O
Z	S-GP
)	O
and	O
BRLF1	S-GP
(	O
R	S-GP
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
and	O
epithelial	B-cell_type
cells	E-cell_type
.	O
In	O
lymphoid	B-cell_type
cells	E-cell_type
,	O
Z	S-GP
or	O

R	S-GP
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA-D	B-DNA
promoter	E-DNA
activity	O
,	O
whereas	O
both	O
transactivators	S-GP
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O
In	O
epithelial	B-cell_type
cells	E-cell_type
,	O
the	O
Z	B-GP
transactivator	E-GP
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA-D	B-DNA
promoter	E-DNA
;	O
the	O
effect	O
of	O
R	S-GP
and	O
Z	S-GP
together	O
was	O
no	O
greater	O
than	O
that	O

of	O
Z	S-GP
alone	O
.	O
Deletional	O
analysis	O
and	O
site-directed	O
mutagenesis	O
of	O
the	O
EA-D	B-DNA
promoter	E-DNA
demonstrated	O
that	O
in	O
epithelial	B-cell_type
cells	E-cell_type
the	O
potential	O
AP-1	B-DNA
binding	I-DNA
site	E-DNA
plays	O
an	O
essential	O
role	O

in	O
Z	S-GP
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O
In	O
lymphoid	B-cell_type
cells	E-cell_type
,	O
only	O
the	O
upstream	B-DNA
sequences	E-DNA
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z/R	S-GP
combination	O
,	O
and	O
the	O
AP-1	B-GP

site	E-GP
is	O
dispensable	O
.	O
These	O
data	O
suggest	O
that	O
EA-D	B-DNA
(	I-DNA
BMRF1	I-DNA
)	I-DNA
promoter	E-DNA
regulation	O
by	O
Z	S-GP
and	O
R	S-GP
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O
Complementary	B-DNA
DNA	E-DNA

encoding	O
the	O
human	B-GP
T-cell	I-GP
FK506-binding	I-GP
protein	E-GP
,	O
a	O
peptidylprolyl	B-GP
cis-trans	I-GP
isomerase	E-GP
distinct	O
from	O
cyclophilin	S-GP
.	O
The	O
recently	O
discovered	O
macrolide	O
FK506	O
has	O
been	O
demonstrated	O
to	O

have	O
potent	O
immunosuppressive	O
activity	O
at	O
concentrations	O
100-fold	O
lower	O
than	O
cyclosporin	O
A	O
,	O
a	O
cyclic	O
undecapeptide	O
that	O
is	O
used	O
to	O
prevent	O
rejection	O
after	O
transplantation	O
of	O
bone	O
marrow	O
and	O
organs	O
,	O

such	O

as	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
.	O
After	O
the	O
recent	O
discovery	O
that	O
the	O
cyclosporin	B-GP
A-binding	I-GP
protein	E-GP

cyclophilin	S-GP
is	O
identical	O
to	O
peptidylprolyl	B-GP
cis-trans	I-GP
isomerase	E-GP
,	O
a	O
cellular	B-GP
binding	I-GP
protein	E-GP
for	O
FK506	O
was	O
found	O
to	O
be	O
distinct	O
from	O
cyclophilin	S-GP
but	O
to	O
have	O
the	O
same	O
enzymatic	O
activity	O
.	O
In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
cDNA	S-DNA
coding	O
for	O
FK506-binding	O
protein	O
(	O
FKBP	S-GP
)	O
from	O
human	O
peripheral	O

blood	O
T	B-cell_type
cells	E-cell_type
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
,	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	O
,	O
reported	O
for	O
bovine	B-GP
FKBP	E-GP
.	O
The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O

The	O
first	O
40	O
residues	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
were	O
identical	O
to	O
those	O
of	O
the	O
reported	O
amino-terminal	O
sequence	O
of	O
bovine	O
FKBP	S-GP
,	O
indicating	O
that	O
the	O
DNA	O
sequence	O
isolated	O
represents	O
the	O
gene	O
coding	O
for	O
FKBP	S-GP
.	O
Computer-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O

acid	O
sequence	O
indicates	O
that	O
FKBP	S-GP
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O

sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	S-GP
.	O
This	O
result	O
suggests	O
that	O
two	O
catalytically	O
similar	O
proteins	O
,	O
cyclophilin	S-GP
and	O
FKBP	S-GP
,	O
evolved	O
independently	O
.	O
In	O
Northern	O
blot	O
analysis	O
,	O

mRNA	B-RNA
species	E-RNA
of	O
approximately	O
1.8	O
kilobases	O
that	O
hybridized	O
with	O
human	B-DNA
FKBP	I-DNA
cDNA	E-DNA
were	O
detected	O
in	O
poly	B-RNA
(	I-RNA
A	I-RNA
)	I-RNA
+	I-RNA
RNAs	E-RNA
from	O
brain	O
,	O
lung	O
,	O
liver	O
,	O
and	O
placental	B-cell_type
cells	E-cell_type
and	O
leukocytes	S-cell_type
.	O
Induction	O

of	O
Jurkat	B-cell_line
leukemic	I-cell_line
T	I-cell_line
cells	E-cell_line
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O

of	O
FKBP	B-RNA
mRNA	E-RNA
.	O
Southern	O
blot	O
analysis	O
of	O
human	B-DNA
genomic	I-DNA
DNA	E-DNA
digested	O
with	O
different	O
restriction	B-GP
enzymes	E-GP
suggests	O
the	O
existence	O
of	O
only	O
a	O
few	O
copies	O
of	O
the	O
DNA	O
sequence	O
encoding	O
FKBP	S-GP
.	O
This	O
is	O
in	O
contrast	O
to	O
the	O
result	O
that	O

as	O
many	O
as	O
20	O
copies	O
of	O
the	O
cyclophilin	B-DNA
gene	E-DNA
and	O
possible	O
pseudogenes	O
may	O
be	O
present	O
in	O
the	O
mammalian	B-DNA
genome	E-DNA
.	O
Involvement	O

of	O
a	O
second	O
lymphoid-specific	B-DNA
enhancer	I-DNA
element	E-DNA
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
gene	E-DNA
expression	O
.	O
To	O
determine	O
whether	O
enhancer	B-DNA
elements	E-DNA
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	B-DNA

(	I-DNA
OCTA	I-DNA
)	I-DNA
-nucleotide	I-DNA
motif	E-DNA
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	E-DNA
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	B-DNA

site	E-DNA

for	O
a	O
putative	B-GP
additional	I-GP
lymphoid-specific	I-GP
transcription	I-GP
factor	E-GP
,	O
designated	O
NF-microB	S-GP
,	O
in	O
the	O
murine	B-DNA
IgH	I-DNA
enhancer	E-DNA

.	O
We	O
demonstrate	O
that	O
the	O
NF-microB-binding	B-DNA
site	E-DNA
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	B-DNA
enhancer	E-DNA
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	B-DNA
enhancer	E-DNA
in	O
cells	O
of	O
the	O
B-cell	B-cell_type
lineage	E-cell_type
but	O
not	O
in	O
nonlymphoid	B-cell_type
cells	E-cell_type
.	O
This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O

OCTA	B-DNA
site	E-DNA
.	O
Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	S-DNA
and	O
OCTA	B-DNA
sites	E-DNA
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
.	O
Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	S-DNA
or	O
E3	B-DNA
site	E-DNA
in	O
a	O
70-base-pair	B-DNA
fragment	E-DNA
of	O
the	O
IgH	B-DNA
enhancer	E-DNA
that	O
lacks	O

the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
completely	O
.	O
Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O

microB	B-DNA
motif	E-DNA
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O
DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O

lymphoid-specific	B-GP
protein	E-GP
binds	O
to	O
the	O
microB	B-DNA
DNA	I-DNA
motif	E-DNA
.	O
Our	O
results	O
suggest	O
that	O
the	O
microB	B-DNA
element	E-DNA
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O

another	O
enhancer	B-DNA
element	E-DNA
is	O
essential	O
for	O
its	O
activity	O
.	O
Stimulation	O
of	O
the	O
human	O
immunodeficiency	O

virus	O
type	O
2	O
(	O
HIV-2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV-2	B-DNA
transactivator	I-DNA
gene	E-DNA
.	O
Human	O
immunodeficiency	O
virus	O

(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O
Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis	O
.	O
The	O
transactivator	B-DNA
(	I-DNA
IE-2	I-DNA
)	I-DNA
gene	E-DNA
of	O
the	O
human	O
cytomegalovirus	O

(	O

CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O
This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O

the	O
HIV-2	B-DNA
tat	I-DNA
gene	E-DNA
and	O
T-cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O

in	O
human	B-cell_type
CD4+	I-cell_type
lymphocytes	E-cell_type
.	O
While	O
the	O
HIV-2	O
and	O
HIV-1	B-DNA
tat	I-DNA
genes	E-DNA
and	O
T-cell	B-GP
activators	E-GP

apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	B-DNA
transactivator	E-DNA
in	O
combination	O
with	O
the	O
HIV-2	B-DNA
tat	E-DNA
or	O
T-cell	B-GP
activators	E-GP
may	O
employ	O
a	O
gene	O
activation	O
pathway	O

with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O
Both	O
HIV-2	O
and	O
CMV	B-DNA
transactivators	E-DNA
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O

as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	B-DNA
transactivator	E-DNA
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O
A	O
significant	O
proportion	O
of	O
transcripts	S-RNA
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	S-GP
.	O
Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
suggests	O

that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	B-cell_type
CD4+	I-cell_type
lymphocytes	E-cell_type
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
element	E-DNA
.	O
Quantitative	O
immunohistochemical	O
analysis	O
of	O

mononuclear	B-cell_type
infiltrates	E-cell_type
in	O
breast	O
carcinomas	O
--	O
correlation	O
with	O
tumour	O
differentiation	O
.	O
Inflammatory	B-cell_type
infiltrates	E-cell_type
were	O
analysed	O

in	O
tissue	O
sections	O
of	O
76	O
breast	O
carcinomas	O
by	O
counting	O
the	O
percentage	O
of	O
macrophages	S-cell_type
,	O
IgA+	B-cell_type
and	I-cell_type
IgG+	I-cell_type
plasma	I-cell_type
cells	E-cell_type
,	O
T	B-cell_type
cells	E-cell_type
with	O
their	O
subpopulations	O
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	E-cell_type
,	O
and	O
by	O
measuring	O
postcapillary	O
venules	O
(	O
PCVs	O
,	O

found	O

in	O
12	O
cases	O
)	O
within	O
the	O
infiltrates	O
.	O
These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O

and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O
A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
extent	O
of	O
inflammation	O
and	O
nuclear	O
grade	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
,	O
and	O
an	O
inverse	O
correlation	O
between	O
inflammation	O
and	O
oestrogen	B-GP
receptor	E-GP
(	O
OR	S-GP
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O

as	O
well	O
as	O
inflammation	O
and	O
progesterone	B-GP
receptor	E-GP
(	O
PR	S-GP
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
The	O
percentage	O

of	O
the	O
OKT8+	B-cell_line
suppressor/cytotoxic	I-cell_line
T	I-cell_line
cells	E-cell_line
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
In	O
addition	O
,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	O
and	O
both	O
the	O
percentage	O

of	O
the	O
OKT8+	B-cell_line
T	I-cell_line
cells	E-cell_line
(	O
P	O
less	O
than	O
0.04	O
)	O
and	O
the	O
Leu-7+	O
natural	B-cell_type
killer	I-cell_type
cells	E-cell_type
(	O
P	O
less	O
than	O
0.03	O
)	O
.	O

Reactivity	O
of	O
lymphocytes	S-cell_line
to	O
a	O
progesterone	B-GP
receptor-specific	I-GP
monoclonal	I-GP
antibody	E-GP
.	O
In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O

of	O
pregnancy	B-cell_type
lymphocytes	E-cell_type
,	O
but	O
not	O
nonpregnancy	B-cell_type
lymphocytes	E-cell_type
,	O
with	O
the	O
progesterone	B-GP
receptor-specific	I-GP
monoclonal	I-GP
antibody	E-GP
mPRI	S-GP
.	O
Using	O
an	O
avidin	S-GP
-biotin	B-GP
peroxidase	E-GP
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+/-	O
3.7	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O

=	O

27	O
)	O
of	O
pregnancy	B-cell_type
lymphocytes	E-cell_type
,	O
while	O
only	O
0.47	O
+/-	O

0.33	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	B-cell_type
lymphocytes	E-cell_type
reacted	O
with	O
the	O
antibody	O
.	O
To	O
characterize	O
the	O
receptor-bearing	O
subset	O
,	O

CD8+	B-cell_line
and	I-cell_line
CD4+	I-cell_line
cells	E-cell_line
were	O
depleted	O
by	O
complement-dependent	O
lysis	O
.	O
Depletion	O
of	O
CD8+	B-cell_line
cells	E-cell_line
was	O
accompanied	O
by	O
62	O
+/-	O
18	O
%	O
loss	O
of	O
progesterone	B-cell_line
receptor-bearing	I-cell_line
cells	E-cell_line
,	O
while	O
depletion	O
of	O
CD4+	B-cell_line
cells	E-cell_line
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	S-cell_line
.	O
In	O
nonpregnancy	B-cell_line
lymphocytes	E-cell_line
a	O
3-day	O
PHA	S-GP
treatment	O
,	O
as	O

well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor-containing	B-cell_type
cells	E-cell_type

.	O
These	O
results	O
suggest	O
that	O
pregnancy	O
,	O
but	O
not	O
nonpregnancy	O
,	O
lymphocytes	S-cell_line
contain	O
progesterone	B-GP
binding	I-GP
structures	E-GP
,	O
and	O
that	O
these	O
are	O
inducible	O
by	O
mitogenic	O
or	O
alloantigenic	O
stimuli	O
.	O
Activation	O
of	O
human	B-cell_line
CD4	I-cell_line
T	I-cell_line
lymphocytes	E-cell_line
.	O

Interaction	O
of	O
fibronectin	S-GP
with	O
VLA-5	B-GP
receptor	E-GP
on	O
CD4	B-cell_line
cells	E-cell_line
induces	O
the	O
AP-1	B-GP
transcription	I-GP
factor	E-GP
.	O
Fibronectin	S-GP
synergized	O
with	O
anti-CD3	B-GP
antibody	E-GP
to	O
promote	O
CD4	S-GP
cell	O
proliferation	O
in	O

a	O
serum-free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-cell_line
cells	E-cell_line
were	O
cultured	O
with	O
anti-CD3	S-GP
alone	O
or	O
fibronectin	S-GP
alone	O
.	O
In	O
addition	O
,	O
anti-CD29	S-GP
(	O
integrin	B-GP

beta	I-GP

1	E-GP
)	O
as	O
well	O
as	O
anti-VLA-5	S-GP
(	O

human	B-GP
fibronectin	I-GP
receptor	E-GP
)	O
antibodies	O
blocked	O
this	O
CD4	B-cell_line
cell	E-cell_line
activation	O
in	O
this	O
system	O
.	O
Although	O

anti-CD3	S-GP
alone	O
or	O
fibronectin	S-GP
alone	O
can	O
not	O
induce	O
IL-2	S-GP
message	O
by	O
CD4	B-cell_line
cells	E-cell_line
,	O
the	O
combination	O
of	O
anti-CD3	S-GP
plus	O
fibronectin	S-GP
induced	O
IL-2	S-GP
message	O
by	O
CD4	B-cell_line
cells	E-cell_line
.	O
In	O
an	O
analysis	O
of	O
the	O

molecular	O
mechanism	O
by	O
which	O
IL-2	S-GP
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	S-GP
-VLA-5	O
fibronectin	B-GP
receptor	E-GP
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	S-GP
pathway	O

of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B-GP
transcriptional	I-GP
factor	E-GP
.	O
Thus	O
the	O
VLA-5	B-GP
fibronectin	I-GP
receptor	E-GP
on	O
CD4	B-cell_line
cells	E-cell_line
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	S-GP
-	O
TCR	S-GP

-mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	S-GP
.	O
Glucocorticoid	B-GP
receptors	E-GP
on	O
mononuclear	B-cell_type
leukocytes	E-cell_type
in	O
Alzheimer	O
's	O
disease	O
.	O
Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O
In	O
an	O
exploration	O
of	O

the	O
potential	O
role	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
in	O
AD	O
,	O
GR	O
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	B-cell_type
leukocytes	E-cell_type
of	O
12	O
AD	O
patients	O

and	O

12	O
healthy	O
controls	O
.	O
GR	O
binding	O
characteristics	O
did	O
not	O
differ	O

between	O
patients	O
and	O
controls	O
or	O
between	O
patients	O
subdivided	O
according	O
to	O
diagnosis	O
or	O
associated	O
clinical	O
features	O
.	O
These	O
data	O
suggest	O
that	O
the	O

abnormalities	O
of	O
the	O
HPA	O
system	O
in	O
AD	O
are	O
not	O
related	O
to	O
a	O
GR	S-GP
deficiency	O
.	O
Oncogene	O
amplification	O
correlates	O
with	O
dense	O
lymphocyte	O
infiltration	O
in	O
human	O
breast	O
cancers	O
:	O
a	O
role	O
for	O
hematopoietic	B-GP
growth	I-GP
factor	E-GP
release	O
by	O

tumor	B-cell_type
cells	E-cell_type
?	O
One	O
hundred	O
six	O
primary	O
breast	O
cancer	O
samples	O
were	O
analysed	O
for	O
c-erbB2	O
,	O
int-2	O
,	O
and	O
c-myc	O
gene	O
amplification	O
.	O

Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42	O
%	O
.	O
Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O

blot	O

techniques	O
.	O
Amplified	O
c-erbB2	B-DNA
gene	I-DNA
sequences	E-DNA
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O
Int-2	S-DNA
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c-myc	S-DNA

was	O
amplified	O
in	O
10.3	O
%	O
.	O
In	O
a	O
non-parametric	O
test	O
(	O
Kruskal-Wallis	O
)	O
a	O
strong	O
negative	O
association	O
was	O
found	O

between	O
high	O
levels	O
of	O
c-erbB2	S-DNA
amplification	O
and	O
absence	O
of	O
estrogen	O

receptor	O
(	O
ER	O
)	O
(	O
P	O
=	O
.0009	O
)	O
or	O
progesterone	B-GP
receptor	E-GP
(	O

PR	S-GP
)	O
(	O
P	O
=	O
.011	O
)	O
expression	O
.	O
No	O
correlations	O
were	O
found	O

between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O

T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ	O
.	O
There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c-erbB2	S-DNA
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(	O
P	O
=	O
0.09	O
)	O
.	O
A	O
somewhat	O
surprising	O
finding	O

however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	S-DNA
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(	O
P	O
=	O
.05	O
)	O
.	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O

considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.0007	O
)	O
.	O
We	O
propose	O
that	O
malignant	O

cell	O
cytokine	S-GP
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O
Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B-GP
factor	I-GP
NF-kappa	I-GP
B	E-GP
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	B-GP
Tax	I-GP
protein	E-GP
.	O
Transient	O
short-term	O
expression	O
of	O
the	O
Tax	B-GP
protein	E-GP
of	O
human	O
T-cell	O
leukemia	O
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	B-GP
factor	I-GP
NF-kappa	I-GP
B	E-GP
.	O
Consistent	O
with	O
findings	O

obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	B-GP

factor	I-GP

NF-kappa	I-GP
B	E-GP
in	O
the	O
nucleus	O
of	O
Namalwa	B-cell_line
B	I-cell_line
lymphoid	I-cell_line
cells	E-cell_line
,	O
which	O
constitutively	O
express	O
Tax	S-GP
.	O
In	O
contrast	O
,	O
NF-kappa	B-GP

B	E-GP
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long-term	O
expression	O
of	O
Tax	S-GP
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	E-cell_line
.	O
The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	S-GP
to	O
activate	O

NF-kappa	B-GP
B	E-GP
was	O
also	O
blocked	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
constitutively	O
expressing	O
Tax	S-GP
.	O
However	O
,	O
the	O
activation	O
of	O
other	O
mitogen-inducible	B-GP
transcription	I-GP
factors	E-GP
,	O
such	O
as	O
Fos	S-GP
and	O
Jun	S-GP
,	O
was	O
unaffected	O
.	O
Thus	O
,	O

depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	S-GP
expression	O
can	O
be	O
quite	O
different	O
.	O
Consequently	O
,	O
one	O

function	O
of	O
Tax	S-GP
in	O
cells	O
infected	O
with	O
HTLV-I	O
might	O
involve	O
cell-type-specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O

pathways	O
.	O
The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O

selective	O
regulation	O
of	O
gene	O
expression	O
.	O
Interferon-gamma	S-GP
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O
The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O

autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O
In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O

further	O
implicating	O
the	O
lymphokine	S-GP
interferon-gamma	S-GP
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O
Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O

as	O

other	O
cytokines	S-GP
,	O
may	O
help	O
explain	O
the	O
gender-specific	O

differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O
Cloning	O
of	O
a	O
transcriptionally	B-GP
active	I-GP
human	I-GP
TATA	I-GP
binding	I-GP

factor	E-GP
.	O
Transcription	B-GP
factor	I-GP
IID	E-GP
(	O
TFIID	S-GP
)	O
binds	O
to	O
the	O
TATA	B-DNA
box	I-DNA
promoter	I-DNA
element	E-DNA
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	B-DNA
genes	E-DNA
transcribed	O
by	O
RNA	B-GP
polymerase	I-GP

II	E-GP
.	O
Complementary	B-DNA
DNA	E-DNA
(	O
cDNA	S-DNA
)	O
encoding	O
a	O
human	B-GP
TFIID	I-GP
protein	E-GP
has	O
been	O
cloned	O
.	O
The	O
human	B-GP
TFIID	I-GP
polypeptide	E-GP
has	O
339	O
amino	O
acids	O
and	O
a	O
molecular	O
size	O
of	O
37	O

,	O

745	O
daltons	O
.	O
The	O
carboxyl-terminal	B-GP
181	I-GP
amino	I-GP
acids	E-GP
of	O
the	O

human	B-GP
TFIID	I-GP
protein	E-GP
shares	O
80	O
%	O
identity	O
with	O
the	O
TFIID	S-GP
protein	O
from	O
Saccharomyces	O
cerevisiae	O
.	O
The	O
amino	B-GP
terminus	E-GP
contains	O
an	O
unusual	O
repeat	O
of	O
38	O
consecutive	O
glutamine	O
residues	O

and	O
an	O
X-Thr-Pro	B-GP
repeat	E-GP
.	O
Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O

coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O
A	O
novel	O
T-cell	B-GP

trans-activator	E-GP
that	O
recognizes	O
a	O
phorbol	B-DNA
ester-inducible	I-DNA
element	E-DNA
of	O
the	O
interleukin-2	B-DNA
promoter	E-DNA
.	O
The	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
promoter	E-DNA
is	O
recognized	O

by	O
several	O
cell-type-specific	B-GP
and	I-GP
ubiquitous	I-GP
transcriptional	I-GP
regulators	E-GP
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O

IL-2	S-GP
production	O
and	O
T-cell	S-cell_type
activation	O
.	O
Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O

the	O

novel	B-GP
T-cell-specific	I-GP
transcriptional	I-GP
activator	E-GP
TCF-1	S-GP
(	O
for	O
T-Cell	B-GP
Factor-1	E-GP
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	B-DNA

response	I-DNA
element	E-DNA
(	O
TCE	S-DNA
)	O
located	O
within	O
the	O
IL-2	B-DNA
promoter	E-DNA
.	O
Although	O
the	O
TCE	S-DNA
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	B-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
site	E-DNA
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	S-GP
is	O
distinct	O

from	O
NF	B-GP
kappa	I-GP
B	E-GP
.	O
However	O
,	O
like	O
NF	B-GP
kappa	I-GP
B	E-GP
,	O
TCF-1	S-GP
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T-cell	O
activators	O
.	O
Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	O
treated	O
by	O
conservation	O
therapy	O
.	O
Risk	O
factors	O
for	O

local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I-II	O
patients	O
with	O
infiltrating	O
ductal	O
carcinomas	O
(	O
median	O
follow-up	O
,	O
71	O
months	O
)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O

.	O
Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate/marked	O
mononuclear	O
cell	O
reaction	O
(	O

MCR	O

)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O

,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B-GP
receptor	E-GP
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O
Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O

in	O
Cox	O
multivariate	O
analysis	O
.	O
These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O
Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR/EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins	O
:	O
tumors	O
with	O
MCR	O
had	O
a	O
28	O
%	O
,	O
and	O
with	O

EIC	O
a	O
22	O
%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years	O
.	O
Premenopausal	O
patients	O

with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2.6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O
For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O

recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade	O
,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	O
with	O
positive	O
or	O
indeterminate	O
margins	O
(	O
31	O
%	O
at	O
5	O
years	O
)	O
.	O
The	O
authors	O

conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O

majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O
High-risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O
The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O
Tax	S-GP
-independent	O
binding	O
of	O
multiple	O

cellular	B-GP
factors	E-GP
to	O
Tax-response	B-DNA
element	I-DNA
DNA	E-DNA
of	O
HTLV-I	O
.	O
The	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	E-DNA
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O

TRE	S-DNA
(	O
Tax-response	B-DNA
element	E-DNA
)	O
that	O
is	O

responsive	O
to	O
the	O
virally	B-GP
encoded	I-GP
transactivator	I-GP
protein	E-GP
Tax	S-GP
.	O
We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B-GP
proteins	E-GP
from	O
C81-66-45	O
cells	O
,	O
an	O

HTLV-I	B-cell_line

immortalized	I-cell_line
Tax-expressing	I-cell_line
human	I-cell_line
T-lymphocyte	I-cell_line
line	E-cell_line
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O

interact	O
with	O
the	O
TRE-DNA	S-DNA
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax-protein	S-GP
.	O
The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O
Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O

proteins	O
.	O
First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	B-GP
proteins	E-GP
were	O
specifically	O
cross-linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE-DNA	B-DNA
fragment	E-DNA
.	O
Second	O
,	O
TRE-DNA	B-GP
binding	I-GP
proteins	E-GP
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O

corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O
Third	O
,	O
only	O

the	O
50	B-GP
kD	I-GP
protein	E-GP
was	O
retained	O
on	O
a	O
biotinylated	O
DNA-streptavidin	O

matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE-DNA	S-DNA
.	O
Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	S-DNA
-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	B-GP
,	I-GP
36	I-GP

to	I-GP
42	I-GP
and	I-GP
110	I-GP
kD	I-GP
proteins	E-GP
and	O
to	O
less	O
extent	O
the	O
50	B-GP
kD	I-GP
factor	E-GP
.	O
Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O

d	O
(	O
I-C	O
)	O
]	O
in	O
all	O
reactions	O
.	O
The	O
cAMP-response	B-DNA
element	E-DNA
CRE	S-DNA
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	B-DNA
base-pair	I-DNA
sequence	E-DNA

,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	S-DNA
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O
This	O
result	O
suggests	O
that	O
the	O
cAMP	B-GP
response	I-GP
element	I-GP
binding	I-GP
protein	E-GP
,	O

CREB	S-GP
,	O
is	O
involved	O
in	O
the	O
protein-TRE-DNA	B-GP
complex	E-GP
and	O
in	O
mediating	O
the	O
Tax	S-GP
response	O
.	O
Two	O
distinct	O
transcription	B-GP
factors	E-GP
that	O
bind	O
the	O
immunoglobulin	B-DNA

enhancer	E-DNA
microE5/kappa	B-DNA
2	I-DNA
motif	E-DNA
.	O
Activity	O
of	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
and	I-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
enhancers	E-DNA
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	B-GP
and	I-GP
developmentally	I-GP
regulated	I-GP
proteins	E-GP
.	O
Two	O
complementary	B-DNA
DNAs	E-DNA
were	O
isolated	O
that	O
encode	O

proteins	O
,	O
denoted	O
ITF-1	S-GP
and	O
ITF-2	S-GP
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5/kappa	B-DNA
2	I-DNA
motif	E-DNA
found	O
in	O
both	O
heavy	B-DNA

and	I-DNA

kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancers	E-DNA
.	O
The	O
complementary	B-DNA
DNAs	E-DNA
are	O
the	O
products	O
of	O
distinct	O

genes	O
,	O
yet	O
both	O
ITF-1	S-GP
and	O
ITF-2	S-GP
are	O
structurally	O
and	O
functionally	O
similar	O
.	O
The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O

helix-loop-helix	B-GP
motifs	E-GP
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O
Elevated	O
glucocorticoid	B-GP
receptor	E-GP
concentrations	O
before	O
and	O
after	O
glucocorticoid	O
therapy	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
.	O
The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	O
binding	O

sites	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O

and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O
Patients	O
with	O
AD	O
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B-GP
receptors	E-GP
(	O
GR	S-GP

)	O

per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	S-GP
affinity	O
did	O
not	O
differ	O

.	O
Methylprednisolone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	S-GP
sites	O
per	O
cell	O
in	O
the	O
steroid-treated	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O
The	O
dissociation	O
constant	O
was	O
not	O
affected	O

by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O
In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	O
in	O
AD	O
and	O
findings	O
of	O
abnormal	O
cAMP	O
and	O
cAMP-phosphodiesterase	O
activity	O
,	O
the	O
elevated	O
GR	S-GP
concentrations	O
in	O
AD	O
lend	O
support	O
to	O
the	O

hypothesis	O
of	O
a	O
compensatory	O
GR	S-GP
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	O
or	O
to	O
altered	O
cAMP-induced	O
GR	S-GP
expression	O
.	O
The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O

a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
.	O
Cyclosporin	O
A	O
and	O

FK506	O
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	S-GP
produced	O
by	O
T	B-cell_type
lymphocytes	E-cell_type
.	O
Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	B-GP
protein	E-GP
,	O
cyclophilin	S-GP
and	O
FKBP	S-GP
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O

Using	O

constructs	O
in	O
which	O
mRNA	S-RNA
production	O
controlled	O
by	O
a	O
specific	O
transcription	B-GP
factor	E-GP
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O

both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF-AT	S-GP
,	O
NFIL2	B-GP
A	E-GP
,	O
NFIL2	B-GP
B	E-GP
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O

NF	B-GP
kappa	I-GP
B	E-GP
.	O
Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O
However	O
,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2+	O
mobilization	O

dependent	O
expression	O
of	O
c-fos	B-RNA
mRNA	E-RNA
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O
Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	B-GP
factors	E-GP
which	O
suggests	O

that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2+	O
dependent	O
step	O
that	O

regulates	O
several	O
transcription	B-GP
factors	E-GP
.	O
The	O
internal	O
methionine	O
codons	O
of	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
II	I-DNA
rex	I-DNA
gene	E-DNA
are	O
not	O
required	O
for	O
p24rex	S-GP
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O
Human	O
T-cell	O
leukemia	O

virus	O
types	O
I	O
(	O
HTLV-I	O
)	O
and	O
II	O
(	O
HTLV-II	O
)	O
have	O
two	O
nonstructural	B-DNA
trans-acting	I-DNA
regulatory	I-DNA
genes	E-DNA
,	O
tax	S-DNA
and	O
rex	S-DNA
,	O
located	O
in	O
the	O
3	B-DNA
'	I-DNA
region	E-DNA
of	O
the	O
viral	B-DNA
genome	E-DNA
.	O
The	O
tax	B-GP
gene	I-GP
product	E-GP
(	O
HTLV-I	B-GP
p40tax	E-GP
and	O
HTLV-II	B-GP
p37tax	E-GP
)	O

is	O

the	O
transcriptional	O
activator	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
.	O
The	O
rex	B-DNA
gene	E-DNA
encodes	O
two	O
protein	O
products	O
,	O
p27rex/p21rex	S-GP
and	O
p26rex/p24rex	S-GP
in	O
HTLV-I	O
and	O
HTLV-II	O

,	O
respectively	O
.	O
Rex	S-GP
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full-length	O
gag/pol	S-GP
and	O
singly	O
spliced	O
env	B-RNA
mRNA	E-RNA
in	O
the	O
cytoplasm	O
of	O
HTLV-infected	B-cell_type
cells	E-cell_type
.	O
Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B-DNA
gene	E-DNA
is	O

critical	O
for	O
Rex	S-GP
production	O
and	O
function	O
.	O
The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	S-GP
function	O
is	O
not	O
known	O
.	O
However	O
,	O

in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV-I	O
rex	B-DNA
gene	E-DNA
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	S-GP
,	O
and	O

by	O
analogy	O
HTLV-II	O
p24rex	S-GP
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax/rex	B-RNA
mRNA	E-RNA
.	O
By	O
using	O
an	O
infectious	O

molecular	O
clone	O
of	O
HTLV-II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-DNA
gene	E-DNA
on	O
Rex	S-GP

protein	O
production	O
and	O
function	O
.	O
Our	O
results	O
indicate	O
that	O
p24rex	S-GP
of	O
HTLV-II	O
is	O

not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-DNA
gene	E-DNA
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O
Astrocytes	S-cell_type
and	O
glioblastoma	B-cell_type
cells	E-cell_type

express	O
novel	O
octamer-DNA	B-GP
binding	I-GP
proteins	E-GP
distinct	O
from	O
the	O
ubiquitous	B-GP
Oct-1	I-GP
and	I-GP
B	I-GP
cell	I-GP
type	I-GP
Oct-2	I-GP
proteins	E-GP
.	O
The	O
'octamer	B-DNA
'	I-DNA
sequence	E-DNA
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O

is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
in	O
B-lymphocytes	S-cell_type
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	B-DNA
genes	E-DNA
in	O
all	O
cell	O
types	O
.	O
In	O
lymphocytes	S-cell_type
,	O
the	O
octamer-binding	B-GP
protein	E-GP
Oct-2A	S-GP
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O

the	O

B-cell	B-DNA
specific	I-DNA
gene	E-DNA
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct-1	O
seems	O
to	O
control	O
general	O
octamer	B-DNA
site	E-DNA
-dependent	O
transcription	O
.	O
Various	O
other	O

genes	O
,	O
for	O
example	O
interleukin-1	B-DNA
and	I-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
,	O
contain	O
an	O
octamer	B-DNA
sequence	E-DNA
in	O
the	O
promoter	S-DNA
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O
This	O
prompted	O
us	O
to	O
analyze	O
the	O

octamer-binding	B-GP
proteins	E-GP
in	O
the	O
latter	O
cells	O
.	O
Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	B-GP
binding	I-GP
proteins	E-GP
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	B-cell_type
mouse	I-cell_type
astrocytes	E-cell_type
.	O
These	O
proteins	O
are	O
differentially	O

expressed	O
in	O
human	B-cell_line
glioblastoma	I-cell_line
and	I-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
The	O
nervous	B-GP
system-derived	I-GP
(	I-GP
N-Oct	I-GP
)	I-GP
proteins	E-GP
bound	O
to	O
the	O
octamer	B-DNA
DNA	I-DNA
sequence	E-DNA
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	S-GP
and	O
Oct-2A	B-GP

proteins	E-GP
.	O
The	O
relationship	O
of	O
the	O
N-Oct	B-GP
proteins	E-GP
to	O
Oct-1	S-GP
and	O
Oct-2A	S-GP
was	O

analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	S-GP
and	O
Oct-2A	S-GP
proteins	O
.	O
On	O
the	O
basis	O
of	O

these	O
assays	O
,	O
all	O
N-Oct-factors	S-GP
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	B-GP

Oct-1	E-GP
and	O
the	O
lymphoid-specific	B-GP
Oct-2A	E-GP
proteins	O
.	O
In	O
melanoma	B-cell_type
cells	E-cell_type
that	O
contain	O
the	O
N-Oct-3	B-GP
factor	E-GP
,	O
a	O
transfected	O
lymphocyte-specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O

repressed	O
upon	O
contransfection	O
with	O
an	O
Oct-2A	B-DNA
expression	I-DNA
vector	E-DNA
.	O
We	O
therefore	O
speculate	O
that	O
N-Oct-3	S-GP
and	O
other	O
N-Oct	B-GP
factors	E-GP
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O

.	O
Detection	O
in	O
non-erythroid	B-cell_type
cells	E-cell_type
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	B-GP
cell	I-GP
transcription	I-GP
factor	E-GP
EF1	S-GP
.	O
The	O
erythroid	B-GP
transcription	I-GP
factor	E-GP

erythroid	B-GP
factor-1	E-GP
(	O
EF1	S-GP
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid-specific	B-DNA
genes	E-DNA
.	O
Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O

sequence-specific	O
DNA-binding	O
characteristics	O
of	O
EF1	S-GP
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non-erythroid	B-cell_type
cell	I-cell_type
types	E-cell_type
.	O
This	O
is	O
the	O
first	O
report	O
of	O

an	O

EF1	S-GP
-like	O
activity	O
in	O
non-erythroid	B-cell_type
cells	E-cell_type
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O

genes	S-DNA
expressed	O
in	O
such	O
cells	O
.	O
Protein	O
kinase	O
inhibitor	O
H-7	O
blocks	O
accumulation	O
of	O
unspliced	B-RNA
mRNA	E-RNA
of	O
human	O
T-cell	O
leukemia	O
virus	O

type	O
I	O
(	O
HTLV-I	O
)	O
.	O
Rex	S-GP
,	O
the	O
post-transcriptional	B-GP
regulator	E-GP
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
,	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O

unspliced	B-RNA
viral	I-RNA
gag-pol	I-RNA
mRNA	E-RNA
.	O
Rex	S-GP
is	O
a	O
phosphoprotein	S-GP
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O
We	O
have	O
examined	O
the	O
role	O
of	O

phosphorylation	O

on	O
Rex	S-GP
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H-7	O
[	O
1-	O
(	O
5-isoquinolinyl-sulfonyl	O
)	O
-2-methylpiperazine	O
]	O
.	O
Treatment	O

of	O
an	O
HTLV-I	B-cell_line
infected	I-cell_line
human	I-cell_line
T-cell	I-cell_line
line	E-cell_line
with	O
H-7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	B-RNA
gag-pol	I-RNA
mRNA	E-RNA
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B-GP
protein	E-GP
synthesis	O
that	O
corresponds	O
with	O

the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	S-GP
.	O
In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O

the	O
level	O
of	O
H-7	O
used	O
.	O
Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	S-GP
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV-I	O
.	O
Increased	O
glucocorticoid	O
responsiveness	O
of	O

CD4+	B-cell_line
T-cell	I-cell_line
clonal	I-cell_line
lines	E-cell_line
grown	O
in	O
serum-free	O
media	O
.	O
CEM-C7	S-cell_line
,	O
a	O
human	B-cell_line
leukemic	I-cell_line
CD4+	I-cell_line
T-lymphocyte	I-cell_line
cell	I-cell_line
line	E-cell_line
and	O
three	O
of	O
its	O
subclones	O
,	O
CEM-4R4	S-cell_line
,	O
CEM-3R43	S-cell_line
,	O
and	O
ICR-27	S-cell_line
,	O
previously	O
cultured	O
in	O
a	O
medium	O
supplemented	O

with	O
5	O
to	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
have	O
been	O
adapted	O
to	O
serum-free	O
media	O
.	O
The	O
best	O
medium	O

of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms/ml	O
each	O
transferrin	S-GP
and	O
insulin	S-GP
+	O
5	O

ng/ml	O

sodium	O
selenite	O
+/-	O
0.1	O
%	O
bovine	B-GP
serum	I-GP
albumin	E-GP
.	O
While	O
growing	O
either	O
with	O

or	O
without	O
albumin	O
,	O
the	O
several	O
clonal	B-cell_line
lines	E-cell_line
of	O
CEM	S-cell_line
cells	O
displayed	O
growth	O
similar	O
to	O
serum-supplemented	O
cultures	O
.	O
Cell	O
proliferation	O
of	O
CEM-C7	S-cell_line
cells	O
cultured	O
in	O
both	O
serum-free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O
with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O

both	O
serum-supplemented	B-cell_line
and	I-cell_line
serum-free	I-cell_line
cultures	E-cell_line
(	O
viability	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
)	O
.	O
Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum-free	O
or	O
serum	O
containing	O
media	O
.	O

The	O
expression	O
of	O
CD4	S-GP
,	O
a	O
marker	O
for	O
T-derived	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
,	O
was	O
not	O
significantly	O
different	O
in	O
serum-free	O
medium	O
.	O
When	O
grown	O

in	O
serum-free	O
medium	O
,	O
CEM-C7	S-cell_line
cells	O
exhibited	O
increased	O
steroid	O
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	B-GP
receptor	E-GP
binding	O

sites	O
,	O
increased	O
induction	O
of	O
glutamine	B-GP
synthetase	E-GP
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	O
.	O
Receptor	O
mutant	O
subclones	O
of	O
CEM-C7	S-cell_line
,	O
which	O
are	O

proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	O
when	O
grown	O
in	O

serum-supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium	O
.	O
The	O
increased	O
sensitivity	O
of	O
CEM-C7	B-cell_line

cells	E-cell_line
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum-free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum-containing	O
medium	O
.	O
Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O

that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O
[	O
Glucocorticoid	B-GP
receptors	E-GP
on	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	E-cell_type
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O

]	O
It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B-GP
receptors	E-GP
(	O
GCR	S-GP
)	O
on	O
peripheral	B-cell_type
mixed	I-cell_type
leucocytes	E-cell_type
in	O
patients	O
with	O
Yang-deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	B-cell_type
leucocytes	E-cell_type
were	O
further	O
separated	O
into	O
mononuclear	B-cell_type
(	I-cell_type
MNL	I-cell_type
)	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
(	I-cell_type
PML	I-cell_type
)	I-cell_type
leucocytes	E-cell_type
,	O
and	O
GCR	S-GP
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	S-cell_type
.	O
GCR	S-GP
on	O

MNL	S-cell_type

and	O
PML	S-cell_type
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+/-	O
413	O
and	O
4433	O
+/-	O
651	O
sites/cell	O
respectively	O

,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+/-	O
962	O
and	O
5622	O
+/-	O
782	O
sites/cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O
GCR	S-GP

on	O
MNL	S-cell_type
,	O
PML	S-cell_type
and	O
mixed	B-cell_type
leucocytes	E-cell_type
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O
The	O
results	O
were	O
3369	O
+/-	O
370	O
,	O
4986	O
+/-	O
419	O

and	O
4524	O
+/-	O
852	O
sites/cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	S-GP
on	O
MNL	S-cell_type
and	O
highest	O
on	O
PML	S-cell_type
.	O
The	O
ubiquitous	B-GP
octamer-binding	I-GP
protein	E-GP
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
.	O
All	O
immunoglobulin	B-DNA
genes	E-DNA
contain	O
a	O
conserved	O
octanucleotide	B-DNA
promoter	I-DNA
element	E-DNA
,	O
ATGCAAAT	O
,	O

which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell-specific	O
transcription	O
.	O
Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O

cDNAs	S-DNA
encoding	O
octamer-binding	B-GP
proteins	E-GP
have	O
been	O
cloned	O
.	O
Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	S-GP
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O

and	O

possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	S-GP
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O

types	O
.	O
The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
is	O
unclear	O
.	O
We	O
have	O
identified	O
two	O
human	B-cell_line

pre-B-cell	I-cell_line
lines	E-cell_line
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	S-GP
yet	O
still	O
express	O
high	O
levels	O
of	O
steady-state	B-RNA
immunoglobulin	I-RNA
heavy-chain	I-RNA

mRNA	E-RNA
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	B-DNA
gene	E-DNA
in	O
vitro	O
.	O
Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	S-GP
made	O
from	O
one	O
of	O
these	O
pre-B	B-cell_line
cells	E-cell_line
or	O
from	O
HeLa	B-cell_line
cells	E-cell_line
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O

immunoglobulin	B-DNA
gene	E-DNA
.	O
Furthermore	O
,	O
OFT-1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	S-GP
when	O
normalized	O

for	O
binding	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
OTF-1	S-GP
,	O
without	O
OTF-2	S-GP
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
and	O
that	O
OTF-2	S-GP
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	E-DNA
expression	O

.	O
Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O
In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	B-GP
receptors	E-GP
on	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
(	O
HML	S-cell_type

)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	S-cell_type
have	O
already	O
been	O
described	O
.	O
In	O

the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	O
.	O
In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	S-cell_type
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O

range	O

for	O
normal	O
persons	O
.	O
A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O

without	O
aldosterone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	O
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O
Plasma	B-GP
renin	E-GP
activity	O
and	O

aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O
The	O
number	O
of	O
mineralocorticoid	B-GP

receptors	E-GP
/cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(	O
n	O
=	O
9	O
)	O
.	O
The	O
independence	O
of	O

intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B-GP
receptors	E-GP
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O

mechanism	O
in	O
the	O
HML	S-cell_type
of	O
patients	O
with	O
essential	O
hypertension	O
.	O
[	O
Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1	O
,	O

25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
determination	O
in	O
lymphocytes	S-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
]	O
The	O
authors	O
provide	O

the	O
results	O
of	O
studying	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
in	O
lymphocytes	S-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O

.	O
It	O
is	O
proposed	O
that	O
the	O
character	O
of	O
their	O
expression	O
under	O
the	O
influence	O
of	O
vitamin	O
D	O
may	O
be	O
used	O
with	O
differential	O
diagnostic	O
purposes	O
in	O
view	O
.	O
Regulation	O
of	O
gene	O
expression	O
with	O
double-stranded	O

phosphorothioate	O

oligonucleotides	O
.	O
Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	B-GP
regulatory	I-GP
proteins	E-GP
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O
Inhibition	O
of	O
sequence-specific	B-GP
DNA-binding	I-GP
proteins	E-GP
was	O
achieved	O

with	O
double-stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	B-DNA
or	I-DNA
kappa	I-DNA
B	I-DNA
consensus	I-DNA
sequences	E-DNA
.	O
The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	B-GP
transcription	I-GP
factor	E-GP

or	O

nuclear	B-GP
factor	I-GP
(	I-GP
NF	I-GP
)	I-GP
-kappa	I-GP
B	E-GP
.	O
The	O

modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O
Octamer-dependent	O
activation	O
of	O

a	O
reporter	B-DNA
plasmid	E-DNA
or	O
NF-kappa	B-GP
B	E-GP
-dependent	O
activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
enhancer	E-DNA

was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	B-cell_line
transfected	I-cell_line
B	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O
Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O

the	O
octamer	B-DNA
consensus	E-DNA
to	O
Jurkat	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
inhibited	O
interleukin-2	S-GP
(	O
IL-2	S-GP
)	O
secretion	O
to	O
a	O
degree	O
similar	O

to	O
that	O
observed	O
with	O
a	O
mutated	B-DNA
octamer	I-DNA
site	E-DNA
in	O
the	O
IL-2	B-DNA
enhancer	E-DNA
.	O
The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O

of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti-viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O
[	O
Effect	O
of	O
the	O
regimen	O
of	O
kidney-tonifying	O
and	O
qi-invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B-GP
receptor	E-GP
]	O
The	O
plasma	O
cortisol	O
concentration	O
and	O

the	O
sites	O
of	O
glucocorticoid	B-GP
receptor	E-GP
(	O
GCR	S-GP
)	O
in	O
the	O
peripheral	B-cell_type
lymphocytes	E-cell_type
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O
In	O
animal	O
experiment	O
,	O
GCR	S-GP
of	O
spleen	B-cell_type
lymphocytic	I-cell_type
cell	E-cell_type
was	O
also	O
measured	O
in	O

18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O
The	O
results	O
showed	O
that	O
GCR	S-GP
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O

in	O

the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
did	O
n't	O
change	O
with	O
aging	O
.	O
So	O
we	O
think	O

that	O
GCR	S-GP
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O
After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney-tonifying	O

and	O
Qi-invigorating	O
,	O
the	O
GCR	S-GP
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O

of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O
Interferon	O
affects	O
nuclear	B-GP
proteins	E-GP
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O
Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	B-cell_type
myelogenous	I-cell_type
leukemia	I-cell_type
(	I-cell_type

CML	I-cell_type
)	I-cell_type
cells	E-cell_type
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	B-GP
proteins	E-GP
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	O
(	O

IFN	O
)	O
-inducible	O
genes	O
.	O
Exposure	O
of	O
CML	B-cell_type
cells	E-cell_type
to	O
IFN-alpha	S-GP
diminished	O
the	O
effect	O
of	O
the	O
CML	B-GP
cytoplasmic	I-GP
proteins	E-GP
on	O
these	O
nuclear	B-GP
protein-DNA	I-GP
complexes	E-GP
.	O
The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN-alpha	S-GP
correlated	O
with	O
the	O
sensitivity	O
to	O

the	O

IFN	S-GP
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	B-GP
protein-DNA	I-GP
complexes	E-GP
.	O
These	O
data	O

suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	S-GP
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B-GP
proteins	E-GP
.	O
Epstein-Barr	B-GP
virus	I-GP
nuclear	I-GP
antigen	I-GP
2	E-GP
transactivates	O
latent	B-GP
membrane	I-GP
protein	E-GP
LMP1	S-GP
.	O
Several	O
lines	O

of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein-Barr	B-GP
virus	I-GP
(	I-GP
EBV	I-GP
)	I-GP
nuclear	I-GP
antigen	I-GP
2	E-GP
(	O
EBNA-2	S-GP
)	O
or	O

leader	B-GP
protein	E-GP
(	O
EBNA-LP	S-GP
)	O
affects	O
expression	O
of	O
the	O
EBV	B-GP
latent	I-GP
infection	I-GP
membrane	I-GP
protein	E-GP
LMP1	S-GP
.	O
We	O
now	O
demonstrate	O
the	O
following	O
.	O
(	O
i	O
)	O

Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	S-GP
under	O
control	O
of	O
simian	B-DNA
virus	I-DNA
40	I-DNA
or	I-DNA
Moloney	I-DNA
murine	I-DNA
leukemia	I-DNA
virus	I-DNA
promoters	E-DNA
resulted	O
in	O
increased	O
LMP1	S-GP
expression	O
in	O
P3HR-1-infected	B-cell_line
Burkitt	I-cell_line

's	I-cell_line

lymphoma	I-cell_line
cells	E-cell_line
and	O
the	O
P3HR-1	S-cell_line
or	O
Daudi	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O
(	O

ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA-LP	S-GP
alone	O
had	O
no	O
effect	O
on	O
LMP1	S-GP
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA-2	S-GP
to	O
affect	O
LMP1	S-GP
expression	O
.	O
(	O
iii	O
)	O
LMP1	S-GP
expression	O
in	O
Daudi	S-cell_line
and	O
P3HR-1-infected	B-cell_line
cells	E-cell_line
was	O
controlled	O

at	O
the	O
mRNA	S-RNA
level	O
,	O
and	O

EBNA-2	S-GP
expression	O
in	O
Daudi	B-cell_line
cells	E-cell_line
increased	O
LMP1	B-RNA
mRNA	E-RNA
.	O
(	O
iv	O
)	O
No	O
other	O
EBV	B-DNA
genes	E-DNA
were	O
required	O
for	O
EBNA-2	S-GP
transactivation	O
of	O
LMP1	S-GP
since	O
cotransfection	O
of	O
recombinant	B-DNA
EBNA-2	I-DNA
expression	I-DNA
vectors	E-DNA
and	O
genomic	O
LMP1	B-DNA
DNA	I-DNA
fragments	E-DNA
enhanced	O
LMP1	S-GP
expression	O
in	O
the	O

EBV-negative	B-cell_line
B-lymphoma	I-cell_line
cell	I-cell_line
lines	E-cell_line
BJAB	S-cell_line
,	O
Louckes	S-cell_line
,	O
and	O
BL30	S-cell_line
.	O
(	O
v	O
)	O
An	O
EBNA-2-responsive	B-DNA
element	E-DNA
was	O
found	O
within	O
the	O
-512	B-DNA
to	I-DNA
+40	I-DNA
LMP1	I-DNA
DNA	E-DNA
since	O

this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	E-DNA
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA-2	B-DNA
expression	I-DNA
vector	E-DNA
.	O
(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA-2	S-GP

transactivated	O
LMP1	S-GP
as	O
well	O
as	O
the	O
EBV	B-GP
type	I-GP
1	I-GP
EBNA-2	E-GP
.	O
(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	S-GP
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	S-GP
,	O
whereas	O
a	O
transformation-competent	B-DNA
EBNA-2	I-DNA
deletion	I-DNA
mutant	E-DNA
did	O
transactivate	O
LMP1	S-GP
.	O
LMP1	S-GP
is	O

a	O
potent	O
effector	O
of	O
B-lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	S-GP
to	O
induce	O
cellular	O
CD23	O
gene	O
expression	O
.	O
Thus	O
,	O
EBNA-2	S-GP
transactivation	O
of	O
LMP1	S-GP
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA-2	S-GP
and	O
underscores	O
its	O
central	O

role	O
in	O
EBV-induced	O
growth	O
transformation	O
.	O
The	O
expression	O
of	O
c-fos	S-DNA
,	O
c-jun	S-DNA
,	O
and	O
c-myc	B-DNA
genes	E-DNA
is	O
regulated	O
by	O

heat	O
shock	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
.	O
The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	B-DNA
protooncogenes	E-DNA
c-fos	S-DNA
,	O
c-jun	S-DNA
,	O
and	O
c-myc	S-DNA
was	O
studied	O
in	O
human	B-cell_type

lymphoid	I-cell_type
cells	E-cell_type
.	O
Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c-fos	O
and	O
c-jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c-myc	B-RNA
mRNA	E-RNA
levels	O

in	O
pre-B	B-cell_line
(	I-cell_line
Hyon	I-cell_line
)	I-cell_line
and	I-cell_line
T	I-cell_line
(	I-cell_line
DND-41	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	E-cell_line
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

The	O

changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	S-DNA
in	O
Hyon	B-cell_line
cells	E-cell_line
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O

;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O
Altered	O
transcription	O
of	O
c-fos	S-DNA
and	O
c-myc	B-DNA
genes	E-DNA
was	O

the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O
Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	B-cell_line
cells	E-cell_line
stabilized	O
the	O
c-myc	B-RNA
mRNA	E-RNA
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min	O
.	O
The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c-myc	B-RNA
mRNA	E-RNA
level	O
,	O

however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	B-DNA
protooncogenes	E-DNA
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	B-DNA
protooncogenes	E-DNA
in	O
the	O
stress	O
response	O
of	O
lymphoid	B-cell_type
cells	E-cell_type
.	O

Mapping	O
of	O
B-cell	B-GP
epitopes	E-GP
of	O
the	O
human	B-GP
hepatitis	I-GP
B	I-GP
virus	I-GP
X	I-GP
protein	E-GP
.	O
The	O
immune	O

response	O
to	O
the	O
X	B-GP
protein	E-GP
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O

of	O
MS2-HBx	B-GP
fusion	I-GP
proteins	E-GP
and	O
synthetic	O
peptides	O
.	O
Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O

multispecific	O
immune	O
response	O
.	O
Each	O
serum	O
contained	O
antibodies	S-GP
to	O
a	O
different	O
set	O
of	O
epitopes	S-GP
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	B-GP
sequence	E-GP
.	O
Some	O
of	O
the	O

epitopes	O

were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	B-GP
proteins	E-GP
;	O
others	O
were	O
detectable	O
only	O

by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O
The	O
carboxy-terminal	B-GP
half	E-GP
of	O
the	O
HBx	B-GP
protein	E-GP
was	O
preferentially	O
recognized	O
by	O
antibodies	S-GP
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O

short	O
immunodominant	B-GP
antigenic	I-GP
region	E-GP
with	O
at	O
least	O
two	O
major	O
nonoverlapping	B-GP
epitopes	E-GP
.	O
Anti-	O
HBx	S-GP
antibody	O
titers	O
as	O

revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O

and	O
asymptomatic	O
carriers	O
.	O
The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	S-GP
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	S-GP
-specific	O
peptide	O
ELISAs	O
.	O

Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O
[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	B-cell_type
leukocytes	E-cell_type
]	O
Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O

)	O
of	O
human	B-cell_type
leukocytes	E-cell_type
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O
Both	O
RM	O
and	O
ChtM	O
showed	O
circadian	O
rhythm	O
.	O
Leukocytes	S-cell_type
migrated	O
most	O
rapidly	O
at	O

night	O
.	O
The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O

significant	O
statistically	O
(	O
P	O
less	O
than	O
0.01	O
)	O

.	O

ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	O
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O

-9	O
)	O
-10	O
(	O
-7	O
)	O
mol/L	O
)	O
which	O
was	O
dose-dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O
The	O
inhibitory	O
effect	O
was	O
much	O
more	O

evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O

(	O
-5	O
)	O
mol/L	O
)	O
and	O
it	O

was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially	O
.	O
It	O
is	O
suggested	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
may	O
be	O
a	O
physiological	O
regulator	O
of	O
the	O
activity	O
of	O
leukocytes	S-cell_type
and	O
its	O
inhibitory	O
action	O

on	O
ChtM	O
may	O
be	O
involved	O
in	O
antiinflammatory	O
mechanisms	O
of	O
GC	O
of	O
pharmacological	O
doses	O
.	O
The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	O
may	O
be	O
mediated	O
by	O
low	B-GP
affinity	I-GP
specific	I-GP
binding	I-GP
sites	E-GP
of	O
glucocorticoid	B-GP
receptors	E-GP

.	O
Heterogeneity	O
of	O
antigen	B-GP
molecules	E-GP
recognized	O
by	O
anti-tax1	B-GP
monoclonal	I-GP
antibody	E-GP
Lt-4	S-GP
in	O
cell	O
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O
Using	O
a	O
monoclonal	B-GP
antibody	E-GP
,	O

Lt-4	S-GP
,	O
directed	O
against	O
human	B-GP
T	I-GP
cell	I-GP
leukemia	I-GP
virus	I-GP
type	I-GP
I	I-GP
(	I-GP
HTLV-I	I-GP
)	I-GP
trans-activator	I-GP
(	I-GP
tax1	I-GP
)	I-GP
antigen	E-GP
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	S-GP
and	O
related	O
antigens	S-GP
in	O
a	O
variety	O
of	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line

bearing	O
HTLV-I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV-I	O
)	O
and	O
HTLV-II	O
,	O
by	O
immunofluorescence	O
and	O

immunoblot	O

assays	O
.	O
Lt-4	S-GP
reacted	O
with	O
all	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	E-cell_line
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	B-cell_line
cell	I-cell_line
lines	E-cell_line
bearing	O
STLV-I	O
,	O
but	O
not	O
with	O
an	O

HTLV-II-bearing	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O
Lt-4	S-GP
detected	O
40	O
kd	O
tax1	B-GP
antigen	I-GP
molecules	E-GP
in	O
most	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	E-cell_line
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	B-GP
kd	I-GP
tax1	I-GP
antigen	E-GP
.	O
In	O
the	O
STLV-I-bearing	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
tax1-related	B-GP
antigen	I-GP
molecules	E-GP
detected	O
by	O
Lt-4	S-GP
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36-41	O
kd	O
.	O
Characterization	O
of	O
the	O
human	B-GP
immunodeficiency	I-GP
virus	I-GP
type	I-GP
1	I-GP
enhancer-binding	I-GP
proteins	E-GP
from	O
the	O
human	B-cell_line

T-cell	I-cell_line
line	E-cell_line
Jurkat	S-cell_line
.	O
The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	B-GP
proteins	E-GP
that	O
bind	O
to	O
the	O

viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
.	O
Among	O
the	O
protein-binding	O
regions	O
of	O
the	O
HIV-1	B-DNA
LTR	E-DNA
is	O
the	O
transcription-enhancer	B-DNA
region	E-DNA
.	O
We	O
show	O

that	O
at	O
least	O
one	O
inducible	S-GP
,	O
C1	S-GP
,	O
and	O
one	O
constitutive	B-GP
,	I-GP
C2	I-GP
,	I-GP
protein	E-GP
can	O
bind	O
to	O
the	O
HIV	B-DNA
enhancer	E-DNA
in	O
Jurkat	B-cell_line
cells	E-cell_line
.	O
The	O

two	O

proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O
Bivalent	O
cations	O

such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	B-DNA
domain	E-DNA
.	O
Both	O
C1	S-GP
and	O
C2	B-GP
proteins	E-GP
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O

interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	E-DNA
.	O
The	O
inducible	B-GP
C1	I-GP
protein	E-GP
was	O
partially	O
purified	O
by	O
three	O

chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross-linking	O
as	O
a	O
47	B-GP
kDa	I-GP
protein	E-GP
.	O
Differences	O
in	O
transcriptional	B-DNA
enhancers	E-DNA
of	O
HIV-1	O
and	O
HIV-2	O
.	O
Response	O
to	O
T	B-cell_type
cell	E-cell_type
activation	O

signals	O
.	O
T	B-cell_type
cell	E-cell_type
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O

one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O
In	O
HIV-1	O
,	O
the	O
sequences	O
that	O

respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
and	O
comprise	O
the	O

transcriptional	B-DNA
enhancer	E-DNA
,	O
which	O
contains	O
two	O
conserved	B-DNA
binding	I-DNA
sites	E-DNA
for	O
the	O
nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
(	O
NF	B-GP
kappa	I-GP
B	E-GP
)	O
.	O
The	O

corresponding	O

region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O

contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	B-DNA

kappa	I-DNA
B	I-DNA
binding	I-DNA
site	E-DNA
.	O
We	O
demonstrate	O
that	O
the	O
HIV-1	B-DNA
LTR	E-DNA
responds	O
better	O
than	O
the	O
HIV-2	B-DNA
LTR	E-DNA
to	O
T	O
cell	O
activation	O
signals	O
.	O
These	O
qualitative	O
differences	O
in	O
the	O

response	O
to	O
T	B-cell_type
cell	E-cell_type
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	B-DNA
or	I-DNA
HIV-2	I-DNA
enhancers	E-DNA
are	O
placed	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	E-DNA
but	O
also	O
when	O
these	O
enhancers	S-DNA
are	O
switched	O
between	O
their	O
respective	O
LTR	S-DNA
.	O
In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	B-GP
kappa	I-GP
B	E-GP
binds	O
to	O
both	O

conserved	O
sites	O
in	O
the	O
HIV-1	B-DNA
transcriptional	I-DNA
enhancer	E-DNA
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	B-DNA
transcriptional	I-DNA
enhancer	E-DNA
.	O
Instead	O
of	O
NF	B-GP

kappa	I-GP
B	E-GP
,	O
the	O
activator	B-GP
protein	I-GP
3	E-GP
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O
In	O
conclusion	O
,	O

HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O
NF-X2	S-GP
that	O
binds	O
to	O
the	O
DRA	B-DNA

X2-box	E-DNA
is	O
activator	B-GP
protein	I-GP
1	E-GP
.	O
Expression	O
cloning	O
of	O
c-Jun	S-GP
.	O
Human	B-GP
class	I-GP
II	I-GP
MHC	I-GP
Ag	E-GP
are	O
a	O
family	O
of	O
cell	B-GP
surface	I-GP
glycoproteins	E-GP
.	O
Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	B-cell_type
lymphocytes	E-cell_type

and	O
thymic	B-cell_type
epithelial	I-cell_type
cells	E-cell_type
.	O
In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN-gamma	S-GP
.	O
Conserved	O

upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	E-DNA
.	O
In	O
the	O
DRA	B-DNA
promoter	E-DNA
,	O
one	O
of	O
these	O
cis-acting	B-DNA
regulatory	I-DNA
motifs	E-DNA
is	O
the	O
X2-box	S-DNA
to	O
which	O
nuclear	B-GP
factor	I-GP
X2	E-GP
(	O
NF-X2	S-GP
)	O
binds	O

.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full-length	B-DNA
cDNA	I-DNA

clone	E-DNA
encoding	O
NF-X2	S-GP
.	O
This	O

cDNA	B-DNA
clone	E-DNA
was	O
isolated	O
by	O
expression	O
cDNA	S-DNA
cloning	O
,	O
and	O
encodes	O
the	O
human	B-GP

c-Jun	I-GP
protein	E-GP
,	O
which	O
together	O
with	O
c-Fos	S-GP
forms	O
the	O
heterodimeric	B-GP
activator	I-GP
protein-1	I-GP
transcription	I-GP

complex	E-GP
.	O
Whereas	O
c-Fos/c-Jun	B-GP
heterodimers	E-GP
do	O
not	O
exist	O
in	O
B	B-cell_line
cells	E-cell_line
,	O

they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	S-DNA
in	O
class	B-cell_line
II	I-cell_line
nonexpressing	I-cell_line
cells	E-cell_line
.	O

Thus	O
,	O
c-Fos/c-Jun	B-GP
heterodimers	E-GP
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-DNA
gene	E-DNA
expression	O
.	O
Synthesis	O
of	O
4	O
,	O
19-disubstituted	O
derivatives	O
of	O
DOC	O
.	O
Radioreceptor	O

assay	O
of	O
some	O
corticosteroid	O
derivatives	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
.	O
Several	O
new	O
4	O
,	O
19-substituted	O
steroids	O

and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	B-GP
1	I-GP
receptors	E-GP
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
.	O
11	O
beta	O
,	O
19-epoxy-4	O
,	O
21-dihydroxypregn-4-ene-3	O
,	O
20-dione	O
(	O
2	O
)	O
was	O

hydrogenated	O
with	O
Pd-C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21-diacetoxy-11	O
beta	O
,	O
19-epoxy-3-hydroxypregnan-20-one	O
(	O

6	O
)	O
and	O
21-acetoxy-11	O
beta	O
,	O
19-epoxy-4-hydroxypregnane-3	O
,	O
20-dione	O
(	O
7	O
)	O
.	O
With	O

hot	O

acetic	O
+	O
p-toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O

beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd-C	O
hydrogenation	O
of	O

3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O

19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O
Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O
Pd-C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4	O
,	O

5-dihydro	O
derivative	O
18	O
,	O
19-chloro-21-acetoxypregn-9	O
(	O
11	O
)	O
-en-20-one	O
(	O
15	O
)	O
,	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3	O
,	O
4-diacetoxy	O
derivative	O
17	O
.	O
When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B-GP
1	I-GP
receptor	E-GP
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O

=	O
100	O
%	O
)	O
.	O
For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O

5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O
Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	S-GP
(	O
nuclear	B-GP
factor	E-GP

of	O
activated	B-cell_type
T-cells	E-cell_type
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B-GP
factor	E-GP
.	O
Nuclear	B-GP
factor	E-GP
of	O
activated	B-cell_type
T-cells	E-cell_type
(	O
NFAT-1	S-GP
)	O
is	O
a	O
transcription	B-GP
factor	E-GP
which	O
is	O
considered	O
to	O
be	O

an	O
important	O
regulator	O
in	O
early	O
T-cell	O
activation	O
.	O
We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT-1	S-GP
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O
The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	S-GP
binding	O

motif	O

that	O
directs	O
transcription	B-GP
of	I-GP
SV40	I-GP
T-antigen	E-GP
in	O
transgenic	O
mice	O
.	O
This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O
NFAT-1	S-GP
activity	O
had	O
previously	O
been	O
thought	O

to	O
be	O
confined	O
to	O
activated	B-cell_type
T-lymphocytes	E-cell_type
upon	O
release	O
of	O
intracellular	B-cell_type
calcium	E-cell_type
.	O
By	O
targeting	O
NFAT-1	S-GP
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O

of	O
NFAT-1	S-GP
activity	O
.	O
Besides	O
in	O
T-lymphocytes	S-cell_type
NFAT-1	S-GP
activity	O
could	O
also	O
be	O
induced	O
in	O
T-lymphocyte-depleted	B-cell_type
spleen	I-cell_type
cells	E-cell_type
and	O
purified	B-cell_type
B-lymphocytes	E-cell_type
and	O

requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	B-GP
kinase	I-GP
C	E-GP
.	O
A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	S-GP

activity	O
between	O
T-lymphocytes	S-cell_type
and	O
non-T-lymphocytes	S-cell_type
was	O
revealed	O
.	O
Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O

the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O
Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O

the	O
NFAT-1	S-GP
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV-LTR/tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O

Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R.	O
K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606-611	O
)	O
.	O
This	O
similarity	O

in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT-1	S-GP
has	O
been	O
shown	O
to	O
bind	O
functional	B-DNA
sequences	E-DNA
in	O
HIV-LTR	S-DNA
suggest	O
a	O

role	O
for	O
NFAT-1	S-GP
in	O
dermal	O
activation	O
of	O
the	O
HIV-LTR	S-DNA
.	O
A	O
novel	O
T-cell	B-GP
protein	E-GP
which	O
recognizes	O
a	O
palindromic	B-DNA
sequence	E-DNA
in	O
the	O

negative	B-DNA
regulatory	I-DNA
element	E-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
.	O
Two	O
major	B-DNA
protein-binding	I-DNA
sites	E-DNA
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	E-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
have	O
been	O
identified	O
.	O
One	O
(	O
site	B-DNA
B	E-DNA
)	O
contained	O
a	O
palindromic	B-DNA
sequence	E-DNA
with	O
homology	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
response	I-DNA
elements	E-DNA
but	O
was	O

distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O
A	O
novel	O
T-cell	B-GP
protein	E-GP
recognized	O
the	O
palindromic	B-DNA
sequence	E-DNA
within	O
site	B-DNA
B	E-DNA
and	O
also	O
bound	O
estrogen-	B-DNA
or	I-DNA
thyroid	I-DNA
hormone-response	I-DNA
elements	E-DNA
with	O

lower	O

affinity	O
.	O
A	O
7-base-pair	O
mutation	O
in	O
the	O
site	B-DNA
B	I-DNA
palindrome	E-DNA
,	O
which	O
destroyed	O
protein	O
binding	O
,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	B-DNA

immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
.	O
Progesterone	O
suppression	O
of	O
pregnancy	B-cell_type
lymphocytes	E-cell_type
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O

This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	B-cell_type
lymphocytes	E-cell_type
is	O
mediated	O
by	O
specific	O
progesterone	B-GP
receptors	E-GP
.	O
The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O

)	O
and	O
a	O
specific	O
glucocorticoid	B-GP
receptor	E-GP
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	B-GP
factor	E-GP
by	O
progesterone-treated	B-cell_line
pregnancy	I-cell_line
lymphocytes	E-cell_line

.	O
RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	B-GP
factor	E-GP
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O
These	O
data	O
suggest	O
that	O
in	O
pregnancy	O

,	O

lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	B-GP
receptors	E-GP
and	O
glucocorticoid	B-GP
binding	I-GP
sites	E-GP
are	O

not	O
involved	O
.	O
The	O
56-59-kilodalton	B-GP
protein	E-GP
identified	O
in	O
untransformed	B-GP
steroid	I-GP
receptor	I-GP
complexes	E-GP
is	O
a	O
unique	B-GP
protein	E-GP
that	O
exists	O
in	O

cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70-	B-GP
and	I-GP
90-kilodalton	I-GP
heat	I-GP
shock	I-GP
proteins	E-GP
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
9S	S-GP
,	O
untransformed	B-GP
progestin	I-GP
,	I-GP
estrogen	I-GP
,	I-GP
androgen	I-GP
,	I-GP
and	I-GP
glucocorticoid	I-GP
receptor	I-GP
complexes	E-GP

in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	B-GP
protein	E-GP
[	O
Tai	O
,	O
P.K.	O
,	O
Maeda	O
,	O
Y.	O
,	O
Nakao	O
,	O
K.	O
,	O
Wakim	O
,	O

N.G.	O
,	O
Duhring	O
,	O
J.L.	O
,	O
&	O
Faber	O
,	O
L.E.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269-5275	O
]	O
.	O
In	O
this	O
work	O

we	O

show	O
that	O
the	O
monoclonal	B-GP
antibody	I-GP
KN	I-GP
382/EC1	E-GP
raised	O
against	O
the	O
rabbit	B-GP
59-kDa	I-GP
protein	E-GP
reacts	O
with	O
9S	S-GP
,	O
untransformed	B-GP
glucocorticoid	I-GP
receptor	I-GP
complexes	E-GP
in	O
cytosol	O
prepared	O
from	O
human	B-cell_line
IM-9	I-cell_line
lymphocytes	E-cell_line
but	O
not	O

with	O
4S	B-GP
salt-transformed	I-GP
receptors	E-GP
.	O
The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	B-GP
antibody	E-GP
is	O
a	O
56-kDa	B-GP
protein	E-GP
(	O
p56	S-GP
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O
There	O
are	O
at	O
least	O
six	O
isomorphs	S-GP
of	O
p56	S-GP
by	O
two-dimensional	O
gel	O
analysis	O
.	O
N-Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	S-GP
is	O
a	O
unique	B-GP
human	I-GP
protein	E-GP
.	O
When	O
p56	S-GP

is	O
immunoadsorbed	O
from	O
IM-9	B-cell_line
cell	E-cell_line
cytosol	O
,	O
both	O
the	O
70-	B-GP
and	I-GP
90-kDa	I-GP
heat	I-GP
shock	I-GP
proteins	E-GP
are	O
coadsorbed	O
in	O
an	O
immune-specific	O
manner	O
.	O
Neither	O
heat	B-GP
shock	I-GP
protein	E-GP
reacts	O
directly	O
with	O
the	O
EC1	B-GP
antibody	E-GP
.	O
We	O
conclude	O
that	O
p56	S-GP
exists	O
in	O

cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	S-GP
and	O
hsp90	S-GP
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	B-GP
steroid	I-GP
receptors	E-GP
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
proto-oncoprotein	S-GP
ets-1	S-GP
defines	O
a	O
transcriptional	B-DNA
activator	I-DNA
sequence	E-DNA
within	O

the	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O
The	O
ets	B-DNA
proto-oncogene	I-DNA
family	E-DNA
is	O

a	O
group	O
of	O
sequence-related	B-DNA
genes	E-DNA
whose	O
normal	O
cellular	O
function	O
is	O
unknown	O
.	O
In	O
a	O
study	O
of	O
cellular	B-GP
proteins	E-GP
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O

murine	O
retroviruses	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
,	O
we	O
have	O
discovered	O
that	O
a	O

member	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	E-DNA
encodes	O
a	O
sequence-specific	B-GP
DNA-binding	I-GP
protein	E-GP
.	O
A	O
mouse	B-DNA
ets-1	I-DNA
cDNA	I-DNA
clone	E-DNA
was	O
obtained	O
by	O
screening	O
a	O
mouse	O
thymus	O
cDNA	O
expression	O
library	O
with	O
a	O
double-stranded	B-DNA
oligonucleotide	I-DNA
probe	E-DNA
representing	O

20	O

bp	O
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
(	O
MSV	O
)	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
.	O
The	O
cDNA	B-DNA
sequence	E-DNA
has	O
an	O
813-bp	B-DNA
open	I-DNA

reading	I-DNA
frame	E-DNA
(	O
ORF	S-DNA
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97.6	O
%	O
identical	O
to	O
the	O
272	B-GP

carboxy-terminal	I-GP
amino	I-GP
acids	E-GP
of	O
the	O
human	B-GP
ets-1	I-GP
protein	E-GP
.	O
The	O
ORF	S-DNA
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
30-kD	B-GP
protein	I-GP
product	E-GP
was	O
shown	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
by	O
mobility-shift	O
assays	O
,	O
Southwestern	O

blot	O
analysis	O
,	O
and	O
methylation	O
interference	O
.	O
A	O
mutant	B-DNA
LTR	E-DNA
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets-1	B-DNA
binding	I-DNA
site	E-DNA
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro	O
.	O
Transcriptional	O
efficiency	O
of	O
the	O
MSV	B-DNA
LTR	I-DNA
promoter	E-DNA

containing	O
this	O
disrupted	O
ets-1	B-DNA
binding	I-DNA
site	E-DNA
was	O
compared	O
to	O
the	O
activity	O
of	O
a	O
wild-type	B-DNA
promoter	E-DNA
in	O
mouse	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
in	O
culture	O
,	O
and	O
15-	O
to	O
20-fold	O
reduction	O
in	O
expression	O
of	O
a	O
reporter	B-DNA
gene	E-DNA

was	O
observed	O
.	O
We	O
propose	O
that	O
ets-1	S-GP
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type-C	O
retroviruses	O
and	O
speculate	O
that	O
ets-related	B-DNA
genes	E-DNA
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B-GP
DNA-binding	I-GP
proteins	E-GP
.	O
Type	B-GP
II	I-GP
estrogen	I-GP

binding	I-GP
sites	E-GP
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
:	O
variations	O
during	O
the	O
menstrual	O
cycle	O
.	O
We	O
have	O
previously	O
reported	O
that	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type

(	O
PBMC	S-cell_type
)	O
contain	O
type	O
II	B-GP
estrogen	I-GP
binding	I-GP
sites	E-GP
(	O
type	B-GP
II	I-GP
EBS	E-GP
)	O
.	O
In	O
this	O
study	O
,	O
the	O
fluctuations	O
of	O
type	B-GP
II	I-GP
EBS	E-GP
during	O
the	O
menstrual	O
cycle	O
were	O
analyzed	O
in	O
6	O
normally	O
menstruating	O
women	O
.	O
Approximately	O
3	O
times	O
higher	O
levels	O
of	O

type	B-GP
II	I-GP
EBS	E-GP
were	O
found	O
in	O
the	O
periovulatory	O
period	O
with	O
respect	O
to	O
both	O
follicular	O
and	O
luteal	O
phases	O
.	O
In	O
postmenopausal	O
women	O
the	O
mean	O
type	B-GP
II	I-GP
EBS	E-GP
levels	O

were	O

similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle	O
.	O
However	O
,	O
in	O
3	O
postmenopausal	O
patients	O

a	O
short	O
course	O
of	O
estrogen	O
or	O
tamoxifen	O
resulted	O
in	O
a	O
marked	O
increase	O
of	O
type	B-GP
II	I-GP
EBS	E-GP
levels	O
.	O
Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O

17	O
beta-estradiol	O
for	O
type	B-GP
II	I-GP
EBS	E-GP
in	O
PBMC	S-cell_type
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O
Mononuclear	B-cell_type
leukocyte	E-cell_type
glucocorticoid	B-GP
receptor	E-GP
binding	O

characteristics	O
and	O
down-regulation	O
in	O
major	O
depression	O
.	O
Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O

to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O
To	O
study	O

whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-DEX-binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	B-GP

receptor	E-GP
affinity	O
(	O
1/Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O
No	O
receptor	O

abnormalities	O

were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O

to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O
DEX	O
(	O
1.0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	B-GP
GC	I-GP
receptor	E-GP

down-regulation	O
.	O
Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down-regulated	O
Bmax	O
after	O
DEX	O
.	O
By	O
paired	O
t-test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O
Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O

receptor	O
down-regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects	O
.	O
These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor-binding	O
abnormality	O
,	O
and	O
they	O

emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC-mediated	O
cell	O
processes	O
in	O
order	O

to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O

Ras-related	B-GP
GTP-binding	I-GP
proteins	E-GP
and	O
leukocyte	S-cell_type
signal	O
transduction	O
.	O
Many	O
aspects	O
of	O
leukocyte	S-cell_type
function	O
are	O
regulated	O
by	O
both	O
heterotrimeric	S-GP

and	O
Ras-related	B-GP
GTP-binding	I-GP
proteins	E-GP
,	O
but	O
there	O
is	O
little	O
definite	O
information	O
about	O
their	O
roles	O
in	O
the	O
specialized	O
processes	O
utilized	O
by	O
leukocytes	S-cell_type
for	O
cell	O
killing	O
.	O
Recent	O
progress	O
in	O

understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	B-GP
NADPH	I-GP
oxidase	E-GP
by	O
the	O
Rac	B-GP
GTP-binding	I-GP
proteins	E-GP
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O
It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	B-GP
oxidase	E-GP
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP-GDP	O
state	O
of	O
Rac	S-GP
.	O
Proteins	O

exist	O

in	O
leukocytes	S-cell_type
able	O
to	O
modify	O
GTP-binding	B-GP
protein	E-GP
function	O

in	O
this	O
manner	O
,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O
Proteins	O
of	O
the	O
Ras	B-GP
superfamily	E-GP
are	O
likely	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
normal	O
phagocyte	O
functions	O
through	O

their	O
ability	O
to	O
modulate	O
the	O
assembly	O
of	O
actin	B-GP
filaments	E-GP
,	O
direct	O
vesicle	O
trafficking	O
and	O
fusion	O
,	O
and	O
so	O
forth	O
.	O
BSAP	S-GP
:	O
a	O
key	O
regulator	O
of	O
B-cell	S-cell_type
development	O
and	O
differentiation	O

.	O
B-cell-specific	B-GP
activator	I-GP
protein	E-GP
(	O
BSAP	S-GP
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
Pax-gene	B-DNA
family	E-DNA
of	O
transcription	B-GP
factors	E-GP
;	O
in	O
the	O
lymphoid	O
system	O
,	O
BSAP	S-GP

is	O
produced	O
only	O
in	O
B	B-cell_type
cells	E-cell_type
.	O
Here	O
,	O
Markus	O
Neurath	O
,	O
Eckhard	O
Stuber	O
and	O
Warren	O
Strober	O
describe	O
the	O
molecular	O
structure	O
of	O
BSAP	S-GP
and	O
focus	O
on	O
the	O

ability	O
of	O
this	O
protein	O
to	O
regulate	O
the	O
expression	O
of	O
B-cell-specific	B-DNA
genes	E-DNA
.	O
They	O
propose	O
that	O
BSAP	S-GP
is	O
a	O
key	B-GP
protein	E-GP
of	O
B	B-cell_type
cells	E-cell_type
and	O
that	O
it	O
not	O
only	O
influence	O
B-cell	O
development	O
but	O
also	O
influences	O
the	O
balance	O
between	O
B-cell	O

proliferation	O

and	O
immunoglobulin	S-GP
secretion	O
at	O
later	O
stages	O
of	O
B-cell	O
differentiation	O
.	O
Down-regulation	O

of	O
NF-kappa	B-GP
B	I-GP
protein	E-GP
levels	O
in	O
activated	O
human	O
lymphocytes	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9	O
;	O
93	O
(	O

1	O
)	O
:	O
524	O
]	O
The	O
effect	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
)	O
D3	O
]	O
,	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties	O
,	O
on	O

nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
(	O
NF-kappa	B-GP
B	E-GP
)	O
proteins	O
was	O
examined	O
in	O
in	B-cell_line
vitro	I-cell_line
activated	I-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	E-cell_line
by	O
Western	O
blot	O
analysis	O
.	O
Over	O
a	O
72-hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50-kDa	B-GP
NF-kappa	I-GP
B	E-GP

,	O

p50	S-GP
,	O
and	O
its	O
precursor	O
,	O
p105	S-GP
,	O
was	O
increased	O
progressively	O
.	O
When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O

precursor	O
were	O
decreased	O
.	O
The	O
effect	O
of	O
the	O
hormone	O
on	O
the	O
levels	O
of	O
p50	S-GP
was	O
demonstrable	O
in	O
the	O
cytosolic	O
and	O
nuclear	O
compartments	O
;	O
it	O
required	O
between	O
4	O
and	O
8	O
hr	O
and	O
was	O
specific	O
,	O
as	O
25-hydroxyvitamin	O
D3	O
and	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
were	O
ineffective	O
.	O
Besides	O
p50	S-GP
,	O
1	O
,	O

25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	B-GP
B	I-GP
protein	E-GP
,	O
namely	O
c-rel	S-GP
.	O
In	O
addition	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O

decreased	O
the	O
abundance	O
of	O
a	O
specific	B-GP
DNA-protein	I-GP
complex	E-GP
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	O
lymphocytes	O
with	O
a	O
labeled	O
NF-kappa	B-GP
B	I-GP
DNA	I-GP
binding	I-GP
motif	E-GP
.	O
Further	O
,	O
1	O
,	O

25	O
(	O
OH	O
)	O
2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF-kappa	B-GP
B	E-GP
in	O
Jurkat	B-cell_line
cells	E-cell_line
transiently	O
transfected	O
with	O
a	O
construct	S-DNA
containing	O
four	O
tandem	B-DNA
repeats	E-DNA
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sequence	E-DNA
of	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
gene	E-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA

acetyltransferase	I-DNA
reporter	I-DNA
gene	E-DNA
.	O
These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF-kappa	B-GP
B	E-GP
during	O
human	O
lymphocyte	O
activation	O
and	O

suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated	O
.	O
The	O
myeloid	B-DNA
zinc	I-DNA
finger	I-DNA
gene	E-DNA
,	O
MZF-1	S-DNA
,	O
regulates	O
the	O
CD34	B-DNA
promoter	E-DNA
in	O
vitro	O
.	O
MZF-1	S-DNA
is	O
a	O
C2H2	B-DNA
zinc	I-DNA
finger	I-DNA
gene	E-DNA
encoding	O
a	O
putative	B-GP
transcriptional	I-GP
regulator	E-GP
of	O

myeloid	O
differentiation	O
.	O
The	O
MZF-1	S-DNA
protein	O
contains	O
13	O
C2H2	B-GP
zinc	I-GP
fingers	E-GP
arranged	O
in	O
bipartite	O
DNA	B-GP
binding	I-GP
domains	E-GP
containing	O
zinc	B-GP
fingers	E-GP
through	O
4	O
and	O
,	O
in	O
the	O
carboxy-terminus	S-GP
,	O
5	O
through	O
13	O
.	O
We	O
previously	O
identified	O
the	O
DNA	B-DNA
consensus	I-DNA
binding	I-DNA
site	E-DNA
recognized	O
by	O
the	O
two	O
DNA	B-GP
binding	I-GP
domains	E-GP
.	O
To	O

assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF-1	S-DNA
,	O
the	O
full-length	O
MZF-1	S-DNA
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	B-GP
binding	I-GP
domain	E-GP
of	O
the	O
yeast	B-GP
transactivator	I-GP
GAL4	E-GP
.	O

The	O

expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	E-DNA
regulated	O

by	O
the	O
thymidine	B-DNA
kinase	I-DNA
promoter	E-DNA
containing	O
GAL4	B-DNA
DNA	I-DNA
binding	I-DNA
sites	E-DNA
into	O
NIH	B-cell_line
3T3	E-cell_line
,	O
293	S-cell_line
,	O

K562	S-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
MZF-1	S-DNA
represses	O
CAT	B-DNA
reporter	I-DNA
gene	E-DNA
expression	O
via	O
GAL4	S-GP
binding	O
sites	O
in	O
the	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
NIH	B-cell_line
3T3	E-cell_line
and	O
293	S-cell_line
.	O
In	O
contrast	O

,	O
MZF-1	S-DNA
activates	O
CAT	B-DNA
reporter	I-DNA
gene	E-DNA
expression	O
in	O
the	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
K562	S-cell_line
and	O
Jurkat	S-cell_line
.	O

The	O
MZF-1	B-DNA
binding	I-DNA
sites	E-DNA
are	O
present	O
in	O
the	O
promoters	S-DNA
of	O
several	O
genes	S-DNA
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	B-DNA
promoter	E-DNA
.	O
MZF-1	S-DNA
transcriptional	O
regulation	O
of	O
this	O

physiologically	B-DNA
relevant	I-DNA
promoter	E-DNA
was	O
assessed	O
in	O
both	O
hematopoietic	S-cell_line
and	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
Recombinant	B-GP
MZF-1	I-GP
protein	E-GP
specifically	O
binds	O
to	O
the	O
consensus	B-DNA
binding	I-DNA
sites	E-DNA
in	O
the	O
CD34	B-DNA
promoter	E-DNA
in	O
mobility	O
shift	O
assays	O
.	O
MZF-1	S-DNA
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O

luciferase	B-DNA
reporter	I-DNA
plasmids	E-DNA
regulated	O
by	O
the	O
CD34	B-DNA
promoter	E-DNA
into	O
both	O
nonhematopoietic	B-cell_line
and	I-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
As	O
with	O
the	O
heterologous	O

DNA	B-GP
binding	I-GP
domain	E-GP
,	O
MZF-1	S-DNA
represses	O
reporter	B-DNA
gene	E-DNA
expression	O
in	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
and	O
activates	O
expression	O
in	O
hematopoietic	B-cell_line

cell	I-cell_line
lines	E-cell_line
.	O
Activation	O
of	O
CD34	S-GP
expression	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF-1	B-DNA
binding	I-DNA
sites	E-DNA
.	O

The	O
cell	O
type-specific	O
regulation	O
of	O
the	O
CD34	B-DNA
promoter	E-DNA
by	O
MZF-1	S-DNA
suggests	O
the	O
presence	O
of	O
tissue-specific	O
regulators/adapters	O
or	O
differential	O

MZF-1	S-DNA
modifications	O
that	O
determine	O
MZF-1	S-DNA
transcriptional	O
regulatory	O
function	O
.	O
The	O
murine	O
BCL6	B-DNA
gene	E-DNA
is	O
induced	O
in	O
activated	B-cell_type
lymphocytes	E-cell_type
as	O

an	O
immediate	B-DNA
early	I-DNA
gene	E-DNA
.	O
The	O
chromosomal	O
translocation	O
involving	O
3q27	S-DNA
is	O
often	O
detected	O
in	O
human	B-cell_type
B-cell	I-cell_type
lymphomas	E-cell_type
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O

large-cell	O
component	O
.	O
The	O
BCL6	B-DNA
gene	E-DNA
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O
Here	O
we	O
cloned	O
the	O
murine	B-DNA
BCL6	I-DNA
(	I-DNA
mBCL6	I-DNA

)	I-DNA
cDNA	E-DNA
from	O
the	O
muscle	B-DNA
cDNA	I-DNA
library	E-DNA
using	O
the	O
human	B-DNA
BCL6	I-DNA
(	I-DNA
hBCL6	I-DNA
)	I-DNA
cDNA	E-DNA
as	O
a	O
probe	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
was	O
95	O
%	O
identical	O
to	O
that	O
of	O
hBCL6	S-GP
.	O
It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel-like	B-GP
zinc-finger	I-GP
motif	E-GP
that	O
are	O
completely	O
identical	O

to	O

those	O
of	O
hBCL6	S-GP
,	O
indicating	O
that	O
the	O
BCL6	B-DNA
gene	E-DNA
is	O
well	O
conserved	O
between	O
humans	O
and	O

mice	O
.	O
Expression	O
of	O
the	O
mBCL6	B-DNA
gene	E-DNA
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O
Furthermore	O
,	O
it	O

was	O
induced	O
in	O
lymphocytes	S-cell_type
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2+	O
ionophore	O
within	O
30	O
min	O

after	O
stimulation	O
.	O
This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O
These	O
results	O
suggest	O
that	O
BCL6	S-GP
plays	O

a	O
role	O
in	O
activated	B-cell_type
lymphocytes	E-cell_type
as	O
an	O
immediate	O
early	O
gene	O
.	O
The	O
role	O
of	O

BSAP	S-GP
(	O
Pax-5	S-GP
)	O
in	O
B-cell	O
development	O
.	O
The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B-cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O
In	O
this	O
manner	O

,	O
the	O
paired	B-DNA
box	I-DNA
containing	I-DNA
gene	E-DNA
Pax-5	S-DNA
,	O
encoding	O
the	O
B	B-GP
cell	I-GP
specific	I-GP
transcription	I-GP
factor	E-GP
BSAP	S-GP

,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O
Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	S-GP

in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	B-GP
heavy-chain	E-GP
gene	O
at	O
late	O

stages	O
of	O
B-cell	O
differentiation	O
.	O
The	O
DNA-binding	O
properties	O
of	O
two	B-GP
heat	I-GP
shock	I-GP
factors	E-GP
,	O
HSF1	S-GP
and	O
HSF3	S-GP

,	O

are	O
induced	O
in	O
the	O
avian	B-cell_line
erythroblast	I-cell_line
cell	I-cell_line
line	E-cell_line
HD6	S-cell_line
.	O
Avian	O

cells	O
express	O
three	O
heat	B-DNA
shock	I-DNA
transcription	I-DNA
factor	I-DNA
(	I-DNA
HSF	I-DNA
)	I-DNA
genes	E-DNA
corresponding	O
to	O
a	O
novel	B-GP
factor	E-GP
,	O
HSF3	S-GP
,	O
and	O

homologs	O
of	O
mouse	O
and	O
human	O
HSF1	S-GP
and	O
HSF2	S-GP
.	O
Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	S-GP
reveals	O
that	O
HSF3	S-GP
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	S-GP
and	O
HSF2	S-GP
and	O

yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O
HSF3	S-GP
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	B-cell_line
cell	I-cell_line
line	I-cell_line
HD6	E-cell_line
,	O
the	O
lymphoblast	B-cell_line
cell	I-cell_line
line	I-cell_line
MSB	E-cell_line
,	O
and	O
embryo	B-cell_line
fibroblasts	E-cell_line

,	O

and	O
yet	O
its	O
DNA-binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O
Acquisition	O
of	O
HSF3	S-GP
DNA-binding	O
activity	O
in	O

HD6	B-cell_line
cells	E-cell_line
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non-DNA-binding	B-GP
dimer	E-GP
to	O
a	O
DNA-binding	B-GP
trimer	E-GP
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	S-GP
is	O
oligomerization	O
of	O
an	O
inert	B-GP
monomer	E-GP
to	O

a	O
DNA-binding	B-GP
trimer	E-GP
.	O
Induction	O
of	O
HSF3	S-GP
DNA-binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	S-GP
.	O
As	O
occurs	O
for	O
HSF1	S-GP
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	S-GP
to	O
the	O
nucleus	O

.	O
HSF	O
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	B-GP
activator	E-GP
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	B-GP
overexpressed	I-GP
HSF3	E-GP
measured	O
by	O
using	O
a	O
heat	B-DNA
shock	I-DNA
element-containing	I-DNA
reporter	I-DNA
construct	E-DNA
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O

chimeric	B-GP
GAL4-HSF3	I-GP
protein	E-GP
on	O
a	O
GAL4	B-DNA
reporter	I-DNA
construct	E-DNA
.	O
These	O
results	O
reveal	O
that	O
HSF3	S-GP
is	O
negatively	O
regulated	O
in	O
avian	B-cell_type
cells	E-cell_type
and	O
acquires	O
DNA-binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O
Direct	O
demonstration	O
of	O
NFATp	S-GP
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O

activated	B-cell_line
HT-2	I-cell_line
cells	E-cell_line
using	O
a	O
specific	O
NFATp	B-GP
polyclonal	I-GP
antibody	E-GP
.	O
Nuclear	B-GP
factor	I-GP
of	I-GP

activated	I-GP
T	I-GP
cells	E-GP
(	O
NFAT	S-GP
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	B-GP
genes	E-GP
,	O
and	O
NFAT	S-GP

DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O
Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	S-GP
is	O
a	O
substrate	O
for	O
calcineurin	S-GP
,	O
a	O
serine/threonine	B-GP
phosphatase	E-GP
.	O
Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	B-GP
NFATp	E-GP
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O

110-130-kDa	O
NFATp	B-GP
protein	E-GP
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O
Treatment	O
of	O
immunoprecipitated	O
NFATp	S-GP
from	O
untreated	O
HT-2	B-cell_line
cells	E-cell_line
with	O
calcineurin	S-GP
resulted	O

in	O

the	O
dephosphorylation	O
of	O
NFATp	S-GP
,	O
demonstrating	O
that	O
NFATp	S-GP
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	S-GP
.	O
NFATp	S-GP
immunoprecipitated	O
from	O

32P-labeled	B-cell_line
HT-2	I-cell_line
cells	E-cell_line
migrated	O
as	O
an	O
approximately	O
120-kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O
Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O

the	O
molecular	O
weight	O
of	O
NFATp	S-GP
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	S-GP
dephosphorylation	O
.	O
The	O
dephosphorylation	O

of	O
NFATp	S-GP
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O
Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O

calcineurin	S-GP
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	S-GP
is	O
a	O
calcineurin	S-GP
substrate	O
in	O
cells	O
.	O
Activation	O
and	O
expression	O
of	O
the	O
nuclear	B-GP
factors	E-GP
of	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O

NFATp	S-GP
and	O
NFATc	S-GP
,	O
in	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	E-cell_type
:	O
regulation	O
upon	O
CD16	S-GP
ligand	O
binding	O
.	O
The	O
putative	O
factors	O
that	O
couple	O
the	O

signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	S-GP
synthesis	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	E-cell_type
have	O
not	O
been	O
elucidated	O
.	O
We	O
report	O
here	O
that	O

the	O
nuclear	B-GP
factor	E-GP
of	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
(	O
NFATp	S-GP
)	O
,	O
a	O
cyclosporin	B-GP
A	I-GP
(	I-GP
CsA	I-GP

)	I-GP
-sensitive	I-GP
factor	E-GP
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	S-GP
,	O
mediates	O
CD16	S-GP
-induced	O
activation	O
of	O
cytokine	B-GP
genes	E-GP
in	O
human	B-cell_type
NK	I-cell_type
cells	E-cell_type
.	O
CD16	S-GP
(	O
Fc	B-GP
gamma	I-GP
RIIIA	E-GP
)	O
-induced	O
expression	O

of	O

cytokine	B-RNA
mRNA	E-RNA
in	O
NK	B-cell_type
cells	E-cell_type
occurs	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
.	O
Stimulation	O
of	O
NK	B-cell_type
cells	E-cell_type
with	O
CD16	S-GP
ligands	O
induces	O
NFAT	S-GP
-like	O
DNA	O

binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA-sensitive	O

and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O
NK	B-GP
cell	I-GP
NFAT	E-GP
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	B-cell_type
cells	E-cell_type
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	S-GP
.	O
Two	O
distinct	O

molecules	O
,	O
NFATp	S-GP
and	O
NFATc	S-GP
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	S-GP
activity	O
.	O
The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	B-GP
and	I-GP
NFATc-	I-GP
specific	I-GP
antibodies	E-GP
indicate	O

that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	S-GP
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	S-GP
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O

mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
.	O
NK	B-cell_type
cells	E-cell_type
do	O
not	O
express	O
NFATc	S-GP
constitutively	O
,	O
but	O
NFATc	B-RNA
mRNA	E-RNA
accumulation	O
is	O
induced	O
in	O

these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O
However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	S-GP
recognizing	O
the	O
T	B-GP
cell	I-GP
NFATc	E-GP
revealed	O

no	O
detectable	O
NFATc	S-GP
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	B-cell_line
ester-stimulated	I-cell_line
cells	E-cell_line
at	O

any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O
These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA-sensitive	B-GP
transcription	I-GP
factors	E-GP
,	O
NFATp	S-GP
and	O
NFATc	S-GP
,	O
are	O
expressed	O
in	O
human	O
NK	B-cell_type
cells	E-cell_type
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O

the	O
case	O
of	O
CD16	O
in	O
NK	B-cell_type
cells	E-cell_type
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	S-GP
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	B-RNA
mRNA	E-RNA
.	O
Interleukin	O
2	O
signaling	O
involves	O

the	O
phosphorylation	O
of	O
Stat	B-GP
proteins	E-GP
.	O
One	O
of	O
the	O
most	O
important	O
cytokines	S-GP
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	E-cell_type

.	O
The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	S-GP
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O
While	O
the	O
binding	O
of	O
IL-2	S-GP
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	S-GP
,	O
Jak-1	S-GP
and	O
Jak-3	S-GP
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O
Since	O
many	O
cytokines	S-GP

that	O

activate	O
Jak	B-GP
kinases	E-GP
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O

activation	O
of	O
members	O
of	O
the	O
Stat	B-GP
family	E-GP
of	O
transcription	B-GP
factors	E-GP
,	O
the	O
ability	O
of	O
IL-2	S-GP
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O
Exposure	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
or	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
cell	I-cell_line

line	E-cell_line
(	O
NKL	S-cell_line
)	O
to	O
IL-2	S-GP
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B-GP
alpha	E-GP
,	O
Stat1	O
beta	O

,	O
and	O
Stat3	S-GP
,	O
as	O
well	O
as	O
of	O
two	O
Stat-related	B-GP
proteins	E-GP
,	O
p94	S-GP
and	O
p95	S-GP
.	O
p94	S-GP
and	O
p95	S-GP
share	O
homology	O
with	O
Stat1	S-GP
at	O
the	O
phosphorylation	B-GP
site	E-GP
and	O
in	O
the	O
Src	B-GP
homology	I-GP
2	I-GP
(	I-GP
SH2	I-GP
)	I-GP
domain	E-GP
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	S-GP
.	O

These	O
Stat	B-GP
proteins	E-GP
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	B-DNA
DNA	I-DNA
sequence	E-DNA
.	O
These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL-2	S-GP
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	B-DNA
genes	E-DNA
involved	O

in	O
immune	O
cell	O
function	O
.	O
Expression	O
of	O
c-fos	S-DNA
correlates	O
with	O
IFN-alpha	S-GP
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O
This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	S-DNA
and	O
p53	B-RNA
transcripts	E-RNA
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O

subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN-alpha	B-GP
2c	E-GP
.	O
Peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
pbmc	S-cell_type
)	O
and	O
bone	B-cell_type
marrow	I-cell_type
cells	E-cell_type
of	O
26	O
patients	O
were	O
examined	O
for	O
c-fos	O
,	O
c-myc	O
,	O

p53	O
and	O
the	O
hybrid	O
bcr/abl	O
mRNA	O
levels	O
.	O
Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c-fos	B-RNA
transcript	E-RNA
levels	O
are	O

significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN-alpha	S-GP
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	S-cell_type

(	O

r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	B-cell_type

cells	E-cell_type
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	S-cell_type
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	B-RNA
mRNA	E-RNA
levels	O
of	O
the	O
hybrid	B-DNA
bcr/abl	E-DNA
,	O
c-myc	S-DNA
and	O
p53	S-DNA
are	O
positively	O

correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN-alpha	S-GP
is	O
accompanied	O
by	O
upregulation	O

of	O
c-fos	S-DNA
and	O
downregulation	O
of	O
c-myc	B-RNA
mRNA	E-RNA
levels	O
in	O
responder	O
patients	O
.	O
Menopause	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
blood	O
monocyte	O
number	O
and	O
a	O
relative	O
decrease	O
in	O
the	O
expression	O
of	O
estrogen	B-GP
receptors	E-GP
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	E-cell_type
.	O
PROBLEM	O
:	O
The	O
clinical	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
estrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
in	O
human	B-cell_type
monocytes	E-cell_type
was	O
evaluated	O
.	O
METHOD	O
:	O
Two	O
color	O
flow	O
cytometry	O
analysis	O
was	O
used	O
on	O
peripheral	O
blood	O
samples	O
of	O
young	O
and	O
postmenopausal	O
females	O
and	O
postmenopausal	O
females	O
treated	O
with	O
estrogen	O
replacement	O
therapy	O
.	O
In	O
addition	O
,	O
the	O
monocyte	O
and	O
lymphocyte	O
counts	O
and	O
the	O
blood	O
estrogen	O
levels	O
of	O
each	O
patient	O
were	O
determine	O
.	O
RESULTS	O
:	O
During	O
menopause	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
the	O
percentage	O
of	O
ER	B-cell_type
positive	I-cell_type
monocytes	E-cell_type
,	O
and	O

an	O

increase	O
in	O
blood	B-cell_type
monocyte	E-cell_type
number	O
,	O
which	O
declines	O
following	O
estrogen	O
replacement	O
therapy	O
to	O
values	O
of	O
the	O
young	O
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
estrogen	O
modulates	O

the	O
monocyte	S-cell_type
numbers	O
and	O
its	O
effects	O
may	O
be	O
mediated	O
through	O
the	O
ER	S-GP
in	O
the	O
monocytes	S-cell_type
.	O
Staphylococcal	B-GP
enterotoxins	E-GP
modulate	O
interleukin	B-GP
2	I-GP

receptor	E-GP
expression	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-GP
protein-tyrosine	I-GP
kinase	I-GP
3	E-GP
(	O
Jak3	S-GP
)	O
and	O
signal	B-GP
transducers	I-GP
and	I-GP
activators	I-GP
of	I-GP
transcription	E-GP
(	O
Stat	B-GP
proteins	E-GP
)	O
.	O

Staphylococcal	B-GP
enterotoxins	E-GP
(	O
SE	S-GP
)	O
stimulate	O
T	B-cell_type
cells	E-cell_type
expressing	O
the	O
appropriate	O
variable	B-GP
region	I-GP
beta	I-GP
chain	I-GP
of	I-GP
(	I-GP
V	I-GP
beta	I-GP

)	I-GP
T-cell	I-GP
receptors	E-GP
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O
Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	S-GP
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	B-cell_type
cells	E-cell_type
.	O
In	O
addition	O
,	O
SE	S-GP
can	O
induce	O
an	O

interleukin-2	S-GP
(	O
IL-2	S-GP
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O
Here	O
,	O
we	O
show	O
that	O
SE	S-GP
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O

transduction	O

through	O
the	O
IL-2	B-GP
receptor	I-GP
(	I-GP
IL-2R	I-GP
)	I-GP
beta	I-GP
and	I-GP
gamma	I-GP
chains	E-GP
(	O
IL-2R	B-GP
beta	E-GP
and	O
IL-2R	B-GP
gamma	E-GP
)	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
.	O
Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O

to	O
SEA	S-GP
and	O
SEB	S-GP
,	O
the	O
expression	O
of	O
IL-2R	B-GP
beta	E-GP
was	O
down-regulated	O
,	O
IL-2R	B-GP
gamma	E-GP
was	O
slightly	O
up-regulated	O
,	O
while	O
IL-2R	B-GP
alpha	E-GP
remained	O
largely	O
unaffected	O
.	O
The	O
changes	O
in	O
the	O
composition	O
of	O
IL-2Rs	S-GP
were	O

accompanied	O
by	O
inhibition	O
of	O
IL-2	S-GP
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-GP
protein-tyrosine	I-GP
kinase	I-GP
3	E-GP
(	O

Jak3	S-GP
)	O
and	O
signal	B-GP
transducers	I-GP
and	I-GP
activators	I-GP
of	I-GP
transcription	E-GP
called	O
Stat3	S-GP
and	O
Stat5	S-GP
.	O
In	O
parallel	O

experiments	O
,	O
IL-2	S-GP
-driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O
After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	S-GP
,	O
the	O
expression	O
of	O
IL-2R	B-GP
beta	E-GP
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B-GP
alpha	E-GP
and	O
IL2R	B-GP
gamma	E-GP
was	O
further	O
up-regulated	O
,	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O

of	O
Jak3	S-GP
and	O
Stat	B-GP
proteins	E-GP
was	O
partly	O
normalized	O
.	O
Yet	O
,	O
IL-2	S-GP
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	S-GP
/Stat	S-GP
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	S-GP

stimulation	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	S-GP
can	O
modulate	O
IL-2R	S-GP
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak/Stat	S-GP
pathway	O
in	O
CD4+	B-cell_line
T-cell	I-cell_line
lines	E-cell_line
.	O
Constitutive	O
NF-kappa	B-GP
B	E-GP
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O

in	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
-deficient	O
mice	O
.	O
Transcription	B-GP
factors	E-GP
belonging	O

to	O
the	O
NF-kappa	B-GP
B	I-GP
family	E-GP
are	O
controlled	O
by	O
inhibitory	B-GP
I	I-GP
kappa	I-GP
B	I-GP
proteins	E-GP
,	O
mainly	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
and	O
I	B-GP
kappa	I-GP
B	I-GP
beta	E-GP
.	O
Apparently	O
normal	O
at	O
birth	O
,	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
-/-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O

defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O
Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	B-GP
NF-kappa	I-GP
B	E-GP

and	O
mRNAs	S-RNA
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF-kappa	B-GP
B	E-GP
.	O
NF-kappa	B-GP
B	E-GP
elevation	O
results	O
in	O
these	O

phenotypic	O

abnormalities	O
because	O
mice	O
lacking	O
both	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
and	O
the	O
p50	B-GP
subunit	E-GP
of	O
NF-kappa	B-GP
B	E-GP
show	O
a	O
dramatically	O

delayed	O
onset	O
of	O
abnormalities	O
.	O
In	O
contrast	O
to	O
hematopoietic	B-cell_type
cells	E-cell_type
,	O
I	B-cell_line
kappa	I-cell_line
B	I-cell_line
alpha-/-	I-cell_line
embryonic	I-cell_line
fibroblasts	E-cell_line
show	O
minimal	O
constitutive	B-GP
NF-kappa	I-GP
B	E-GP
,	O
as	O
well	O
as	O
normal	O
signal-dependent	O

NF-kappa	B-GP
B	E-GP
activation	O
that	O
is	O
concomitant	O
with	O
I	B-GP
kappa	I-GP
B	I-GP
beta	E-GP
degradation	O
.	O
Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
,	O

is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B-GP
B	E-GP
in	O
fibroblasts	S-cell_type
.	O
However	O
,	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF-kappa	B-GP
B	E-GP
in	O
fibroblasts	S-cell_type
.	O
These	O

results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	B-GP
kappa	I-GP
B	E-GP
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF-kappa	B-GP
B	E-GP
.	O
Interleukin-7	S-GP
can	O
induce	O
the	O
activation	O
of	O
Jak	B-GP
1	E-GP

,	O
Jak	B-GP
3	E-GP
and	O
STAT	B-GP
5	I-GP
proteins	E-GP
in	O
murine	O
T	B-cell_type
cells	E-cell_type
.	O
The	O
activation	O
of	O
Janus	B-GP
protein	I-GP
tyrosine	I-GP
kinases	E-GP
(	O
Jak	S-GP
)	O
and	O
STAT	B-GP
(	I-GP
signal	I-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
)	I-GP
proteins	E-GP
has	O
recently	O
been	O

linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	S-GP
.	O
IL-7	S-GP
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose-dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-GP
1	E-GP
and	O
Jak	B-GP
3	E-GP
and	O

concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	B-GP
proteins	E-GP
.	O
The	O
STAT	B-GP
proteins	E-GP
utilized	O

by	O
IL-7	S-GP
were	O
identical	O
to	O
those	O
induced	O
by	O
IL-2	S-GP
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	B-GP
5	I-GP
isoforms	E-GP
.	O
Moreover	O
,	O
the	O
induction	O
of	O

both	O

Jak	B-GP
1	I-GP
and	I-GP
3	E-GP
,	O
and	O
STAT	B-GP
5	E-GP
activity	O
strongly	O
correlated	O
with	O
the	O
growth-promoting	O
effects	O
of	O
IL-7	S-GP
,	O
suggesting	O
that	O

this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL-7	S-GP
-induced	O
proliferation	O
.	O
Cytokine	S-GP
-modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O
Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase/5-lipoxygenase	O
anti-inflammatory	O
compound	O
currently	O

under	O
clinical	O
investigation	O
.	O
It	O
has	O
been	O
shown	O
to	O
possess	O
anti-inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL-2	S-GP
induced	O
signal	O
transduction	O
.	O
The	O
current	O
study	O
was	O

conducted	O
to	O
evaluate	O
the	O
cytokine	S-GP
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O
In	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type

cells	E-cell_type
(	O
PBMC	S-cell_type
)	O
stimulated	O
with	O
OKT3/PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	S-cell_type
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O
Additionally	O
,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	S-GP
(	O
IC50	O
=	O
0.5	O
microM	O
)	O
and	O
the	O
cytokines	S-GP
IL-2	S-GP
,	O
IL-6	S-GP
and	O

TNF	B-GP

alpha	E-GP
(	O
IC50	O
=	O
10-12	O
microM	O
)	O
.	O
Cytotoxicity	O
was	O
not	O

demonstrated	O
at	O
these	O
concentrations	O
.	O
Add-back	O
experiments	O
with	O
either	O
cytokines	S-GP
(	O
IL-2	S-GP
or	O

IL-6	S-GP
)	O
,	O
LTB4	S-GP
or	O
conditioned	O
media	O
failed	O
to	O
restore	O
the	O
proliferative	O
response	O
in	O
the	O
presence	O
of	O
tepoxalin	O
.	O
However	O
,	O
the	O
concurrent	O
addition	O

of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O

by	O
tepoxalin	O
.	O
Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	B-GP
kappa	I-GP
B	E-GP
,	O
a	O
transcription	B-GP
factor	E-GP
which	O
acts	O
on	O
several	O
cytokine	B-DNA
genes	E-DNA
.	O
Tepoxalin	O

's	O
effect	O
on	O
NF	B-GP
kappa	I-GP
B	E-GP
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O
These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	S-cell_type
may	O

be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O

ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	B-GP
kappa	I-GP
B	E-GP
and	O
subsequent	O
inhibition	O
of	O
cytokine	S-GP
production	O
.	O
N-	B-GP
and	I-GP
C-terminal	I-GP
sequences	E-GP

control	O
degradation	O
of	O
MAD3/I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-GP
B	E-GP
activity	O
.	O
The	O
proteolytic	O
degradation	O
of	O
the	O
inhibitory	B-GP
protein	E-GP
MAD3/I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
in	O
response	O
to	O

extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	B-GP
factor	E-GP
NF-kappa	B-GP
B	E-GP
.	O
Analysis	O
of	O
the	O
expression	O

of	O
human	B-GP
I	I-GP
kappa	I-GP
B	I-GP
alpha	I-GP
protein	E-GP
in	O
stable	O
transfectants	O
of	O
mouse	B-cell_line
70Z/3	I-cell_line
cells	E-cell_line
shows	O
that	O
,	O

as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-GP
B	E-GP
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O
In	O
addition	O
,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	S-GP
inhibitor	O
N-Ac-Leu-Leu-norleucinal	O
inhibits	O
this	O

ligand-induced	O

degradation	O
and	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
,	O
stabilizes	O
a	O
hyperphosphorylated	O
form	O
of	O
the	O
human	B-GP
I	I-GP
kappa	I-GP
B	I-GP
alpha	I-GP

protein	E-GP
.	O
By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	B-cell_line
line	E-cell_line
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand-induced	O
phosphorylation	O
and	O

the	O
degradation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
.	O
Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	B-GP
terminus	E-GP
of	O
the	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
molecule	O
up	O
to	O
amino	B-GP
acid	I-GP
279	E-GP
abolishes	O
constitutive	O
but	O
not	O
ligand-inducible	O
phosphorylation	O
and	O
inhibits	O
ligand-inducible	O
degradation	O
.	O
Further	O
analysis	O
reveals	O
that	O
the	O
inducible	O
phosphorylation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP

maps	O
to	O
two	O
serines	O
in	O
the	O
N	B-GP
terminus	E-GP
of	O
the	O
protein	O
(	O
residues	O
32	O
and	O
36	O
)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	O
ligand-induced	O
degradation	O
,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O

to	O
abolish	O
inducible	O
phosphorylation	O
of	O
the	O
protein	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Microtubules	S-GP
mediate	O
cellular	O
25-hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
monocytes	E-cell_type
.	O
The	O

genomic	O
actions	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
are	O
mediated	O
by	O
the	O
intracellular	O
vitamin	B-GP
D	I-GP
receptor	E-GP
(	O
VDR	S-GP
)	O
.	O
Although	O
immunocytochemistry	O
has	O
shown	O

that	O
disruption	O
of	O
microtubular	O
assembly	O
prevents	O
nuclear	O
access	O
of	O
the	O
sterol-VDR	B-GP
complex	E-GP
,	O
the	O
role	O
of	O
microtubules	S-GP
in	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
has	O
not	O
been	O
studied	O
in	O
viable	B-cell_type
cells	E-cell_type
.	O
Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	B-cell_type
monocytes	E-cell_type
.	O
Monocytes	O
convert	O
25	O
(	O
OH	O
)	O
D3	O
to	O
1	O
,	O
25	O

(	O
OH	O
)	O
2D3	O
and	O
to	O
24-hydroxylated	O

metabolites	O

more	O
polar	O
than	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
Microtubule	O
disruption	O
totally	O
abolished	O
the	O
ability	O
of	O
exogenous	O
1	O

,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
own	O
synthesis	O
and	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	E-RNA
and	O
activity	O
,	O
without	O
affecting	O
either	O
total	O
1	O
,	O
25	O
(	O
OH	O
)	O

2D3	O
uptake	O
or	O
maximal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	S-GP
binding	O
.	O
Thus	O
,	O
intact	O
microtubules	S-GP
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O
Interestingly	O
,	O
microtubule	S-GP
disruption	O
also	O
decreased	O
monocyte	S-cell_type

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O

by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	B-GP
mitochondrial	I-GP
1	I-GP
alpha-hydroxylase	E-GP
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O

transport	O
.	O
Microtubule	O
disruption	O
did	O
not	O
affect	O
total	O
cellular	O
25	O
(	O
OH	O
)	O
D3	O
uptake	O
but	O
reduced	O
its	O
intracellular	O
trafficking	O
to	O
the	O
mitochondria	O
.	O
Thus	O
,	O
microtubules	S-GP
participate	O
in	O
intracellular	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
.	O
Relationship	O

between	O
Rap1	B-GP
protein	E-GP
phosphorylation	O
and	O
regulation	O
of	O
Ca2+	O
transport	O
in	O
platelets	S-cell_type
:	O
a	O
new	O
approach	O
.	O
Although	O
the	O
interrelationship	O

between	O
the	O
two	O
messengers	O
Ca2+	O
and	O
cyclic	O
AMP	O
in	O
platelet	O
function	O
is	O
well	O
documented	O
,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established	O
.	O
We	O
investigated	O
here	O
the	O
question	O
of	O
the	O
regulation	O
of	O
platelet	B-GP
Ca	I-GP
(	I-GP
2+	I-GP
)	I-GP
-ATPases	E-GP

by	O
cyclic	O
AMP	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-GP

protein	E-GP
using	O
a	O
pathological	O
model	O
.	O
We	O
first	O
found	O
experimental	O
conditions	O
where	O
Ca	O
(	O
2+	O
)	O
-transport	O
by	O
platelet	O
membrane	O
vesicles	O
appeared	O

to	O
be	O
dependent	O
on	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-GP
protein	E-GP
.	O
Then	O
,	O
we	O
studied	O
platelets	S-cell_type
of	O
patients	O
with	O
congestive	O
heart	O
failure	O
for	O
their	O
expression	O
of	O
the	O

potential	O

97	B-GP
kDa	I-GP
Ca	I-GP
(	I-GP
2+	I-GP
)	I-GP
-ATPase	I-GP
target	E-GP
of	O
regulation	O
through	O
the	O
Rap1	B-GP
protein	E-GP
as	O
well	O
as	O

the	O
phosphorylation	O
of	O
the	O
Rap1	B-GP
protein	E-GP
using	O
the	O
catalytic	B-GP
subunit	E-GP
of	O
the	O
cyclic	B-GP
AMP-dependent	I-GP
protein	I-GP
kinase	E-GP
(	O
C.	B-GP
Sub	I-GP
.	E-GP
)	O
.	O
In	O
the	O
first	O
patients	O
studied	O
,	O

we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	B-GP
kDa	I-GP
Ca	I-GP
(	I-GP
2+	I-GP
)	I-GP
-ATPase	E-GP
by	O
Western	O
blotting	O
using	O
the	O
PL/IM	B-GP
430	I-GP
monoclonal	I-GP
antibody	E-GP
which	O
specifically	O
recognized	O
this	O

isoform	O
.	O
In	O
contrast	O
,	O
the	O
Rap1	B-GP
protein	E-GP
was	O
differentially	O
phosphorylated	O
when	O
using	O
15	O
micrograms/ml	O
of	O
the	O
C.	B-GP
Sub	I-GP
.	E-GP
These	O
results	O
allowed	O
us	O
to	O
use	O
these	O

pathological	O
platelets	S-cell_type
to	O
study	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
Rap1	B-GP
protein	E-GP
and	O
the	O
regulation	O
of	O
Ca2+	O
transport	O
by	O
selecting	O
a	O
patient	O
with	O
severe	O
heart	O
failure	O
.	O
We	O
could	O
show	O
a	O
decrease	O
in	O
the	O
expression	O
as	O
well	O
as	O
in	O
the	O
phosphorylation	O
of	O
Rap1	B-GP
protein	E-GP
and	O
demonstrate	O
a	O
lower	O
effect	O
of	O
C.	B-GP
Sub	I-GP
.	E-GP
on	O
Ca2+	O
transport	O

.	O
Finally	O
,	O
by	O
studying	O
a	O
further	O
series	O
of	O
patients	O
,	O
we	O
could	O
confirm	O
that	O
the	O
decrease	O
in	O
Rap1	B-GP
protein	E-GP
expression	O
in	O
heart	O
failure	O
,	O
whatever	O
its	O
extent	O
,	O
was	O
variable	O
,	O
and	O
could	O
strictly	O
correlate	O
the	O
expression	O

of	O
Rap1	B-GP
protein	E-GP
with	O
the	O
stimulatory	O
effect	O
of	O
C.	B-GP
Sub	I-GP
.	E-GP
on	O
Ca2+	O
transport	O
.	O
Besides	O
the	O
evidence	O

for	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
Rap1	B-GP
protein	E-GP
in	O
platelets	S-cell_type
from	O
patients	O
with	O
heart	O
failure	O
,	O
these	O
findings	O
constitute	O
a	O
new	O
approach	O
in	O
favour	O
of	O
the	O
regulation	O
of	O
platelet	O
Ca2+	O
transport	O
through	O
the	O

phosphorylation	O
of	O
the	O
Rap1	B-GP
protein	E-GP
.	O
An	O
IRF-1	S-GP
-dependent	O
pathway	O
of	O
DNA	O
damage-induced	O
apoptosis	O
in	O
mitogen-activated	B-cell_line
T	I-cell_line
lymphocytes	E-cell_line
.	O
Lymphocytes	S-cell_line
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage-induced	O
apoptosis	O
,	O
a	O
response	O

which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O
The	O
tumour	B-GP
suppressor	I-GP
p53	E-GP
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	S-cell_type
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53	S-GP
-independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O

mediate	O
the	O
same	O
event	O
in	O
mitogen-activated	B-cell_line
mature	I-cell_line
T	I-cell_line
lymphocytes	E-cell_line
.	O
Here	O
we	O
show	O
DNA	O
damage-induced	O
apoptosis	O
in	O
these	O
T	B-cell_type
lymphocytes	E-cell_type
is	O
dependent	O
on	O
the	O
antioncogenic	B-GP
transcription	I-GP
factor	I-GP
interferon	I-GP
regulatory	I-GP
factor	E-GP
(	B-GP
IRF	I-GP
)	I-GP
-1	E-GP
.	O
Thus	O
two	O
different	O
anti-onco-genic	B-GP
transcription	I-GP
factors	E-GP
,	O
p53	S-GP

and	O

IRF-1	S-GP
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O
We	O

also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin-1	B-DNA
beta	I-DNA
converting	I-DNA
enzyme	I-DNA
(	I-DNA
ICE	I-DNA
)	I-DNA
gene	E-DNA
,	O
a	O
mammalian	B-GP
homologue	E-GP
of	O
the	O
Caenorhabditis	B-DNA
elegans	I-DNA
cell	I-DNA
death	I-DNA
gene	E-DNA
ced-3	S-DNA
,	O
is	O
IRF-1	S-GP
-dependent	O
.	O
Ectopic	O

overexpression	O
of	O
IRF-1	S-GP
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	B-DNA
gene	E-DNA
for	O
ICE	S-GP
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation-induced	O
apoptosis	O
.	O
Circadian	O
rhythm	O
of	O
glucocorticoid	B-GP
receptors	E-GP
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	E-cell_type
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O
1	O
)	O

There	O
exists	O
a	O
CR	O
of	O
GR	S-GP
in	O
human	B-cell_type
leukocytes	E-cell_type
,	O
PMN	S-cell_type
,	O
and	O
monocytes	S-cell_type
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O

trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O
The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O
2	O
)	O
The	O
FI	O
of	O

the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	S-cell_type
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	S-GP
.	O
This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	S-GP
may	O
be	O
of	O
functional	O
significance	O
.	O

3	O
)	O
In	O
Cushing	O
's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	S-GP
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O

was	O

disturbed	O
.	O
This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	S-GP
from	O
that	O
of	O
cortisol	O

.	O
4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	S-GP
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O
These	O
results	O

strongly	O
suggest	O
that	O
the	O
main	O
``	O
circadian	O
pacemaker	O

''	O
of	O
GR	S-GP
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	O
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line

lines	E-cell_line
from	O
multiple	O
sclerosis	O
patients	O
and	O
a	O
healthy	O
control	O
producing	O
a	O
putative	O
new	O

human	O
retrovirus	O
and	O
Epstein-Barr	O
virus	O
.	O
On	O
several	O
occasions	O
we	O
have	O
observed	O
retrovirus-like	O
particles	O
(	O
RVLPs	O
)	O
by	O
transmission	O
electron	O
microscopy	O
(	O
EM	O
)	O
of	O
cultured	B-cell_line
T	I-cell_line

cells	E-cell_line
from	O
a	O
patient	O
with	O
MS	O
.	O
Later	O
we	O
established	O
spontaneously	O
formed	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line

lines	E-cell_line
(	O
LCLs	S-cell_line
)	O
from	O
a	O
patient	O
with	O
an	O
MS-like	O
disease	O
and	O
from	O
another	O
patient	O
with	O
MS	O
who	O
had	O
a	O
reactivated	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O
Both	O
LCLs	S-cell_line
were	O
found	O

by	O
EM	O
to	O
produce	O
RVLP	O
and	O
EBV	O
particles	O
.	O
Reverse	O
transcriptase	O
(	O
RT	O
)	O
assays	O
were	O
positive	O
in	O
purified	O
viral	O
material	O
from	O
both	O
LCLs	S-cell_line
.	O
To	O
substantiate	O
these	O
findings	O
we	O
initiated	O
an	O
intensified	O

culturing	O

procedure	O
and	O
were	O
able	O
to	O
establish	O
LCLs	S-cell_line
from	O
5	O
out	O
of	O
21	O
consecutive	O
MS	O
patients	O
and	O
1	O
out	O
of	O
13	O
consecutive	O

healthy	O
controls	O
.	O
All	O
LCLs	S-cell_line
were	O
found	O
to	O
produce	O
both	O
RVLP	O
and	O
EBV	O
particles	O
by	O
EM	O
.	O
Whether	O
the	O
putative	O
new	O
retrovirus	O
(	O
es	O
)	O
and	O
EBV	O
have	O

any	O
causal	O
relationship	O
to	O
MS	O
is	O
still	O
not	O
known	O
,	O
but	O
the	O
findings	O
support	O
this	O
possibility	O
.	O
Identification	O
of	O
an	O
ionomycin/cyclosporin	B-DNA
A-responsive	I-DNA
element	E-DNA
within	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
enhancer	E-DNA
.	O
Activation	O
through	O
the	O

Ca2+/	O
calcineurin	S-GP
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	B-DNA
genes	E-DNA
.	O

The	O
conserved	B-DNA
cis-acting	I-DNA
sequence	E-DNA
,	O
GGAAAA	O
,	O
and	O
transcription	B-GP
factors	E-GP
binding	O
to	O
this	O
sequence	O
are	O
involved	O

in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2+	O
concentrations	O
.	O
Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non-cytokine	B-DNA
gene	E-DNA
,	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
(	I-DNA
TCRG	I-DNA

)	I-DNA
enhancer	E-DNA
.	O
Results	O
from	O
site-directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O

that	O
this	O
sequence	O
mediates	O
the	O
ionomycin-induced	O
activation	O
of	O
the	O
TCRG	B-DNA
enhancer	E-DNA
.	O
Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	B-RNA
mRNA	E-RNA
levels	O
,	O
but	O
not	O

mRNA	O

levels	O
for	O
T	B-GP
cell	I-GP
receptor	I-GP
alpha	I-GP
and	I-GP
-beta	E-GP
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

Coexpression	O
of	O
NF-kappa	B-GP
B/Rel	E-GP
and	O
Sp1	S-GP
transcription	B-GP
factors	E-GP
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell-T-cell	O

syncytia	O
.	O
Productive	O
infection	O
of	O
T	B-cell_type
cells	E-cell_type
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
typically	O
requires	O
that	O
the	O
T	B-cell_type
cells	E-cell_type
be	O
stimulated	O
with	O
antigens	O

or	O
mitogens	O
.	O
This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B-GP
factor	E-GP
NF-kappa	B-GP
B	E-GP
,	O
which	O
synergizes	O
with	O
the	O
constitutive	B-GP
transcription	I-GP
factor	E-GP
Sp1	S-GP
to	O

drive	O
the	O
HIV-1	B-DNA
promoter	E-DNA
.	O
Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV-1	O
takes	O
place	O
in	O
nonactivated	O
memory	B-cell_type
T	I-cell_type
cells	E-cell_type
after	O

syncytium	O
formation	O
with	O
dendritic	B-cell_type
cells	E-cell_type
(	O
DCs	S-cell_type
)	O
.	O
These	O
syncytia	O
lack	O
activated	B-cell_type
cells	E-cell_type
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki-67	O
cell	O
cycle	O
antigen	O
.	O
The	O
expression	O
and	O
activity	O
of	O

NF-kappa	B-GP

B	E-GP
and	O
Sp1	S-GP
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	B-cell_type
cells	E-cell_type
and	O
DCs	S-cell_type
from	O
humans	O
and	O
mice	O

.	O
We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O
T	B-cell_type
cells	E-cell_type
lack	O
active	O
NF-kappa	B-GP
B	E-GP
but	O
express	O

Sp1	S-GP
as	O
expected	O
.	O
DCs	S-cell_type
express	O
high	O
levels	O
of	O
all	O
known	O
NF-kappa	B-GP
B	E-GP
and	O
Rel	B-GP
proteins	E-GP
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	S-GP
,	O
p50	S-GP
,	O
and	O
p65	S-GP
.	O

However	O
,	O
DCs	S-cell_type
lack	O
Sp1	S-GP
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV-1	O
to	O
replicate	O
in	O
purified	O
DCs	S-cell_type
.	O
Coexpression	O
of	O
NF-kappa	B-GP
B	E-GP
and	O
Sp1	S-GP
occurs	O
in	O

the	O
heterologous	B-cell_type
DC-T-cell	I-cell_type
syncytia	E-cell_type
that	O
are	O
induced	O
by	O
HIV-1	O
.	O
Therefore	O
,	O
HIV-1-induced	O
cell	O
fusion	O
brings	O
together	O
factors	O

that	O
upregulate	O
virus	O
transcription	O
.	O
Since	O
DCs	S-cell_type
and	O
memory	O
T	B-cell_type
cells	E-cell_type
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	B-cell_type
syncytia	E-cell_type
could	O
develop	O
in	O
infected	O

individuals	O
and	O
lead	O
to	O
chronic	O
HIV-1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O
Cupric	O
ion	O
blocks	O
NF	B-GP
kappa	I-GP

B	E-GP
activation	O
through	O
inhibiting	O
the	O
signal-induced	O
phosphorylation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP

.	O
A	O
transcription	B-GP
factor	E-GP
NF	B-GP
kappa	I-GP
B	E-GP
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	B-DNA
genes	E-DNA
including	O
HIV	O
,	O

is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B-GP
protein	I-GP
I	I-GP
kappa	I-GP
B	E-GP
.	O
Various	O
extracellular	O
signals	O

induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
to	O
release	O
NF	B-GP
kappa	I-GP
B	E-GP
.	O
Cu2+	O
was	O

found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	B-GP
kappa	I-GP
B	E-GP
induced	O
by	O
TNF-alpha	S-GP
,	O

TPA	O
,	O
or	O
H2O2	O
.	O
Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF-alpha	S-GP
in	O
the	O
presence	O
of	O
Cu2+	O
resulted	O
in	O
the	O
release	O
of	O
NF	B-GP
kappa	I-GP
B	E-GP
from	O
I	B-GP

kappa	I-GP

B	I-GP
alpha	E-GP
,	O
indicating	O
that	O
Cu2+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	B-GP
kappa	I-GP
B-I	I-GP
kappa	I-GP
B	I-GP
complex	E-GP

.	O
Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
was	O
observed	O
upon	O
TNF-alpha	S-GP
stimulation	O
in	O
the	O
presence	O
of	O
Cu2+	O
.	O
These	O
results	O
indicate	O
that	O
Cu2+	O
inhibits	O
the	O
release	O
of	O
NF	B-GP
kappa	I-GP
B	E-GP
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O

the	O
phosphorylation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
.	O
Cloning	O
a	O
cDNA	S-DNA
from	O
human	O
NK/T	B-cell_type
cells	E-cell_type
which	O
codes	O
for	O
a	O

protein	O
with	O
high	O
proline	O
content	O
.	O
A	O
cDNA	B-DNA
clone	E-DNA
,	O
B4-2	S-DNA
,	O
was	O
isolated	O
from	O
a	O
natural	B-DNA
killer	I-DNA
(	I-DNA
NK	I-DNA

)	I-DNA
minus	I-DNA
T	I-DNA
cell	I-DNA
subtractive	I-DNA
library	E-DNA
.	O
The	O
B4-2	S-DNA
clone	O
coded	O
for	O
an	O
mRNA	S-RNA
of	O
2061	O
bp	O
in	O
length	O
.	O
It	O
encodes	O
a	O
deduced	O
327	B-GP
aa	I-GP
protein	E-GP
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
35.2	O
kDa	O
.	O
Searching	O
of	O
B4-2	B-DNA
DNA	E-DNA
and	O
protein	O
sequences	O
against	O
various	O
databases	O
revealed	O

no	O
high	O
homology	O
to	O
other	O
sequences	O
.	O
However	O
,	O
B4-2	S-DNA
has	O
an	O
unusually	O
high	O
proline	O
content	O
(	O
13	O
%	O
)	O

,	O
contains	O
a	O
putative	O
nuclear	B-GP
targeting	I-GP
sequence	E-GP
,	O
and	O
has	O
several	O
SPXX	B-GP
motifs	E-GP
which	O
are	O
frequently	O
found	O
in	O
gene	B-GP
regulatory	I-GP
proteins	E-GP
.	O
One	O
of	O
the	O
stretches	O
of	O

prolines	O

in	O
B4-2	S-DNA
closely	O
resembles	O
the	O
ligand	O
for	O
proteins	O
with	O
SH3	B-GP
domains	E-GP
.	O
Northern	O
hybridization	O
data	O
showed	O
that	O

B4-2	S-DNA
is	O
not	O
a	O
lymphoid	B-DNA
specific	I-DNA
gene	E-DNA
and	O
is	O
expressed	O
in	O
a	O
hepatoma	B-cell_line
cell	I-cell_line
line	E-cell_line
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O

in	O
a	O
variety	O
of	O
other	O
cells	O
.	O
A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B-GP

B4-2	E-GP
recognizes	O
a	O
32-34	B-GP
kDa	I-GP
protein	E-GP
in	O
lymphocytes	S-cell_type
.	O
Activation	O
of	O
JAK3	S-GP
,	O
but	O
not	O
JAK1	S-GP

,	O
is	O
critical	O
for	O
IL-2	S-GP
-induced	O
proliferation	O
and	O
STAT5	S-GP
recruitment	O
by	O
a	O
COOH-terminal	B-GP
region	E-GP
of	O
the	O
IL-2	B-GP
receptor	I-GP

beta-chain	E-GP
.	O
A	O
number	O
of	O
cytokines	S-GP
and	O
growth	B-GP
factors	E-GP
use	O
the	O
JAK	S-GP
-STAT	S-GP
pathway	O
to	O
signal	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
.	O
While	O
homodimerizing	B-GP
cytokine	I-GP
receptors	E-GP
may	O
transmit	O
signal	O
via	O
a	O
single	O
form	O

of	O
JAK	S-GP
(	O
i.e	O
.	O
growth	B-GP
hormone	I-GP
receptors	E-GP
)	O
,	O
several	O
multicomponent	B-GP
cytokine	I-GP
receptors	E-GP
have	O
been	O
shown	O
to	O

require	O
simultaneous	O
activation	O
of	O
pairs	O
of	O
different	O
JAK	B-GP
kinases	E-GP
(	O
i.e	O
.	O
interferon	B-GP
receptors	E-GP
)	O
.	O
Recent	O
evidence	O
for	O
a	O
preferential	O
coupling	O
of	O
JAK3	S-GP
to	O
interleukin-2	B-GP
receptor-gamma	E-GP
(	O
IL-2R	B-GP
gamma	E-GP
)	O
and	O
JAK1	S-GP

to	O
IL-2R	B-GP
beta	E-GP
supports	O
the	O
concept	O
of	O
heterotrans-activation	O
of	O
JAK1	S-GP
and	O
JAK3	S-GP
caused	O
by	O
IL-2	S-GP

-induced	O

heterodimerization	O
of	O
their	O
receptor	O
partners	O
.	O
The	O
present	O
study	O
verified	O
the	O
ability	O
of	O
IL-2	S-GP
to	O
cause	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
JAK1	S-GP
and	O
JAK3	S-GP
,	O
but	O
demonstrated	O

that	O
IL-2	S-GP
stimulated	O
JAK3	S-GP
to	O
a	O
significantly	O
larger	O
extent	O
than	O
JAK1	S-GP
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
and	O
the	O
YT	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O
This	O

conclusion	O
was	O
based	O
upon	O
several	O
independent	O
criteria	O
,	O
including	O
more	O
vigorous	O
tyrosine	O
phosphorylation	O
of	O
JAK3	S-GP
,	O
more	O
marked	O
enzymatic	O
activation	O
of	O
JAK3	S-GP
as	O
well	O
as	O
higher	O
abundance	O
of	O
JAK3	S-GP
in	O
activated	O
IL-2	B-GP
receptor	I-GP
complexes	E-GP
.	O
Furthermore	O
,	O
when	O
human	B-GP
IL-2R	I-GP
beta	E-GP
was	O
stably	O
expressed	O
in	O

murine	B-cell_line
BA/F3	I-cell_line
cells	E-cell_line
,	O
robust	O
IL-2	S-GP
-induced	O
proliferation	O
and	O
JAK3	S-GP
activation	O
occurred	O
without	O
detectable	O
involvement	O
of	O
either	O
JAK1	S-GP
,	O
JAK2	S-GP
or	O
TYK2	S-GP
.	O
We	O
therefore	O
propose	O
that	O
IL-2	B-GP
receptor	E-GP
signal	O
transduction	O
does	O
not	O
depend	O
on	O
equimolar	O
heterodimerization	O
of	O
JAK1	S-GP

and	O
JAK3	S-GP
following	O
IL-2	S-GP
-induced	O
heterodimerization	O
of	O
IL-2R	B-GP
beta	E-GP
and	O
IL-2R	B-GP
gamma	E-GP
.	O
Nonetheless	O
,	O
a	O
membrane-proximal	B-GP
region	E-GP
of	O
human	O
IL-2R	B-GP
beta	E-GP
(	O
Asn240-Leu335	S-GP
)	O
was	O
critical	O
for	O
JAK3	S-GP
activation	O
,	O
and	O
the	O
amount	O
of	O
JAK3	S-GP
present	O
in	O
activated	O
IL-2	B-GP
receptor	I-GP
complexes	E-GP

increased	O
with	O
time	O
,	O
suggesting	O
that	O
stabilization	O
of	O
JAK3	S-GP
binding	O
to	O
the	O
receptor	B-GP
complex	E-GP
relies	O
on	O
both	O
IL-2R	B-GP
beta	E-GP
and	O
IL-2R	B-GP
gamma	E-GP
.	O
Moreover	O
,	O
STAT5	S-GP
was	O
found	O
to	O
be	O
the	O
predominant	O
STAT	B-GP
transcription	I-GP
factor	E-GP
used	O

by	O
IL-2	S-GP
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
and	O
specifically	O
required	O
a	O
COOH-terminal	B-GP
region	E-GP
of	O
IL-2R	B-GP
beta	E-GP
(	O
Ser386-Val525	S-GP
)	O
,	O
while	O
STAT5	S-GP
recruitment	O
was	O
not	O
correlated	O
to	O
activation	O
of	O
IL-2R	B-GP
gamma	E-GP
or	O
JAK3	S-GP

.	O
Up-regulation	O
of	O
high-affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
.	O
Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O

mechanism	O
of	O
action	O
remains	O
unknown	O
.	O
DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole-cell	O
binding	O
assay	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
PEER	S-cell_line
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+/-	O
0.53	O
nmol/L	O
,	O
mean	O
+/-	O
SE	O
,	O
n	O
=	O

4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2+	O
ionophore	O
A23187	O
.	O
Bound	O
[	O
3H	O
]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O
These	O
results	O
not	O

only	O

indicate	O
the	O
existence	O
of	O
a	O
DHEA	B-GP
receptor	E-GP
,	O
but	O
also	O
suggest	O
that	O
T	B-cell_type
cells	E-cell_type

become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal-induced	O
activation	O
.	O
Ubiquitin-mediated	O
processing	O
of	O
NF-kappa	B-GP
B	E-GP
transcriptional	B-GP
activator	I-GP

precursor	E-GP
p105	S-GP
.	O
Reconstitution	O
of	O
a	O
cell-free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin-carrier	B-GP
protein	E-GP
,	O
E2	S-GP
,	O
and	O
a	O
novel	O
ubiquitin-protein	B-GP
ligase	E-GP
,	O
E3	S-GP
,	O
involved	O
in	O
conjugation	O
.	O
In	O
most	O
cases	O
,	O
the	O
transcriptional	B-GP
factor	E-GP
NF-kappa	B-GP
B	E-GP
is	O
a	O
heterodimer	S-GP
consisting	O
of	O
two	O
subunits	O
,	O
p50	S-GP
and	O
p65	S-GP
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	B-DNA
family	E-DNA
.	O
p50	S-GP
is	O

translated	O
as	O
a	O
precursor	O
of	O
105	B-GP
kDa	E-GP
.	O
The	O
C-terminal	B-GP
domain	E-GP
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	B-GP
p50	I-GP
subunit	E-GP
consisted	O
of	O
the	O

N-terminal	B-GP
region	E-GP
of	O
the	O
molecule	O
.	O
The	O
mechanism	O
of	O
generation	O
of	O
p50	S-GP
is	O
not	O
known	O
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	S-GP
-proteasome	S-GP
system	O
is	O
involved	O
in	O
the	O
process	O
;	O

however	O

,	O
the	O
specific	O
enzymes	S-GP
involved	O
and	O
the	O
mechanism	O
of	O
limited	O

proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O
Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V.J.	O
,	O
Rando	O
,	O
O.J.	O

,	O
Goldberg	O
,	O
A.L.	O
,	O
and	O
Maniatis	O
,	O
T.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773-785	O
)	O
have	O
shown	O
that	O
ubiquitin	S-GP
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell-free	O
system	O
of	O
a	O
truncated	O

,	O
artificially	O
constructed	O
,	O
60-kDa	B-GP
precursor	E-GP
.	O
They	O
have	O
also	O

shown	O
that	O
proteasome	S-GP
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell-free	O

processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O

the	O
ubiquitin	S-GP
-proteasome	S-GP
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	S-GP
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	S-GP
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O

the	O
ubiquitin-carrier	B-GP
protein	E-GP
,	O
E2-F1	S-GP
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	S-GP
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	B-GP
precursor	E-GP
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320-kDa	B-GP
species	E-GP
of	O
ubiquitin-protein	B-GP
ligase	E-GP
,	O
is	O
involved	O
in	O
the	O
process	O
.	O
This	O
novel	O

enzyme	O
is	O
distinct	O
from	O
E6-AP	S-GP
,	O
the	O
p53-conjugating	B-GP
ligase	E-GP
,	O
and	O
from	O
E3	B-GP
alpha	E-GP
,	O
the	O
``	B-GP

N-end	I-GP
rule	I-GP
''	I-GP
ligase	E-GP
.	O
Flutamide	O
in	O
the	O
treatment	O
of	O
hirsutism	O
:	O
long-term	O
clinical	O
effects	O
,	O
endocrine	O
changes	O
,	O
and	O
androgen	B-GP
receptor	E-GP
behavior	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long-term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-GP
receptor	E-GP
status	O
,	O
in	O
hirsute	O
women	O
.	O
DESIGN	O
:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months	O
.	O
Barrier	O
or	O
intrauterine	O
contraception	O
was	O
used	O
during	O
the	O
study	O
in	O
sexually	O
active	O
women	O
.	O
Safety	O
parameters	O
were	O
assessed	O
throughout	O
the	O
study	O
.	O
Hirsutism	O
,	O
graded	O
by	O

the	O
modified	O
Ferriman-Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment	O
.	O
Gonadotropin-releasing	O
hormone	O
and	O
ACTH	O
stimulation	O
tests	O

were	O

performed	O
before	O
and	O
after	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O
In	O
addition	O
,	O
the	O
concentration	O
of	O
androgen	B-GP
receptors	E-GP

in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
was	O
measured	O
,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment	O
.	O
RESULTS	O
:	O
Flutamide	O
was	O
well	O
tolerated	O

in	O
all	O
women	O
,	O
with	O
the	O
noticeable	O
exception	O
of	O
one	O
patient	O
who	O
presented	O
increased	O
serum	B-GP
transaminase	E-GP
after	O
8	O
months	O
of	O
therapy	O
.	O
Hirsutism	O
markedly	O
improved	O
in	O
all	O

women	O
during	O
the	O
treatment	O
(	O
Ferriman-Gallwey	O
score	O
after	O
1	O
year	O
:	O
4.1	O
+/-	O
0.5	O

versus	O
14.1	O
+/-	O
0.9	O
)	O
.	O
A	O
reduction	O

of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH-stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O

17	O
alpha-hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O
Cycles	O
remained	O
ovulatory	O
.	O
Before	O
treatment	O
,	O
the	O
number	O
of	O
androgen	B-GP
receptors	E-GP

was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O
This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O
CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O

but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O
Androgen	O
receptor	O
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O
Flutamide	O
affects	O
androgen	B-GP
receptor	E-GP
behavior	O
during	O
the	O

menstrual	O
cycle	O
.	O
The	O
meaning	O
of	O
this	O
finding	O
remains	O
to	O
be	O
elucidated	O
.	O
Constitutive	O
expression	O
of	O
HIV-1	B-GP
tat	I-GP
protein	E-GP
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	E-cell_line
using	O

a	O
BK	O
virus	O
vector	O
.	O
The	O
production	O
and	O
characterization	O
of	O
Jurkat	B-cell_line
cell	I-cell_line
lines	E-cell_line
that	O
constitutively	O
express	O
functional	O
human	B-GP
immune	I-GP
deficiency	I-GP
virus	I-GP
type	I-GP
1	I-GP
(	I-GP
HIV-1	I-GP
)	I-GP
tat	I-GP
protein	E-GP
,	O
using	O

a	O
BK	O
virus	O
plasmid	O

expression	O
vector	O
and	O
HIV-1	B-DNA
tat	I-DNA
cDNA	E-DNA
,	O
is	O
described	O
.	O
An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	B-cell_line
cell	I-cell_line
lines	E-cell_line

as	O
compared	O
with	O
control	B-cell_line
cell	I-cell_line
lines	E-cell_line
was	O
observed	O
.	O
A	O
PEBP2	B-GP
alpha/AML-1-related	I-GP
factor	E-GP
increases	O

osteocalcin	B-DNA
promoter	E-DNA
activity	O
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	E-DNA
.	O
To	O
identify	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	E-DNA
and	O

trans-acting	B-GP
factors	E-GP
,	O
we	O
initiated	O
an	O
analysis	O
of	O
the	O
promoter	S-DNA
of	O
a	O
mouse	B-DNA

osteocalcin	I-DNA
gene	E-DNA
,	O
an	O
osteoblast-specific	B-DNA
gene	E-DNA
.	O
In	O
this	O
promoter	O

,	O
we	O
identified	O
two	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	E-DNA
(	O
Ducy	O
,	O

P.and	O

Karsenty	O
,	O
G.	O
(	O
1995	O
)	O
Mol.Cell.Biol.15	O
,	O
1858-1869	O
)	O
.	O
The	O
sequence	O
of	O
one	O
of	O
these	O

elements	S-DNA
,	O
OSE2	O
,	O
is	O
identical	O
to	O
the	O
DNA-binding	B-DNA
site	E-DNA
of	O
the	O
PEBP2	B-GP
alpha/AML-1	I-GP
transcription	I-GP
factors	E-GP
,	O
the	O
mammalian	B-GP
homologues	E-GP
of	O
the	O
Drosophila	B-GP
Runt	I-GP
protein	E-GP
.	O
Here	O
we	O
show	O
,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B-GP
protein	E-GP
,	O
and	O
a	O

specific	O
antiserum	O
against	O
AML-1	B-GP
proteins	E-GP
in	O
DNA-binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family	O
,	O
AML-1B	S-GP
,	O

binds	O

specifically	O
to	O
OSE2	O
and	O
is	O
immunologically	O
related	O
to	O
OSF2	S-GP
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O

that	O
binds	O
to	O
OSE2	O
.	O
By	O
DNA	O
cotransfection	O
experiments	O
,	O
we	O
also	O
demonstrate	O
that	O
AML-1B	S-GP
can	O
increase	O
the	O
activity	O
of	O
a	O
short	O
osteocalcin	B-DNA
promoter	E-DNA
through	O
its	O

binding	O
to	O
OSE2	O
.	O
Lastly	O
,	O
the	O
different	O
mobilities	O
of	O
osteoblast	B-GP
nuclear	I-GP
extract-DNA	I-GP
complexes	E-GP
compared	O
with	O
T-cell	B-GP
nuclear	I-GP
extract-DNA	I-GP
complexes	E-GP
,	O
along	O
with	O
the	O
inability	O

of	O
OSF2	S-GP
to	O
be	O
upregulated	O
by	O
retinoic	O
acid	O
,	O
unlike	O
the	O
other	O
PEBP2	B-GP
alpha	I-GP
factors	E-GP
,	O
suggest	O
that	O
OSF2	S-GP
is	O
a	O
new	O
member	O
of	O
this	O
family	O
of	O
transcription	B-GP
factors	E-GP
.	O
Thus	O
,	O

this	O
study	O
demonstrates	O
that	O
AML-1B	S-GP
can	O
increase	O
gene	O
expression	O
of	O
an	O
osteoblast-specific	B-DNA
gene	E-DNA
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	E-DNA
and	O
presents	O
evidence	O
that	O
OSF2	S-GP
is	O
a	O
member	O
of	O
the	O
PEBP2	B-GP
alpha/AML-1	I-GP
family	E-GP
of	O
transcription	B-GP
factors	E-GP
.	O
Initiation	B-GP
binding	I-GP
repressor	E-GP
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
of	O
the	O
histone	B-DNA

h5	I-DNA
gene	E-DNA
,	O
is	O
a	O
glycosylated	B-GP
member	E-GP
of	O
a	O
family	O
of	O
cell	B-GP
growth	I-GP
regulators	E-GP
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O

1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O
Initiation	B-GP
binding	I-GP
repressor	E-GP
[	O
corrected	O
]	O
(	O
IBR	S-GP
)	O
is	O
a	O
chicken	B-GP
erythrocyte	I-GP
factor	E-GP
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
of	O
the	O
histone	B-DNA
h5	I-DNA
gene	E-DNA
,	O
repressing	O

its	O
transcription	O
.	O
A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	B-cell_type
erythroid	I-cell_type
precursors	E-cell_type
,	O
do	O
not	O
have	O
IBR	S-GP
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	S-GP
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	S-GP
sites	O
.	O
We	O
have	O

cloned	O

the	O
IBR	B-DNA
cDNA	E-DNA
and	O
studied	O
the	O
relationship	O
of	O
IBR	S-GP
and	O
IBF	S-GP
.	O
IBR	S-GP
is	O
a	O
503-amino-acid-long	B-GP
acidic	I-GP
protein	E-GP
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	B-GP
NRF-1/alpha-Pal	I-GP
factor	E-GP
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	B-GP
factors	E-GP
P3A2	S-GP
and	O
erected	B-GP
wing	I-GP
gene	I-GP
product	E-GP
(	O
EWG	S-GP
)	O
.	O
We	O
present	O
evidence	O

that	O
IBR	S-GP
and	O
IBF	S-GP
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O
We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	S-GP
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	S-GP
and	O
that	O
the	O
dimer	S-GP
is	O
the	O
relevant	B-GP
DNA-binding	I-GP
species	E-GP
.	O

The	O
evolutionarily	O
conserved	O
N-terminal	B-GP
half	E-GP
of	O
IBR/F	S-GP
harbors	O
the	O
DNA-binding/dimerization	B-GP
domain	E-GP
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	B-GP
kinase	I-GP
II	I-GP
sites	E-GP
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O

bipartite	B-GP
nuclear	I-GP
localization	I-GP
signal	E-GP
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O

nuclear	O
targeting	O
.	O
Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	B-GP
RCGCRYGCGY	I-GP
consensus	E-GP
constitutes	O
high-affinity	O
IBR/F	B-DNA
binding	I-DNA
sites	E-DNA
and	O
that	O
the	O
direct-repeat	B-DNA
palindrome	E-DNA
TGCGCATGCGCA	O
is	O
the	O
optimal	B-DNA
site	E-DNA
.	O
A	O
survey	O
of	O
genes	S-DNA
potentially	O
regulated	O
by	O
this	O

family	O
of	O
factors	S-GP
primarily	O
revealed	O
genes	S-DNA
involved	O
in	O
growth-related	O
metabolism	O
.	O
Triggering	O
of	O
the	O
human	O
interleukin-6	O
gene	O
by	O
interferon-gamma	O
and	O

tumor	O
necrosis	O
factor-alpha	O
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-GP
regulatory	I-GP
factor-1	E-GP
,	O
NF	B-GP
kappa	I-GP
B	E-GP
,	O
and	O
Sp1	S-GP
transcription	B-GP
factors	E-GP
.	O
We	O
investigated	O
the	O
molecular	O
basis	O

of	O
the	O
synergistic	O
induction	O
by	O
interferon-gamma	S-GP
(	O
IFN-gamma	S-GP
)	O
/	O
tumor	B-GP
necrosis	I-GP
factor-alpha	E-GP
(	O
TNF-alpha	S-GP
)	O
of	O
human	B-DNA
interleukin-6	I-DNA
(	I-DNA
IL-6	I-DNA
)	I-DNA
gene	E-DNA
in	O
THP-1	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Functional	O
studies	O
with	O
IL-6	B-DNA
promoter	E-DNA
demonstrated	O
that	O
three	O
regions	O
are	O

the	O
targets	O
of	O
the	O
IFN-gamma	S-GP
and/or	O
TNF-alpha	S-GP
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O
The	O
three	O

regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-73	O
and	O
-36	O
,	O
which	O
is	O
the	O
minimal	B-DNA
element	E-DNA
inducible	O

by	O

LPS	O
or	O
TNF-alpha	S-GP
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-181	O
and	O
-73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN-gamma	S-GP
and	O
TNF-alpha	S-GP
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	B-DNA

element	I-DNA
upstream	E-DNA
of	O
-224	O
,	O
which	O
was	O
inducible	O
by	O
IFN-gamma	S-GP
alone	O
.	O
LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	B-GP
kappa	I-GP
B	E-GP
activation	O
by	O
the	O
p50/p65	B-GP
heterodimers	E-GP
.	O
Synergistic	O
induction	O
of	O
the	O
IL-6	B-DNA
gene	E-DNA
by	O
IFN-gamma	S-GP
and	O
TNF-alpha	S-GP
,	O
in	O
monocytic	B-cell_type
cells	E-cell_type
,	O
involved	O
cooperation	O
between	O
the	O
IRF-1	S-GP
and	O

NF	B-GP
kappa	I-GP
B	I-GP
p65	I-GP
homodimers	E-GP
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	B-DNA
control	I-DNA
element	E-DNA
present	O
in	O
the	O
IL-6	B-DNA
promoter	E-DNA
.	O
This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	B-GP
Sp1	I-GP
factor	E-GP

,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN-gamma	S-GP
.	O
Mutation	O
of	O
Jak3	S-GP
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	S-GP
in	O
lymphoid	O
development	O
.	O
Males	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	B-DNA
receptor	I-DNA
gamma	I-DNA
chain	I-DNA
(	I-DNA
gamma	I-DNA
c	I-DNA
)	I-DNA
gene	E-DNA
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin-2	S-GP
(	O

IL-2	S-GP
)	O
,	O
IL-4	S-GP
,	O
IL-7	S-GP
,	O
IL-9	S-GP
,	O
and	O
IL-15	S-GP
.	O
The	O
Janus	B-GP
family	I-GP

tyrosine	I-GP
kinase	E-GP
Jak3	S-GP
is	O
the	O
only	O
signaling	O
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B-GP
c	E-GP
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	S-GP
might	O
cause	O
an	O
XSCID-like	O
phenotype	O
.	O
A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O

analysis	O
.	O
An	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
cell	I-cell_line
line	E-cell_line
derived	O
from	O
her	O
lymphocytes	S-cell_type
had	O
normal	O
gamma	B-GP
c	E-GP
expression	O
but	O
lacked	O

Jak3	B-GP

protein	E-GP
and	O
had	O
greatly	O
diminished	O
Jak3	B-RNA
messenger	I-RNA
RNA	E-RNA
.	O
Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele	O

:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B-GP
JH4	I-GP
domain	E-GP
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	S-GP
JH2	O
domain	O
.	O
The	O
lack	O
of	O
Jak3	S-GP
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL-4	S-GP
to	O

activate	O
Stat6	S-GP
in	O
the	O
EBV-transformed	B-cell_line
cell	I-cell_line
line	E-cell_line
from	O
the	O
patient.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B-GP
c	E-GP
are	O
dependent	O
on	O
Jak3	S-GP
and	O
that	O
Jak3	S-GP
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O

.	O
Constitutive	O
overexpression	O
of	O
the	O
L-selectin	B-DNA
gene	E-DNA
in	O
fresh	O
leukemic	B-cell_type
cells	E-cell_type
of	O
adult	O
T-cell	O
leukemia	O
that	O

can	O
be	O
transactivated	O
by	O
human	B-GP
T-cell	I-GP
lymphotropic	I-GP
virus	I-GP
type	I-GP
1	I-GP
Tax	E-GP
.	O
L-selectin	S-GP
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O

vascular	O
endothelium	O
.	O
Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L-selectin	B-DNA
gene	E-DNA
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O
To	O
understand	O
the	O
mechanism	O
of	O
leukemic	B-cell_type
cell	E-cell_type
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O

expression	O
and	O
regulation	O
of	O
L-selectin	B-RNA
mRNA	E-RNA
in	O
fresh	O
leukemic	B-cell_type
cells	E-cell_type
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L-selectin	B-DNA
promoter	E-DNA
to	O
human	B-GP
T-cell	I-GP
lymphotropic	I-GP
virus	I-GP
type	I-GP
1	I-GP
(	I-GP
HTLV-1	I-GP
)	I-GP
Tax	E-GP
,	O
which	O
is	O
a	O
viral	B-GP
transcriptional	I-GP
transactivator	E-GP
.	O
Flow	O
cytometry	O
showed	O
that	O
L-selectin	S-GP
was	O
expressed	O
on	O
fresh	O

ATL	B-cell_line

cells	E-cell_line
along	O
with	O
other	O
activation	B-GP
antigens	E-GP
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	B-cell_line
cells	E-cell_line
overexpressed	O
that	O
L-selectin	B-RNA
mRNA	E-RNA
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O

stimulation	O
.	O
Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L-selectin	B-RNA
mRNA	E-RNA
in	O
the	O
infiltrating	O
leukemic	B-cell_type
cells	E-cell_type
in	O
the	O
liver	O

of	O
two	O
ATL	O
patients	O
.	O
Intravenous	O
injection	O
of	O
a	O
rat	B-cell_line
T-cell	I-cell_line
line	E-cell_line
that	O
overexpresses	O
L-selectin	S-GP
showed	O
increased	O
organ	O
infiltration	O

.	O
The	O
induction	O
of	O
Tax	S-GP
expression	O
in	O
JPX9	B-cell_line
cells	E-cell_line
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	S-RNA
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O
Chloramphenicol	B-GP
acetyltransferase	E-GP
(	O
CAT	S-GP
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L-selectin	B-DNA
promoter	E-DNA
by	O
Tax	S-GP
.	O
The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L-selectin	S-GP
was	O
significantly	O
increased	O

in	O
ATL	O
patients	O
(	O
mean	O
+/-	O
SD	O
,	O
4	O
,	O
215.4	O
+/-	O
4	O
,	O
111	O
ng/mL	O
)	O

compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+/-	O
SD	O
,	O
1	O
,	O
148.0	O
+/-	O
269.0	O
ng/mL	O
and	O

991.9	O
+/-	O
224	O
ng/mL	O
,	O
respectively	O
)	O
.	O
These	O
results	O
indicated	O
that	O
ATL	B-cell_line
cells	E-cell_line
constitutively	O
overexpress	O
the	O
L-selectin	B-DNA
gene	E-DNA
that	O
can	O
be	O
transactivated	O
by	O

HTLV-1	O
Tax	S-GP
.	O
The	O
overexpression	O
of	O
L-selectin	S-GP
,	O
as	O
well	O
as	O
of	O
inflammatory	B-GP
cytokines	E-GP
,	O

by	O
ATL	B-cell_line
cells	E-cell_line
may	O
provide	O
a	O
basis	O
for	O
ATL	B-cell_line
cells	E-cell_line
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O
Human	O
herpesvirus	O

6	O
variant	O
A	O
,	O
but	O
not	O
variant	O
B	O
,	O
infects	O
EBV-positive	B-cell_line
B	I-cell_line
lymphoid	I-cell_line
cells	E-cell_line
,	O
activating	O
the	O
latent	B-DNA
EBV	I-DNA
genome	E-DNA
through	O

a	O
BZLF-1	S-GP
-dependent	O
mechanism	O
.	O
Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV-positive	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O
Here	O
we	O
have	O
confirmed	O
and	O
extended	O
such	O
observations	O
,	O
showing	O
that	O
(	O
1	O
)	O
this	O
phenomenon	O
is	O
restricted	O
to	O

the	O
variant	O
A	O
of	O
HHV-6	O
:	O
in	O
fact	O
two	O
isolates	O
belonging	O
to	O
the	O
HHV-6	O
variant	O
B	O
(	O
BA92	O
and	O

Z29	O
)	O
were	O
neither	O
able	O
to	O
infect	O
any	O
B	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O
independently	O
of	O
the	O
EBV	O
status	O
,	O
nor	O
to	O
induce	O
the	O
EBV	O
genome	O
expression	O
.	O
The	O
only	O
exception	O
is	O
represented	O
by	O
the	O
P3HR1	B-cell_line
cells	E-cell_line

,	O

in	O
which	O
,	O
however	O
,	O
the	O
infection	O
by	O
the	O
variant	O
B	O
does	O
not	O
determine	O
induction	O
of	O
EBV	B-GP
antigens	E-GP
;	O
(	O
2	O
)	O
the	O
presence	O
of	O
the	O
EBV	B-DNA
genome	E-DNA

contributes	O
to	O
the	O
susceptibility	O
of	O
the	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
to	O
HHV-6	O
infection	O
,	O
increasing	O
the	O
binding	O
sites	O
and	O
the	O
percentage	O
of	O
infectable	B-cell_type
cells	E-cell_type
,	O
as	O
detected	O
by	O
immunoelectron	O
microscopy	O
;	O
and	O
(	O
3	O
)	O
HHV-6	B-cell_line

infected	I-cell_line
T	I-cell_line
cells	E-cell_line
,	O
transfected	O
with	O
plasmids	S-DNA
bearing	O
the	O
promoter	B-DNA
regions	E-DNA
of	O
the	O
EBV	O
early	O
genes	O
BZLF1	O
and	O
BMRF1	S-DNA
,	O
show	O
a	O
strong	O
transactivation	O
of	O
these	O
promoters	S-DNA
.	O
Evidence	O
for	O
normal	O
vitamin	B-RNA
D	I-RNA
receptor	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	E-RNA
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O
Absorptive	O
hypercalciuria	O
(	O
a	O
stone-forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O

.	O
Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	E-DNA
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O
We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphism	E-DNA
(	O
Bsm	O
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	B-DNA
gene	E-DNA
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race-	O
and	O
age-matched	O
control	O
subjects	O
.	O
There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	S-GP
alleles	O
in	O
the	O
patient	O
population	O
when	O

compared	O

with	O
the	O
normal	O
population	O
.	O
The	O
coding	O
region	O
of	O
VDR	B-RNA
messenger	I-RNA
RNA	E-RNA
was	O
also	O
normal	O

,	O
as	O
determined	O
by	O
both	O
DNA	B-DNA
sequence	E-DNA
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	O
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O

.	O
On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	S-GP
and	O
are	O
not	O
linked	O

to	O
a	O
common	O
VDR	B-DNA
genotype	E-DNA
.	O
Transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
human	B-GP
C-type	I-GP
lectin	I-GP
leukocyte	I-GP
receptor	E-GP
AIM/CD69	S-GP
and	O
functional	O
characterization	O
of	O
its	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha-responsive	I-DNA
elements	E-DNA
.	O
The	O
human	B-GP
activation	I-GP
antigen	E-GP
CD69	S-GP
is	O
a	O
member	O
of	O
the	O
C-type	B-GP
animal	I-GP
lectin	I-GP
superfamily	E-GP
that	O
functions	O

as	O
a	O
signal-transmitting	B-GP
receptor	E-GP
.	O
Although	O
the	O
expression	O
of	O
CD69	S-GP
can	O
be	O
induced	O
in	O
vitro	O
on	O
cells	O
of	O
most	O
hematopoietic	O
lineages	O
with	O

a	O
wide	O
variety	O
of	O
stimuli	O
,	O
in	O
vivo	O
it	O
is	O
mainly	O
expressed	O
by	O
T-lymphocytes	S-cell_type
located	O
in	O
the	O
inflammatory	O
infiltrates	O
of	O
several	O
human	O
diseases	O
.	O
To	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
constitutive	O
and	O

inducible	O
expression	O
of	O
CD69	S-GP
by	O
leukocytes	S-cell_type
,	O
we	O
isolated	O
the	O
promoter	B-DNA
region	E-DNA
of	O
the	O
CD69	S-GP
gene	O
and	O
carried	O
out	O
its	O
functional	O
characterization	O
.	O
Sequence	O
analysis	O
of	O
the	O
5'-flanking	B-DNA
region	E-DNA
of	O
the	O
CD69	B-DNA
gene	E-DNA
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	B-DNA
element	E-DNA
30	B-DNA
base	I-DNA
pairs	I-DNA

upstream	E-DNA

of	O
the	O
major	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	B-GP
factors	E-GP
(	O
NF-kappa	B-GP
B	E-GP
,	O
Egr-1	S-GP
,	O
AP-1	S-GP
)	O

,	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene	O
.	O
Transient	O
expression	O
of	O
CD69	B-DNA
promoter-based	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	E-DNA
in	O
K562	B-cell_line

cells	E-cell_line
indicated	O
that	O
the	O
proximal	B-DNA
promoter	I-DNA
region	E-DNA
spanning	O
positions	O
-78	O
to	O
+16	O
contained	O
the	O
cis-acting	B-DNA
sequences	E-DNA
necessary	O
for	O
basal	O
and	O
phorbol	O
12-myristate	O
13-acetate-inducible	O
transcription	O
of	O
the	O
CD69	B-DNA
gene	E-DNA
.	O
Removal	O
of	O
the	O
upstream	O
sequences	O
located	O
between	O
positions	O
-78	O
and	O
-38	O
resulted	O

in	O
decreased	O
promoter	O
strength	O
and	O
abolished	O
the	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
We	O
also	O
found	O
that	O
tumor	B-GP
necrosis	I-GP
factor-alpha	E-GP
(	O
TNF-alpha	S-GP
)	O
is	O
capable	O
of	O
inducing	O
the	O
surface	O
expression	O
of	O
the	O

CD69	S-GP
molecule	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
of	O
fusion	O
plasmids	O
that	O
contain	O
5'-flanking	O
sequences	O
of	O
the	O
CD69	S-GP
gene	O
,	O
suggesting	O
that	O
this	O
cytokine	O
may	O
regulate	O
in	O
vivo	O
the	O
expression	O
of	O
CD69	S-GP
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Characterization	O
of	O
5	B-DNA
'	I-DNA
end	I-DNA
of	I-DNA
human	I-DNA
thromboxane	I-DNA
receptor	I-DNA
gene	E-DNA
.	O
Organizational	O
analysis	O
and	O
mapping	O
of	O

protein	B-DNA
kinase	I-DNA
C	I-DNA
--	I-DNA
responsive	I-DNA
elements	E-DNA
regulating	O
expression	O
in	O
platelets	S-cell_type
.	O
Platelet	B-GP
thromboxane	I-GP
receptors	E-GP
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O
To	O
determine	O
if	O
platelet	O
thromboxane	B-GP
receptors	E-GP
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O

human	B-DNA
genomic	I-DNA
DNA	I-DNA
clones	E-DNA
containing	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	E-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
.	O
The	O
exon-intron	B-DNA
structure	E-DNA
of	O
the	O
5	B-DNA
'	I-DNA
portion	E-DNA
of	O

the	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	B-DNA
sequence	E-DNA
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
genomic	I-DNA
clone	E-DNA
with	O
that	O
of	O
a	O
novel	B-DNA
human	I-DNA
uterine	I-DNA
thromboxane	I-DNA
receptor	I-DNA
cDNA	E-DNA
that	O
extended	O
the	O
mRNA	S-RNA
141	B-DNA
bp	I-DNA
further	I-DNA
upstream	E-DNA
than	O
the	O
previously	B-DNA
identified	I-DNA
human	I-DNA
placental	I-DNA
cDNA	E-DNA
.	O
A	O
major	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
was	O
located	O

in	O
three	O
human	O
tissues	O
approximately	O
560	B-DNA
bp	I-DNA

upstream	E-DNA

from	O
the	O
translation	B-DNA
initiation	I-DNA
codon	E-DNA
and	O
380	B-DNA
bp	I-DNA
upstream	E-DNA
from	O
any	O

previously	O
identified	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
.	O
The	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
has	O
neither	O
a	O
TATA	S-DNA
nor	O
a	O

CAAT	B-DNA
consensus	I-DNA
site	E-DNA
.	O
Promoter	O
function	O
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	E-DNA
of	O

the	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter/chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
chimera	I-DNA
plasmids	E-DNA
into	O
platelet-like	O
K562	B-cell_line
cells	E-cell_line
.	O
Thromboxane	O
receptor	B-DNA
promoter	E-DNA
activity	O
,	O
as	O
assessed	O

by	O
CAT	S-GP
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O
Functional	O
analysis	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
constructs	E-DNA
in	O
transfected	O
K562	B-cell_line
cells	E-cell_line
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
promoter	O
to	O
a	O
cluster	O
of	O
activator	B-DNA
protein-2	I-DNA
(	I-DNA
AP-2	I-DNA
)	I-DNA
binding	I-DNA
consensus	I-DNA

sites	E-DNA
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
.	O
These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	B-DNA

receptor	I-DNA
gene	E-DNA
and	O
demonstrate	O
that	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
expression	O
can	O
be	O
regulated	O
by	O
activation	O

of	O
protein	B-GP
kinase	I-GP
C	E-GP
via	O
induction	O
of	O
an	O
AP-2-like	B-GP
nuclear	I-GP
factor	E-GP
binding	O
to	O
upstream	B-DNA
promoter	I-DNA
elements	E-DNA
.	O
These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	B-GP
thromboxane	I-GP
receptors	E-GP
after	O

acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
transcription	O
in	O
platelet-progenitor	B-cell_type
cells	E-cell_type
.	O
Estrogen	B-GP
receptor	E-GP
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O

killer	O
cell	O
activity	O
in	O
early-stage	O
breast	O
cancer	O
patients	O
.	O
Confirmation	O
of	O
a	O
model	O
.	O
Previous	O
work	O
of	O
ours	O
has	O
demonstrated	O
that	O
a	O
significant	O
amount	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
variance	O
after	O
surgery	O
in	O
stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
both	O
the	O
estrogen	B-GP
receptor	E-GP

(	O
ER	S-GP
)	O
status	O
of	O
the	O
tumor	O
and	O
by	O
social	O
factors	O
,	O
namely	O
,	O
perceived	O
social	O
support	O
and	O
seeking	O
social	O
support	O
as	O
a	O
general	O
coping	O
strategy	O
.	O
As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value	O
,	O
we	O
sought	O
to	O
test	O

the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow-up	O
NK	O
activity	O
in	O
this	O

serially	O

assessed	O
group	O
of	O
patients	O
.	O
It	O
was	O
found	O
that	O
the	O
most	O
significant	O
variable	O
predicting	O
NK	O
activity	O
at	O
follow-up	O
was	O

tumor	O
ER	S-GP
concentration	O
,	O
with	O

higher	O
NK	O
activity	O
associated	O
with	O
ER	S-GP
-status	O
.	O
In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O
If	O
,	O
as	O
the	O
literature	O
suggests	O
,	O
NK	O
activity	O
is	O

relevant	O
to	O
breast	O
cancer	O
control	O
,	O
and	O
since	O
ER	S-GP
-tumors	O
have	O
a	O
worse	O
prognosis	O
,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	O
are	O
resistant	O
to	O
control	O
by	O
NK	B-cell_type
cells	E-cell_type
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	B-cell_type
cells	E-cell_type
to	O
the	O
tumor	O
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	O
prevent	O
local	O

tumor	O
control	O
at	O
the	O
site	O
of	O
action	O
.	O
The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O
This	O

finding	O
,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	O
cancer	O
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	O
support	O
variable	O
.	O
Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O

for	O
this	O
patient	O
population	O
.	O
Solution	O
structure	O
of	O
the	O
sequence-specific	B-DNA
HMG	I-DNA
box	E-DNA
of	O
the	O
lymphocyte	B-GP
transcriptional	I-GP
activator	E-GP
Sox-4	S-GP
.	O
Two	O
groups	O
of	O
HMG	B-GP
box	I-GP
proteins	E-GP
are	O
distinguished	O
.	O
Proteins	O
in	O
the	O
first	O
group	O
contain	O
multiple	O
HMG	B-GP
boxes	E-GP
,	O
are	O
non-sequence-specific	O
,	O
and	O
recognize	O
structural	O
features	O
as	O
found	O
in	O
cruciform	B-DNA
DNA	E-DNA
and	O
cross-over	B-DNA
DNA	E-DNA
.	O
The	O
abundant	O
chromosomal	B-GP
protein	E-GP
HMG-1	S-GP
belongs	O
to	O
this	O
subgroup	O
.	O
Proteins	O
in	O
the	O
second	O
group	O
carry	O
a	O
single	B-GP
HMG	I-GP
box	E-GP
with	O
affinity	O

for	O
the	O
minor	O
groove	O
of	O
the	O
heptamer	B-DNA
motif	E-DNA
AACAAAG	O
or	O
variations	O
thereof	O
.	O
A	O
solution	O
structure	O
for	O
the	O

non-sequence-specific	O
C-terminal	B-GP
HMG	I-GP
box	E-GP
of	O
HMG-1	S-GP
has	O
recently	O
been	O
proposed	O
.	O
Now	O
,	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
sequence-specific	B-GP
HMG-box	E-GP
of	O
the	O
SRY-related	B-GP
protein	E-GP
Sox-4	S-GP
.	O
NMR	O
analysis	O
demonstrated	O
the	O

presence	O
of	O
three	O
alpha-helices	S-GP
(	O
Val10-Gln22	S-GP
,	O
Glu30-Leu41	S-GP
and	O
Phe50-Tyr65	S-GP
)	O
connected	O
by	O
loop	B-GP
regions	E-GP
(	O
Ser23-Ala49	S-GP
and	O
Leu42-Pro49	S-GP
)	O

.	O

Helices	B-GP
I	I-GP
and	I-GP
II	E-GP
are	O
positioned	O
in	O
an	O
antiparallel	B-GP
mode	E-GP
and	O
form	O
one	O
arm	O

of	O
the	O
HMG	B-GP
box	E-GP
.	O
Helix	B-GP
III	E-GP
is	O
less	O

rigid	O
,	O
makes	O
an	O
average	O
angle	O
of	O
about	O
90	O
degrees	O
with	O
helices	B-GP
I	I-GP
and	I-GP
II	E-GP
,	O
and	O
constitutes	O
the	O
other	O
arm	O
of	O
the	O
molecule	O
.	O
As	O

in	O
HMG1B	S-GP
,	O
the	O
overall	O
structure	O
of	O
the	O
Sox-4	S-GP
HMG	B-GP

box	E-GP
is	O
L-shaped	O
and	O
is	O
maintained	O
by	O
a	O
cluster	O
of	O
conserved	O
,	O
mainly	O
aromatic	O
residues	O
.	O
Nuclear	B-GP
factor-IL6	E-GP
activates	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	E-DNA
in	O
T	B-cell_type

cells	E-cell_type
.	O
Positive	B-DNA
regulatory	I-DNA
element	I-DNA
I	E-DNA
(	O
PRE-I	S-DNA
)	O
is	O
a	O
strong	O
enhancer	B-DNA
element	E-DNA
essential	O
for	O

expression	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
gene	E-DNA
.	O
To	O
identify	O
transcription	B-GP
factors	E-GP
binding	O
to	O
PRE-I	S-DNA
,	O
we	O
screened	O

a	O
cDNA	B-DNA
expression	I-DNA
library	E-DNA
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
and	O
isolated	O
a	O
cDNA	S-DNA
encoding	O
nuclear	B-GP
factor	E-GP
(	B-GP
NF	I-GP
)	I-GP
-IL6	E-GP
(	O
also	O
known	O
as	O
C/EBP	B-GP
beta	E-GP

)	O
.	O
NF-IL6	B-RNA
mRNA	E-RNA
was	O
found	O
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	E-cell_line
and	O
in	O
the	O
mouse	B-cell_line
Th2	I-cell_line
clone	E-cell_line
D10	S-cell_line
,	O

but	O
not	O
in	O
Th1	B-cell_line
clone	I-cell_line
29	E-cell_line
.	O
rNF-IL6	S-GP
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE-I	S-DNA
.	O
PRE-I	S-DNA
forms	O
multiple	B-GP
DNA-protein	I-GP
complexes	E-GP
with	O
nuclear	O
extracts	O
from	O
Jurkat	B-cell_line

cells	E-cell_line
.	O
Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	S-GP
by	O
using	O
anti-C/EBP	B-GP
beta	I-GP
Abs	E-GP
.	O
Overexpression	O
of	O
NF-IL6	S-GP
enhanced	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA

reporter	I-DNA

gene	E-DNA
linked	O
to	O
the	O
PRE-I-thymidine	B-GP
kinase	E-GP
or	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	E-DNA

more	O
than	O
10-fold	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
.	O
Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	B-DNA
binding	I-DNA
sites	E-DNA
located	O
at	O
positions	O
-44	O
to	O

-36	O
(	O
C/EBP	B-GP
proximal	E-GP
)	O
and	O
-87	O
to	O
-79	O
(	O
C/EBP	B-GP
medial	E-GP
)	O
,	O
respectively	O
.	O
Our	O
results	O
demonstrate	O
that	O
NF-IL6	S-GP
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
.	O
Identification	O
of	O

an	O
I	B-GP
kappa	I-GP
B	I-GP
alpha-associated	I-GP
protein	I-GP
kinase	E-GP
in	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	E-cell_line
and	O
determination	O
of	O
its	O
phosphorylation	B-GP
sites	E-GP
on	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP

.	O
Nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
(	O
NF-kappa	B-GP
B	E-GP
)	O
is	O
stored	O
in	O

the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	B-GP
kappa	I-GP
B	E-GP

.	O
Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
,	O

which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O
We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-dependent	O
cell-free	O
activation	O
system	O
of	O
NF-kappa	B-GP

B	E-GP
in	O
association	O
with	O
the	O
induction	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
phosphorylation	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	S-GP
in	O
cell	O
extracts	O
from	O
the	O
LPS-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line

cell	I-cell_line
line	E-cell_line
,	O
THP-1	S-cell_line
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
.	O
LPS	O
stimulation	O
transiently	O
enhanced	O

the	O

I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
-bound	B-GP
kinase	E-GP
activity	O
in	O
THP-1	B-cell_line
cells	E-cell_line
.	O
Mutational	O
analyses	O
of	O
I	B-GP
kappa	I-GP
B	E-GP
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O

phosphorylation	B-GP
sites	E-GP
by	O
the	O
bound	O
kinase	S-GP
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C-terminal	B-GP
acidic	I-GP
domain	E-GP
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
.	O
Moreover	O
,	O

we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C-terminal	B-GP
acidic	I-GP
domain	E-GP
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
,	O
blocked	O
the	O
LPS-induced	O
NF-kappa	B-GP
B	E-GP
activation	O
as	O

well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
in	O
a	O
cell-free	O
system	O
using	O
THP-1	B-cell_line
cells	E-cell_line
.	O
These	O
results	O
suggested	O
that	O
the	O
bound	B-GP
kinase	E-GP
is	O
involved	O
in	O
the	O
signaling	O
pathway	O

of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C-terminal	B-GP
region	E-GP
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
and	O
subsequent	O
dissociation	O
of	O
the	O
NF-kappa	B-GP
B	E-GP
.	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	I-GP
complex	E-GP
.	O
Bik	S-GP
,	O
a	O

novel	O
death-inducing	B-GP
protein	E-GP
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl-2	B-GP
family	I-GP
proteins	E-GP
and	O
interacts	O
with	O
viral	O

and	O
cellular	B-GP
survival-promoting	I-GP
proteins	E-GP
.	O
The	O
survival-promoting	O
activity	O
of	O
the	O
Bcl-2	B-GP
family	E-GP
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	B-GP
proteins	E-GP
.	O
We	O
have	O
identified	O
a	O
novel	O
cellular	B-GP
protein	E-GP
,	O
Bik	S-GP
,	O
that	O
interacts	O
with	O

the	O
cellular	B-GP
survival-promoting	I-GP
proteins	E-GP
,	O
Bcl-2	S-GP
and	O
Bcl-xL	S-GP
,	O
as	O
well	O
as	O
the	O
viral	B-GP
survival-promoting	I-GP
proteins	E-GP
,	O
Epstein	B-GP
Barr	I-GP
virus-BHRF1	E-GP
and	O
adenovirus	B-GP
E1B-19	I-GP
kDa	E-GP
.	O
In	O
transient	O
transfection	O
assays	O
,	O
Bik	S-GP
promotes	O
cell	O
death	O
in	O
a	O
manner	O
similar	O
to	O
the	O
death-promoting	B-GP
members	E-GP
of	O
the	O
Bcl-2	B-GP

family	E-GP
,	O
Bax	S-GP
and	O
Bak	S-GP
.	O
This	O
death-promoting	O
activity	O
of	O
Bik	S-GP
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl-2	S-GP
,	O
Bcl-XL	S-GP
,	O
EBV-BHRF1	S-GP
and	O
E1B-19	B-GP
kDa	E-GP
proteins	O
suggesting	O
that	O
Bik	S-GP
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	B-GP
and	I-GP
viral	I-GP
anti-apoptotic	I-GP
proteins	E-GP
.	O

While	O

Bik	S-GP
does	O
not	O
show	O
overt	O
homology	O
to	O
the	O
BH1	S-GP
and	O
BH2	S-GP
conserved	O
domains	O
characteristic	O
of	O
the	O
Bcl-2	B-GP
family	E-GP
,	O
it	O
does	O
share	O
a	O
9	O

amino	B-GP
acid	I-GP
domain	E-GP
(	O
BH3	S-GP
)	O
with	O
Bax	S-GP
and	O
Bak	S-GP
which	O
may	O
be	O
a	O
critical	O
determinant	O
for	O
the	O
death-promoting	O
activity	O

of	O
these	O
proteins	O
.	O
The	O
human	B-DNA
TCF-1	I-DNA
gene	E-DNA
encodes	O
a	O
nuclear	B-GP
DNA-binding	I-GP
protein	E-GP
uniquely	O
expressed	O
in	O
normal	B-cell_line
and	I-cell_line
neoplastic	I-cell_line
T-lineage	I-cell_line
lymphocytes	E-cell_line
.	O
The	O
TCF-1	B-DNA
gene	E-DNA
encodes	O
a	O
putative	B-GP
transcription	I-GP
factor	E-GP
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O

a	O
number	O
of	O
T-cell	B-DNA
enhancers	E-DNA
.	O
TCF-1	B-RNA
mRNA	E-RNA
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell-specific	O
fashion	O
within	O
a	O
set	O
of	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line

cell	I-cell_line
lines	E-cell_line
.	O
In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O
We	O
have	O
now	O
raised	O
a	O
monoclonal	B-GP
antibody	E-GP
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	B-GP
TCF-1	I-GP
protein	E-GP
.	O
As	O

expected	O
,	O
the	O
TCF-1	B-GP
protein	E-GP
was	O
detectable	O
only	O
in	O
cell	B-cell_line
lines	I-cell_line
of	I-cell_line
T	I-cell_line
lineage	E-cell_line
.	O
Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O
Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF-1	B-GP
protein	E-GP
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3+	B-cell_line
T	I-cell_line
cells	E-cell_line
in	O
peripheral	O
lymphoid	O

tissues	O

.	O
Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	O
kD	O
to	O
55	O
kD	O
,	O
resulting	O
from	O

extensive	O
alternative	O
splicing	O
.	O
The	O
TCF-1	S-GP
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T-cell	B-cell_type
malignancies	E-cell_type
of	O
various	O
stages	O

of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	B-cell_type
neoplasms	E-cell_type
.	O
These	O
observations	O
imply	O
a	O
T	O
cell-specific	O
function	O
for	O

TCF-1	S-GP
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf-1	O
knock-out	O
mice	O
.	O
In	O

addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF-1	S-GP
expression	O
can	O
serve	O
as	O
a	O
pan-T-lineage	O
marker	O
in	O
the	O
diagnosis	O

of	O
lymphoid	O
malignancies	O
.	O
Cross-linking	O
of	O
Fc	B-GP
gamma	I-GP
receptors	E-GP
activates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
-driven	O
transcription	O

in	O
human	B-cell_type
monocytes	E-cell_type
.	O
Elevation	O
of	O
the	O
levels	O
of	O

circulating	B-GP
immune	I-GP
complexes	E-GP
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O
Here	O
we	O
report	O
that	O
cross-linking	O
of	O

Fc	B-GP
gamma	I-GP
RI	E-GP
or	O
Fc	B-GP
gamma	I-GP
RII	E-GP
by	O
adherent	B-GP
human	I-GP
IgG	E-GP
or	O
by	O
specific	O
anti-Fc	B-GP
gamma	I-GP
R	I-GP
mAb	E-GP
activates	O
HIV-1	O
gene	O

expression	O
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	E-cell_line
BF24	S-cell_line
and	O
increased	O
HIV	B-RNA
RNA	E-RNA
expression	O
in	O
monocytes	S-cell_type
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription-PCR	O
.	O
In	O
THP-1	B-cell_line
cells	E-cell_line
,	O
Fc	B-GP
gamma	I-GP
R	E-GP
cross-linking	O

induced	O
NF-kappa	B-GP
B	E-GP
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	B-DNA
region	E-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O

of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O
Anti-TNF-alpha	B-GP
antibody	E-GP
but	O
not	O
anti-IL-1	B-GP
beta	I-GP
antibody	E-GP
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-	O
LTR	S-DNA

-driven	O

transcription	O
and	O
the	O
induction	O
of	O
NF-kappa	B-GP
B	E-GP
by	O
Fc	B-GP
gamma	I-GP
R	E-GP
cross-linking	O
.	O
These	O
results	O
indicate	O

that	O
Fc	B-GP
gamma	I-GP
R	E-GP
can	O
mediate	O
a	O
TNF-alpha	S-GP
-dependent	O
induction	O
of	O
HIV-1	B-DNA
gene	E-DNA
transcription	O
and	O
suggest	O
that	O
immune	B-GP
complexes	E-GP
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O

infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	S-cell_type
.	O
Signalling	O
via	O
CD28	S-GP
of	O
human	B-cell_line
naive	I-cell_line
neonatal	I-cell_line
T	I-cell_line
lymphocytes	E-cell_line
.	O
Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O
We	O
have	O
examined	O
the	O
role	O
of	O
CD28	S-GP
in	O
modulating	O
the	O
'naive	O
'	O
neonatal	O
T	O
cell	O
response	O

to	O
anti-CD2	S-GP
-mediated	O
activation	O
.	O
To	O
compare	O
the	O
role	O
of	O
CD28	S-GP
,	O
neonatal	S-cell_type
and	O
adult	B-cell_type
T	I-cell_type
cells	E-cell_type
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	B-GP
anti-CD2	I-GP
antibodies	E-GP
in	O
the	O
presence	O
or	O
absence	O
of	O
anti-CD28	B-GP
MoAb	E-GP
.	O
With	O
anti-CD2	S-GP
alone	O
,	O
neonatal	B-cell_type
T	I-cell_type
cells	E-cell_type
proliferated	O
slightly	O
but	O
produced	O
no	O
detectable	O
IL-2	S-GP
,	O
whereas	O
adult	O
T	B-cell_type
cells	E-cell_type
proliferated	O
vigorously	O
,	O
with	O
significant	O
IL-2	S-GP
production	O
.	O
Costimulation	O
with	O
anti-CD28	B-GP
MoAb	E-GP

greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
cells	E-cell_type
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
whereas	O
adult	B-cell_type
T	I-cell_type
cells	E-cell_type
showed	O
only	O
slight	O
increases	O
.	O
Although	O
IL-2	S-GP
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O

anti-CD28	B-GP

MoAb	E-GP
,	O
neonatal	B-cell_type
T	I-cell_type
cell	E-cell_type
IL-2	S-GP
production	O
remained	O
lower	O
than	O

in	O
adults	O
.	O
In	O
contrast	O
,	O
enhancement	O
of	O
IL-2	B-RNA
mRNA	E-RNA
expression	O
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O

.	O
Anti-	O
CD28	B-GP
MoAb	E-GP
costimulation	O
increased	O
NF	B-GP
kappa	I-GP
B	E-GP
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O

.	O
The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
to	O
anti-CD2	S-GP
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	B-GP
kappa	I-GP
B	E-GP
induction	O
,	O
reduced	O
IL-2	B-RNA
mRNA	E-RNA
expression	O

and	O
deficient	O
IL-2	S-GP
production	O
.	O
Although	O
anti-CD28	B-GP
MoAb	E-GP
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL-2	O
levels	O
remain	O
lower	O
than	O
in	O
adults	O

,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O
TCL1	O
oncogene	O
activation	O
in	O
preleukemic	B-cell_type
T	I-cell_type
cells	E-cell_type
from	O
a	O
case	O
of	O
ataxia-telangiectasia	O
.	O
The	O
TCL1	B-DNA
oncogene	E-DNA
on	O
human	B-DNA
chromosome	E-DNA
14q32.1	S-DNA

is	O
involved	O
in	O
chromosome	O
translocations	O
[	O
t	B-DNA
(	I-DNA
14	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q11	I-DNA
;	I-DNA
q32.1	I-DNA
)	E-DNA
and	O
t	B-DNA
(	I-DNA
7	I-DNA
;	I-DNA
14	I-DNA

)	I-DNA
(	I-DNA
q35	I-DNA
;	I-DNA
q32.1	I-DNA
)	E-DNA
]	O
and	O
inversions	O
[	O
inv14	B-DNA
(	I-DNA
q11	I-DNA
;	I-DNA
q32.1	I-DNA
)	E-DNA

]	O
with	O
TCR	B-DNA
alpha/beta	I-DNA
loci	E-DNA
in	O
T-cell	O
leukemias	O
,	O
such	O
as	O
T-prolymphocytic	O
(	O
T-PLL	O
)	O
.	O
It	O
is	O
also	O
involved	O
in	O

T-	O
acute	O
and-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia-telangiectasia	O
(	O
AT	O
)	O
,	O
an	O
immunodeficiency	O
syndrome	O
.	O
Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	O
expanded	O
T	B-cell_type
cells	E-cell_type
in	O
AT	O
patients	O
before	O
the	O

appearance	O
of	O
the	O
overt	O
leukemia	O
.	O
We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	B-RNA
mRNA	E-RNA
and	O
protein	S-GP
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
(	O
PBLs	S-cell_type
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O
We	O
found	O

that	O

the	O
TCL1	B-DNA
gene	E-DNA
was	O
overexpressed	O
in	O
the	O
PBLs	S-cell_type
of	O
an	O
AT	O
patient	O
with	O

a	O
large	B-cell_line
clonal	I-cell_line
T-cell	I-cell_line
population	E-cell_line
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	S-cell_type
of	O
the	O
other	O
cases	O
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B-DNA
genomic	I-DNA
locus	E-DNA
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B-DNA

locus	E-DNA
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	B-DNA
part	E-DNA
of	O
chromosome	B-DNA
14	E-DNA
.	O
These	O
data	O
indicate	O
that	O
TCL1	S-DNA
is	O
activated	O

in	O
preleukemic	B-cell_line
clonal	I-cell_line
cells	E-cell_line
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	B-DNA
locus	E-DNA
at	O
14q11	S-DNA
.	O
Deregulation	O
of	O
TCL1	S-DNA

is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O
C/EBP	B-GP
proteins	E-GP
activate	O

transcription	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
in	O
macrophages/	O
monocytes	S-cell_type
.	O
Three	O
binding	O
sites	O
for	O
C/EBP	B-GP
proteins	E-GP
are	O
found	O
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
(	O

V.M.	O
Tesmer	O
,	O
A.Rajadhyaksha	O
,	O
J.Babin	O
,	O
and	O
M.Bina	O
,	O
Proc.Natl.Acad.Sci.	O
USA	O
90	O
:	O
7298-7302	O
,	O
1993	O
)	O
.	O
We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C/EBP	B-GP
proteins	E-GP
and	O
C/EBP	B-DNA
sites	E-DNA
in	O
regulating	O
transcription	O
from	O
the	O
HIV-	B-DNA
1	I-DNA
LTR	E-DNA
in	O
monocytes/macrophages	S-cell_type
.	O
Inhibition	O
of	O
endogenous	B-GP
C/EBP	I-GP
proteins	E-GP
,	O
using	O
either	O
an	O
excess	O
of	O
C/EBP	B-DNA

binding	I-DNA
sites	E-DNA
or	O
a	O
trans-	B-DNA
dominant	I-DNA
negative	I-DNA
inhibitor	E-DNA
,	O
demonstrated	O
that	O
C/EBP	B-GP
proteins	E-GP
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV-1	B-DNA
LTR	E-DNA
transcription	O
in	O
the	O

promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	E-cell_line
.	O
Northern	O
(	O
RNA	O
)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF-IL6	S-GP
is	O
the	O
only	O
known	O
C/EBP	B-GP
family	I-GP
member	E-GP
which	O
is	O
increased	O

when	O

U937	B-cell_line
cells	E-cell_line
are	O
activated	O
.	O
Mutational	O
analyses	O
of	O
the	O
HIV-1	B-DNA
LTR	E-DNA
showed	O
that	O
one	O
C/EBP	B-DNA
site	E-DNA
is	O
required	O

for	O
normal	O
LTR	S-DNA
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C/EBP	B-DNA
sites	E-DNA
are	O
functionally	O
equivalent	O
.	O
However	O
,	O
transcription	O
from	O
crippled	B-DNA
HIV-1	I-DNA
LTRs	E-DNA
lacking	O
C/EBP	B-DNA
sites	E-DNA
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	B-cell_line
cells	E-cell_line
.	O
Several	O
models	O

are	O
suggested	O
for	O
how	O
elevated	O
NF-IL6	S-GP
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	S-GP
expression	O
,	O
and	O

HIV	O
replication	O
.	O
Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	S-DNA
and	O
their	O
activation	O
by	O
T-cell	S-cell_type
activators	O
.	O
The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O

of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O
Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	B-DNA
elements	E-DNA
in	O
their	O
long	B-DNA
terminal	I-DNA
repeats	E-DNA

(	O
LTRs	S-DNA
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B-DNA
elements	E-DNA
in	O
the	O
HIV-2	B-DNA
LTR	E-DNA
.	O
The	O
HIV-2	B-DNA
LTR	E-DNA
was	O
found	O
to	O
contain	O
two	O
enhancers	S-DNA
.	O
One	O
of	O
these	O
enhancers	S-DNA
is	O

,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	B-DNA
enhancer	E-DNA
.	O
This	O
enhancer	S-DNA
in	O
HIV-1	O
is	O
the	O
T-cell	B-DNA
activation	I-DNA
response	I-DNA
element	E-DNA

;	O
in	O
HIV-2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	B-DNA
enhancer	E-DNA
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T-cell	O
activators	O
.	O
The	O
second	O
enhancer	S-DNA
interacts	O
with	O

two	O

nuclear	B-GP
binding	I-GP
proteins	E-GP
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O

for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O
Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O

to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O
NF-M	S-GP
(	O
chicken	B-GP
C/EBP	I-GP
beta	E-GP
)	O
induces	O
eosinophilic	O
differentiation	O
and	O
apoptosis	O
in	O
a	O
hematopoietic	B-cell_line
progenitor	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O
CAAT/enhancer	B-GP
binding	I-GP
proteins	E-GP
(	O
C/EBPs	S-GP
)	O
are	O
transcriptional	O
activators	O
implicated	O

in	O
the	O
differentiation	O
processes	O
of	O
various	O
cell	O
lineages	O
.	O
We	O

have	O
shown	O
earlier	O
that	O
NF-M	S-GP
,	O
the	O
chicken	B-GP
homolog	E-GP
of	O
C/EBP	B-GP
beta	E-GP
,	O
is	O
specifically	O

expressed	O
in	O
myelomonocytic	B-cell_type
and	I-cell_type
eosinophilic	I-cell_type
cells	E-cell_type
of	O
the	O
hematopoietic	O
system	O
.	O
To	O
investigate	O
the	O
role	O
of	O
NF-M	S-GP
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lineage	E-cell_line
commitment	O
,	O
we	O
constructed	O
a	O
conditional	O
form	O
of	O
the	O
protein	O
by	O
fusing	O

it	O
to	O
the	O
hormone	B-GP
binding	I-GP
domain	E-GP
of	O
the	O
human	B-GP
estrogen	I-GP
receptor	E-GP
.	O
This	O
construct	O
was	O
stably	O
expressed	O
in	O
a	O
multipotent	B-cell_line
progenitor	I-cell_line
cell	I-cell_line
line	E-cell_line
transformed	O
by	O
the	O
Myb-Ets	B-GP
oncoprotein	E-GP
.	O

We	O
report	O
here	O
that	O
both	O
NF-M-dependent	B-DNA
promoter	I-DNA
constructs	E-DNA
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta-estradiol	O
to	O
the	O
NF-M-estrogen	B-cell_line
receptor	I-cell_line
expressing	I-cell_line
progenitors	E-cell_line
.	O
At	O
the	O
same	O
time	O
,	O
we	O
observed	O
a	O
down-regulation	O
of	O
progenitor-specific	B-GP

surface	I-GP

markers	E-GP
and	O
the	O
up-regulation	O
of	O
differentiation	B-GP
markers	E-GP
restricted	O
to	O
the	O
eosinophil	S-cell_type
and	O
myeloid	B-cell_type
lineages	E-cell_type
.	O
In	O
addition	O
to	O

the	O
onset	O
of	O
differentiation	O
,	O
cell	O
death	O
was	O
induced	O
with	O
typical	O
apoptotic	O
features	O
.	O
Our	O
results	O
suggest	O
that	O
NF-M	S-GP

plays	O
an	O
important	O
role	O
in	O
commitment	O
along	O
the	O
eosinophil	B-cell_type
lineage	E-cell_type
and	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O
Prolactin	S-GP
and	O
interleukin-2	B-GP
receptors	E-GP
in	O
T	B-cell_type
lymphocytes	E-cell_type
signal	O
through	O
a	O

MGF-STAT5-like	B-GP
transcription	I-GP
factor	E-GP
.	O
The	O
cell	O
surface	O
receptors	O
for	O
PRL	S-GP
and	O
interleukin-2	S-GP
(	O
IL-2	S-GP
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O
They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O

of	O
over-lapping	O
sets	O
of	O
genes	O
of	O
T	B-cell_type
cells	E-cell_type
.	O
PRL	S-GP
and	O
IL-2	S-GP
receptor	O
activation	O
are	O
both	O
linked	O

to	O
the	O
Jak/Stat	S-GP
(	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	E-GP
)	O
pathway	O
.	O
We	O
investigated	O
the	O
ability	O
of	O
PRL	S-GP
and	O
IL-2	S-GP
to	O
activate	O
Stat	B-GP
proteins	E-GP

in	O
different	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
The	O
DNA	O
binding	O
specificities	O
,	O
the	O
reactivities	O
toward	O
Stat-specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL-2	S-GP
-and	O
PRL-induced	B-GP
DNA-binding	I-GP
proteins	E-GP

in	O
Nb2	B-cell_line
and	I-cell_line
C196	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
were	O
investigated	O
.	O
A	O
comparison	O
with	O
the	O
Stat	B-GP
proteins	E-GP
induced	O

by	O
interferon-gamma	S-GP
,	O
PRL	S-GP
,	O
and	O
IL-6	S-GP
in	O
T47D	B-cell_line
mammary	I-cell_line
tumor	I-cell_line
cells	E-cell_line
was	O
made	O
.	O
We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O

for	O

one	O
of	O
the	O
PRL-	B-GP
and	I-GP
IL-2-induced	I-GP
factors	E-GP
.	O
A	O
transcription	O
factor	O
closely	O
related	O
to	O

mammary	B-GP
gland	I-GP
factor-Stat5	E-GP
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL-2	S-GP
and	O
PRL	S-GP
with	O
their	O
respective	O
receptors	O
.	O
Activation	O
of	O
a	O
second	O
protein	O
related	O

to	O
Stat1	S-GP
was	O
also	O
observed	O
.	O
Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	S-GP
as	O
a	O
regulator	O

of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	B-GP
factors	E-GP
mammary	B-GP
gland	I-GP
factor-Stat5	E-GP
and	O
Stat1	S-GP
play	O
a	O
role	O
in	O
the	O
regulation	O

of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O
ETS1	S-GP
transactivates	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	E-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line

stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O
Activation	O
of	O
T	B-cell_type
helper	I-cell_type
cells	E-cell_type
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	S-GP
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O

.	O
Granulocyte-macrophage	B-GP
colony-stimulating	I-GP
factor	E-GP
(	O
GM-CSF	S-GP
)	O
is	O
one	O
such	O
cytokine	S-GP
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O
Cis-acting	B-DNA

elements	E-DNA
with	O
NF	B-GP
kappa	I-GP
B	E-GP
,	O
AP-1	S-GP
and	O
ETS-like	B-DNA
motifs	E-DNA
have	O
been	O
identified	O
in	O
the	O
promoter	O

region	O
of	O
the	O
GM-CSF	B-DNA
gene	E-DNA
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O
A	O
number	O
of	O
the	O
ETS	B-GP

family	E-GP
of	O
transcription	B-GP
factors	E-GP
are	O
expressed	O
in	O
T	B-cell_type
cells	E-cell_type
,	O
including	O
ETS1	S-GP

and	O
ELF1	S-GP
.	O
Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	S-DNA
)	O
,	O
located	O
within	O
the	O
CLE0	B-DNA
element	E-DNA
,	O
-47	B-DNA
to	I-DNA
-40	I-DNA
upstream	E-DNA
of	O
the	O
GM-CSF	B-DNA
transcription	I-DNA
initiation	I-DNA
site	E-DNA
.	O
Exogenous	O
ETS1	S-GP

,	O

but	O
not	O
ELF1	S-GP
,	O
can	O
transactivate	O
GM-CSF	S-GP
,	O
through	O
the	O
GM5	S-DNA
site	O
,	O
in	O
a	O
PMA/ionomycin	O

dependent	O
manner	O
.	O
Other	O
unidentified	O
ETS-like	B-GP
factors	E-GP
present	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
are	O
also	O
capable	O
of	O
binding	O
GM5	S-DNA
.	O
Mutation	O
of	O
the	O
core	O
ETS	B-DNA
binding	I-DNA
site	E-DNA
from	O

-GGAA-	B-DNA
to	I-DNA
-GGAT-	E-DNA
prevents	O
the	O
binding	O
of	O
ETS-like	B-GP
factors	E-GP
with	O
the	O
exception	O
of	O
ETS1	S-GP
.	O
The	O
GM-CSF	B-DNA
promoter	E-DNA
,	O
modified	O

in	O
this	O
way	O
to	O
be	O
ETS1	S-GP
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	S-GP
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O
Together	O
these	O
data	O
suggest	O
that	O
ETS1	S-GP
may	O

be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM-CSF	S-GP
production	O
associated	O
with	O
T	B-cell_type
cell	E-cell_type
activation	O
.	O
Quantitation	O
of	O
beta	B-RNA
1	I-RNA
triiodothyronine	I-RNA
receptor	I-RNA

mRNA	E-RNA
in	O
human	O
tissues	O
by	O
competitive	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
Thyroid	O
hormones	O
act	O
by	O
binding	O
to	O
nuclear	B-GP
receptor	I-GP
proteins	E-GP
,	O
the	O
thyroid	B-GP
hormone	I-GP
receptors	I-GP
(	I-GP
TR	I-GP
)	I-GP
alpha	I-GP
and	I-GP
beta	E-GP
.	O
Data	O

from	O
cell	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
TR	S-GP
expression	O
may	O
be	O
regulated	O
to	O
modulate	O
target	O
organ	O
responsiveness	O
to	O
thyroid	O
hormone	O
.	O

To	O
investigate	O
whether	O
such	O
adaptive	O
changes	O
in	O
TR	S-GP
expression	O
occur	O
in	O
humans	O
,	O
we	O
determined	O

the	O
mRNA	O
levels	O
of	O
the	O
hTR	B-GP
beta	I-GP
1	E-GP
in	O
various	O
thyroid	O
states	O
.	O
Patients	O
with	O
overt	O
hypo	O
-or	O
hyperthyroidism	O
were	O
enrolled	O
in	O
the	O

study	O
.	O
Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
and	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O
For	O
comparison	O
,	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O

were	O
determined	O
in	O
lymphocytes	S-cell_type
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O
Human	B-RNA
TR	I-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
in	O
lymphocytes	S-cell_type
were	O

1.8	O

+/-	O
0.4	O
,	O
1.9	O
+/-	O
0.5	O
,	O
1.1	O
+/-	O
0.4	O
10	O
(	O
-18	O
)	O
mol/microgram	O
RNA	O
in	O
hypo-	O

,	O
eu	O
-and	O
hyperthyroid	O
patients	O
,	O
respectively	O
,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell	O
.	O
Although	O
the	O
mean	O

hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
were	O
40	O
%	O
lower	O
in	O
hyperthyroid	O
than	O
in	O
euthyroid	O
subjects	O
,	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O

.	O
Similar	O
levels	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
were	O
detected	O
in	O
thyroid	O
gland	O
from	O
euthyroid	O
patients	O
.	O
In	O
summary	O
,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O

determination	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
in	O
small	O
human	O
tissue	O
samples	O

,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	O
RNA	O
.	O
Absolute	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
are	O
very	O
low	O
with	O
an	O
estimated	O

one	O
molecule	O
of	O
mRNA	S-RNA
being	O
present	O
in	O
a	O
mononuclear	B-cell_type
blood	I-cell_type
cell	E-cell_type
or	O
thyrocyte	S-cell_type
.	O
No	O
up-regulation	O
of	O
hTR	B-GP
beta	I-GP
1	E-GP

was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O
However	O
,	O
there	O
is	O
a	O
non-significant	O
trend	O
towards	O
a	O
down-regulation	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
in	O
hyperthyroid	O
patients	O
.	O
Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	B-DNA
inhibitory	I-DNA
protein	I-DNA
repressor	I-DNA
element	E-DNA
in	O
the	O
human	B-DNA
interleukin-3	I-DNA
promoter	E-DNA
.	O
T	O

cell	O
expression	O
of	O
interleukin	B-GP
3	E-GP
(	O
IL-3	S-GP
)	O
is	O
directed	O
by	O
positive	B-DNA
and	I-DNA
negative	I-DNA
cis-acting	I-DNA
DNA	I-DNA
elements	E-DNA
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	E-DNA

.	O
A	O
strong	O
repressor	B-GP
element	E-GP
,	O
termed	O
nuclear	B-GP
inhibitory	I-GP
protein	E-GP
(	O
NIP	S-GP
)	O
,	O
was	O
previously	O
mapped	O

to	O
a	O
segment	O
of	O
the	O
IL-3	B-DNA
promoter	E-DNA
between	O
nucleotides	B-DNA
-271	I-DNA
and	I-DNA
-250	E-DNA
.	O
Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	B-DNA
promoter	E-DNA
.	O

DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O
Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O

NIP	B-DNA
region	E-DNA
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O
Complex	B-GP
1	E-GP
results	O
from	O

binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3	B-DNA
'	I-DNA
portion	E-DNA
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O

.	O

Complex	B-GP
2	E-GP
corresponds	O
to	O
binding	O
of	O
transcription	B-GP
factor	E-GP
(	O
upstream	B-GP
stimulatory	I-GP
factor	E-GP
)	O
to	O
an	O
E-box	B-DNA

motif	E-DNA
in	O
the	O
5	B-DNA
'	I-DNA
portion	E-DNA
of	O
the	O
NIP	B-DNA
region	E-DNA
.	O
DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	B-GP
stimulatory	I-GP
factor	E-GP
but	O
is	O
clearly	O
distinct	O
.	O

To	O
determine	O
which	O
of	O
the	O
latter	O
two	O
complexes	O
represents	O
NIP	S-GP
activity	O
,	O
we	O
incorporated	O
small	O
alterations	O
into	O
the	O
NIP	B-DNA
site	E-DNA
of	O
an	O
IL-3	B-DNA
promoter-linked	I-DNA
reporter	I-DNA
construct	E-DNA
and	O
examined	O
their	O

effects	O
on	O
NIP	S-GP
-mediated	O
repression	O
.	O
Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	B-GP
3	E-GP
;	O
both	O

repressor	O
activity	O
and	O
complex	B-GP
3	E-GP
binding	O
require	O
the	O
consensus	B-DNA
sequence	E-DNA
CTCACNTNC	O
.	O

The	O
hematopoietic	B-GP
transcription	I-GP
factor	E-GP
PU.1	S-GP
is	O
downregulated	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
PU.1	S-GP
is	O
a	O
hematopoietic	B-GP
transcription	I-GP
factor	E-GP
belonging	O
to	O
the	O
Ets-family	S-GP
.	O

It	O
is	O
identical	O
to	O
the	O
Spi-1	B-DNA
oncogene	E-DNA
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus-forming	O
virus-induced	O
murine	O
erythroleukemias	O
.	O
PU.1	S-GP
seems	O
to	O
be	O
required	O
for	O
early	O

development	O
of	O
multiple	B-cell_type
hematopoietic	I-cell_type
lineages	E-cell_type
,	O
but	O
its	O
expression	O
in	O
mature	B-cell_type
cells	E-cell_type
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell-and	B-cell_type
monocyte/macrophage-differentiation	I-cell_type
lineage	E-cell_type
.	O
It	O
binds	O
the	O
so-called	O

Pu	B-DNA
box	E-DNA
,	O
an	O
important	O
tissue-specific	B-DNA
regulatory	I-DNA
DNA	I-DNA
element	E-DNA
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O

cell	B-cell_type
lineages	E-cell_type
.	O
We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	S-GP
during	O
human	O
B-cell	O
development	O
using	O
a	O
panel	O
of	O
B-cell	B-cell_line
lines	E-cell_line
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	B-cell_line
precursors	E-cell_line
to	O
differentiated	B-cell_line
plasma	I-cell_line
cells	E-cell_line

.	O
PU.1	B-RNA
mRNA	E-RNA
expression	O
and	O
PU.1	S-GP
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O

in	O

cell	B-cell_line
lines	E-cell_line
representing	O
pro-B	B-cell_line
,	I-cell_line
pre-B	I-cell_line
,	I-cell_line
and	I-cell_line
mature	I-cell_line
B	I-cell_line
cells	E-cell_line
.	O
We	O
could	O

also	O
show	O
Pu	B-DNA
box	E-DNA
-dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O

transient	O
transfections	O
in	O
these	O
cell	B-cell_line
lines	E-cell_line
.	O
In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	B-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	E-cell_line

,	O
representing	O
differentiated	B-cell_type
,	I-cell_type
plasma	I-cell_type
cell-like	I-cell_type
B	I-cell_type
cells	E-cell_type
,	O
PU.1	S-GP
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	B-DNA
box	E-DNA
-dependent	O
transactivation	O
were	O
absent	O
or	O
detectable	O
at	O
a	O
very	O
low	O

level	O
.	O
In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O
The	O

findings	O
in	O
the	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	E-cell_line
represent	O
the	O
first	O
examples	O
of	O
B	B-cell_type
cells	E-cell_type
with	O
downregulated	O
PU.1	S-GP
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	S-GP
is	O
expressed	O
and	O

active	O
in	O
plasmacytoma	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	S-GP
expression	O
and	O
activity	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	E-cell_line
represents	O
a	O
malignancy-associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O

regulation	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
B	I-cell_type
cells	E-cell_type
.	O
Regulation	O
of	O
granulocyte-macrophage	B-GP
colony-stimulating	I-GP
factor	E-GP
and	O
E-selectin	S-GP
expression	O
in	O
endothelial	B-cell_type
cells	E-cell_type
by	O
cyclosporin	O

A	O
and	O
the	O
T-cell	B-GP
transcription	I-GP
factor	E-GP
NFAT	S-GP
.	O
Nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cells	E-GP
(	O
NFAT	S-GP
)	O
was	O
originally	O
described	O
as	O
a	O
T-cell-specific	B-GP
transcription	I-GP
factor	E-GP
athat	O
supported	O
the	O
activation	O
of	O
cytokine	S-GP
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	S-GP
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O

)	O
.	O
As	O
we	O
observed	O
that	O
activated	B-cell_type
endothelial	I-cell_type
cells	E-cell_type
also	O
expressed	O
NFAT	S-GP
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	B-cell_type

cells	E-cell_type
.	O
Significantly	O
,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	S-GP
in	O
endothelial	B-cell_type
cells	E-cell_type
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
regulatory	I-DNA
elements	E-DNA
that	O
use	O
NFAT	S-GP
by	O
60	O
%	O
.	O
CsA	O
similarly	O
mediated	O
a	O
reduction	O

of	O
up	O
to	O
65	O
%	O
in	O
GM-CSF	B-RNA
mRNA	E-RNA
and	O
protein	O
expression	O
in	O
activated	B-cell_type
endothelial	I-cell_type
cells	E-cell_type
.	O
CsA	O
also	O
suppressed	O
E-selectin	S-GP
,	O
but	O
not	O
vascular	B-GP
cell	I-GP
adhesion	I-GP
molecule-1	E-GP
(	O
VCAM-1	S-GP
)	O
expression	O
in	O
endothelial	O
cells	O
,	O
even	O
though	O
the	O
E-selectin	B-DNA

promoter	E-DNA

is	O
activated	O
by	O
NF-kappa	B-GP
B	E-GP
rather	O
than	O
NFAT	S-GP
.	O
Hence	O
,	O
induction	O
of	O
cell	O
surface	O
expression	O
of	O
this	O
leukocyte	B-GP
adhesion	I-GP
molecule	E-GP

by	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
-alpha	E-GP
was	O
reduced	O
by	O
40	O
%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29	O
%	O
decrease	O
in	O
neutrophil	S-cell_type
adhesion	O
.	O
The	O
effects	O
of	O
CsA	O
on	O

endothelial	B-cell_type
cells	E-cell_type
were	O
also	O
detected	O
at	O
the	O
chromatin	S-DNA
structure	O
level	O
,	O
as	O
DNasel	B-DNA
hypersensitive	I-DNA
sites	E-DNA
within	O
both	O
the	O
GM-CSF	S-GP
enhancer	O
and	O
the	O

E-selectin	B-DNA
promoter	E-DNA
were	O
suppressed	O
by	O
CsA	O
.	O
This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	S-GP
in	O
endothelial	B-cell_type
cells	E-cell_type
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O
Costimulation	O
requirement	O
for	O

AP-1	S-GP
and	O
NF-kappa	B-GP
B	E-GP
transcription	O
factor	O
activation	O
in	O
T	B-cell_type
cells	E-cell_type
.	O
The	O
transcriptional	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	E-DNA
requires	O
T-cell	S-cell_type
costimulation	O

delivered	O
by	O
the	O
TCR	S-GP
and	O
the	O
auxiliary	B-GP
receptor	I-GP
CD28	E-GP
.	O
Several	O
transcription	B-GP
factors	E-GP
participate	O
in	O
IL-2	S-GP
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP-1-like	B-GP
factors	E-GP
and	O
NF-kappa	B-GP
B	E-GP
.	O
Protein	O
phosphorylation	O
has	O
an	O
important	O

role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP-1	B-GP
protein	E-GP
c-Jun	S-GP
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	B-GP
inhibitor	E-GP
,	O
I	B-GP
kappa	I-GP
B	E-GP
,	O
from	O
NF-kappa	B-GP

B	E-GP
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O
We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T-cell	O
costimulation	O
.	O
Furthermore	O
,	O
in	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
the	O
kinetics	O
of	O
the	O

two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O
According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O

entities	O

.	O
Whereas	O
TPCK	S-GP
inhibits	O
phosphorylation	O
of	O
I	B-GP
kappa	I-GP
B	E-GP
and	O
,	O
consequently	O
,	O
activation	O

of	O
NF-kappa	B-GP
B	E-GP
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	S-GP
,	O
the	O
MAP	B-GP
kinase-related	I-GP
kinase	E-GP
that	O
phosphorylates	O
the	O
transactivation	B-GP

domain	E-GP
of	O
c-Jun	S-GP
.	O
We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T-cell	O

costimulation	O
.	O
Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	B-GP
factors	E-GP
,	O
AP-1	S-GP
and	O
NF-kappa	B-GP
B	E-GP
.	O
Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	S-GP
and	O
CD28	S-GP
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B-GP
kappa	I-GP
B	E-GP
phosphorylation	O
and	O
NF-kappa	B-GP
B	E-GP
activation	O
on	O
the	O
one	O
hand	O

,	O
and	O
JNK	S-GP
activation	O
and	O
c-Jun	S-GP
phosphorylation	O
on	O
the	O
other	O
.	O
We	O

are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1	S-GP
/	O
NF-kappa	B-GP
B	E-GP
pathway	O
.	O

Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	E-cell_type
by	O
NF-kappa	B-GP
B/Rel	E-GP
transcription	B-GP

factors	E-GP
.	O
CD4+	B-cell_line
macrophages	E-cell_line
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	B-cell_type
cells	E-cell_type
in	O
bone	O
marrow	O
,	O
and	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	E-cell_type
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O

1	O
(	O
HIV-1	O
)	O
replication	O
.	O
HIV-1-infected	O
myeloid	B-cell_type
cells	E-cell_type
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O

participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	E-cell_type
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	B-GP
receptors	E-GP
associated	O
with	O
cellular	O

activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	S-GP
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens	O
.	O
Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA-binding	O
activity	O
of	O
cellular	B-GP
transcription	I-GP
factors	E-GP
such	O
as	O

NF-kappa	B-GP
B	E-GP
.	O
NF-kappa	B-GP
B	E-GP
binds	O
to	O
the	O
HIV-1	B-DNA
enhancer	E-DNA
region	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
and	O
contributes	O
to	O

the	O

inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents	O
.	O
Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	B-GP
inhibitor	E-GP
I	B-GP

kappa	I-GP
B	E-GP
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF-kappa	B-GP
B	E-GP
DNA-binding	O
activity	O
.	O
Both	O
N-	O
and	O
C-terminal	O
residues	O
of	O
I	B-GP
kappa	I-GP
B	E-GP
alpha	O
are	O
required	O
for	O
inducer-mediated	O
degradation	O
.	O
Chronic	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	E-cell_type
leads	O
to	O
constitutive	O

NF-kappa	B-GP
B	E-GP
DNA-binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O
Increased	O
intracellular	O
stores	O
of	O
latent	B-GP

NF-kappa	I-GP
B	E-GP
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF-kappa	B-GP
B	E-GP
-dependent	O
cytokine	S-GP
gene	O
expression	O
.	O
In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge	O
,	O
cytokine	S-GP
gene	O
expression	O
is	O
rapidly	O
induced	O
,	O
enhanced	O
,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O

HIV-1-infected	B-cell_line
myeloid	I-cell_line
cells	E-cell_line
compared	O
with	O
uninfected	B-cell_type
cells	E-cell_type
.	O
Elevated	O
levels	O
of	O
several	O
inflammatory	B-GP
cytokines	E-GP
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O

HIV-1-infected	O
individuals	O
.	O
Secretion	O
of	O
myeloid	B-GP
cell-derived	I-GP
cytokines	E-GP
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O
Steroid	O
mediated	O
lysis	O
of	O
lymphoblasts	S-cell_type
requires	O
the	O
DNA	O
binding	O
region	O

of	O
the	O
steroid	O
hormone	O
receptor	O
.	O
Glucocorticoids	O
kill	O
certain	O
types	O
of	O
lymphoblasts	S-cell_type
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O
It	O
is	O
clear	O
that	O
sufficient	O

numbers	O
of	O
functional	O
glucocorticoid	B-GP
receptors	E-GP
are	O
required	O
to	O
mediate	O
lysis	O
,	O
but	O
whether	O
they	O
do	O
so	O

through	O
the	O
classical	O
model	O
of	O
steroid	O
hormone	O
activation	O
and	O
modulation	O
of	O
gene	O
expression	O
has	O
not	O
been	O
established	O
.	O
In	O
this	O
report	O
we	O
have	O
asked	O

which	O
region	O
(	O
s	O
)	O
of	O
the	O
steroid	B-GP
receptor	E-GP
are	O
important	O
for	O
mediating	O
lysis	O
in	O
leukemic	B-cell_type
T	I-cell_type
lymphoblasts	E-cell_type
.	O
CEM-ICR	B-cell_line
27	I-cell_line

leukemic	I-cell_line
lymphoblasts	E-cell_line
,	O
a	O
clone	O
of	O
CEM	B-cell_line
cells	E-cell_line
which	O
lack	O
functional	O
glucocorticoid	B-GP
receptors	E-GP
and	O
therefore	O
are	O
neither	O
lysed	O
by	O
dexamethasone	O
nor	O
capable	O
of	O
showing	O
glutamine	B-GP
synthetase	E-GP
induction	O
,	O
were	O
provided	O
with	O
steroid	B-GP
receptors	E-GP

by	O
DNA	O
transfections	O
of	O
various	O
receptor	O
gene	O
constructs	O
.	O
We	O
measured	O
steroid	O
mediated	O
lysis	O
,	O
receptor	O

number	O
and	O
induction	O
of	O
glutamine	B-GP
synthetase	E-GP
in	O
the	O
transfected	B-cell_line
cells	E-cell_line
.	O
Our	O
results	O
provide	O
evidence	O
that	O

the	O

lysis	O
mechanism	O
in	O
the	O
ICR27	B-cell_line
lymphoblasts	E-cell_line
is	O
restored	O
when	O
functional	O
receptor	O
number	O
is	O
restored	O
.	O
The	O

DNA	B-GP
binding	I-GP
region	E-GP
specifying	O
high	O
affinity	O
for	O
GRE	B-DNA
sites	E-DNA
is	O
required	O
.	O
Lysis	O

is	O
mediated	O
by	O
any	O
steroid	O
that	O
allows	O
for	O
activation	O
of	O
the	O
receptor	O
containing	O
such	O
a	O
region	O
.	O
Our	O
data	O
support	O
the	O
view	O
that	O
steroid-mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid-receptor	B-GP
complexes	E-GP
with	O
the	O
genome	O

.	O
Functional	O
characterization	O
of	O
the	O
murine	B-GP
homolog	E-GP
of	O
the	O
B	B-GP
cell-specific	I-GP
coactivator	E-GP
BOB.1/OBF.1	S-GP
.	O
B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B-DNA
motif	E-DNA
requires	O

the	O
Oct1	S-GP
or	O
Oct2	B-GP
protein	E-GP
and	O
additional	O
B	B-GP
cell-restricted	I-GP
cofactors	E-GP
.	O
One	O
such	O
cofactor	S-GP
,	O
BOB.1/OBF.1	S-GP
,	O
was	O
recently	O
isolated	O
from	O
human	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O
Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	B-GP
homolog	E-GP
.	O
Full-length	O
cDNAs	S-DNA
and	O
genomic	B-DNA
clones	E-DNA

were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined.	O
Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O

sequence	O
identity	O
between	O
mouse	B-GP
and	I-GP
human	I-GP
BOB.1/OBF.1	E-GP
.	O
The	O
NH2-terminal	B-GP
126	I-GP
amino	I-GP
acids	E-GP
of	O
BOB.1/OBF.1	S-GP
are	O
both	O
essential	O
and	O
sufficient	O
for	O

interaction	O
with	O
the	O
POU	B-GP
domains	E-GP
of	O
either	O
Oct1	S-GP
or	O
Oct2	S-GP
.	O
This	O
protein-protein	O

interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B-GP
proteins	E-GP
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O

the	O
Oct	S-DNA
-DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB.1/OBF.1	S-GP
to	O
Oct1	S-GP
or	O
Oct2	S-GP
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O
BOB.1/OBF.1	S-GP
can	O

efficiently	O

activate	O
octamer-dependent	O
promoters	O
in	O
fibroblasts	S-cell_type
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer-dependent	B-DNA

enhancer	E-DNA
activity	O
.	O
Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	S-GP
with	O
the	O
GAL4	B-GP
DNA	I-GP
binding	I-GP
domain	E-GP
reveals	O
that	O
both	O
NH2-	B-GP
and	I-GP
COOH-terminal	I-GP
domains	E-GP
of	O

BOB.1/OBF.1	S-GP
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH-terminal	B-GP
domain	E-GP
is	O
more	O
efficient	O
in	O

this	O
transactivation	O
assay	O
.	O
Consistent	O
with	O
the	O
failure	O
of	O
full-length	B-GP
BOB.1/OBF.1	E-GP
to	O
stimulate	O
octamer-dependent	B-DNA

enhancer	I-DNA
elements	E-DNA
in	O
non	B-cell_type
B	I-cell_type
cells	E-cell_type
,	O
the	O
GAL4	B-GP
fusions	E-GP
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	O
position	O
.	O
Anti-immunoglobulin	B-GP
M	E-GP
activates	O
nuclear	B-GP
calcium/calmodulin-dependent	I-GP
protein	I-GP
kinase	I-GP
II	E-GP
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
.	O

We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	B-GP
protein	E-GP
,	O
Ets-1	S-GP
,	O
is	O
phosphorylated	O
in	O
a	O
calcium-dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O

Ig	O
)	O
M	O
on	O
B	B-cell_type
lymphocytes	E-cell_type
.	O
As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	B-GP
kinase	I-GP
C	E-GP
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium/calmodulin-dependent	B-GP
protein	I-GP
kinase	E-GP
(	O
CaM	B-GP
kinase	E-GP
)	O
might	O
phosphorylate	O
the	O
Ets-1	B-GP
protein	E-GP
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O

.	O
The	O
dephosphorylated	O
form	O
of	O
Ets-1	S-GP
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	O
,	O
suggesting	O
that	O
the	O
operative	B-GP
kinase	E-GP

should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O
We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	E-cell_line
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	S-GP
protein	O
.	O
Activity	O
of	O
the	O
CaM	B-GP

kinases	E-GP
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	B-GP
kinase	I-GP
family	E-GP
,	O
KN-62	O
.	O
Stimulation	O
of	O

cells	O

with	O
anti-IgM	S-GP
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	B-GP
kinase	E-GP
that	O
could	O
phosphorylate	O

the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN-62	O
.	O
Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	S-GP
specific	O
for	O
CaM	B-GP
kinase	I-GP
II	E-GP
.	O
Two-dimensional	O
phosphopeptide	O

maps	O
of	O
the	O
Ets-1	S-GP
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti-IgM	S-GP
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	O
cells	O
.	O
Incubation	O
of	O
isolated	B-GP
Ets-1	I-GP
protein	E-GP
with	O
purified	O
CaM	B-GP
kinase	I-GP
II	E-GP
produced	O
phosphorylation	O

of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti-IgM	S-GP
or	O
ionomycin	O
.	O
These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O

by	O
the	O
antigen	B-GP
receptor	E-GP
on	O
B	B-cell_type
lymphocytes	E-cell_type
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	B-GP
CaM	I-GP
kinase	I-GP
II	E-GP
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O

regulation	O
of	O
DNA-binding	B-GP
proteins	E-GP
.	O
Transcriptional	O
activation	O
and	O
repression	O
,	O
two	O
properties	O
of	O
the	O
lymphoid-specific	B-GP
transcription	I-GP
factor	E-GP
Oct-2a	S-GP
.	O
The	O
lymphoid-specific	B-GP
transcription	I-GP
factor	E-GP
Oct-2a	S-GP
contains	O
two	O
transcriptional	B-GP
activation	I-GP
domains	E-GP
which	O

are	O
located	O
within	O
the	O
N-terminal	S-GP
and	O
C-terminal	B-GP
regions	E-GP
.	O
To	O
study	O
their	O
differential	O
activation	O
properties	O
,	O
we	O
linked	O
the	O
isolated	O
effector	B-GP
domains	E-GP
to	O
the	O
GAL4	B-GP
DNA-binding	I-GP
domain	E-GP
.	O
We	O

have	O
shown	O
that	O
both	O
activating	O
regions	O
of	O
Oct-2a	S-GP
,	O
isolated	O
from	O
their	O
natural	O
context	O
,	O
can	O

activate	O
transcription	O
as	O
promoter	B-GP
factors	E-GP
.	O
In	O
contrast	O
to	O
the	O
C-terminus	S-GP
,	O
activation	O
by	O
the	O
N-terminal	B-GP
domain	E-GP
is	O
dependent	O
on	O
a	O
yet	O
unidentified	O
factor	O
(	O

s	O
)	O
binding	O
to	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
enhancer	E-DNA
.	O
The	O
results	O
obtained	O
by	O
duplication	O
of	O
activation	B-GP
domains	E-GP
or	O
their	O
mixed	O
combination	O
suggest	O
that	O
the	O
domains	O
are	O
functionally	O
independent	O

.	O
However	O
,	O
activation	O
from	O
a	O
remote	O
position	O
could	O
only	O
be	O
achieved	O
with	O
the	O
C-terminus	S-GP
of	O
Oct-2a	S-GP
in	O
B	B-cell_type
cells	E-cell_type
.	O
In	O
lymphoid	B-cell_type
cells	E-cell_type
,	O
higher	O
activation	O
levels	O
were	O
observed	O
,	O
suggesting	O
that	O
distinct	O
B-cell-specific	B-GP
cofactors	E-GP
in	O
concert	O
with	O

the	O

effector	B-GP
domains	E-GP
of	O
Oct-2a	S-GP
might	O
be	O
involved	O
in	O
mediating	O
transcription	O
from	O
proximal	O
and	O
remote	O

positions	O
.	O
Furthermore	O
,	O
we	O
identified	O
a	O
repression	O
domain	O
at	O
the	O
N-terminus	O
of	O
Oct-2a	S-GP
.	O
When	O
transferred	O
to	O
a	O
potent	O

activator	O
,	O
transcriptional	O
stimulation	O
was	O
inhibited	O
efficiently	O
.	O
These	O
results	O
underscore	O
the	O
modular	O
structure	O
of	O
Oct-2a	S-GP
with	O
separable	O
domains	O

for	O
activation	O
and	O
repression	O
and	O
suggest	O
that	O
Oct-2a	S-GP
might	O
have	O
complex	O
regulatory	O
functions	O
in	O
vivo	O
.	O
Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	S-cell_type

and	O
polymorphonuclear	B-cell_type
leukocytes	E-cell_type
requires	O
the	O
presence	O
of	O
the	O
bacterial	O
flagellum	O
.	O
Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O

poorly	O
understood	O
.	O
To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P.	O
aeruginosa	O
PAK	O
lacking	O
pili	O

,	O
flagella	O
,	O
and	O
the	O
RpoN	B-GP
sigma	I-GP
factor	E-GP
were	O
undertaken	O
.	O
The	O
RpoN	O
mutant	O
,	O
lacking	O
pili	O
,	O
flagella	O
,	O

and	O
nonpilus	B-GP
adhesins	E-GP
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	S-cell_type
and	O
neutrophils	S-cell_type
.	O
Pili	O
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P.	O
aeruginosa	O
.	O
The	O
presence	O
of	O
a	O
flagellum	O

was	O
not	O
required	O
for	O
binding	O
of	O
P.	O
aeruginosa	O
to	O
macrophages	S-cell_type
but	O
was	O
critical	O

for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O

a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O
Identification	O
of	O
essential	O
GATA	S-DNA
and	O
Ets	B-DNA
binding	I-DNA
motifs	E-DNA
within	O
the	O
promoter	O
of	O

the	O

platelet	B-DNA
glycoprotein	I-DNA
Ib	I-DNA
alpha	I-DNA
gene	E-DNA
.	O
Platelet	B-GP
glycoprotein	E-GP
(	O
GP	S-GP
)	O
Ib-IX-V	S-GP
is	O
a	O
multisubunit	B-GP
adhesion	I-GP
receptor	E-GP
that	O

supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O
The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O

bleeding	O
disorder	O
associated	O
with	O
``	B-cell_type
giant	I-cell_type
''	I-cell_type
platelets	E-cell_type
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O
To	O
understand	O
better	O
the	O
expression	O
of	O
the	O

GP	B-GP
Ib-IX-V	I-GP
complex	E-GP
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	B-DNA
elements	E-DNA
supporting	O
the	O
expression	O
of	O
the	O
alpha-subunit	S-GP
of	O
the	O
complex	O
(	O
GP	B-GP
Ib	I-GP
alpha	E-GP

)	O
.	O
GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	E-DNA
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	B-cell_type

erythroleukemia	I-cell_type
cells	E-cell_type
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	S-GP
,	O
luciferase	S-GP
.	O
Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	E-DNA
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	E-cell_type

.	O

In	O
cells	O
of	O
nonhematopoietic	B-cell_type
lineage	E-cell_type
,	O
human	B-cell_type
endothelial	E-cell_type
and	O
HeLa	B-cell_type
cells	E-cell_type
,	O
the	O
GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	E-DNA
activity	O
was	O

no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	B-DNA
constructs	E-DNA
.	O
Gel	O
shift	O
assays	O
and	O
site-directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	S-DNA
and	O
Ets	B-DNA
binding	I-DNA
motifs	E-DNA

93	B-DNA
and	I-DNA
150	I-DNA
nucleotides	I-DNA
upstream	E-DNA
of	O
the	O
transcription	B-DNA
start	I-DNA
site	E-DNA
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O
The	O
results	O
define	O
essential	O

cis-acting	B-DNA
elements	E-DNA
responsible	O
for	O
the	O
expression	O
of	O
GP	B-GP
Ib	I-GP
alpha	E-GP
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	B-cell_type
platelets	E-cell_type
into	O
the	O
bloodstream	O
.	O
CD30	S-GP
ligation	O
induces	O
nuclear	B-GP
factor-kappa	I-GP
B	E-GP
activation	O
in	O

human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
CD30	S-GP
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B-GP
necrosis	I-GP
factor/nerve	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
superfamily	E-GP
.	O
In	O
this	O

report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	B-cell_line
cells	E-cell_line
(	O
Hodgkin	B-cell_line
's	I-cell_line
disease-derived	I-cell_line
,	I-cell_line
T	I-cell_line
cell-like	I-cell_line
,	I-cell_line
CD30+	I-cell_line
cells	E-cell_line
)	O
with	O
the	O
agonistic	B-GP
anti-CD30	I-GP
monoclonal	I-GP
antibodies	E-GP
(	O
mAb	S-GP
)	O
M44	S-GP
and	O
M67	S-GP
,	O
two	O

nuclear	B-GP
factor	I-GP
(	I-GP
NF	I-GP
)	I-GP
-kappa	I-GP
B	E-GP
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O
The	O
effect	O
of	O
the	O
mAb	S-GP
towards	O

NF-kappa	B-GP
B	E-GP
activation	O
was	O
rapid	O
,	O
as	O
it	O
occurred	O
within	O
20	O
min	O
,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h	O
.	O
By	O
comparison	O
,	O
an	O
isotype-matched	B-GP
antibody	E-GP
had	O
no	O
effect	O
on	O
NF-kappa	B-GP
B	E-GP
activation	O
.	O
Moreover	O
,	O
in	O
human	B-cell_line

T	I-cell_line
helper	I-cell_line
(	I-cell_line
Th	I-cell_line
)	I-cell_line
clones	E-cell_line
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30+	O

,	O

respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30	S-GP
-mediated	O
NF-kappa	B-GP
B	E-GP
activation	O
correlated	O
with	O

the	O
proportion	O
of	O
CD30+	B-cell_line
cells	E-cell_line
.	O
In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF-kappa	B-GP
B	I-GP
complexes	E-GP

induced	O
following	O
CD30	S-GP
engagement	O
were	O
shown	O
to	O
contain	O
p50	B-GP
NF-kappa	I-GP
B1	E-GP
,	O
p65	B-GP
RelA	E-GP
,	O
and	O
possibly	O
other	O
transcription	B-GP
factors	E-GP
.	O
Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF-kappa	B-GP
B	E-GP
rank	O
among	O
the	O
short-term	O
cellular	O
responses	O
elicited	O
following	O
CD30	S-GP
ligation	O
.	O
Pathogenesis	O
of	O
atherosclerosis	O
.	O
The	O
earliest	O
lesion	O
in	O
the	O
development	O
of	O
an	O
atherosclerotic	O
plaque	O
is	O

the	O
fatty	O
streak	O
.	O
This	O
chronic	O
inflammatory	O
reaction	O
results	O
from	O
a	O
sequence	O
of	O
events	O
that	O
begins	O
with	O
the	O
trapping	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
the	O

subendothelial	O
space	O
of	O
the	O
artery	O
wall	O
.	O
The	O
trapped	O
LDL	O
is	O
seeded	O
with	O
oxidative	O

species	O
released	O
by	O
the	O
overlying	O
endothelium	O
,	O
and	O
lipid	O
oxidation	O
is	O
initiated	O
within	O
the	O
LDL	O
particle.	O
Some	O
of	O
the	O
lipids	O
that	O
result	O
lead	O
to	O
the	O
activation	O
of	O
NFkB-like	B-GP
transcription	I-GP
factors	E-GP
that	O
cause	O
the	O
expression	O
of	O
genes	O
whose	O
protein	B-GP
products	E-GP
mediate	O
monocyte	O
binding	O
,	O
monocyte	S-cell_type
chemotaxis	O
into	O
the	O
subendothelial	O
space	O
,	O
and	O
conversion	O
into	O
macrophages	S-cell_type
.	O

At	O
least	O
1	O
major	B-DNA
gene	E-DNA
modulates	O
the	O
oxidation	O
of	O
LDL	O
lipids	O
and/or	O
the	O
biologic	O
response	O
to	O
these	O
lipids	O
.	O
The	O
inverse	O
relation	O
between	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
atherosclerotic	O

events	O
may	O
in	O
part	O
be	O
due	O
to	O
enzymes	S-GP
associated	O
with	O
HDL	O
that	O
destroy	O
the	O
biologically	O
active	O
lipids	O
generated	O
in	O
LDL	O
.	O
Estrogen	S-GP
and	O
progesterone	B-GP

receptors	E-GP

in	O
vernal	O
keratoconjunctivitis	O
.	O

PURPOSE	O
:	O
Sex-related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O

)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O
METHODS	O
:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	S-GP
and	O

progesterone	B-GP
receptors	E-GP
by	O
using	O
monoclonal	B-GP
antibodies	E-GP
with	O
a	O
peroxidase-antiperoxidase	O
technique	O
.	O
RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	B-GP
receptors	E-GP
.	O
Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	S-GP
and	O
progesterone	B-GP
receptors	E-GP
with	O
eosinophil	B-GP
cationic	I-GP
protein	E-GP
showed	O
that	O

approximately	O
70	O
%	O
of	O
positive	B-cell_type
cells	E-cell_type
were	O
eosinophils	S-cell_type
.	O
CONCLUSIONS	O
:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	S-GP
,	O
may	O

influence	O
the	O
activity	O
of	O
eosinophils	S-cell_type
in	O
patients	O
with	O
VKC	O
.	O
CIITA	S-GP
activates	O
the	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
in	O
mouse	O
T	O
cells	O
.	O
It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	B-GP
class	I-GP

II	I-GP

molecules	E-GP
are	O
expressed	O
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
after	O

activation	O
but	O
not	O
in	O
mouse	B-cell_type
T	I-cell_type
cells	E-cell_type
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O

.	O
Recently	O
the	O
MHC	B-GP
class	I-GP
II	I-GP
transactivator	E-GP
(	O
CIITA	S-GP
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	B-GP
regulatory	I-GP
factor	E-GP
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
.	O
Here	O
we	O

show	O
that	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	S-GP
transcripts	O
while	O
MHC	O
class	O
II-negative	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
and	O
mouse	B-cell_type
T	I-cell_type
cells	E-cell_type
do	O
not	O
.	O
The	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
in	O
mouse	B-cell_type
T	I-cell_type
cells	E-cell_type

can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	B-DNA
CIITA	I-DNA
cDNA	E-DNA
.	O
These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	S-GP
explains	O
the	O
expression	O
or	O

lack	O
of	O
expression	O
of	O
MHC	B-GP
class	I-GP
II	E-GP
in	O
human	S-cell_type
and	O
mouse	B-cell_type
T	I-cell_type
cells	E-cell_type
respectively	O
.	O
Anti-Ro	B-GP
(	I-GP
SSA	I-GP
)	I-GP
autoantibodies	E-GP

are	O

associated	O
with	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
beta	I-DNA
genes	E-DNA
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O
Several	O

of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	O
lupus	O
erythematosus	O
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	S-GP
.	O
Associations	O
between	O
HLA	B-GP
class	I-GP
II	I-GP
antigens	E-GP
and	O
autoantibodies	S-GP
to	O
the	O
ribonucleoproteins	S-GP
Ro	B-GP
(	I-GP
SSA	I-GP
)	E-GP
and	O
La	B-GP
(	I-GP
SSB	I-GP
)	E-GP
have	O
been	O
reported	O
in	O
these	O

patients	O
.	O
Because	O
HLA	B-GP
class	I-GP
II	I-GP
molecules	E-GP
present	O
antigen	O
to	O
T	B-GP
cell	I-GP
receptors	E-GP
(	O
TCRs	S-GP
)	O
,	O
we	O
have	O
searched	O
for	O
a	O
TCR	B-DNA
gene	E-DNA
associated	O
with	O
the	O
production	O
of	O
anti-Ro	B-GP
(	I-GP
SSA	I-GP

)	I-GP
antibodies	E-GP
.	O
A	O
pair	O
of	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	E-DNA
(	O
RFLPs	S-DNA
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B-DNA
constant	I-DNA
region	I-DNA
C	I-DNA
beta	I-DNA
1	E-DNA
and	O
the	O

other	O
to	O
the	O
C	B-DNA
beta	I-DNA
2	I-DNA
gene	E-DNA
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O

of	O
the	O
TCR	B-DNA
beta	I-DNA
locus	E-DNA
.	O
This	O
RFLP	B-DNA
pair	E-DNA
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B-GP
(	I-GP
SSA	I-GP
)	E-GP
precipitins	O
,	O
84	O
%	O
of	O
anti-	O
Ro	B-GP

(	I-GP

SSA	I-GP
)	E-GP
-positive	O
patients	O
lacking	O
La	B-GP
(	I-GP
SSB	I-GP
)	E-GP
precipitins	S-GP
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O

both	O
precipitins	S-GP
(	O
P	O
=	O
0.0004	O
)	O
.	O
This	O
disproportionate	O
occurrence	O
in	O
a	O
subset	O
of	O
lupus	O
patients	O

indicates	O
that	O
these	O
RFLPs	S-DNA
are	O
not	O
disease	O
susceptibility	O
markers	O
,	O
but	O
rather	O
are	O
important	O
markers	O
for	O
TCR	B-DNA
genes	E-DNA
whose	O
products	O
are	O
involved	O
in	O
the	O
production	O
of	O
anti-Ro	B-GP

(	I-GP
SSA	I-GP
)	I-GP
antibodies	E-GP
.	O
The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	S-DNA
and	O
HLA	B-GP
class	I-GP
II	I-GP
antigens	E-GP
previously	O
associated	O
with	O
the	O
anti-	O
Ro	B-GP
(	I-GP
SSA	I-GP
)	E-GP
response	O
make	O
this	O
antibody	O
,	O
suggesting	O

that	O
interactions	O
between	O
products	O
of	O
these	O
loci	B-DNA
occur	E-DNA
in	O
response	O
to	O
Ro	B-GP
(	I-GP
SSA	I-GP
)	E-GP
.	O
Inhibition	O
of	O
NF-AT	S-GP
-dependent	O
transcription	O
by	O
NF-kappa	B-GP
B	E-GP
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
subsets	E-cell_type
.	O
Activation	O
of	O
individual	O
CD4+	B-cell_line
T	I-cell_line
cells	E-cell_line
results	O
in	O
differential	O
lymphokine	S-GP
expression	O
:	O
interleukin	B-GP
2	E-GP
(	O
IL-2	S-GP
)	O

is	O
preferentially	O
produced	O
by	O
T	B-cell_line
helper	I-cell_line
type	I-cell_line
1	I-cell_line
(	I-cell_line
TH1	I-cell_line
)	I-cell_line
cells	E-cell_line
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	S-GP
is	O
synthesized	O
by	O
TH2	B-cell_line
cells	E-cell_line
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O
The	O
Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-dependent	I-GP
factor	E-GP
NF-ATp	S-GP
plays	O
a	O
key	O
role	O
in	O

the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	B-DNA
genes	E-DNA
.	O
However	O
,	O
while	O
IL2	S-GP
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
protein	B-GP
kinase	I-GP
C	E-GP
-dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	B-GP
IL4	E-GP
transcription	O
through	O
the	O
Ca	O

(	O
2+	O
)	O
-dependent	O
pathway	O
is	O
diminished	O
by	O
protein	B-GP
kinase	I-GP
C	E-GP
stimulation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
.	O
This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF-ATp	S-GP
and	O
NF-kappa	B-GP
B	E-GP
to	O
the	O
P	B-DNA
sequence	E-DNA
,	O
an	O
element	O
located	O
69	B-DNA
bp	I-DNA
upstream	E-DNA
of	O
the	O
IL4	B-DNA

transcription	I-DNA

initiation	I-DNA
site	E-DNA
.	O
Human	B-DNA
IL4	I-DNA
promoter	E-DNA
-mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
stimulated	O
with	O
the	O
NF-kappa	B-GP
B-activating	I-GP
cytokine	E-GP
tumor	B-GP

necrosis	I-GP
factor	I-GP
alpha	E-GP
and	O
suppressed	O
in	O
RelA-overexpressing	B-cell_line
cells	E-cell_line
.	O
In	O
contrast	O
,	O
protein	B-GP
kinase	I-GP
C	E-GP
stimulation	O
or	O
RelA	S-GP
overexpression	O
does	O
not	O
affect	O
the	O
activity	O
of	O
a	O
human	B-DNA
IL4	I-DNA
promoter	E-DNA
containing	O
a	O
mouse	B-DNA
P	I-DNA
sequence	E-DNA
,	O
which	O
is	O
a	O
higher-affinity	B-DNA
site	E-DNA
for	O
NF-ATp	S-GP
and	O
a	O
lower-affinity	B-DNA
site	E-DNA
for	O
RelA	S-GP
.	O
Thus	O
,	O
competition	O
between	O

two	O
general	O
transcriptional	B-GP
activators	E-GP
,	O
RelA	S-GP
and	O
NF-ATp	S-GP
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	B-GP
kinase	I-GP
C	E-GP
stimulation	O
on	O
IL4	S-GP
expression	O
and	O

may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	B-cell_line
cells	E-cell_line
.	O
Regulation	O
of	O
the	O
balance	O
of	O
cytokine	S-GP
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	S-GP
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	S-GP
and	O
inflammatory	O
synovial	O
fluids	O
.	O
The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O

production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	S-GP
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O
Many	O
cytokines	S-GP
activate	O
signal	B-GP
transducer	I-GP

and	I-GP
activation	I-GP
of	I-GP
transcription	I-GP
(	I-GP
STAT	I-GP
)	I-GP
transcription	I-GP
factors	E-GP
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O
We	O
used	O
mononuclear	B-cell_line
cell	I-cell_line

priming	I-cell_line
cultures	E-cell_line
and	O
inflammatory	B-cell_type
synovial	I-cell_type
fluids	E-cell_type
(	O
SFs	S-cell_type
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	S-GP
production	O
and	O
STAT	S-GP
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O
Exposure	O
to	O
SFs	S-cell_type
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O

of	O
interferon	B-GP
(	I-GP
IFN	I-GP
)	I-GP
-gamma	E-GP
,	O
but	O
not	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
4	E-GP
,	O
production	O
by	O
effector	B-cell_type
cells	E-cell_type
generated	O
in	O
priming	O
cultures	O
.	O
SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	S-GP
and	O
IL-10	S-GP
and	O
inhibition	O
of	O
IL-12	S-GP

expression	O

,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O
SFs	S-cell_type
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	B-GP
factor	I-GP
Stat1	E-GP
,	O
but	O
not	O
Stat3	S-GP
,	O
during	O

the	O
priming	O
period	O
,	O
and	O
Stat1	S-GP
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	S-GP
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN-gamma	S-GP
production	O
.	O
Active	O
Stat3	S-GP
,	O
but	O
not	O
Stat1	S-GP
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O

joints	O
.	O
These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	O
and	O
Stat3	O
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	B-cell_type
cell	E-cell_type
differentiation	O
and	O
in	O
the	O
pathogenesis	O

of	O
inflammatory	O
synovitis	O
.	O
Triggering	O
of	O
complement	B-GP
receptors	E-GP
CR1	S-GP
(	O
CD35	S-GP
)	O
and	O
CR3	S-GP
(	O
CD11b/CD18	S-GP
)	O
induces	O
nuclear	O
translocation	O
of	O
NF-kappa	B-GP
B	E-GP
(	O
p50/p65	S-GP
)	O
in	O
human	B-cell_type
monocytes	E-cell_type
and	O
enhances	O
viral	O
replication	O

in	O
HIV-infected	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
.	O
Monocyte/macrophages	S-cell_type
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O
Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	S-GP
such	O

as	O
TNF-alpha	S-GP
in	O
vitro	O
.	O
The	O
effect	O
of	O
LPS	O
and	O
TNF-alpha	S-GP
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA-binding	B-GP
heterodimer	E-GP
NF-kappa	B-GP
B	E-GP

(	O
p50/p65	S-GP
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV-long	B-DNA
terminal	I-DNA
repeat	E-DNA
.	O
The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	B-GP
receptors	E-GP
CR1	S-GP
(	O
CD35	S-GP
)	O
and	O
CR3	S-GP
(	O
CD11b/CD18	S-GP
)	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_line

human	I-cell_line
monocytic	I-cell_line
cells	E-cell_line
.	O
Monocytic	B-cell_line
cell	I-cell_line
lines	E-cell_line
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O

HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	B-GP
(	I-GP
ab	I-GP
'	I-GP
)	I-GP
2	I-GP
fragments	E-GP
of	O
monoclonal	B-GP
anti-CR1	E-GP
or	O
anti-CR3	B-GP
Abs	E-GP
or	O
with	O
C3	B-GP
fragments	E-GP
.	O

Stimulation	O

of	O
CR1	S-GP
or	O
CR3	S-GP
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell-associated	O
and	O
released	O
p24	B-GP
Ag	E-GP
in	O
cell	B-cell_line
cultures	E-cell_line
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	B-cell_line
cultures	E-cell_line
triggered	O
with	O
LPS	O

.	O
We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	S-GP
or	O
CR3	S-GP
induces	O
the	O
nuclear	O
translocation	O

of	O
NF-kappa	B-GP
B	E-GP
p50/p65	S-GP
in	O
infected	B-cell_type
cells	E-cell_type
.	O
Translocation	O
of	O
NF-kappa	B-GP
B	E-GP
p50/p65	S-GP
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	S-GP
or	O

CR3	S-GP
of	O
uninfected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	E-cell_type
from	O
HIV-seronegative	O
donors	O
.	O
The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF-alpha	S-GP
.	O
TNF-alpha	S-GP
did	O
not	O
mediate	O
the	O
translocation	O
of	O
NF-kappa	B-GP
B	E-GP
p50/p65	S-GP

induced	O
by	O
triggering	O
of	O
complement	B-GP
receptors	E-GP
.	O
Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	B-cell_type
monocytes	E-cell_type
through	O
interaction	O
of	O
the	O

cells	O
with	O
complement-opsonized	B-GP
particles	E-GP
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	B-GP
receptor	E-GP
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF-kappa	B-GP
B	I-GP
complex	E-GP
.	O
Attenuation	O
of	O
gamma	B-GP
interferon	E-GP
-induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	B-cell_type
phagocytes	E-cell_type
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O

of	O
signaling	O
through	O
Janus	B-GP
kinases	E-GP
and	O
Stat1	S-GP
.	O
The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B-GP
interferon	E-GP
is	O
impaired	O
in	O
mononuclear	B-cell_type
phagocytes	E-cell_type
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O

.	O
The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B-GP
interferon	E-GP
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O

cellular	B-GP
protein	I-GP
tyrosine	I-GP
kinases	E-GP
,	O
including	O
the	O
Janus	B-GP
kinases	E-GP
Jak1	S-GP
and	O
Jak2	S-GP
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B-GP
factor	I-GP
Stat1	E-GP
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B-GP
interferon	E-GP
,	O
a	O
model	O
system	O
for	O

examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	S-GP
and	O
Jak2	S-GP
and	O
phosphorylation	O
of	O
Stat1	S-GP

was	O
developed	O
in	O
phorbol	B-cell_line
12-myristate	I-cell_line
13-acetate-differentiated	I-cell_line
U-937	I-cell_line
cells	E-cell_line
.	O
Analysis	O
of	O
whole-cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B-GP
interferon	E-GP
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O
Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O

control	B-cell_type

cells	E-cell_type
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h	O
.	O
Jak1	S-GP
,	O
Jak2	S-GP
,	O
and	O
Stat1	S-GP
were	O
immunoprecipitated	O
from	O
control	O

and	O
interferon-treated	B-cell_line
cells	E-cell_line
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O
Tyrosine	O
phosphorylation	O
of	O
Jak1	S-GP
,	O
Jak2	S-GP
,	O

and	O
Stat1	S-GP
increased	O
markedly	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
in	O
U-937	B-cell_line
cells	E-cell_line
incubated	O
with	O
gamma	B-GP
interferon	E-GP
.	O
In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	S-GP
,	O
Jak2	S-GP
,	O
and	O
Stat1	S-GP
was	O
markedly	O
impaired	O
.	O
This	O
effect	O

was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O
Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	B-cell_line
cells	E-cell_line
were	O
also	O
obtained	O
with	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	E-cell_type
.	O
These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	B-cell_type

mononuclear	I-cell_type
phagocytes	E-cell_type
with	O
L.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B-GP
interferon	E-GP
-mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak-	O
Stat1	S-GP
pathway	O
.	O
Unresponsiveness	O
to	O

gamma	B-GP
interferon	E-GP
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania-infected	B-cell_type
cells	E-cell_type
.	O
Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	B-GP
attachment	I-GP
region	I-GP
binding	I-GP

protein	E-GP
and	O
the	O
NF-muNR	B-GP
enhancer	I-GP
repressor	E-GP
.	O
Implications	O
for	O
regulation	O
of	O
immunoglobulin	B-GP
heavy	I-GP
chain	E-GP
expression	O
.	O
The	O
immunoglobulin	B-GP
heavy	I-GP
chain	E-GP
(	O
IgH	S-GP
)	O
intronic	O
enhancer	O
stimulates	O
transcription	O
from	O
functional	O
promoters	O
in	O
B	O

lymphocytes	O
but	O
not	O
other	O
cell	O
types	O
.	O
The	O
observation	O
that	O
binding	O
sites	O
for	O
the	O
nuclear	B-GP
factor-mu	I-GP
negative	I-GP
regulator	I-GP
(	I-GP
NF-muNR	I-GP
)	I-GP
enhancer	I-GP
repressor	I-GP
overlap	I-GP
nuclear	I-GP

matrix	I-GP
attachment	I-GP
regions	E-GP
(	O
MARs	S-GP
)	O
in	O
this	O
enhancer	S-DNA
has	O
lead	O
to	O
the	O
hypothesis	O
that	O
the	O
cell	O
type	O
specificity	O
of	O
the	O
enhancer	S-DNA
might	O

be	O
controlled	O
by	O
regulating	O
nuclear	O
matrix	O
attachment	O
(	O
Scheuermann	O
,	O
R.	O
H.	O
,	O
and	O
Chen	O
,	O
U.	O
(	O
1989	O
)	O
Genes	O

&	O
Dev.	O
3	O
,	O
1255-1266	O
)	O
.	O
To	O
understand	O
the	O
role	O
of	O
MARs	S-GP
in	O
IgH	B-DNA
enhancer	E-DNA
regulation	O

,	O
we	O
have	O
identified	O
a	O
novel	O
MAR-binding	B-GP
protein	E-GP
,	O
MAR-BP1	S-GP
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	S-GP
associated	O
with	O
the	O
IgH	B-DNA

enhancer	E-DNA
.	O
Purified	O
MAR-BP1	S-GP
migrates	O
as	O
a	O
33-kDa	B-GP
protein	E-GP
,	O
and	O
it	O
can	O
be	O
found	O
in	O
nuclear	O
matrix	O

preparations	O

from	O
a	O
number	O
of	O
different	O
types	O
of	O
lymphoid	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
Although	O
specific	O
binding	O
sites	O
have	O
been	O

difficult	O
to	O
localize	O
by	O
chemical	O
or	O
enzymatic	O
footprinting	O
procedures	O

,	O
NF-muNR	S-GP
binding	O
sites	O
are	O
critical	O
for	O
efficient	O
MAR-BP1	S-GP
binding	O
.	O
Indeed	O
,	O
binding	O
of	O
the	O
IgH	B-DNA
enhancer	E-DNA
to	O
either	O
intact	O
nuclear	O
matrix	O

preparations	O
or	O
to	O
MAR-BP1	S-GP
is	O
mutually	O
exclusive	O
to	O
NF-muNR	S-GP
binding	O
.	O
These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
for	O
cell-type	O
specific	O
regulation	O
in	O
which	O
binding	O
of	O
the	O
NF-muNR	B-GP
repressor	E-GP
to	O
the	O
IgH	B-DNA
enhancer	E-DNA
prevents	O
nuclear	O
matrix	O
attachment	O
in	O
inappropriate	O
cells	O
by	O
interfering	O
with	O
MAR-BP1	S-GP
/enhancer	S-DNA
interaction	O
.	O
PU.1	S-GP
(	O
Spi-1	S-GP
)	O
and	O
C/EBP	B-GP
alpha	E-GP
regulate	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	E-DNA
.	O
Growth	B-GP
factor	I-GP
receptors	E-GP
play	O

an	O
important	O
role	O
in	O
hematopoiesis	O
.	O
In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	B-GP
factors	E-GP
activating	O
the	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA

)	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	E-DNA
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
receptor	I-DNA
alpha	I-DNA
promoter	E-DNA
directs	O
reporter	B-DNA
gene	E-DNA
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B-cell_type
cells	E-cell_type
,	O

which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O
The	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	E-DNA
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-53	O

and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B-DNA
constructs	E-DNA
.	O
We	O
show	O
that	O
the	O
myeloid	O
and	O
B	B-GP
cell	I-GP
transcription	I-GP
factor	E-GP
PU.1	S-GP
binds	O

specifically	O
to	O
this	O
site	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	B-DNA
site	E-DNA
located	O
upstream	O
of	O
the	O
PU.1	B-DNA
site	E-DNA
between	O
positions	O
-70	O
and	O
-54	O
is	O
involved	O
in	O
positive-negative	O
regulation	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	E-DNA
activity	O

.	O

C/EBP	B-GP
alpha	E-GP
is	O
the	O
major	O
CCAAT/enhancer-binding	B-GP
protein	E-GP
(	O
C/EBP	S-GP
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O

of	O
U937	B-cell_line
cells	E-cell_line
.	O
Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA

site	E-DNA
or	O
the	O
C/EBP	B-DNA
site	E-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	E-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	E-cell_type
only	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O

,	O
PU.1	S-GP
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU-SF	S-GP
)	O
when	O
binding	O
the	O
GM-CSF	B-GP
receptor	I-GP
alpha	E-GP
promoter	O
PU.1	B-DNA
site	E-DNA
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	S-GP

on	O
a	O
myeloid	B-DNA
PU.1	I-DNA
binding	I-DNA
site	E-DNA
.	O
The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	B-DNA
cell	I-DNA
enhancer	I-DNA
sites	E-DNA
and	O

can	O
be	O
formed	O
by	O
addition	O
of	O
PU.1	S-GP
to	O
extracts	O
from	O
certain	O
nonmyeloid	B-cell_type
cell	I-cell_type
types	E-cell_type
which	O
do	O
not	O

express	O
PU.1	S-GP
,	O
including	O
T	B-cell_type
cells	E-cell_type
and	O
epithelial	B-cell_type
cells	E-cell_type
,	O
but	O
not	O
from	O
erythroid	B-cell_type
cells	E-cell_type
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU-SF	B-GP
complex	E-GP
binds	O
to	O
PU.1	S-GP
sites	O
found	O
on	O
a	O
number	O

of	O
myeloid	B-DNA
promoters	E-DNA
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU.1	B-DNA
site	E-DNA
adjacent	O
to	O
a	O
single-stranded	O
region	O
.	O
Expression	O
of	O
PU.1	S-GP
in	O

nonmyeloid	B-cell_type
cells	E-cell_type
can	O
activate	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	E-DNA
.	O
Deletion	O
of	O
the	O
amino-terminal	B-GP
region	E-GP
of	O
PU.1	S-GP
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU-SF	S-GP
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O

that	O
formation	O
of	O
the	O
PU-SF	B-GP
complex	E-GP
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	E-DNA
.	O
Finally	O
,	O
we	O
demonstrate	O
that	O
C/EBP	B-GP
alpha	E-GP
can	O
also	O
active	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	E-DNA
in	O

nonmyeloid	B-cell_type
cells	E-cell_type
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
HMG-I	S-GP
binds	O
to	O
GATA	B-DNA
motifs	E-DNA
:	O
implications	O
for	O

an	O
HPFH	O
syndrome	O
.	O
We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	B-GP
protein	E-GP
HMG-I	S-GP
to	O
the	O
human	B-DNA
gamma-globin	I-DNA
promoter	E-DNA
.	O
We	O
find	O
that	O
HMG-I	S-GP
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	B-DNA
motifs	E-DNA
in	O
the	O
gamma-globin	B-DNA
promoter	E-DNA
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	B-GP
factor	I-GP

GATA-1	E-GP
.	O
A	O
naturally	O
occurring	O
mutation	O
(	O
-175	O
T-C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG-I	S-GP
results	O
in	O
overexpression	O
of	O
gamma-globin	S-GP
in	O
adult	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	E-cell_type
(	O
HPFH	S-cell_type
)	O
and	O
up-regulation	O
of	O
the	O
gamma-globin	B-DNA

promoter	E-DNA
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG-I	S-GP
does	O
not	O
bind	O
to	O
this	O
mutant	B-DNA

sequence	E-DNA
.	O
A	O
survey	O
of	O
GATA	B-DNA
motifs	E-DNA
from	O
other	O
globin	B-DNA
cis-elements	E-DNA
demonstrates	O
HMG-I	S-GP
binding	O
to	O
most	O
of	O
them	O
.	O
These	O
findings	O
implicate	O
HMG-I	S-GP
in	O
the	O
HPFH	S-cell_type
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	B-GP
complexes	E-GP
that	O
regulate	O
globin	O
gene	O
expression	O

.	O
Constitutive	O
activation	O
of	O
different	O
Jak	B-GP
tyrosine	I-GP
kinases	E-GP
in	O
human	B-GP
T	I-GP
cell	I-GP
leukemia	I-GP
virus	I-GP
type	I-GP
1	I-GP
(	I-GP
HTLV-1	I-GP
)	I-GP

tax	I-GP
protein	E-GP
or	O
virus-transformed	B-cell_line
cells	E-cell_line
.	O
HTLV-1	O

infection	O

causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O
The	O
viral	B-GP
encoded	I-GP

protein	E-GP
tax	S-GP
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O
Our	O
previous	O

data	O
obtained	O
from	O
a	O
tax	S-GP
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	S-GP
transforms	O
mouse	B-cell_type
fibroblasts	E-cell_type
but	O
not	O
thymocytes	S-cell_type
,	O
despite	O
comparable	O
levels	O
of	O
tax	S-GP
expression	O
in	O
both	O
tissues	O
.	O
Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O

130-kD	B-GP
protein	E-GP
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	S-GP
transformed	B-cell_line
fibroblast	I-cell_line
B	I-cell_line
line	E-cell_line
and	O
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
lines	E-cell_line
,	O
but	O
not	O
in	O
thymocytes	S-cell_type
from	O
Thy-tax	O
transgenic	O
mice	O
.	O
Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	B-GP
kinase	I-GP
specific	I-GP
antibodies	E-GP
,	O
identified	O

p130	O
as	O
Jak2	S-GP
in	O
the	O
tax	S-GP
transformed	O
mouse	B-cell_line
fibroblastic	I-cell_line
cell	I-cell_line
line	E-cell_line
and	O
Jak3	S-GP
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line

T	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
Phosphorylation	O
of	O
Jak2	S-GP
in	O
tax	B-cell_line
transformed	I-cell_line
cells	E-cell_line
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O
Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O

in	O

Balb/c3T3	B-cell_line
cells	E-cell_line
using	O
a	O
supernatant	O
from	O
the	O
B	B-cell_line
line	E-cell_line
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O
Both	O
phosphorylation	O
and	O
proliferation	O
were	O

inhibited	O
by	O
IL-6	B-GP
neutralizing	I-GP
antibodies	E-GP
.	O
Constitutive	O
phosphorylation	O
of	O
Jak	B-GP
kinases	E-GP

may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	B-cell_type
infected	I-cell_type
human	I-cell_type
T	I-cell_type
cells	E-cell_type
and	O
the	O
transgenic	O
mouse	O
model	O

.	O
Regulation	O
of	O
c-jun	B-RNA
mRNA	E-RNA
expression	O
by	O
hydroxyurea	O
in	O
human	B-cell_line
K562	I-cell_line
cells	E-cell_line
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O

)	O
:	O
409	O
]	O
Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O
In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B-GP
hemoglobin	E-GP
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c-jun	S-DNA
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	E-cell_line
.	O
HU	O
induced	O
a	O
dose-dependent	O
stimulation	O
of	O
c-jun	S-DNA
synthesis	O

.	O
The	O
levels	O
of	O
c-jun	B-RNA
mRNA	E-RNA
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O

2	O
h	O
.	O
This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O
Both	O
nuclear	O
run-on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O

HU	O
regulates	O
c-jun	B-RNA
mRNA	E-RNA
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O

as	O
well	O
as	O
stabilizing	O
the	O
c-jun	B-RNA
mRNA	E-RNA
.	O
In	O
addition	O
,	O
the	O
level	O
of	O
jun	B-GP
protein	E-GP
was	O
elevated	O
by	O
2	O
to	O
5-fold	O

within	O

4	O
h	O
in	O
HU	B-cell_line
treated	I-cell_line
cells	E-cell_line
.	O
Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1	S-GP
/CAT	S-GP
activity	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O

post-transcription	O
regulation	O
of	O
c-jun	S-DNA
during	O
erythroid	O
differentiation	O
.	O
In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O

on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B-GP
receptors	E-GP
.	O
Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O

(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well-documented	O
biological	O
phenomenon	O
.	O
While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O

(	O
PHA	O
)	O
-induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B-GP
mitogen	E-GP

(	O
PWM	S-GP
)	O
-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O
To	O
further	O
explore	O
the	O

link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B-GP
receptor	E-GP
function	O
,	O

dose-response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	S-GP
-induced	O
T-cell	O
mitogenesis	O
,	O
PWM	S-GP
-generated	O
B-cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O
Glucocorticoid	O
effects	O
were	O
assessed	O

in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O

and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O

.	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	S-GP
-induced	O
B-cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O

administered	O

in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O

vivo	O
.	O
These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O

to	O
glucocorticoid	B-GP
receptor	E-GP
function	O
.	O
The	O
decrease	O
in	O
PWM	S-GP
-generated	O
B-cell	O
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	O
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid-mediated	O
induction	O
of	O
interleukin-1	B-GP
receptor	E-GP
synthesis	O
.	O
Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O

situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O
Application	O
of	O
a	O
``	O
formamide	O
free	O
''	O
and	O
thus	O
``	O
material	O
preserving	O
''	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	S-DNA
of	O
the	O
myf3	B-DNA
gene	E-DNA
revealed	O
the	O
following	O
results	O
:	O
Human	B-cell_type
rhabdomyosarcoma	I-cell_type
cells	E-cell_type
,	O
characterized	O

by	O
a	O
high	O
expression	O
of	O
myf3	S-DNA
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O
RNase	S-GP
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O
In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	B-cell_type
lymphocytes	E-cell_type
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O

this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O
Correspondingly	O
,	O
RNase	S-GP
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O
In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O

hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O
Oncogenicity	O
of	O
human	B-cell_line
papillomavirus-	I-cell_line
or	I-cell_line
adenovirus-transformed	I-cell_line
cells	E-cell_line
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O

natural	B-cell_type
killer	I-cell_type
cells	E-cell_type
.	O
The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O

to	O

differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	S-GP
and	O
E7	B-GP
proteins	E-GP
to	O
target	B-cell_type
cells	E-cell_type
for	O
rejection	O
by	O
the	O
host	B-cell_type

natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	E-cell_type
response	O
.	O
As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	S-GP
-and	O
E7	S-GP
-expressing	O
human	B-cell_line
fibroblastic	I-cell_line
or	I-cell_line
keratinocyte-derived	I-cell_line
human	I-cell_line
cells	E-cell_line
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	S-cell_type
or	O
interferon	B-cell_line
(	I-cell_line
IFN	I-cell_line
)	I-cell_line
-activated	I-cell_line
NK	I-cell_line
cells	E-cell_line
.	O
Cells	O
expressing	O

the	O
E1A	B-GP
oncoprotein	E-GP
were	O
selectively	O
killed	O
by	O
unstimulated	B-cell_line
NK	I-cell_line
cells	E-cell_line
,	O
while	O
the	O

same	O
parental	B-cell_type
cells	E-cell_type
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	B-GP
oncoprotein	E-GP
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O
The	O
ability	O

of	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	E-cell_line
to	O
selectively	O
kill	O
virally	O
transformed	O
cells	O
depends	O
on	O
IFN	S-GP

's	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	O
(	O
i.e.	O
,	O
non-viral	B-cell_line
oncogene-expressing	E-cell_line
)	O
but	O
not	O
virally	B-cell_line
transformed	I-cell_line
cells	E-cell_line
.	O
E1A	S-GP
blocked	O

IFN	S-GP

's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus-transformed	B-cell_line
cells	E-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line

cells	E-cell_line
.	O
The	O
extent	O
of	O
IFN	S-GP
-induced	O
NK	O
cell	O
killing	O
of	O
E1A-expressing	B-cell_line
cells	E-cell_line
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	S-GP
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	S-GP
to	O
block	O
IFN	S-GP
-stimulated	O
gene	O
expression	O
in	O
target	B-cell_type
cells	E-cell_type
.	O
In	O
contrast	O
,	O
E7	S-GP
blocked	O
neither	O
IFN	S-GP
-stimulated	O
gene	O
expression	O
nor	O

IFN	S-GP
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV-transformed	B-cell_line
cells	E-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	E-cell_line
.	O
In	O
conclusion	O
,	O
E1A	S-GP
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	B-cell_type
cell	E-cell_type
response	O
,	O
whereas	O
the	O

E7	B-GP
oncoprotein	E-GP
lacks	O
this	O
activity	O
.	O
Regulation	O
of	O
IkB	B-GP
alpha	E-GP
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O
The	O
Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-dependent	I-GP
phosphatase	E-GP
calcineurin	S-GP
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O

,	O
synergizes	O
with	O
PKC	S-GP
-induced	O
activation	O
of	O
nuclear	B-GP
factor	I-GP
(	I-GP
NF	I-GP
)	I-GP
-kappa	I-GP
B	E-GP
in	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O

which	O
these	O
two	O
pathways	O
lead	O
to	O
NF-kappa	B-GP
B	E-GP
activation	O
.	O
While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O

monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	E-cell_line
calcineurin	S-GP
is	O
also	O
sufficient	O
to	O
activate	O
NF-kappa	B-GP
B	E-GP
.	O
Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
PKC-dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B-GP
alpha	E-GP
,	O
we	O
focused	O

on	O
the	O
regulation	O
of	O
IkB	B-GP
alpha	E-GP
phosphorylation	O
.	O
While	O
PKC	S-GP
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B-GP
alpha	E-GP
in	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
co-activation	O

of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B-GP
alpha	E-GP
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O
Activation	O
of	O
Ca	O

(	O

2+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B-GP
alpha	E-GP
in	O

Jurkat	B-cell_line
T	E-cell_line
or	O
in	O
U937	B-cell_line
cells	E-cell_line
.	O
Treatment	O
of	O
T	B-cell_type
cells	E-cell_type
with	O
the	O
selective	O
PKC	S-GP
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA-induced	O
IkB	B-GP
alpha	E-GP
phosphorylation/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O

but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B-GP
alpha	E-GP
induced	O
by	O
TNF-alpha	S-GP
,	O
a	O
PKC	S-GP
-independent	O
stimulus	O
.	O
Contrary	O
to	O
the	O
interaction	O
with	O
PKC	S-GP
,	O
Ca	O
(	O
2+	O
)	O

-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	S-GP
not	O
at	O
the	O
level	O
of	O
IkB	B-GP
alpha	E-GP
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O
These	O
results	O
indicate	O

that	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	S-GP
calcineurin	S-GP
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF-kappa	B-GP
B	E-GP
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	S-GP
-dependent	O
and	O

-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B-GP
alpha	E-GP
phosphorylation	O
and	O
degradation	O
.	O
Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
binding	O
.	O
Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O

a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O
Oxidative	O
stress	O
enhances	O
nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
(	O
NF-kappa	B-GP
B	E-GP
)	O
activity	O
,	O
and	O
NF-kappa	B-GP

B	E-GP
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B-GP
cytokines	E-GP
.	O
Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O
This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O

a	O
water-soluble	O
emulsion	O
of	O
alpha-tocopherol	O
.	O
Alpha-tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF-kappa	B-GP
B	E-GP
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O
In	O
vitro	O
treatment	O
of	O

a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B-GP
B	E-GP
binding	O
and	O
an	O
increase	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
messenger	I-RNA
RNA	E-RNA
levels	O
.	O
Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF-kappa	B-GP
B	E-GP
binding	O
activity	O
in	O
comparison	O
with	O
the	O

binding	O

of	O
normal	O
livers	O
.	O
These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha-tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O

eliminated	O
increased	O
NF-kappa	B-GP
B	E-GP
binding	O
.	O
It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF-kappa	B-GP
B	E-GP
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O

liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	B-GP
cytokine	E-GP
synthesis	O
.	O
Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	B-GP
B	E-GP
activity	O
through	O
induction	O
of	O
I	B-GP
kappa	I-GP
B	E-GP
synthesis	O

[	O
see	O
comments	O
]	O
Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O
They	O
inhibit	O
synthesis	O
of	O
almost	O

all	O
known	O
cytokines	S-GP
and	O
of	O
several	O
cell	B-GP
surface	I-GP
molecules	E-GP
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O

this	O
activity	O
has	O
been	O
unclear.	O
Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
(	O
NF-kappa	B-GP
B	E-GP
)	O

activation	O
in	O
mice	O
and	O
cultured	B-cell_line
cells	E-cell_line
.	O
This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B-GP
kappa	I-GP
B	E-GP
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF-kappa	B-GP
B	E-GP
in	O
inactive	B-GP
cytoplasmic	I-GP

complexes	E-GP
.	O
Because	O
NF-kappa	B-GP
B	E-GP
activates	O
many	O
immunoregulatory	B-DNA
genes	E-DNA
in	O
response	O
to	O
pro-inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O

of	O
the	O
anti-inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O
Transcriptional	O
repression	O
of	O
the	O
interleukin-2	B-DNA
gene	E-DNA
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	B-GP
complex	E-GP
formation	O

by	O
a	O
nuclear	B-GP
hormone	I-GP
receptor	E-GP
.	O
T-lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O

D3	O

,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O

factor	O
mRNA	O
levels	O
.	O
We	O
report	O
here	O
that	O
1	O
,	O
25	O

(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	S-GP
expression	O
by	O
the	O
vitamin	B-GP
D3	I-GP
receptor	E-GP
(	O
VDR	S-GP
)	O
.	O
We	O
therefore	O
examined	O
vitamin	O
D3-mediated	O
repression	O
of	O
activated	O
IL-2	S-GP
expression	O
by	O
cotransfecting	O
Jurkat	B-cell_line
cells	E-cell_line
with	O
IL-2	B-DNA
promoter/reporter	I-DNA
constructs	E-DNA
and	O
a	O

VDR	B-DNA
overexpression	I-DNA
vector	E-DNA
and	O
by	O
DNA	O
binding	O
.	O
We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O

(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	B-DNA
region	E-DNA
encompassing	O
an	O
important	O
positive	B-DNA
regulatory	I-DNA
element	E-DNA
,	O
NF-AT-1	S-DNA
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	B-GP
transcription	I-GP
factor	E-GP
,	O

NFATp	S-GP

,	O
as	O
well	O
as	O
by	O
AP-1	S-GP
.	O
VDR	B-GP
DNA-binding	I-GP
mutants	E-GP
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O

in	O
vivo	O
;	O
the	O
VDR	B-GP
DNA-binding	I-GP
domain	E-GP
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	S-GP
expression	O
.	O
These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	S-GP
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	S-GP
repression	O
.	O
By	O
combining	O
partially	B-GP
purified	I-GP
proteins	E-GP
in	O
vitro	O
,	O
we	O

observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	B-GP
complex	E-GP
upon	O
inclusion	O
of	O
VDR	S-GP
or	O
VDR-retinoid	B-GP
X	I-GP
receptor	E-GP
.	O
Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR-retinoid	B-GP
X	I-GP
receptor	I-GP
heterodimer	E-GP
blocks	O
NFATp/AP-1	B-GP
complex	E-GP
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O

NF-AT-1	B-DNA
element	E-DNA
.	O
This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-GP
activators	E-GP
of	O
the	O
IL-2	B-DNA
gene	E-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O

act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O
Tissue-specific	O
regulation	O
of	O
the	O
rabbit	B-DNA
15-lipoxygenase	I-DNA
gene	E-DNA
in	O
erythroid	B-cell_type
cells	E-cell_type
by	O
a	O
transcriptional	B-DNA
silencer	E-DNA
.	O
The	O
15-lipoxygenase	B-DNA
(	I-DNA
lox	I-DNA
)	I-DNA
gene	E-DNA
is	O
expressed	O
in	O
a	O
tissue-specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	B-cell_type
cells	E-cell_type
but	O
also	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	E-cell_type
and	O
eosinophils	S-cell_type
.	O
We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	B-DNA

'	I-DNA
flanking	I-DNA
DNA	E-DNA
of	O
the	O
15-lox	B-DNA
gene	E-DNA
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	B-cell_line
cell	I-cell_line
lines	E-cell_line
but	O
not	O
in	O
two	O
erythroid	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	B-DNA
'silencer	I-DNA
'	E-DNA

since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O
The	O
main	O
activity	O
of	O
the	O
silencer	S-DNA
has	O
been	O
mapped	O
to	O
the	O

first	O
900	O
bp	O
of	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	E-DNA
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	B-GP
factor	E-GP
present	O
in	O
non-	O
erythroid	B-cell_type
cells	E-cell_type
but	O
not	O
in	O

erythroid	B-cell_type
cells	E-cell_type
.	O
These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
sites	E-DNA
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	B-DNA
lox	I-DNA
promoter	I-DNA

fragment	E-DNA
.	O
The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	E-DNA
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	B-DNA
sites	E-DNA
for	O
the	O
GATA	B-GP
family	E-GP
of	O
transcription	B-GP
factors	E-GP
.	O
Phosphorylation	O
of	O
the	O
transcription	B-GP
factor	E-GP
NFATp	S-GP
inhibits	O
its	O

DNA	O

binding	O
activity	O
in	O
cyclosporin	B-cell_line
A-treated	I-cell_line
human	I-cell_line
B	E-cell_line
and	O
T	B-cell_type
cells	E-cell_type
.	O
Cyclosporin	O
A	O
(	O
CsA	O

)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	B-GP
factor	E-GP
of	O
activated	O
T	B-cell_type
cells	E-cell_type
(	O
NFAT	S-GP
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O

cytokine	O
genes	O
.	O
This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	S-GP
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	S-GP
component	O
to	O
the	O
nucleus	O
.	O
Here	O
we	O
report	O
that	O
CsA	O

treatment	O
of	O
Raji	B-cell_line
B	E-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	S-GP
that	O

is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-GP
complex	E-GP
with	O
Fos	S-GP
and	O
Jun	S-GP
.	O
Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	S-GP
migration	O
on	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O

its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O
Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	S-GP
or	O
alkaline	B-GP
phosphatase	E-GP
restores	O
NFATp	S-GP
DNA	O
binding	O
activity	O
and	O
its	O

ability	O
to	O
reconstitute	O
an	O
NFAT	B-GP
complex	E-GP
with	O
Fos	S-GP
and	O
Jun	S-GP
proteins	O
.	O
These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA-sensitive	O

regulation	O

of	O
NFATp	S-GP
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O
Transcription	B-GP
factors	E-GP
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O

activation	O
.	O
We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O

activation	O
.	O
In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O

lymphocyte	O
activation	O
.	O
Treatment	O
of	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O
This	O
inhibitory	O
effect	O

was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time-frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O
It	O
therefore	O
was	O
of	O
interest	O
to	O

establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O
Taking	O
the	O
IL-2	B-DNA
gene	E-DNA
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O

effect	O
of	O
cysteamine	O
treatment	O
on	O
early	B-DNA
gene	E-DNA
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B-GP
factors	E-GP
AP-1	S-GP
,	O

NF-kappa	B-GP

B	E-GP
,	O
NF-AT	S-GP
and	O
Oct1	S-GP
,	O
whose	O
functions	O
are	O
required	O
for	O

expression	O
of	O
the	O
IL-2	S-GP
mRNA	O
.	O
Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	B-RNA
mRNA	E-RNA
and	O
secretion	O
of	O
IL-2	S-GP
into	O
the	O
culture	O
medium	O
.	O
The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O

least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	B-GP
factor	E-GP
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	S-GP
and	O
NF-kappa	B-GP
B	E-GP
extracted	O
from	O
mitogen-stimulated	B-cell_type
cells	E-cell_type
were	O
significantly	O
inhibited	O
by	O

cysteamine	O
treatment	O
.	O
Interestingly	O
,	O
Oct1	O
and	O
NF-AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O
The	O
identification	O
of	O
regulatory	B-GP

proteins	E-GP
,	O
such	O
as	O
transcription	B-GP
factors	E-GP
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O

to	O
G1	O
phase	O
transition	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O
Sex	O
and	O
age	O
distribution	O
of	O
1	B-GP
,	I-GP
25	I-GP
(	I-GP
OH	I-GP
)	I-GP
2D3	I-GP
receptors	E-GP
in	O
peripheral	B-cell_type
blood	I-cell_type

mononuclear	I-cell_type
cells	E-cell_type
from	O
normal	O
human	O
subjects	O
.	O
Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
PBMC	S-cell_type
)	O
.	O
We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O
Twenty	O
two	O
healthy	O

men	O
aged	O
21-66	O
yr	O
(	O
mean	O
+/-	O
SD	O
41.0	O
+/-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22-60	O

yr	O
(	O
38.9	O
+/-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O
The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+/-	O
0.66	O
x	O
10	O
(	O

-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+/-	O
0.92	O
fmol/10	O

(	O
7	O
)	O
PBMC	S-cell_type
vs	O
4.43	O
+/-	O
1.38	O
fmol/10	O
(	O
7	O
)	O
PBMC	S-cell_type
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O
Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O
No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
postmenopausal	O

women	O

.	O
Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	B-GP
receptors	E-GP
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O

.	O
Expression	O
of	O
Id2	O
and	O
Id3	O
mRNA	O
in	O
human	B-cell_type
lymphocytes	E-cell_type
.	O
Helix-loop-helix	B-GP
(	I-GP
HLH	I-GP
)	I-GP
transcription	I-GP
factors	E-GP
are	O
involved	O
in	O
cellular	O

growth	O
and	O
differentiation	O
.	O
The	O
Id	S-GP
(	O
inhibitor	O
of	O
DNA	O
binding	O
and	O
differentiation	O
)	O
HLH	B-GP
proteins	E-GP
,	O
in	O
a	O

dominantly	O
negative	O
fashion	O
,	O
regulate	O
transcriptional	O
activities	O
of	O
basic	B-GP
HLH	I-GP
proteins	E-GP
.	O
We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B-RNA
and	I-RNA
Id3	I-RNA
mRNA	E-RNA
in	O
human	B-cell_line
leukemia/lymphoma	I-cell_line
lines	E-cell_line
and	O
patient	O
samples	O

,	O
as	O
well	O
as	O
resting	O
and	O
activated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	E-cell_line
from	O
peripheral	O
blood	O
(	O
PBL	S-cell_type
)	O
.	O
The	O
Id2	B-RNA
mRNA	E-RNA
was	O
abundantly	O
expressed	O
in	O
5/12	B-cell_line
T-cell	E-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	E-cell_line
,	O
and	O
Id3	B-RNA
mRNA	E-RNA
was	O
detected	O
in	O
4/12	B-cell_line
T-cell	E-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	E-cell_line
.	O
Interestingly	O
,	O
Id2	S-RNA
,	O
but	O
not	O
Id3	S-RNA
,	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
4/5	B-cell_line
T-cell	I-cell_line
lines	E-cell_line
infected	O
with	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
(	O
ATL-1k	S-cell_line
,	O
MT-2	S-cell_line
,	O
S-LB1	S-cell_line
)	O

and	O
type	O
II	O
(	O
Mo	S-cell_line
)	O
.	O
Another	O
unexpected	O
finding	O

was	O
that	O
T-cell	O
leukemias	O
and	O
T-cell	B-cell_line
lines	E-cell_line
often	O
expressed	O
either	O

Id2	S-RNA
or	O
Id3	B-RNA
mRNA	E-RNA
.	O
In	O
addition	O
,	O
resting	B-cell_type
PBL	E-cell_type
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B-RNA
mRNA	E-RNA
,	O
but	O
not	O
Id3	B-RNA
mRNA	E-RNA
.	O

Upon	O

PHA	S-GP
-stimulation	O
,	O
Id2	S-GP
expression	O
decreased	O
and	O
Id3	S-GP
levels	O
increased	O

with	O
biphasic	O
kinetics	O
.	O
Taken	O
together	O
,	O
our	O
studies	O
revealed	O
three	O
unexpected	O
findings	O
which	O

require	O
further	O
analysis	O
:	O
(	O
1	O
)	O
expression	O
of	O
Id2	B-RNA
mRNA	E-RNA
is	O
often	O
associated	O
with	O
lymphocytic	O
transformation	O
by	O
HTLV-I	O
or	O
-II	O
;	O
(	O
2	O
)	O
T-cells	O
usually	O

express	O
either	O
Id2	S-GP
or	O
Id3	B-RNA
mRNA	E-RNA
,	O
but	O
B-cells	O
often	O
express	O
both	O
simultaneously	O
;	O
(	O
3	O
)	O
non-dividing	O
,	O
normal	O
PBL	S-cell_type
express	O
high	O
levels	O
of	O
Id2	S-GP
and	O
no	O
Id3	B-RNA
mRNA	E-RNA
;	O
and	O
with	O
the	O
onset	O
of	O

cellular	O
proliferation	O
,	O
levels	O
of	O
Id2	B-RNA
mRNA	E-RNA
decrease	O
while	O
levels	O
of	O
Id3	B-RNA
mRNA	E-RNA
increase	O
,	O
suggesting	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
closely	O
related	O
genes	S-DNA
is	O
disparate	O

.	O
Salicylates	O
inhibit	O
lipopolysaccharide-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
.	O
Binding	O
of	O
plasma	B-GP
Factor	I-GP
VII/VIIa	E-GP
to	O
the	O
tissue	B-GP
factor	I-GP
(	I-GP
TF	I-GP
)	I-GP
receptor	E-GP
initiates	O
the	O
coagulation	B-GP
protease	E-GP
cascades	O
.	O
TF	O
expression	O
by	O
circulating	B-cell_type
monocytes	E-cell_type
is	O

associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O
Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
TF	I-DNA

gene	E-DNA
in	O
monocytic	B-cell_type
cells	E-cell_type
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-GP
heterodimers	E-GP

to	O
a	O
kappa	B-DNA
B	I-DNA
site	E-DNA
in	O
the	O
TF	B-DNA
promoter	E-DNA
.	O
Here	O
,	O
we	O
report	O
that	O

a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	B-DNA
gene	E-DNA
transcription	O
in	O
human	B-cell_type
monocytes	E-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	E-cell_line
at	O
clinically	O
relevant	O
doses	O
.	O
Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	E-GP
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-GP
heterodimers	E-GP
.	O
In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	E-DNA
.	O
These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-DNA
gene	E-DNA
transcription	O
in	O
monocytic	B-cell_type
cells	E-cell_type
by	O
preventing	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-GP

heterodimers	E-GP

.	O
The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O

and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O
Activation	O
of	O
the	O

signal	O
transducer	O
and	O
transcription	O
(	O
STAT	S-GP
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O
Critical	O
role	O

for	O
IL-6	S-GP
.	O
The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	S-GP
with	O
TCR	S-GP
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O
The	O
activation	O
of	O

signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-GP
(	I-GP
STAT	I-GP
)	I-GP
proteins	E-GP
in	O
a	O
primary	O
TCR	S-GP
-mediated	O
activation	O
of	O
T	B-cell_type
cells	E-cell_type
have	O
been	O
explored	O
.	O
In	O
purified	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	E-cell_type
,	O
nuclear	B-GP
STAT	I-GP
proteins	E-GP
were	O
activated	O
approximately	O
3	O

h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	B-GP
Abs	E-GP
.	O
These	O
STAT	B-GP
proteins	E-GP
were	O
detected	O
by	O
using	O
the	O
IFN-gamma-activated	B-DNA
sequence	E-DNA
(	O
GAS	S-DNA
)	O
and	O
related	O
oligonucleotides	O

as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	B-GP
Abs	E-GP
indicated	O
that	O
they	O
contained	O
STAT-3	S-GP
and	O
additional	O

proteins	O
crossreactive	O
with	O
the	O
STAT	B-GP
family	E-GP
.	O
The	O
induction	O
of	O
STAT	S-GP
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O

,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B-GP
factor	E-GP
produced	O
by	O
the	O
activated	O
T	B-cell_type
cells	E-cell_type
.	O
As	O
neutralizing	B-GP
anti-IL-6	I-GP
Abs	E-GP
effectively	O
down-regulated	O
the	O
early	O
induction	O
of	O
STAT	B-GP

proteins	E-GP

and	O
as	O
exogenously	O
added	O
IL-6	S-GP
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	S-GP
-mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O

that	O
IL-6	S-GP
is	O
the	O
factor	O

responsible	O
for	O
the	O
activation	O
of	O
STAT	B-GP
proteins	E-GP
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O
The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	B-cell_type
B	I-cell_type

lymphocytes	E-cell_type
by	O
Epstein-Barr	O
virus	O
.	O
B	B-cell_type
lymphocytes	E-cell_type
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O
Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O

with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
Because	O
it	O
is	O
not	O
clear	O

at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	B-DNA
cycle-associated	I-DNA
genes	E-DNA
in	O
quiescent	B-cell_type

and	I-cell_type
stimulated	I-cell_type
cells	E-cell_type
.	O
We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	B-DNA
genes	E-DNA
,	O
cdc-2	S-DNA
,	O
cyclin	B-DNA
E	E-DNA
,	O
CD23	S-DNA
,	O
and	O

cyclin	B-DNA
D2	E-DNA
,	O
are	O
up-regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV-mediated	O
immortalization	O
.	O
Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O

into	O
the	O
cell	O
cycle	O
.	O
Transient	O
stimulation	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	S-GP
,	O
anti-IgM	S-GP
,	O
and	O
IL4	S-GP
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	S-cell_type
cell	O

cycle	O

activation	O
.	O
Expression	O
of	O
the	O
chemokine	B-GP
receptor	E-GP
BLR2/EBI1	S-GP
is	O
specifically	O
transactivated	O
by	O
Epstein-Barr	B-GP
virus	I-GP
nuclear	I-GP
antigen	I-GP
2	E-GP
.	O
In	O

our	O
attempt	O
to	O
identify	O
chemokine	B-GP
receptors	E-GP
that	O
are	O
related	O
to	O
Burkitt	B-GP
's	I-GP
lymphoma	I-GP

receptor	I-GP
1	E-GP
(	O
BLR1	S-GP
)	O
and	O
are	O
expressed	O
in	O
activated	B-cell_type
lymphocytes	E-cell_type
we	O
used	O
RT-PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	B-GP
transmembrane	I-GP
receptor	E-GP

termed	O
BLR2	S-GP
.	O
The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G-protein	B-GP
coupled	I-GP
chemokine	I-GP
receptors	E-GP
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B-GP
EBI1	E-GP
.	O
Northern	O
blot	O
analysis	O

revealed	O
that	O
BLR2	B-RNA
mRNA	E-RNA
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	B-cell_line
and	I-cell_line
anti-CD3-treated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	E-cell_line
.	O
BLR2-specific	B-RNA
mRNA	E-RNA
could	O
be	O
detected	O
in	O
all	O
Epstein-Barr	B-cell_line
virus	I-cell_line
positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O
We	O
show	O

that	O
transcription	O
of	O
the	O
BLR2	B-DNA
gene	E-DNA
could	O
be	O
specifically	O
induced	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
negative	I-cell_line
BL	I-cell_line
41	I-cell_line
cells	E-cell_line
via	O
estrogen-mediated	O
activation	O
of	O
Epstein-Barr	B-GP
virus	I-GP
nuclear	I-GP
antigen	I-GP
2	E-GP

,	O
a	O
key	O
regulator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	E-DNA
in	O
immortalized	B-cell_line
B	I-cell_line
cells	E-cell_line
.	O
Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	S-GP
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	B-cell_type
lymphocytes	E-cell_type
and	O
in	O
viral	O
pathogenesis	O
.	O
A	O
central	O
role	O
for	O
a	O
single	B-DNA
c-Myb	I-DNA
binding	I-DNA
site	E-DNA
in	O
a	O
thymic	B-DNA
locus	I-DNA
control	I-DNA

region	E-DNA

.	O
Locus	B-DNA
control	I-DNA
regions	E-DNA
(	O
LCRs	S-DNA
)	O
are	O
powerful	O
assemblies	O
of	O
cis	B-DNA
elements	E-DNA
that	O
organize	O
the	O

actions	O
of	O
cell-type-specific	B-GP
trans-acting	I-GP
factors	E-GP
.	O
A	O
2.3-kb	B-GP
LCR	E-GP
in	O
the	O
human	B-DNA
adenosine	I-DNA
deaminase	I-DNA
(	I-DNA
ADA	I-DNA
)	I-DNA
gene	I-DNA
first	I-DNA
intron	E-DNA
,	O
which	O
controls	O
expression	O
in	O
thymocytes	S-cell_type
,	O
is	O
composed	O
of	O
a	O
200-bp	B-DNA
enhancer	I-DNA
domain	E-DNA
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O

chromatin	S-DNA
.	O
Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	S-DNA
contains	O
a	O
28-bp	B-DNA
core	I-DNA
region	E-DNA
and	O
local	O
adjacent	O
augmentative	O
cis	B-DNA
elements	E-DNA
.	O
We	O
now	O
show	O
that	O
the	O
core	O

contains	O
a	O
single	O
critical	O
c-Myb	B-DNA
binding	I-DNA
site	E-DNA
.	O
In	O
both	O
transiently	B-cell_line
cotransfected	I-cell_line
human	I-cell_line
cells	E-cell_line
and	O
stable	O
chromatin-integrated	B-cell_line
yeast	I-cell_line
cells	E-cell_line

,	O
c-Myb	S-GP
strongly	O
transactivated	B-DNA
reporter	I-DNA
constructs	E-DNA
that	O
contained	O
polymerized	B-DNA
core	I-DNA
sequences	E-DNA
.	O
c-Myb	B-GP
protein	E-GP

was	O
strongly	O
evident	O
in	O
T	B-cell_type
lymphoblasts	E-cell_type
in	O
which	O
the	O
enhancer	S-DNA
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O
Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c-myb	S-DNA
expression	O
with	O
that	O
of	O
mouse	B-DNA
ADA	E-DNA
and	O
human	B-DNA
ADA	I-DNA
LCR	E-DNA
-directed	O
transgene	O

expression	O
.	O
Point	O
mutation	O
of	O
the	O
c-Myb	B-DNA
site	E-DNA
within	O
the	O
intact	O
2.3-kb	B-GP
LCR	E-GP
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O

LCR	S-DNA

activity	O
in	O
transgenic	B-cell_line
thymocytes	E-cell_line
.	O
Within	O
the	O
context	O
of	O
a	O
complex	B-DNA
enhancer	E-DNA
and	O
LCR	S-DNA
,	O
c-Myb	S-GP

can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte-specific	B-DNA
gene	E-DNA
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O
A	O
regulatory	B-DNA
element	E-DNA
in	O
the	O
human	B-DNA

interleukin	I-DNA
2	I-DNA
gene	I-DNA
promoter	E-DNA
is	O
a	O
binding	B-DNA
site	E-DNA
for	O
the	O
zinc	B-GP
finger	I-GP
proteins	E-GP
Sp1	S-GP
and	O
EGR-1	S-GP
.	O
Activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	E-DNA
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O

function	O
.	O
Prior	O
studies	O
have	O
identified	O
several	O
transcription	B-GP
factors	E-GP
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	E-DNA
in	O

stimulated	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
.	O
Here	O
we	O
describe	O
a	O
novel	O
regulatory	B-DNA
element	E-DNA
within	O
the	O
IL-2	B-DNA

promoter	E-DNA
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cell	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
domain	E-DNA
.	O
This	O
region	O
(	O
termed	O
the	O
zinc	B-DNA

finger	I-DNA
protein	I-DNA
binding	I-DNA
region	E-DNA
(	O
ZIP	S-DNA
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	B-GP
finger	I-GP
proteins	E-GP
:	O
the	O
constitutively	B-GP

expressed	I-GP
transcription	I-GP
factor	E-GP
Sp1	S-GP
and	O
the	O
inducible	B-GP
early	I-GP
growth	I-GP
response	I-GP
protein	E-GP
EGR-1	S-GP
.	O
In	O
unstimulated	B-cell_type
cells	E-cell_type
which	O
do	O
not	O
secrete	O
IL-2	S-GP
,	O
only	O
Sp1	S-GP

binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	B-cell_line
IL-2	I-cell_line
secreting	I-cell_line
cells	E-cell_line
the	O
inducible	B-GP
EGR-1	I-GP
protein	E-GP
recognizes	O
this	O
element	O
.	O
In	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
,	O

the	O
ZIP	B-DNA
site	E-DNA
serves	O
as	O
an	O
activator	O
for	O
IL-2	S-GP
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	S-DNA
and	O
NFAT	B-DNA
binding	I-DNA
sites	E-DNA
is	O
required	O
for	O
maximal	O
IL-2	B-DNA

promoter	E-DNA

activity	O
.	O
These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	B-DNA
site	E-DNA
for	O
IL-2	B-DNA
promoter	E-DNA
activity	O
.	O
Activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	E-DNA
by	O

the	O
LEF-1	B-GP
HMG	I-GP
protein	E-GP
on	O
nucleosome-assembled	B-DNA
DNA	E-DNA
in	O
vitro	O
.	O
Lymphoid	B-GP
enhancer-binding	I-GP
factor	I-GP
1	E-GP
(	O
LEF-1	S-GP
)	O
is	O
a	O
regulatory	B-GP
high	I-GP
mobility	I-GP
group	I-GP
(	I-GP

HMG	I-GP
)	I-GP
protein	E-GP
that	O
activates	O
the	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR	I-DNA
alpha	I-DNA
)	I-DNA
enhancer	E-DNA
in	O
a	O
context-restricted	O
manner	O
in	O
T	B-cell_type

cells	E-cell_type
.	O
In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
enhancer	E-DNA
,	O
which	O
contains	O
DNA-binding	B-DNA
sites	E-DNA
for	O
LEF-1	S-GP

and	O
Ets-1	O
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF-1	S-GP
.	O
First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1-binding	B-DNA
site	E-DNA
inhibit	O
the	O
activity	O
of	O
multimerized	B-DNA
copies	E-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	E-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
,	O
and	O
that	O
LEF-1/GAL4	S-GP

can	O
activate	O
a	O
GAL4-substituted	B-DNA
HIV-1	I-DNA
enhancer	E-DNA
80-	O
to	O
100-fold	O
in	O
vivo	O
.	O
Second	O
,	O
recombinant	B-GP
LEF-1	E-GP
is	O
shown	O
to	O
activate	O
HIV-1	O
transcription	O
on	O
chromatin-assembled	B-DNA
DNA	E-DNA
in	O
vitro	O
.	O
By	O
using	O

a	O
nucleosome	S-GP
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	S-DNA
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O

the	O
DNA	O
with	O
LEF-1	S-GP
(	O
or	O
LEF-1	S-GP
and	O
Ets-1	S-GP
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O

promoter-binding	B-GP

protein	E-GP
,	O
Sp1	S-GP
.	O
Addition	O
of	O
TFE-3	S-GP
,	O
which	O
binds	O
to	O
an	O
E-box	B-DNA
motif	E-DNA
upstream	O
of	O

the	O
LEF-1	B-DNA
and	I-DNA
Ets-1	I-DNA
sites	E-DNA
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O
Individually	O
or	O
collectively	O
,	O
none	O
of	O
the	O
three	O
enhancer-binding	B-GP
proteins	E-GP
(	O
LEF-1	S-GP
,	O
Ets-1	S-GP
,	O
and	O
TFE-3	S-GP
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O

of	O
Sp1	S-GP
.	O
A	O
truncation	B-GP
mutant	E-GP
of	O
LEF-1	S-GP
(	O
HMG-88	S-GP
)	O
,	O
which	O
contains	O
the	O
HMG	B-GP
box	E-GP
but	O
lacks	O
the	O
trans-activation	B-GP
domain	E-GP
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B-DNA
DNA	E-DNA
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O

HMG	B-GP
domain	E-GP
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O
We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF-1	S-GP
in	O
vitro	O
is	O
a	O
chromatin	S-DNA
-dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans-activation	B-GP
domain	E-GP
in	O
addition	O
to	O
the	O
HMG	B-GP
domain	E-GP
.	O
HIV-1	B-GP
envelope	I-GP

glycoproteins	E-GP
induce	O
activation	O
of	O
activated	O
protein-1	S-GP
in	O
CD4+	B-cell_type
T	I-cell_type
cells	E-cell_type
[	O
published	O
erratum	O
appears	O
in	O
J	O

Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O
Activation	O
of	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	E-cell_type
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-cell_line
positive	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
and	O
purified	B-cell_type
T	I-cell_type
cells	E-cell_type
from	O
normal	O
individuals	O
,	O
we	O

have	O
demonstrated	O
that	O
native	B-GP
envelope	I-GP
glycoproteins	E-GP
of	O
HIV	O
,	O
gp	B-GP
160	E-GP
,	O
can	O
induce	O
activation	O
of	O
transcription	B-GP
factor	I-GP
,	I-GP
activated	I-GP
protein-1	E-GP
(	O
AP-1	S-GP
)	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	S-GP
are	O
mediated	O
through	O
the	O
CD4	B-GP
molecule	E-GP
,	O
since	O
treatment	O
of	O
gp160	S-GP
with	O
soluble	O
CD4-IgG	S-GP
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B-cell_line
negative	I-cell_line
T	I-cell_line

cell	I-cell_line
lines	E-cell_line
fail	O
to	O
be	O
stimulated	O
with	O
gp160	S-GP
.	O
Immunoprecipitation	O
of	O
the	O
gp	B-GP
160	E-GP
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-GP
antibodies	E-GP
to	O
Fos	S-GP
and	O
Jun	B-GP
proteins	E-GP
indicates	O
that	O
AP-1	B-GP
complex	E-GP
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O
The	O
gp160-induced	B-GP
AP-1	I-GP
complex	E-GP
is	O
dependent	O
upon	O

protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis-independent	O
.	O
This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B-GP
kinase	I-GP
C	E-GP
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O

channel	O

blocker	O
or	O
cyclosporine	O
A	O
.	O
This	O
gp160	S-GP
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	B-cell_type
cells	E-cell_type
:	O
pre-treatment	O
of	O
CD4+	B-cell_type
T	I-cell_type
cells	E-cell_type
with	O
gp160	S-GP
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O

inhibited	O
anti-CD3	S-GP
-induced	O
interleukin-2	S-GP
secretion	O
.	O
Effects	O
similar	O
to	O
gp160	S-GP
were	O
seen	O
with	O
anti-CD4	B-GP
mAb	E-GP
.	O
The	O
aberrant	O
activation	O
of	O
AP-1	S-GP
by	O
gp160	S-GP
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	E-cell_type
could	O
result	O
in	O
up-regulation	O
of	O
cytokines	S-GP
containing	O
AP-1	B-DNA
sites	E-DNA
,	O
e.g	O
.	O
interleukin-3	S-GP
and	O
granulocyte	B-GP
macrophage	I-GP
colony-stimulating	I-GP
factor	E-GP
,	O
and	O
concurrently	O
lead	O
to	O
T	B-cell_type
cell	E-cell_type
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	S-GP
secretion	O
.	O
